CA2475069A1 - Amine derivatives as protease inhibitors - Google Patents

Abstract

<SEE FORMULA (I)>
<SEE FORMULA (a) <SEE FORMULA (b) The present invention relates to novel alkanoyl-substituted heterocyclic derivatives which are cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making; according to Formula (1) in which: A comprises a heteromonocyctic ring containing 5 to 6 ring member atoms or a fused heteropolyeyclic ring system containing 8 to 14 ring member atoms, wherein each ring contains 5 to 7 ring member atoms, X1 is a ring member carbon atom and each ring member atom other than X1 is a carbon atom or a heteroatom, with the proviso that (i) at least one ring member atom is a heteroatom and (ii) when A is a heteromonocyclic radical containing 5 ring member atoms, no more than two of the ring member atoms comprising A are heteroatoms; n is 0, 1, 2 or 3. X2 is -C- or -CH-; X2 is a bond or a divalent group of Formula (a) or (b); R1 - R8 = as in the application.

Description

AMINE DERIUATTYES AS PROTEASE INHIBITORS
THE INVENTION
This application relates to compounds and compositions for treating.diseases associated with cysteine protease activity, particularly diseases associated with activity of cathepsins B, K, LorS.
DESCRIPTION OF THE FIELD
Cysteine proteases represent a class of peptidases characterized by the presence of a cysteine residue in the catalytic site of the enzyme. Cysteine proteases are associated with the 1 Q normal degradation and processing of proteins. The aberrant activity of cysteine proteases, e.g.
as a result of increased expression or enhanced activation, however, may have pathological consequences. in this regard, certain cysteine proteases are associated with a number of disease states, including arthritis, muscular dystrophy; inflammation, tumor invasion, giomerulonephritis, malaria, periodontal disease, metachromatic Ieukodystrophy and others. For i5 example; increased cathepsin B levels and redistribution of the enzyme are found in tumors;
thus, suggesting a role for the enzyme in tumor invasion and metastasis. in addition, aberrant cathepsin B activity is implicated in such disease states as rheumatoid arthritis, osteo arthritis, pneumocystis carinii, acute panereatitis, inflammatory airway disease and bone and joint disorders.
20 The prominent expression of cathepsin K in osteociasts and osteoclast-related multinucleated cells and its high collagenolytic activity suggest that the enzyme is involved in ososteoclast-mediated hone resorption and, hence, in bone abnormalities such as occurs in osteoporosis. In addition, cathepsin K expression in the lung and its elasrinolytic activity suggest that the enzyme plays a role in pulmonary disorders as well.
25 Cathepsin L is implicated in normal lysosomal proteolysis as well as several disease states, including, but not limited to, metastasis of melanomas. Cathepsin S is implicated in Alzheimer's disease and certain autoimmune disorders, including, but not limited to juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves' disease, myasthenia gravis, systemic lupus erythemotasus, rheumatoid arthritis and Hashimoto's thyroiditis; allergic disorders, including, but not limited to asthma; and allogeneic invnune responses, including, but not limited to; rejection of organ transplants or tissue grafts.
In view of the number of diseases wherein it is recognized that an increase in cysteine protease activity contributes to the pathology andlor symptomatology of the disease, molecules which are_shown to inhibit the activity of this class of enzymes, in particular molecules which are inhibitors of cathepsins B, K, L andlor S, will be useful as therapeutic agents.
SUMMARY OF THE INVENTION
In one particular embodiment, the present invention relates to protease inhibitors ~f Formula I:
RZ R5 ~
R
RlXZ.N Xt R7 . R (R8)n in which:
A comprises a heteromonocyclic ring containing 5 to 6 ring member atoms or a fused heteropolycyclic ring system containing S to 14 ring member atoms, wherein each ring contains S to 7 ring member atoms, X' is a ring member carbon atom and each ring member atom other I5 than X' is a carbon atom or a heteroatom, with the proviso that (i) at least one ring member atom is a heteroatom and (ii) when A is a heteromonocycIic radical containing 5 ring member atoms, no more than two of the ring member atoms comprising A are heteroatoms;
nis0, l,2or3;
X' is =C- or -CH-;
X2 is a bond or a divalent group of Formula (a) or (b):
R11 R12 R20 Ril R12 ~\~N~x3-~ ~~N X~~N~,Xg R9 R11 Rt3 (a) (b) wherein:
_2_ X3 and X4 independently are -C(O)- or -CH2S(0~~~
R9 and R'° independently are hydrogen, (C,.~alkyY or as defined below;
R" at each occurrence independently is hydrogen or (C,_6)alkyl;
R'Z and R'3 independently are (i) (C~.~)alkyl optionally substituted with cyano, halo, vitro, 'NR'4R14~ _~14(~(O)ORl4' _~t4C(O)NR'4R'49 -NR'4C(NR'4)NR'4R'4, _~RI4~ _~R14~ _C(o)OR14~ _C(O)~I4RI4' _~'(~)2~t4R14~ -~.1(p)(~R14)OR'4, -OP(O)(OR'4)OR'4, -NR'4C(O)Rts~ _S(O)Rts~ -S(O)aRls~ _C(O)Rls~ _ORIS~ -sR,6~
_S(O)Rts~ _S(O)zRle~ _C(O)Rts~ _C(O)ORts~ _OC(O)Rn~ _yaRn' _~t7C(O)Rte~
_NRt7C(O)ORts~ _C(~)~16R27~ _S(O)~'°Rn~ -NRnC(O)NR'6Rn or -NR"C(NR")NR'6R", wherein R'4 at each occurrence independently is hydrogen, (C,_6)alkyl or halo-substituted (CI_3)alkyl, R's is (C,~)alkyl or halo-substituted (C,_3)alkyl, halo, (C,~)alkyl or R'6 is (C3_,a)~Ycloalkyl(C~)alkyl, hetero(C3.~2)cycloalkyl(C~)alkyl, (C~,Z)aryl(Cab)alkyl, hetero(Cs.,Z)aryl(C~)alkyl, (C~.,~polycycloaryl(C~)aIkyl ar hetero(Cs_t2)polycycloaryl(C~)alkyl and R" is 1~ hydrogen or (C»)alkyl, and wherein within R'6 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryI ring optianally is substituted by a group selected from -R's, -XSOR's, -XsSR's, -XsS(O)R's, -XsS(O)ZR'a, -XsC(O)R's, -XsC(O)OR's, -XsOC(O)R's, _XsNR'$Rt9~ _Xs~lsC(O)Rls9 _XsNRt9C(O)ORts~
_XSC(O)~18RI9~ _X5~(O~2NRt8R19~ _XS~t9C(O)NRtaRl9 or -XsNR'9C(NR'9)NR'sR'9, wherein Xs is a bond or (C;~,)alkylen~, R's is hydrogen or (C,~)alkyl and R'9 is (C3_,2)cycloalkyl(Co~)alkyl, hetero(C3_=2)cycloalkyl(Ca6)alkyl, (C~,2)aryl(C~)alkyl, hetero(C~12)aryl(C~)alkyl, (Cø~2)polycycloaryl(C~)alkyl or hetero(Cs_t2)polycycloaryl(C~)alkyl, or (ii) a group selected from (C~,2)cycloalkyl(C~)alkyl, hetero(C3_t2)cycloalkyl(C~)alkyl, (C~l~aryl(Co.,b)alkyl, hetero(Cs.l2)aryl(Co-b)alkyl, (C~l~polycycloaryl(C~)alkyl and hetero(Cs.l~polycycloaryl(C~)alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected from -R's, -XsOR's, -XSSR's, -XsS(O)R's, -XsS(O)zR's, -XsC(O)R's, -XsC(O)ORIS' _XsOC(O)Rte9 _XSNR18RI9~ -Xs~tsC(O)Rts~ _Xs~tvC(O)ORIS~
-XSC(O)NR'sR'9, -XSS(03zNR'sR'9, -XSNR'9C(O)NR'sR'9 or -X'NR'9C(NR'9)NR'$R'~, wherein Xs, R's and R'9 are as defined above; wherein within R'Z andlor R'3 any alicyclic or aromatic ring system present may be substituted further by I to S radicals independently selected from (C,,~)alkyl, {C»)alkylidene, cyano, halo, halo-substituted (C,.,aaikyl, vitro, -XsNR'4Rz4, -XsNR'4C(O)OR'.4, _XsNRI4C~O)NR14R14~ _XSN'R14C~Ri4)~14R14~ _XSOR14~ _XSSRi4~ -XsC(O)oRl4' _XsC(O)y4Rta~ -xsS(O)z~~4R~i~4~~ _Xsp(O)(OR'4)OR'4, -X'OP(O){OR'4)OR'4, _Xsy4C(O)RIS~ -Xss(O)RIS~ _xsS(O)zRu ~d -XsC(O)RIS~ wherein Xs, R14 and R's are as defined above; or R'2 together with R9 andlor R's together with R'° form trimethylene;
tetramethylene or phenylene-1,2-dimethyiene; optionally substituted with 1 to 3 radicals independently selected from (C,.~)alkyl, (C,,~alkylidene, cyano, halo; halo-substituted 70 (C,~,)alkyl, vitro, oxo, -XSNR'4C(O)OR'4, -XsNR'4C(O)NR'4R'$, _X5~14C~~14}NR'''RI49 -XSOR14~ -XS~R14~ -XsC(O)OR'4, -XsC(O)NR74Rla~
-XsS(O)2NR'°R'4, -XSP(O)(OR'4)OR'4, -XsOP(O)(OR'4}OR'4, -XsNR'°C(O)R's,.
-XsS(O}R's, -XsS(O)zIt's and -XsC{O)R's, wherein Xs, R'4 and R's are as defined above; and R' is -X6X'R~°, wherein Xg is -C(O)-, -C(O)C(O)- or -S(O)2-, X' is a bond, -O- or -NRZ'-, wherein R2' is hydrogen or (CI~)alkyl, and R~ is (i) {C,,~)alkyl optionally substituted by cyano, halo, vitro, -NR'°R'4, -NR'aC(O)OR'4, -NR'4C(O)NR'°R14' -~r4Cy4)NR'4R'4, _ORt4~ -SR14' -C(O)ORi4' -C(O}NR14R14~ -S(O)INRI4RI4~ -p(O)(OR'4)OR'4, -OP{O)(OR'4)OR'", -NR'4C(O)R~s~ -S(O)Ras' _S(O)xRls~ -C(o)RIS~ _pltz2, _SR'~, -S{O)R~, -S(O)zR22, -C(O)RD, -C(O)ORS, -C(O)NR~R~, -NRzzR~, -NR~C(O)R'~, -NR23C(O)ORu, -NR23C(O)NRZZR23 Or -NRz3C(NR23)NRZZR~, wherein R''' and R's are as defined above, R~
is (C3_i_)cycloalkyl(Co~,)alkyl, hetero(C~.,~cycloalkyl(C~)alkyl, (C~.,2)aryl(C~)alkyl, hetero(Cs.;z)aryl(C~)alkyl, (C9.,~}bicycloaryl(Co.~)aIkyl or hetero(C8_~Z)bicycloaryl(C,~..6)alkyl and R~ at each occurrence independently is hydrogen or (C~~)alkyi, ar (ii) {C3_iz)cycloalkyl(C~)alkyI, hetero(C~.,~cycloalkyl(C~)alkyl, (C~.l~aryl(C~,6)alkyI, hetero(Cs_,~aryl(C~)alkyl, (Cg_~2)bicycloaryl(C~)alkyl or hetero(C$_a2)bicycloaryl(C~)alkyl or (iii) (C~)cycloalkyl(Co.~)alkyl, hetero(C~)cycloalkyl(C~)alkyl, phenyl(C~alkyl or hetero{Cs_b)aryl(C~alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by -R'~, -XsOR~°, -XsSR'~, -XSS(O)R2°, -X5S(O)ZR~, -XsC(O}R~', -XsC(O)OR~°, -X5C(O)NR~'R's, -XSNRz'R=s, -X3NR~C(O)R~'', -XsNRzsC(~)OR24, -XSNR2sC(O)NR~R~
or -XSNR'~C(NR~)NR~°Ru; wherein Xs is as defined above, R~ is (C3,~)cycloalkyl(C~)alkyl, hetero(C~)cycloalkyl(C~)alkyl, phenyl(C,~)alkyl or hetero(Cs~aryl(C~)alkyl and R~ at each occurrence independently is hydrogen or (C,.~)alkyl; wherein within R' any alicyclic or aromatic ring system present may be substituted further by i to 5 radicals independently selected from (C,.~)alkyl, {C,~)alkylidene, cyano, halo, halo-substituted (C,~,)alkyl, nitro, -XsNR'4R'4, _X3~14C~O)OR14~ -XsNRI4C{o)NR14R14~ _X5~14C~)4)~14R14~ -X5o~14~ -XSSR14~
-XsC(O~~R14~ _XsC(O)NR14R14~ -XSS{Oy'4R14~ -Xsp(O){OR'4)OR'4, -XSOP(O)(OR'4)OR'4, -XSNR'4C(O)R's, -XsS{0)R's, -XsS(O)2Rls ~d -XsC(0)R's, wherein Xs, R'4 and R's are as defined above; or when X2 is a divalent group of formula (a) or (b) then R' may also represent hydrogen, carboxy, oxalo or carbamoyl;
R= is hydrogen or (C,.b)aIkyl;
R3 is (i) (C,~)alkyl optionally substituted with cyano, halo, vitro, -SRzb, -C{O)OR~, _C(O)NR2sR26, -p(O)(ORzb)OR26, -OP(O)(0Rz6)OR~, -S(0)R27, -S(0)zRzy or -G(O)Rz', wherein R~ at each occurrence independently is hydrogen, (C,~)alkyl or halo-substituted (C,-3)alkyl and Rr' is (C,~)alkyl or halo-substituted (C,_3)alkyl, or (ii) (Cs~cycloalkyl{Cz_3)alkyl, hetero(C3~)cycloalkyl(Cz_3)alkyl, (C6,z)aryl(Cz_3)alkyl or hetero(C~)aryl(Cz_3)alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl optionally is substituted further with I to 5 radicals independently selected from {C,~alkyl, (C,~)alkylidene, cyano, halo, halo-substituted (C1.4)alkYl, vitro, -XSNR'"C(0)OR'4, ..XSNR'''C(0)NR14R14~ -X5~14C~14j~14R14~
.
-xsORt4~ -XsSRl4~ -XsC(O)OR14~ -xsC(O)NR1aR14~ -Xss(O)zNR"R14~ -Xsp(O)(OR'4)OR'4, -XSOP(O)(OR'4)OR'4, -XSNR'4C(O)R's, -XsS{0)R's, -XsS(O)zR's and -XSC(O)R's, wherein Zu Xs, R'4 a:~ld R's are as defined above, provided that when R3 is unsubstituted {C,_s)alkyl and R4 is hydrogen or unsubstituted (C,_s)alkyl, then X2 may not represent (i) a bond when R' is -C(0)Rz°, -C(O)zRz° or -S(O)zRz° in which R'° is (C,.~)alkyl, phenyl(C,~)alkyl, phenyl, (C3.7)cycloalkyi, camphan-10-yl, naphth-1-yl, naphth-2-yl, phenyl substituted by one or more of (C,~)alkyl, perfluoro{C,.~)alkyl, {C,~)alkoxy, hydroxy, halo, amido, vitro, amino, (C,~,)alkylamino, (C,~)dialkylamino, carboxy or (C,,~)alkoxycarbonyl, or naphth-I-yI or naphth-2-yl substituted by one or more of (C,.~)alkyl, perfluoro(C,~)alkyl, (C,,~)alkoxy, hydroxy, halo, amido, vitro, amino, carboxy or (C~~)alkoxycarbonyl or (ii) a divalent group of formula (a) or (b) in which the moiety R'z is methyl, isopropyl, n-butyl, sec-butyl; tent-butyl, 1-methylgropyl, benzyl, naphth-1-ylmethyl, naphth-2-ylmethyl, thien-2-ylmethyl, thien-3-ylmethyl, or wherein R9 and R'z form ethylene, trimethylene, hydroxy-substituted trimethylene, tetramethylene or phenylene-I,2-dimethylene; or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form {C~)cycloalkyIene or (Cs.8)heterocycloalkylene, wherein said cycloalkylene or hetexocycloalkylene is optionally substituted with 1 to 3 radicals independently selected from (C,~)alkyl, (C,~alkylidene, cyano, halo, halo-substituted (C~~)alkyl, vitro, -XsNR'4C(O)OR'4, -XsNR'°C(O)NR'4R14~ _xsNRI4C~R14)NR'4R14, -Xs~R14~ -XsSRl4' -XsC(O)OR14' -XsC(O)y4R14~ _xsS(O)zNR'4R14~ _Xsp(O)(OR'4)OR'°, -XSOP(O)(OR'4)OR'4, -XsNR'4C(O)R's, -XsS{O)R's, -XsS{U)zR's and -X5C{O)R's, wherein Xs, R'°
and R's are as defined above;
R' is hydrogen, (C,.~alkyl or as defined above;
Rs is hydrogen and R6 is hydroxy or Rs and R6 together form oxo;
R' is a group selected from cyano, halo, vitro, -Rte, -X3NRz9Rs°, -XsI~'Rz~C(G)ORZ9, -XsNR3oC(O)NR2sR3o, -XsNRsoC(NRso)NR29Rs°, -XSORZ9, -XsSRz9' -XsC(O)OR~, -XsC(O)NR29R3°, -XSS(O)2NR29R30~ _xsp(p)(OR~OR~'', -XsOP(O)(ORz9)OR~, -XsNR3°C(O)R3', -XSS(O)R3', -XsS(O)zR3' and -XSC{O)R3', wherein Xs is as defined above, Rz9 is hydrogen or -R3', Rs° at each occurrence is hydrogen or (C,~)alkyl and R3' is (Cl.~)alkyl, 75 (C3.l~cycloalkyl(C~)alkyl, hetero(C3_,~cycloallyl(C~)alkyl, (C~lz)aryl(C~)alkyl or hetero(CS_li)aryl(C°.~)alkyl, wherein within R' any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Cl~)alkyl, {C~~)alkylidene, cyano, halo, halo-substituted (C,~)alkyl, vitro, -XsNR'4R'4, -XSNR'4C(O)OR'4, -XS~I4c(O)~14RI4~ _X3~t4C~~14)~14R74~ -XSoRl4~ _x5SR14~ -X5C(~)OR149 -XsC(O)lvTR'4R'4, -Xss(O)zNR14R,1~4,~ _Xsp(O)(OR14)OR'4, -XsOP(U)(OR'4)OR'4, -XsNR'4C(O)R's, -XsS(O)R's, -XsS(O)zR's and -XSC{O)R's, wherein Xs, R'4 and R's are as defined above; and R$ at each occurrence independently is selected from (C~.s)alkyl, (Cl,~)alkylidene, cyano, halo, halo-substituted (C,,~)alkyl, vitro, -XsNR'4R'4, -XsNR'4C(O)OR'4, -XsNR'4C(O)NR'4R74~ -XsNRI4C(Ny4)NR'4R14~ -XsORl4~ _XsSRl4~ -XsC(~)ORt4~
-XSC{O)N,R14R74~ -Xss(~)2~74RI4~ -Xsp{O)(OR~4)OR'°, -XSOP(U)(OR'4)OR'4, -Xs~l4C(O)Rls~ -XsS(O)R's, -XsS(O)2R's and -XsC(O)R's, wherein Xs, R'4 and R's are as defined above; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.; but excluding compounds selected from the group consisting of ((S)-1-{ (S)-1-[(S)-1-(1-benzooxazol-~-yl-methanoyl)-3-methyl-butyIcarbamoyl~-3-methyl-butylcarbamoyl}-3-methyl-butyl)-carbamic acid benzyl ester, { 1-[1-(1-111-imidazol-2-yl-methanoyl)-3-methyl-butylcarbamoyl]-3-methyl-butyl }-carbamic acid tart-butyl ester, [(S)-3-methyl-1-((S)-3-methyl-I-{ 1-[1-(2-trimethylsilanyl-ethoxymethyl~lH
imidazol-2-yl]-methanoyl}-butylcarbamoyl)-butyl]-carbamic acid benzyl ester, { (S)-1-[(S)-1-(I-1X imidazol-2-yl-methanoyl)-3-methyl-butylcarbamo~l]-3-methyl-butyl }-carbamic acid benzyl ester, ((S)-1-{ (S)-1-[1-(1-benzyl-1H-imidazol-2-yl)-methanoyl]-3-methyl-butylcarbamoyl}-3-methyl-butyl)-carbamic acid benzyl ester, {(S)-1-[(Sr1-(1-1H
imidazol-2-yl-methanoyl)-3-methyl-butylcarbamoyl]-3-methyl-butyl }-carbamic acid tart-butyl ester, 3-{ [1-(4-chloro-phenyl)-methanoyl]-amino}-4-oxo-4-pyridin-3-yl-butyric acid ethyl ester, 4-furan-2-yl-4-oxo-3-{ jI-(4-trifluoromethyi-phenyl)-methanoyl]-amino}-butyric acid ethyl ester, 3-(2-methyl-propanoylamino)-4-oxo-4-thiophen-2-yl-butyric acid ethyl ester, 4-oxo-4-thiophen-2-yl-3-[(1 p-tolyl-methanoyl)-amino]-butyric acid ethyl ester, 4-(5-bromo-thiophen-2-yl}-3-{ [1-(4-chloro-phenyl)-methanoyl]-amino}-4-oxo-butyric acid ethyl ester, 3-{[i-(4-chloro-phenyl)-methanoyl]-amino}-4-(5-methyl-thiophen-2-yl)-4~-oxo-butyric acid ethyl ester, 4-oxo-4-thiophen-3-yI-3-[(1 p-to)yl-methanoyl)-amino]-butyric acid ethyl ester, 3-{ [1-(4-methoxy-phenyl)-methanoyl]-amino}-4-oxo-4-thiophen-3-yl-butyric acid ethyl ester, 3-{ [I-(3,4-dichloro-phenyl)-methanoyl]-amino}-4-oxo-4-thiophen-3-yl-butyric acid ethyl ester, 4-fluoro-N-[1-(1-thiophen-3-yl-methanoyl)-propyl]-benzamide, 4-{[1-(4-fluoro-phenyl)-methanoyl]-amino}-5-oxo-S-thiophen-3-yl-pentanoic acid ethyl ester and 3-{ [I-(4-fluoro-phenyl)-methanoyl]-amino}-2-methyl-4-oxo-4-thiophen-3-yl-butyric acid ethyl ester.
In another particular embodiment, the present invention relates to protease inhibitors of Formula I:

R
Rry2. N XI R7 R (R8)n in which:
A comprises a heteromonocycIic ring containing 5 to 6 ring member atoms or a fused heteropolycycIic ring system containing 8 to 14 ring member atoms, wherein each ring contains 5 to 7 ring member atoms, X' is a ring member carbon atom and each ring member atom other than X' is a carbon atom or a heteroatom, with the proviso that (i) at least one ring member atom is a heteroatom and (ii) when A is a heteromonocyclic radical containing 5 ring member atoms, no more than two of the ring member atoms comprising A are heteroatoms;
nis0, l,2or3;
X' is =C- or -CH-;
XZ is a bond or a divalent group of Formula (a) or (b):
Rii Rig Rio Rii R12 wN~Xg- ~I~l ~.N~X3~~.
t I

(a) (b) wherein:
X3 and X4 independently are -C{O)- or -CHZS(O)2-;
R9 and R'° independently are hydrogen, (Cj~)alkyl or as defined below;
70 R" at each occurrence independently is hydrogen or (Cl-6)alkyl;
R'Z and R'3 independently are (i) (C,~)alkyl optionally substituted with cyano, halo, IlltrO, -NRt4R14~ _~14~{O~OR14~ _~14C(O)~14R14~ _~14C~14)~14R149 -OR14' -sRl4~ _C~o)OR14~ -C{~)~14R14' -S{O)2~TR'14R14~ -P(o)~~R14)OR'4, -OP(O)(OR'4)OR'4, -NR'4C(O)Rls~ _S(O)Rls~ -S(O)ZRIS~ _C(~)Rrs~ _ORIS~ _SR16' -S(O)R'6, -S(O)2R'6, -C(O)R'6, -C(O)OR'6, -OC(O)R'6, -NR'eRm, -NR"C{O)R16' _~nC(O)ORIS~ _C(O)ysRa~ _S(O)zNR'6Rt~~ -NR17C(O)NRISRm or -NR"C(NR")NR'6R", wherein R'4 at each occurrence independently is hydrogen, (C,.~)alkyI or halo-substituted (C~_3)alkyl, R's {Cl~)aikyl or halo-.substituted (C~_3)aIkyl, R'° is (C3_12)cycloaIkyl(C~)alkyl, hetero{C~,2)cycloalkyl(C~)alkyl, 24 (C~."~aryJ(C~alkyl, hetero(C~I~aryl(C~)alkyl, (C~,~polycycloaryl(C~alkyl or hetera(C8.12)Polycycloaryl(Co_6)alkyl and R" is hydrogen or (C~~)alkyl, and wherein within R'6 said eycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or ' heterpolycycloaryl ring optionally is substituted by a group selected from -R'$, -XsOR'$, _XsSRIS~ _Xss(O)Rn~ -x5f(O)2RI8~ _XsC(O)Rla~ -XsC(~)ORra~ _Xs~C(O)R=$~
_Xs~18R19~ _XsNRr9C(O)Rls9 _Xs~mC{O)~Rls~ -XsC(O)NR18R19~
-XsS(O)zNR'8R'9, _XsNR'9C{O)NR'8R'9 or _XsNR'9C(NR'~NR18R19~ wherein Xs is a bond or {C,~)alkylene, R'$ is hydrogen or (C,~alkyl and R'9 is _8-(C~,~cycloalkyl(C~)alkyl, hetero(C3.i~cycloalkyl(C~}alkyl, (C~,z)aryl(C~)alkyl;
hetero(Cs.,~aryl(C~)alkyl, (C~,i)polycycloaryl(C~)alkyl or hetero(Cs.,z)polycycloaryl(C~}alkyl, or (ii) a group selected from (C~.,~cycioalkyl(C°.,6)alkyl, hetero(C~.~~cycloalkyl(C°.6)alkyl, {C~,~aryl(C~)alkyl, hetero(Cs.,z)aryl(C~)alkyl' (C~.,~polycycloaryl(C°.~)alkyl and hetero(C&,~polycycloaryl(Co-6)alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected from-R's, -XsOR's, -XsSR'$, -XsS(O)R'$, -XsS(O~R'$, -X5C(O)R'8, -XsC(O)ORIS~ -XsOC(O)Rls9 -XsysRa°~ -Xsy9C(O)R1s -XsNR'9C(O)OR's, -XsC(O)y sRl9~ -XsS(O)zNR'sRI9~ _XS~l9C(O)~t8R19 or ' XSNR'9C(NR'9)NR'sR'9, wherein Xs, R's and R'9 are as defined above; wherein within R'z and/or R'3 any alicyclic or aromatic ring system present may be substituted further by 1 to S radicals independently selected from (C,.~)alkyl, (C,_6)alkylidene, cyano, halo, halo-substituted (C,~)alkyl, vitro, -XSNR'4R'4, -XsNR'4C(O)OR'4, -X5~74C(O)NRI4Ri4' -XsNR~4C(ya)p4R14~ -XSOR14~ _XsSRl4~ -XSC(O)OR14~
-XsC(~)NR1aR14~ _XsS(O)zNR'4Rla~ _Xsp(O)(OR'4)OR'4, -XsOP(O)(OR'4)OR'4, -XsI'TR'4C(O)R's, -XsS(O)R's, -XsS(O)zR's and -XSC(O)R's, wherein Xs, R'4 and Rls are as defined above; or R'z together with R9 and/or R'3 together with R'° form trimethylene, tetr~methylene or phenylene-1,2-dimethylene, , optionally substituted with 1 to 3 radicals independently selected from (C,~)alkyl, (C~.~)alkylidene, cyano, halo, halo-substituted (C,~)alkyl, vitro, oxo, -XSNR'~C(O)OR'°, -XSNR'4C(O)NR'°R'4, -XSNR'4C(NR'4}NR'°R'4, -XSORI4~ _xsSRl4~ _XSC(o)oRl4~ _XsC(O)~14RI4~
-XsS(O)zNR'4R'4, -XsP(O)(OR'4)OR'4, -XSOP(O)(OR'4)OR'4, -XsNR'4C{O)R's, .
-XSS(O)R's, -XSS(O)zR's and -XsC(O)R's, wherein Xs, R'4 and R's are as defined above; and R' is -X6X'Rz°, wherein X6 is -C(O)-, -C(O)C(O)- or -S(O)z-, X' is a bond, -O- or -NRZ'-, wherein Rz' is hydrogen or (C,.~)alkyI, and Rz° is (i) (C,.~alkyl optionally substituted by cyano, halo, vitro, -NR'4R'4, -NR'4C(O)OR'4, -NR'4C(O)NR'4R'4, -NR'4C(NR'4)NR"R'4, -OR'4, -SR'4, -C(O)OR'4, -C(O)NRI4R14~ -S(O)zNR'4R14~ _p(O)(OR")OR's, -OP(O)(OR'4)OR'4, -NR'4C(O)Ris~ _S(O)RIS~ _S(O)zRls~ -C(O)Rls~ _~Rzz~ -SRn~ -S(~)R~~
-S(O)zRzz~ -C{O)Rzz, -C(O)ORzz, -C(O}NRzzRzs~ -~zzRza~ _~z3C(O)Ru' _NR~C(O}ORS, .. .

-NRz3C(O)NR'~R~ or -NR23C(NR~)h'tR~R'~, wherein R'4 and R's are as defined above, R~
is (C~I~cycloalkyl(C~)alkyl, hetero{C~.,z)cycloalkyl(C~)alkyl, (C~tz)aryl(C~)alkyl, hetero(C~.~~aryl(C~alkyl, (C~,~bicycloaryl(C~alkyl or hetero(C:~,z)bicycloaryi(C~)alkyl and R~ at each occurrence independently is hydrogen or (C,.~)alkyl, or (ii) (C3_,z)cycloalkyl(C~)alkyl, hetero(C3_l~cycloalkyl(C~jalkyl, (C~,z)aryl(C~aIkyl, diphenyl(C~alkyl, hetero{Cs.,2)aryl(C~)alkyl, dihetero(Cs.~)aryl(C~)alkyl, (C9_,~bicycloaryl(C~6)alkyl or hetero(C$_12)bicycloaryl(C~)alkyl wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be substituted by -Rz4, -XSOR~'; -XSSR~, -XSS(O)R~, -XSS(O)zR~~ -XSC(~)R',a, -XSC{O)ORz4~ -XSC(O)~24R25~ _XsNRzaRzs~ -Xs~zsC(O)Rz4' -XSNR'~C(O)OR'~, -XSNR'~C(O)NR~'R'~ or -XsNRz3C(NRz3)NRz4R's, wherein Xs is as defined above, R'~ is (C3_,z)cycloalkyl(Co.,b)alkyl, hetero(C~,,)cycloalkyl(C~)alkyl, (C~lz)aryl(C~.6)alkyl, hetero(C~,~aryl(C~)alkyl, (C9_,z)bicycloaryl(Co~)alkyl or hetero(C&,z)bicycloaryl(C~)alkyl and Rzs at each occurrence independently is hydrogen or (C,~)alkyl; wherein within R: any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C,.~)alkyl, {C,.~)alkylidene, cyano, halo, halo-substituted (Cl~)alkyl, nitro, -XSNR'4R'4, -XsNR'4C(O)OR'4, -XSNR'4C(O)IvTR'4R'4, -Xs~l4C~R14)~l4Ru~ _XSORi4~ _XSSRi4~ -XSC(O)oRl4~ -XsC{O)NRl4R~e~
'X3'S(O)2~TR14RI4' -Xsp(p)(OR'4)OR'°, -XSOP(O)(OR'4)OR'4, -XSNR'4C(O)R's, -XsS(O)RIS~
-XSS(O)zR's and -XSC(O)R's, wherein Xs, R'4 and R's are as defined above; or when Xz is a 2d divalent group of formula (a) or (b) then R' may also represent hydrogen, carboxy, oxalo or carbamoyl;
Rz is hydrogen or (C,~)alkyl;
R3 is (i) {C,~)alkyl optionally substituted with cyano, halo, vitro, -SR's, -C(O)OR''', -C(O)NR'~R~°, -P(O)(ORz°)OR'~, -OP{O)(ORz')ORz°, -S(O)RB, -S(O)zR~ or -C(O)RD, wherein Rz4 at each Qccurrence independently is hydrogen, (C,,~)alkyl or halo-substituted (C,_3)alkyl and R'~ (C,_6)alkyl or halo-substituted (C,.3)alkyI, or {ii) (C~)cycIoalkyl(Cz_3)aIkyl, hetero(C~)cycloalkyl(Cz_3)alkyl, {C~,2)aryl(C2_3)alkyl or hetero(C~)aryl(Cz_3)alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl optionally is substituted further with 1 to 5 radicals independently selected from (C,,~)alkyl, (C,~)alkylidene, cyano, halo, halo-substituted (C,~alkyl, vitro, -XSNR'4C(O)OR'4, -XSNR'4C(U)NR'4R'4, -XSNR'4C(NR'4)NR'4R'4, -XSOR149 -x3SR14~ -XSC{O)ORI4~ -XS~{O)~14R14' -XSS(O)2~14R74~ -Xsp{O)(OR'4)OR'4, -XSOP(O)(OR'4)OR'4, -XsNR'4C{O)R'3, -XSS(O)R's, -XsS{O)zR's and -XSC(O)R's, wherein Xs, R'4 and R's are as defined above, provided that when R' is unsubstituted (C~.s)alkyl and R4 is hydrogen or unsubstituted (C,.s)adkyl, then X2 may not represent (i) a bond when It' is -C(O)Rz°, -C(O)2Rz° or -S(O)ZR~° in which R~°
is~(C,.~)alkyl, phenyl(C,~)alkyl, phenyl, (Cs.
~)cycloaIkyl, carnphan-10-yl, naphth-1-yl, naphth-2-yl, phenyl substituted by one or more of (C,, ,alkyl, perfluoro(C~~alkyl, (C,.,~alkoxy, hydroxy, halo, amido, vitro, amino, (C,,~alkylamino, (Cl~dialkylamino, carboxy or (C,~)alkoxycarbonyl, or naphth-1-yl or naphth-2-yl substituted by one or more of (Cl.~)alkyl, perfluoro(C~,,)alkyl, (C,~)alkoxy, hydroxy, halo, amido, vitro, amino, carboxy or (C,,~)alkoxycarbonyl or (ii) a divalent group of fonmula (a) or (b) in which the moiety R'2 is methyl, isopropyl, n-butyl, sec-butyl, tern-butyl, 1-methylpropyl, benzyl,,naphth-1-ylmethyl, 7 0 naphth-2-ylmethyl, thien-2-ylmethyl, thien-3-ylmethyl, or wherein R9 and' R'2 form ~ethyleile;
' trirriethylene, hydroxy-substituted trimethylene, teiramethylene or phenylene-1,2-dimethylene; or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form (C3_$)cycloalkylene or (C~)heterocycloalkylene, wherein said cycloalkylene or heterocycioalkylene is optionally substituted with 1 to 3 radicals independently selected from (C~.~)alkyl, (C~.~)alkylidene, cyano, halo, halo-substituted (C,.~)alkyl, vitro, -XsNR'4C(O)OR'4, -Xs~l4C(O)NrR14R14~ -Xsp4Cy4)NR'"R14~ -XsORl4' -XsSRr4~ -XsC(O)OR'4, -XsC(O)NRI4R14~ -XSS~O)xNR14R14~ -XsP(O)(OR'4)OR'4, -XSOP(O)(OR'4)OR'4, -XsNR'4C(O)R's, -XsS(O)R's, -XsS(~}ZR's and -XSC(O)R's, wherein Xs, R'4 and R's are as defined above;
R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form (C3.8)cycloalkylene or (Cs.B)heterocycloalkylene, wherein said cycloalkylene or heterocycloalkylene is optionally substituted with 2 to 3 radicals independently selected from (C,.s)aikyl, (C~.~)alkylidene, cyano, halo, halo-substituted (Cl~)alkyl, vitro, -XsNR'4C(O)OR'4, -XsNRI4C(O}y4Ri4~ _XsNRIeC(ya)y4R14~ _XsORl4~ -XsSRl4t _XsC(O)ORl4;
-XsC(O)NR'°R'4~ _XsS(p)z~14R14~ -Xsp(O)(OR'4)OR'4, -XsOP(O)(OR'4)OR'4, -XsNR'4C(O}R's, -XsS(O)R's, -XsS(O)2R's and -XSC(O)R's, wherein X5, R'4 and R's are as defined above;
R4 is hydrogen, (C~.~)atkyl or as defined above;
Rs is hydrogen and R° is hydroxy or Rs and R6 together form oxo;
R' is a group selected from cyano, halo, vitro, -Rte, -XsNR29R30, _X5~3°C(O)OR29, -X5NR3°C(O)NR29R3°, -XsNR30C(NR30)NR~R3°, -XsOR~'', -XsSR~'', -XSC(O}ORS, -XsC(O}NR~gR3°, -X5S(O)_NR29R3°, -X5P(O)(OR3~OR'-9, -XsOP(O)(ORz9)OR~, _Xs~3oC(O)Rw~ _XsS(O)Rzo9 _Xss(O)zRz°~ 'XsC(O)Rzo and -C(O)NR4zCHR°3C(O}OR~~
wherein Xs and Rz° are as defined as above, R~ is hydrogen or -Rz°, wherein Rz° is defined as above, R3° at each occurrence is hydrogen or (C,~}alkyl, R°z is hydrogen, (C,~aIkyl or together with R43 forms trimethylene, tetramethylene or phenylene-1,2-dimethylene, optionally substituted with hydroxy or oxo, and R43 is as defined above or is (i) (C,.~}alkyl optionally substituted with cyano, halo, vitro, -NR'4R'4, -NR'4C(O}OR''', -NR'4C(O}NR"R'°, -NR'4C(NR'a)NRI4R74y _OR~a~ -SRr4~ _C(O)ORre~ _C(O)~14R14~ _S(o)z~J4Rl4~ -p(p)(OR")OR'4, -OP(O)(OR'4)OR'4, -IvTR'4C(0}Rrs~ _S(O}R~s~ _S(0}'R~s~ -C(O)Rrs' _OR~s~ -SR~s~
_s(O)R~e~
-S(~)zR~a~ _C(0)Rrs~ -C(0)ORre~ _OC(O)Rrs~ _NRr6Rn~ _NRnC(O)Rn~ -y7C(O)OR~6~
-C(O)NR'aRp _S(O)zNR'6R~7~ _~nC(O)NyaRn flr _~rzC7)NR'SR~: or (ii) a group selected from (C~l~eycloalkyl(C~,.6)alkyl, hetero(C~,z)cycloalkyl(C~)alkyl, (Cb.,z)aryI(C~)alkyl, hetero(Cs_,~aryl(Ca~alkyl, {C9.,~polycycloary3(C°.6)alkyl and hetero(C&l2~olycycloaryl(C°..6)aIkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected fronn -R'g, 't5 -XSOR'8, -XSSR'a, -X5S(O)R's, -XsS(O}2818' _XsC(O)R~s~ -XsC(O)OR'g, -XsOC(0)R'8, _XsNRrsRr9~ _Xs~aC(O)R~s~ _Xs~r9C(O)OR~a~ _XsC(O}~I8RI9~ _Xss(O)z~'sRts~
-XsNR'9C(0)NR'BR'9 or -XsNR'gC(NR'9)NR'BR'9, wherein Xs, R'°, R's, R'6, R", R'e and R'9 are as defined above; wherein within R' any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C~_6)alkyl, (C~,~)alkylidene, cyano, halo, halo-substituted (C,~)alkyl, vitro, -XSNR'4R''°, -XsNR'4C(O)OR''', 'X5~74C(O)~74R14~ -Xs~r4C(NRr4)NR'4Rr4~ _XsORm~ _XsSRm~ -XsC(O}OR'e~
_XsC(O}NRr4Rra~ _~SS(Q)2~14R74~ -Xsp(O)(OR'4)OR''°, -XsOp(O)(ORr"}OR''', -XsNR'4C(0)R's, -XsS(0}R's, -XsS(0)zR's and -XsC(0}R's, wherein Xs, R'°
and R's are as defined above; and R8 at each occurrence independently is selected from (C,~)alkyl, halo-substituted (C~.~)alkyl, (Cr.s)alkylidene, cyano, halo, halo-substituted (Ci~,)alkyl, vitro, -XsNR'°R14~
_Xs~l4C(O)OR14~ _Xsy4C(0 NR'4R'4, -XSNRJ4C(NR14)NR'4R14~ _XSORId' _XssR)4' _XsC(O) flRr4~ _XSC(O}~14RI4y -XsS(0)zNR"Rr4~ -Xsp(O)(OR'4)OR'4, -XsOP(O)(OR'4)OR'°, -XSNR'4C(O}R's, -XsS(0)R's, -XsS(0}zR's and -X5C(O}R's, wherein Xs is a bond or (C~~)alkylene, R'4 at each occurrence independently is hydrogen, (C,~)alkyl or haIo-substituted (C~_3}alkyl and R's (C,.~)alkyl or halo-substituted (C,_3)alkyl; and the N oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
In a further embodiment, the present invention relates to a compound of formula I:
R2 Rs i R .Xar N Xt R~
R~ 4 R (R$)~
in which:
A comprises a benzooxazole or naphthooxazole ring, each substituted by a group R' and optionally substituted with a group Rg, wherein R~ is hydrogen, halo, (CI_4)alkoxy, (C1~)alkoxycarbonyl, vitro or phenyl, R8 at each occurrence independently is halo, (C1~)alkoxy, (Cl~)alkoxycarbonyl, vitro or trifluoromethyl;
nis0, l,2or3;
X' is =C-;
XZ is a bond or a divalent group of Formula (a):
Rt r Rt2 ~~ N~ X3, (a) X3 is -C-(O) or -CH2S(O)2-;
wherein within Formula (a) R9 is hydrogen, Rj 1 is hydrogen or methyl and R12 is (CI~)alkyl substituted with -SR14, -S(O)Ri4 or -S(O)aRi4, wherein R14 is (C6_i2)aryl(Co~)alkyl or hetero(CS_12)aryl(Co-6)alkyl; wherein within R12 the aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C1_6)alkyl, (C1_6)alkylidene, cyano, halo, halo-substituted (Ci_4)alkyl, vitro, -XSNR1aR14, -XSNR14C(p)OR14, 1~

-X5~14~-r(O)~14R14' -X5~14C~14)~14R14' -XSOR14' -XSS,R14' -XS(~(O)OR14, -XSc(~)~14R14' -x5s(O)2~14R1214~'1~-XSP(O)(~R14)OR14, -XSOP(O)(OR~4)OR14, -xs~l4C(O)Rls, -XSS(O)R15, -X5S(O)2Rls ~d -XsC(O)Rls, wherein XS is a bond or (C1_6)alkylene, R14 at each occurrence independently is hydrogen, (Cl_6)alkyl or halo-substituted (C1_3)alkyl and R15 is (Cl~)alkyi or halo-substituted (Cl_3)alkyl;
Rl is -X6X~R2°, wherein X6 is -C(O)- or -S(O)2-, X' is a bond, -O- or -NR21-, wherein R21 is hydrogen or (Cl_6)alkyl, and R2° is (i) (C1_6)alkyl optionally substituted by -C(O)OR14 or (ii) (C3_12)cycloalkyl(Co_6)alkyl, hetero(C3_12)cycloalkyl(Co_6)alkyl, (C~12)aryl(Co_s)alkyl or hetero(CS_12)aryl(Co_6)alkyl or (iii) (C3~)cycloalkyl(Co_6)alkyl, hetero(C3_6)cycloalkyl(Co_6)allcyl, phenyl(Co_6)alkyl or hetero(CS_6)aryl(Co_6)alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by -XSOR24'-XSC.(O)R24' -XSCr(o)OR24, -x5C(O)NR24R25' -X5~24R25' -Xs~2sC(O)Rz4~ -~r5~25C((~)oR24, -XS~R25C,(o)~24R,25 ~r .
-XS~25~.~25)~24R25~ wherein XS is a bond or (C1_6)alkylene, R24 is (C3_6)cycloalkyl(Co~)alkyl, hetero(C3_6)cycloalkyl(Co_~)alkyl, phenyl(Co_6)alkyl or hetero(CS_6)aryl(Co-6)alkyl and R25 is hydrogen or (Cl_6)alkyl; wherein within Rl any alicyclic or aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (Cl_6)alkyl, halo, halo-substituted (Cl~)alkyl, -OR14 and -C(O)OR14 wherein R14 is as defined above, or when X2 is a divalent group of formula (a) then Rl may be, but is not limited to, hydrogen or oxalo;
R2 is hydrogen;
R3 is hydrogen, (C1~)alkyl (optionally substituted with cyano, halo, vitro, -SR24' -~(O)OR24' -C(o)~24R24' -P(O)(~R24)OR24, -Oh(O)(OR24)OR24, -S(O)R25 -S(O)2R25 or -C(O)R25, wherein R24 at each occurrence independently is hydrogen, (C1_6)alkyl or halo-substituted (C1_3)alkyl and R25 is halo, (C1_6)alkyl or halo-substituted (C1_3)alkyl) or (C6_12)aryl(C2_3)alkyl, wherein said aryl optionally is substituted further with 1 to 5 radicals independently selected from (C1_6)alkyl, (C1_6)alkylidene, cyano, halo, halo-substituted (C1_4)alkyl, vitro,-X$NR14C(O)ORl4, -x5~14C(O)~14R14' 13a -X~14C~14)~14R14' -XsORIa' -XsSRIa' -XsC(~)OR14' -XsC(o)~14R14' -Xs~SV(tCO)ZN\1R'ila~Ria, -XsP(O)(~RIa)OR~a, -XSOP(O)(ORIa)ORIa, -XsNRIaC(O)Rts9 -X5S(O)Rls, -XSS(O)2Rls and -XsC(O)Rls, wherein Xs is a bond or (C1~)alkylene and R'a and Rls are as defined above, or R3 and Ra or R3 and Ra taken together with the carbon atom to which both R3 and R4 are attached form cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene;
Ra is hydrogen or as defined above; and Rs and R6 together form oxo; and the N oxide derivatives, and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
In a further embodiment, the present invention relates to a pharmaceutical composition comprising a compound of formula I or II as defined above, or a N-oxide derivative, individual steoizimer, or mixture steoizimer thereof, or a pharmaceutically acceptable salt thereof in admixture with one or more suitable excipients.
In a further embodiment, the present invention relates to use of a compound of formula I as defined above, or an N oxide derivative thereof or an individual steoizimer or a mixture of steoizimers thereof or a pharmaceutically acceptable salt thereof to treat a disease selected from the group consisting of juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonitis, plaque rupture and atheroma in an animal in need of such treatment.
In a further embodiment, the present invention relates to use of a compound of formula II as defined above, or an N oxide derivative thereof or an individual steoizimer or a mixture of steoizimers thereof or a pharmaceutically acceptable salt thereof to treat, a disease selected from the group consisting of juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneurnonitis, plaque rupture and atheroma in an animal in need of such treatment.
13b In a further embodiment; the present invention relates to use of a compound of formula I or II as described above or a N oxide derivative thereof; or an individual stereoisomer or mixture of stereoisomers thereof; or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use to treat, in an animal, a disease selected from the group consisting of juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonitis, plaque rupture and atheroma.
In a further embodiment, the present invention relates to use of a compound of formula I or II as described above or a N oxide derivative thereof; or an individual stereoisomer or mixture of stereoisomers thereof; or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use to treat, in an animal, a disease selected from the group consisting of juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonitis, plaque rupture and atheroma.
In another particular embodiment, the present invention relates to a compound of Formula II:
R3z O~ a ~0 SwX~ R2 RS

R
Ro N 1 R7 g ~ R3 4 X A
R O ~ ~RE)n in which:
A comprises a heteromonocyclic ring containing 5 to 6 ring member atoms or a fused heteropolycyclic ring system containing 8 to 14 ring member atoms, wherein each ring contains 5 to 7 ring member atoms, X' is a ring member:,carbon atom and each ring member atom other than X' is a carbon atom or a heteroatom, with the proviso that at least one ring member atom is a heteroatom;
13c nis0, l,2or3;
X' is =C- or -CH-;
X8 is (C~.~alkylene;
R' is hydrogen, carboxy, axalo, carbamoyl or -XbX'R~°, wherein Xs is -C(Q~, -C(O)C(O)- or -S(O)z-, X' is a bond, -O- or -NR~'-, wherein Ra' is hydrogen or (C,~alkyI, and R~° is (i) (C;.~)aIkyl optionally substituted by cyano, nalo, vitro, =IYR'°R'4, -NR'''C(O)OR'a, -NR~4C(O)~ryaR~e~ _NR~4C(y<~NR'''R~4~ _ORu~ -SR'4, -C(0)OR'4, -C{0)NR"Ra~
-S(0)zNR"R'4, -P(O)(OR'4)OR"; -OP(O)(OR'°)OR", -NROsC(0)R's, -S(O)R's; -S(O)ZRu, .
-C(0)R's, -ORu, -SRu, -S(0)RZZ, -S(O)zIt~, -C(O)RD, -C(O)OR'~; -C(O)NRnR~, .
1 G -NR~zR~, -NR=3C(O)Rz=, -NR~C{O)OR~,-NR=~C(O)NRZZR~ or -NR~C(NR~)NRuR~, wherein R" at each occurrence independently is hydrogen, (C~.~)alkyl or halo-substituted UC~.3)alicyl, R's is (C,.6)alkyl or halo-substituted (C,.3)alkyl, R~ as (~_l~'icycloal'r.-Y1(C~;alkyh hetero(C~.,~cycloalkyl(C~)alkyl, (C~i~aryl(C~)alkyl, hetero(Cs.,2)aryl(C~)alkyl, (C9.~~bicycloaryl(C~)alkyl or hetero(Ca.,~bicycloaryl(Ca,.b)alkyl and R'a at each occurrence independently is hydrogen or (C,~)alkyl, or (ii) (C3.~~cycloalkyl{Co.,b)alkyl, 13d hetero(Cs.,~cycIoalkyl{C~alkyl, (C~.la)aryl{C~)alkyl, hetero(Cs.~~aryl(Co-b)alkyl, (C9_~~bicycloaryl(C~)alkyl or hetero(Cs.,~bicycloaryl(C~)alkyl or (iii) (C~)cycloalkyl(C~)alkyl, hetero(C~cycloalkyl(C~)alkyl, phenyl(C~alkyI or hetero(Cs,~)aryl(C~.b)alkyl substituted by -XSOR~, -XsSRu, -XSS(O)R'~, -XsS(O)aR?'', -X'C(O)Rz4, -X5C(O}ORz'', -XsC(O)NRz'°Ru, -XSNRz''R~, -XsNR'sC(O)R~, -XSNR~C(O)OR~', -XSNRzsC(O}NR~'Rzs or -XsNRuC(NRzs}NR~'R'-s, wherein Xs is a bond or (C~.~alkylene, Rz° is (C3~)cycloalkyl(C~alkyl, hetero(C3.~)cycloalkyl(C~)alkyl, phenyl(C~alkyl or hetero(C~aryl(C~)alkyl and R~ at each occurrence independently is hydrogen or (C,~)alkyl; wherein within R' any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C,~)alkyl, (C~~)alkylidene, cyano, halo, halo-substituted (C~.~)alkyl, vitro, -XsNR'4R'4, -XsNR'4C{O)OR'4, -XsNRI4C{~)NR14R14~ -XsNRI4C~R14)NR'4R14~ -XsORl4~ -XsSRl4~ -XsC{~}OR,4~
-XSC(o)~14R14~ _XSS(0~2~14R14~ -Xsp{O){ORI4)OR'4, -XSOP(O){OR'4)OR'4, -XsNR'4C{O)R's, -XsS(O}R's, -XsS(O)zR's and -XSC(O)R's, wherein Xs, R'4 and R's are as defined above;
Rz is hydrogen or (C,.~alkyl;
R3 is {i) (CL.6)alkyl optionally substituted with cyano, halo, vitro, -NR'4R'4, _~14C{O)ORl4' _NRI4C(O)NR14R14~ -~14'''~~14)~14R14' -~R149 -SR14' -c{o)OR14' -C{O)~laRl4~ -S(O}zNR'°R14~ -p{O){OR'4}OR'4, -OP(O)(OR'4)OR'4, -NR'4C(O)Rls~
-S(O)R's, -S(O)zRls~ -C(O)R~s~ -ORIe' -SRIS~ _S{~)Rls~ _S(O)zRls~ _C{~}R16~ -C~~)OR,6~
_OC(O)Rle~ -yeRn~ _~p{O)Rls~ _N'R17C(O)ORl6r _C(O)NR~~Ray _S(O)z~leRn~
=NR"C{O)NR'6R" or -NR"C(NR")NR'6R", wherein R'4 at each occurrence independently is hydrogen, (Cl.~)alkyl or halo-substituted (C~_3)alkyl, R's is (C,.~)alkyl or halo-substituted (C,_3)alkyl, R'6 is {C3_,~cycloalkyl{C~)alkyl, hetero(C~.,z)eycloalkyl(C~)alkyl, (C~.,z)aryl(Co-b)alkyl, hetero(Cs_lz)aryl(C~)alkyl, (C9_lz}Polycycloaryl{C~)aIky1 or hetero(C8.lz)polycycloaryl(Co..b)alkyl and R" is hydrogen or (C,.~)aIkyl, and wherein within R'6 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected from -R'$, -XSOR'8, -XSSR'e, -XSS(O)R'$, -Xss(O)zRls~ _XsC{O}Rls~ -XsC{0)ORIS~ -XsdC(O)Rla~ _XsNRIaRo~ -X5~19C{O)Rls~
-XsNR'9C(O)OR'$, -XsC(O)NR'$R'9, -XsS(O)zNR'$R'9, -XsNR'9C{O)NR'8R'9 or _X5~19C~19)~1R18R19~ wherein Xs is as defined above, R'$ is hydrogen or (C,~)alkyl and R'9 is (C3.I~Zl)~c~~ycloalkyI(C~)alkyl, hetero(C3.,~cycloalkyl(C~)alkyl, (C6_l~aryl(C~)alkyl, hetero(Cs.,~ary1(Co.b)alkyl, (C~.,~polycycloaryl(C~)alkyl or hetero(C&,~polycycloaryl(Co-b)alkyl, or (ii) a group selected from (C3.,2)cycloalkyl(Co-6)alkyl;
hetero(Cs.,~cycIoalkyl(C~)alkyl, (Cb.,Z)aryl(C~.6)aIkyl, hetero(Cs,,~aryl(C~)alkyl, 4~.,~PaIYcYcloaryl(C~)aIkyl and hetero(C&,~polycycloaryl(C~)aIkyl, wherein said cycloalkyl;
heterocycloalkyl, aryl, heteroaryI, poIycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected from -R's, -XSOR'8, -XSSR's, -XSS(O)R'8, -XSS(O)2R's, _XsC(O}Rls~ _XsC{O}ORIS~ _XsOC{O}Rls~ _XsNRlaRis~ _XspsC(~)R~s' -Xsy 9C(O}OR~e~
_XsC(O)~laRls~ _XSS(O)2~I8RI9~ _~S~t9C(O}~18R19 or _X3~T9C~lS~~18R19~
wherein Xs, R's and R'9 are as defined above; wherein within R'' andlo\rl~Rl'~3 alny alicycIic or ~0 aromatic ring system present may be substituted further by 1 to 5 radicals'independently selected from (C,~)alkyl, (C~.~)alkyIidene, cyano, halo, halo-substituted (C,.')alkyl; vitro, _Xsy4R14~ _XsNRIaC(O)ORIa~ _Xs~~RIaC(O)NR14R14~ _Xs~laC~aa}yaR~a~ _XsORI'~
_XsSRn~ _XsC(O)ORIa~ -XSC(O)~14R14~ _XsS(o~yaRla~ _Xsp(O}(OR'')OR", -XSOP(O)(OR")OR'°, -XSNR''C(O)R's, -XsS{O}R's, -XsS{O)2Ris and -XSC(O)R's, wherein Xs, R" and R's~are as defined above, or R3 and R' taken together with the carbon atom to which both R3 and R' are attached form {C~s)cycloalkylene or (C~s)heterocycloalkylene, wherein said cycloalkylene or heterocycloaIkylene is optionally substituted with 1 to 3 radicals independently selected from (C,~)alkyl, (C,.~)alkylidene, cyano, halo, halo-substituted (C,~)aIkyl, vitro, -XSNR"C(O)OK'°, -XSNR'4C(O}NR'"R14~ _XsNRIaC~RIa)NR"Rv4~ _XsORIe~ _XsSRl4~ _XsC(O)oR~4~
_X3C(O}~14R1<~ _XSS(0)2~14R14' _Xsp(O)(OR'°)OR'°, -XsOP(O)(OR")OR", =XSNR'4C(O)R'3, -XSS(O}R's, -XSS{O)2R's and -XSC(O)R's, wherein Xs, R" and R'3 are as defined above;
R4 is hydrogen, (C,~)aIkyl or as defined above;
Rs is hydrogen and R6 is hydroxy or Rs and R6 together form oxo;
R' is a group selected from cyano, halo, vitro, -RZ9, -XSNR2'Rs°, -XSNR3oC(O)OR~, _X3~30C(Q)~29R30~ _XsNRaoC~R3o}~zgRso~ _Xs~R29~ _XSSR29~ _x5C(~)oR29~
_XsC(O}NR29Rr30~ _Xss(O)zNR~R3°~ 'Xsp(O)(OR3°}OR$9, -XSOP(O){OR29)ORz9, _X3~30C(O)R3', -XSS(O)R3', -XSS(O)ZR3' and -XSC(O)R3', wherein Xs is as defined above, R~ is hydrogen or -R3', R3° at each occurrence is hydrogen or (C,_6)alkyl and R3' is (C,~)alkyl, (C3.,2)cycloalkyl(C~)alkyl, hetero(C:3_,Z)cycloalkyl(C~.6)alkyl, (C~,~aryl(C~)alkyi or hetero(Cs_,~aryl(C~)alkyl, wherein within R' any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C~~)alkyl, (C,.~lkylidene, cyano, halo, halo-substituted (C~~)alkyl, vitro, -XSNR"R", -XsNR"C(O)OR'4, -XS~id'",{~)~14R145 -XsyaC(~~4)NR"Ry4~ _XsOR~e~ _XsSR~4~ _XsC(O)OR14~ .
-XsC{O)NR~4R~4~ _'x5s~(~)2NR1dRl4~ _Xsp(O)(OR'4)OR", -XsOP(O)(OR")OR", -XsNR'4C(O)R's; -XSS(O)R's, -XsS(O)aR's and -XsC(O)R's, wherein Xs, R" and R'f are as defined above; and Rs at each occurrence independently is selected from (C~~)alkyl, (Cl~alkylidene, cyano, halo, halo-substituted (C,~)aIkyl, vitro, -XSNR"R", -XsNR"C(O)OR", -XsNRI4C~o)~14R14~ _X5~14C~I4)~t4R14~ _XSORI4~ _XSSR14' _XSC(O)OR~4' ~,, _XsC(O)NR'4R~'' _XsS(O)ZW4R~4~ _XsP(OXOR'°)OR", -XSOP(O)(OR"'~OR'°, s~
-XsNR"C{O)R's, -XsS(O)R's, -XsS(O)2R's and -XsC(O)R's, wherein Xs, R" and R'$
are as defined above;
R9 is hydrogen or (C~.~)alkyl; and R3z is (C~_$)alkyl, (C3_~Z)cycloalkyl(C~)alkyl, hereto(C3.,2)cycloalkyl(C~)alky~, (C'.,z)aryl(C°.6)all~yl, hetero(C~12)aryl(C~)alkyl;
(C9.,2)polycycloaryl(C~alkyl or hereto(C8.,2)polycycloaryl(C0.6)alkyl, wherein within R3° any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Cu)alkyl, (Ca~,)alkylidene, cyano, halo, halo-substituted (C,~)alkyl, vitro, -XsNR'4R", _~sNR"C(O)OK'", -X5~14C(O)NR14Ri4~ -Xsy4C~i4)NR'4R'4,. _XsOR", -XsSR", -XsC(O)OR", -X5C{O)NR'4R'4, _XsS{O)2W4R~4' -Xsp(O)(OR")OR", -XSOP(O)(OR'')OR", -XsNR'4C(O)R's, -XsS{O)R's, -XsS(O)ZR's and -X$C(O)R's, wherein XS, R" and R's are as defined above; and the N oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and tha pharmaceutically acceptable salts thereof.
In another particular embodiment, the present invention relates to a pharmaceutical composition which contains a compound of Formula I or II, or a N oxide derivative, prodrug derivative, individual isomer or mixture of isomers, or a pharmaceutically acceptable salt thereof in admixture with one or more suitable excipients.
In another particular embodiment, the present invention relates to method of treating a disease in an animal in which inhibition of a cysteine protease can prevent;
inhibit or ameliorate the pathology andlor symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of compound of Formula I or II
or a N-a~cide derivative, prodrug derivative, individual isomer or mixture of isomers or a pharmaceutically acceptable salt thereof.
In another particular embodiment, the present invention relates to processes for preparing compounds of Formula I and II and the N-oxide derivatives, prodrug derivative, protected derivatives, individual isomers and mixtures of isomers, and the pharmaceutically acceptable salts thereof as set forth in "Detailed Description of the Invention°'.
In another particular embodiment, the present invention relates to protease inhibitors of Formula III:
Ra R5 Rsx2~,.N x1 R~
R3 ~ A

III
in which:
. A comprises a heteromonocyclic radical containing 5 to 6 annular atoms or a fused heteropolycyclic radical containing 8 to 14 annular atoms, wherein each ring contains 5 to ?
annular atoms, X' is an annular carbon atom and each annular atom other than X' optionally is a heteroatom, with the proviso that when A is a heteromonocyclic radical containing 5 annular atoms, no more than two of the annular atoms comprising the ring are heteroatoms;
X' is selected from =C- and -CH-;
Xz is a bond or a divalent group of Formula (a) or (b):

yNe~.X3-~ ~oN.X6.X~N~X~~X3~

(b) wherein:
X3 and XS independently are -C(O)- or -S{O)2-, X' is -CI-IR"-, -CHZCHR"- or -CHR"CHZ- and X6 is -CHR'Z-, -CHZCHR'Z-or -CHR''-CH2- wherein:
R" and R'~ are independently (i) (Cs_6)alkyl or halo-substituted(C,~)aIkyl optionally substituted with -OR'3, -SR", -S(O)R'3, -S{~)2Ri3, _C(~)R13, -C{~)~R13, _~13R14, -~14C((~)OR13, -C{O)NR'3R14, '${~)2~13R14~ _NRIaC(O)~13R14 or -~14C~R14)NR'3R14, wherein R13 is hydrogen, (C1~)alkyl, (C~.l~cycloalkyl(C~3)alkYl, hetero(C3.ycYcloaikyl(Co.a)alkyl. (C~.12)aryl(Co-3)alkyl or hetero(Cs.l~aryl(Co-3)alkyl and R'4 is hydrogen or (C,.~)aIkyl, or (ii) (C3_y2)cycloalkyl(C°.3)alkyl, hetero(C~12)cyeloalkyl(Ca3)alkyl, (C6lz)aryl{C°.3)alkyl, hetero(Cs.,z)aryl(Co-3lalkyl, {C~12)PolYcycloaryl(C°.3)alkYl or hetero(C&12)polycycloaryl(C°.3)alkyl optionally substituted with -R's, -X70R1s, _x~SRls~ _S(O)Rls, _S(O)2R~s~ -C{O)Ru, -C{O)OR's, -X'NR'sRls, 70 -X'NR'bC(O)OR's, -C(O)NR'sR'6: -S{C?)=NR'sRl6, _NRISC{O)NR'sRle or -NR'bC(NR'6)NR'sR'b, wherein X' is a bond or methylene, R's is (C3.12)cycloalkyl(C°.3)alkyl, hetera(C3.l~cycloalkyl(Co-3)alkyl, (C~.lz)aryl(C°.3)alkyl, hetero(Cs_12)aryl(C~3)alkyl, (C~~2)polycycloaryl(Ca3)alkyl or hetero(C8.1?)polycycloaryl(C°.3)aIkyl and R'6 is hydrogen or (C,,°)alkyl, or (iii) together with R9 or R'° , respectively, when X4 is -CHR"- andlor X6 is -CHR'2-, forms trimethylene, tetramethylene or phenylene-1,2-dimethylene, optionally substituted with hydroxy or oxo; wherein any 1 to 3 annular atoms of any aromatic ring with available valences comprising R" andlor R'2 are optionally independently substituted with halo, vitro, cyano, (C1.~)alkyl, halo-substituted(C1.~)alkyl, -OR", -C(O}R", -C(0}OR", -C(O)NR"R", 'S(~)2~17Ri?, _X~NR17R1', -X'NR"C(O)OR", -X'NR"C(O)NK"R'a or -X'NR"C(NR")NR"R", wherein X' is as defned above and each R"
independently is hydrogen or {C1.°)aIkyI; and R' and R'° are independently hydrogen, (C~.S)alkyl or as defined above;
R' is hydrogen or -X$X9R'$, wherein X8 is -C(O)- or -S(O)2-, X9 is a bond, -O-or -NR'9-, wherein R'9 is hydrogen or (C~.~)alkyl, and R'$ is {i) (Cx~)alkyl or halo-substituted(C1.~)alkyl optionally substituted with -OR'3, -SR'3, -S(O)R'3, -S{O)ZR'3, _C(O)R73~ -C(O)OR13, _~13R14i -~14C(o)~R13, _~(O)~7~13R14, _s{~)2~13R14, -NR'4C(O)NR'3R'4 or -NR'4C(NR'4)NR13R14~ wherein R'3 and R'4 are as defined above, or (ii) (Cs.l~cycloalkyl(C°.6)alkyl, hetero(C~t~cycloalkyl(C~)alkyl, (C~12)aryl(C~)alkyl, diphenyl{C~)alkyl, lletero(Cs.l~ary1(C~)alkyl, dihetero(C~)aryl(C~)alkyl, (C9.,2)polycycloaryl(C~)alkyl or hetero(C&12)polycycloaryl(C~)alkyl optionally substituted with -Rls~ _X~OR~s~ -X7SR's, -S(O)R1s' _S(~~)zRis~ _C(O)Ris~ -C(O)ORus _XysRm~
-X7~76C(O)OR15~ ,~(O)NR'sRie~ -S{~)zNR'sR~s~ -yeC{~)~15R16 or -~16C~16)~75R96~ wherein X', R's and R'6 are as defined above; wherein any 1 to 3 annularlja~tlo~ms of any aromatic ring with available valences comprising R' optionally independently are substituted with halo, vitro, cyano, (C,.~)alkyl, halo-subsdtuted(C,.,~alkyl, -OR", -C(O)Rn, -C(O)OR», -C(O)NR"R", -S(O)2NR17R1?~ -1781?~
-X'NR"C(O)OK", -X'NR"C(O)NR"R" or -X'NR"C(NR")NR"R", wherein X' aad R"
are as defined above;
Rz is hydrogen or (C,~)alkyl;
R3 is phenyl(Cz_3)alkyl, hetero(Cs_6)aryl(Cz.3)alkyl, (Cs.~)cycloalkyl(Cz_3)alkyl oa~
hetero(Cs.~)cycloalkyl(Cz_3)alkyl, wherein any 1 to 3 annular atoms of any aromatic rgng with available valences comprising R~ optionally independently are substituted with halo, vitro, cyano, (C,_6)alkyl, halo-substituted(C,.~)alkyl, -OR", -C(O)R", -C(O)OR", -C{O)NR"R", -S{O)zNR"Rm~ _X7NRnR17~ -X7~17C{O)ORn~ -X7y7C{O)NRl7Rn oa -X'NR"C(NR")NR"R", wherein X' and R" are as defined above, and R° is hydrogen or R3 and R4 are both methyl, ethyl or propyl or together with the carbon atom to which both R3 and R4 are attached form cyclopropylene, cyclobutylene or cyclopentylene;
Rs is hydrogen and Rd is hydroxy or Rs and Rs together form oxo;
R' is halo, vitro, -Rz°, -ORz°, -C(O)Rz", -C(O)ORz°, -S{O)zNRz°Rz', -C{O)NRz°Rz' or -C{O)NRnCHRz3C(O)ORz° and bonded to any annular carbon atom with a free valence comprising A, wherein:
Rz° is hydrogen or R'$, wherein R's is as defined above;
RZ' is hydrogen or (C,~)alkyl;
R'~ is hydrogen, (C,_~aIkyl or together with R~ forms ttimethylene o~
phenylene-1,2-dimethylene, optionally substituted with hydroxy or oxo; and R~ is as defined above or is (i) (C,.~)alkyl or halo-substituted(C,.~alkyl optionally substituted with -OR'3, -SR'3, -S(O)R'3, -S(~)zR'3, -C{O)R'3, -C(O)OR''s, _NRisR~a~ -~laC{O)~Rn~ _C{O)NR'3R~a~ -S(O)-~y3R14~ -~14C{O)NRt3Rt< or -NR'°C(NR'°)NR'3R'a, wherein R'3 and R'4 are as defined above, or (ii) (C~.,°)cycloalkyl{Co-3)alkyl, hetero(C~,°)cycloalkyl{C~3)alkyl, (C~,z)aryI(Co-3)alkyl, hetero(C~sz)aryl(Co-g)alkYl, (C9.,z)PolYcYclaaryl(C0.3)alkyl or hetero(C~~a)polycycloaryl(C~,3)alkyl optionally substituted with -R's, -X'OR's, -X'SR's, -s(o)Rrs~ -g(p)zRis~ -C(p)Ris ~(p)OR's, -X?1VR95R16~ _x~aaC(~)~Ris~
_C(p)NR~sR~a~ _s(p)zNR'sR~a~ _yaC(O)ysR~a or _~laC(NRl6)~ISR16~
wherein X', R's and R'a are as defined above; wherein any 1 to 3 annular atoms of any aromatic ring with available valences comprising R~° and/or Rz' optionally independently are substituted with halo, vitro, cyano, (C,~)alkyl, halo-substituted(C,,~)alkyl, -OR's, -C(O)R", -C(O)OR", -C(~)NR"R", _S(O)iNRnRn. _~'NRnR'?, -XfiTR"C(O)OR", -X'NR"C(~)NR"R" OT -X71~R17C(~17)~1TR17s wherein X' and R" are as defined above; and R8 is hydrogen, halo, hydroxy; formyl, carboxy, carbamoyl, sulfamoyl or (C~,~)alkyl and bonded io any annular carbon atom with a free valence comprising A; and tlae N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.

Definitions:
Unless otherwise stated, the falIowing terms used in the specification and claims are defined for the purposes of this Application and have the meanings given this Section:
"Alicyclic" means a moiety characterized by arrangement of the carbon atoms in closed non-aromatic ring structures having properties resembling those of aIiphatics and may be saturated or partially unsaturated with two or more double or triple bonds.
"Aliphatic" means a moiety characterized by straight ar branched chain arrangement of the constituent carbon atoms and may be saturated or partially unsaturated with two or more double or triple bonds.
"Alkenyl" means alkyl, as defined in this Application, provided that the radical is comprised of at least one double band. Hence, optionally substituted (Ci~,)alkenyl as used in this Application to define R32 includes 2-bromovinyl (-CH~HBr), buts-1,3-dienyl (-CHCH-CH~Hz), 2-chioro-I-methylpropenyl (-C(CH3~C1-CH3), 2-chlorovinyl (-CH~HCI), 4-isopropenyl (-C(CH3~CH~, 1-methylpropenyl (-C(CH3}CH-CH3), 2-methylpropenyl (-CH~(CH3)2), 2-nitrovinyl (-CH~HNO=), propenyl (-CH~H-CH3), 2-trifluoromethylvinyl (-CH:CH-CF3), trifluorovinyl (-CF~F2), vinyl (-CH~H2), and the like).
"Alkoxy" means the radical -OR, wherein R is alkyl as defined in this Application, having the number of carbon atoms indicated (e.g:, (C,~)alkoxy includes the radicals methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoXy, isobutoxy, tart-butoxy, vinyloxy, allyloxy, 1-propenyloxy, isopropenyloxy, I-butenyloxy, 2-butenyloxy, 3-butenyloxy, 2-methylallyloxy, ethynyloxy, 1-propynyloxy, 2-propynyloxy, and the like).
"AlkyD" represented by itself means a straight or branched, saturated or unsaturated, aliphatic radical having the number of carbon atoms indicated (e.g. (C,~)alkyl includes methyl, ethyl, propyl, isopropyl, butyl, see-butyl, isobutyl, ten-butyl, vinyl, allyl, 1-propenyl, isopropenyl, J I-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like).
Alkyl represented along with another radical (e.g, as in arylalkyl) means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g. (Ce,l~laryl(C~.6)alkyl includes phenyl, benzyl, phenethyl, I-phenylethyl 3-phenylpropyl, and the Iike).
"Alkylene", unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical having the number of carbon atoms indicated (e.g.
(C~~)alkylene includes methylene (-CH2-), ethylene (-CHiCH2-), trimethylene (-CH2CHiCH2-), 2-methyltrimethylene (-CH2CH(CH3}CHa-), tetramethylene (-CH2CHzCH2CH2-), 2-butenylene (-CH2CH=CHCH2-), 2-methyltetramethylene (-CHZCH(CH3)CH~CHz-), pentamethylene 0 (-CH2CHZCHZCH2CH2-) and the like). Far example: » group of Formula (a), wherein R" is hydrogen and R'2 taken together with R' forms optionally substituted trimethylene is depicted by the following illustration:
R-RI
in which R is an optional hydroxy or oxo group and X3 and R' are as defined in the Summary of 5 the Invention for Formulae I and Il.
"AIkyIidene" means a straight or branched saturated or unsaturaeed, aliphatic, divalent radical having the number of carbon atoms indicated (e.g. (C~~)alkylidene includes methylene (~HZ), ethylidene (:CHCH3), isopropylidene (:C(CH3)2), propylidene (:CHCHZCH3), allylidene (~iCH~H~, and the like).
"Amino" means the radical -NHZ. Unless indicated otherwise, Lhe comgounds of the invention containing amino moieties include protected derivatives thereof.
Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.
"Animal" includes humans, non-human mammals (e.g. dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, or the like) and non-mammals (e.g. birds, or the tike).
"Aryl" means a monocyclic or bicyclic ring assembly (fused or linked by a single bond) containing the total number of ring carbon atoms indicated, wherein each ring is comprised of 6 ring carbon atoms and is aromatic or when fused with a second ring forms an aromatic ring i 0 assembly. For example,(C~~z)aryl as used in this Application to define R' includes phenyl, naphthyl and biphenylyl.
"Aromatic" means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp2 hybridized and the total number of pi electrons is equal to 4n + 2.
"Carbamoyl" means the radical -C(O)NH2. Unless indicated otherwise, the compounds of the invention containing carbamoyl moieties include protected derivatives thereof. Suitable protecting groups for carbamoyl moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like and both the unprotected and protected derivatives fall within the scope of the invention.
"Carboxy" means the radical -C(O)OH. Unless indicated otherwise, the compounds of the invention containing carboxy moieties include protected derivatives thereof. Suitable protecting groups for carboxy moieties include benzyl, tent-butyl, and the like. For example; a compound of Formula I wherein R' contains a carboxy moiety may exist as either the unprotected or a protected derivative, e.g. wherein R' is methoxycarbonyl, and both the unprotected and protected derivatives fall within the scope of the invention.
.
"CycloaIkyl" means a saturated or partially unsaturated, monocyclic ring, bicyclic ring assembly (directly linked by a single bond or fused) or bridged polycyclic ring assembly containing the number of ring member carbon atoms indicated, and any carbocyclic ketone, thioketone or iniinoketone derivative thereof (e.g. (C3.l~cycIoalkyl includes cyclopropyl;
cyclobutyi, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclohexylyl, cyclopentylcyclohexyl, bicyclo[2.2.2~octyl, adamantan-1-yl, decahydronaphthalenyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo~2.2.Ijhept-1-yI, and the like).

"Cycloalkylene" means a saturated or partially unsaturated, monocyclic ring os bridged polycyclic ring assembly containing the number of annular carbon atoms indicated, and any carbocyclic ketone, thioketone or iminoketone derivative thereof. For example, the instance wherein R' and R4 together with the carbon atom to which both R~ and R4 are attached form (C~cycloalkylene" includes, but is not limited to, the following:

~/N ~ ~/N
in which R2, Rs and R6 are as defined in the Summary of the Invention, and any substituted derivative thereof.
"Disease" specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition which may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the "side effects" of such therapy.
"Fused heteropolycyclic ring system" means a saturated, partially saturated or aromatic moiety containing two or more rings, wherein at least two ring member atoms of one ring are common to a second ring containing the number of ring member atoms indicated in which at least one of the ring member atoms is a heteroatom and any carbocyclic ketone, thioketone, iminoketone or substituted derivative thereof . For example, the term "a fused heteropolycyclic radical containing 8 to 14 ring member atoms" as used in this Application to define A may include acridinyl, benzofuryl, benzooxazolyl, benzothiazolyl, carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, indazolyl, indolinyl, indolyl, indoIizinyl, isobenzofuryl, isochromenyl;
isochromanyl, isoindolinyl, isoquinolyl, naphthyridinyl, perimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyI, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolizinyl, quinazolinyl, quinolizinyl, quinolyl, quinoxalinyl, quinuclidinyl, xanthenyl, and the like.
"Guanidino" means the radical -NHC(NH)NHz. YJnless indicated otherwise, the compounds of the invention containing guanidino moieties include protected derivatives thereof.
Suitable protecting groups for aminA moieties include acetyl, rert-butoxycarbonyl, benzyloxycarbonyl, and the like and both the unprotected and protected derivatives fall within the scope of the invention.
"Halo" means fluoro, chloro, bromo or iodo.
"Halo-substituted alkyl", as a ,group or part of a group, means "alkyl"
substituted by one or more "halo" atoms, as such terms are defined in this Application. Halo-substituted alkyl ' includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g.
halo-substituted (C~.3)alkyl includes chloromethyl, dicloromethyl, difluoromethyl, trifluromethyl, 2,2,2-trifluoroethyl, pexfluoroethyl, 2,2.,2-trifluoro-i,l-dichloroethyl, and the like).
"Heteroaryl" means aryl, as defined herein, provided that one or more of the ring member carbon atoms indicated, is replaced by heteroatom moiety selected from -N-, -NR-, -O- or -S-, wherein R is hydrogen. (C,.~)alkyl or a protecting group, and each ring contained therein is comprised of 5 to 6 ring member atoms. For example, hetero(C~12)aryl as used in this Application includes benzofuryl, benzooxazolyl, benzothiazolyl, [2,4']bipyridinylyl, carbazolyl, carbolinyl, chromenyl, cinnolinyl, furazanyl, furyl, imidazolyl, indazolyl, indolyl, indolizinyl, isobenzofuryl, isochromenyl, isoaxazolyl, isoquinolyl, isothiazolyl, naphthyridinyl, oxazolyl, perimidinyl, 2-phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyradazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolizinyl, pyrrolidinyl, pyrrolyl, pyranyl, quinazolinyl, quinoIizinyl, quinolyl, quinoxalinyl, tetrazolyl, thiazolyl, 4-thiazol-4-ylphenyl, thienyl, xanthenyl, and the like.
"Heteroatom moiety" includes -N:, -NR-, -O-, -S- or -S(O)2-, wherein R is hydrogen, (C~.~)alkyl or a protecting group.
"Heterocycloalkyl" means cycloalkyl, as defined herein, provided that one or more of the ring member carbon atoms indicated is replaced by heteroatom moiety selected from -N:, -NR-, -O- or -S-, wherein R is hydrogen, (C,.~)alkyl or a protecting group, and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g. the term hetero(CS_~~cycloalkyl includes [1,4']bipiperidinylyl, dihydrooxazolyl, morpholinyl, 1-morpholin-4-ylpiperidinyl, piperazinyl, piperidyl, pirazolidinyl, pirazolinyl, pyrrolinyl, pyrrolidinyl, quinuclidinyl, and the Iike).
Suitable protecting groups include tert-butoxycarbonyl, benzyioxycarbonyD, benzyl, 4-methoxybenzyl, 2-riitrobenzyl, and the dike. For example, a compound of Formula I wherein R' is piperidin-4-ylcarbonyl may exist as either the unprotected or a protected derivative, e.g.
wherein R' is 1-tert-butoxycaxbonylpiperidin-4-ylcarbonyl, and both the unprotected and 3o protected derivatives fall within the scope of the invention.
"Heterocycloalkylene" means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms indicated, is replaced by heteroatom moiety selected from -N;, -NR-, -O-, -S- or -S(O)2-, wherein R is hydrogen or (C,.~)alkyl. For example, the instance wherein R3 and Ra together with the carbon atom to which both R' and R" are attached form hetero(C~.$)cycloalkylene" includes, but is not limited to, the following:
R2 R5 R6 ~ r R2 R5 R6 N N
w N
R
in which R is hydrogen, (C,.~)alkyl or a protecting group and R2 is as defined in the Summary of the Invention, and any substituted derivative thereof.
"Heteromonocyclic" means a saturated, partially saturated or aromatic monocyclic radical containing the number of ring member atoms indicated in which at Ieast one of the ring member atoms is a heteroatom and any carbocyclic ketone, thioketone, iminoketone or substituted derivative thereof. For example, the term "a heteromonocyclic containing 5 to 6 ring member atoms" as used in this Application to define A may include dihydrooxazolyl, furazanyl, furyl, imidazolyl, imidazolidinyl, imidazolinyl, isooxazoIyl, isothiazolyl, thiazolyl, thienyl, morpholinyl, oxazolyl, piperazinyl, piperidinyl, pirazolidinyl, pirazolinyl, pyranyl, pyrazinyl, pyradazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrazolyl, and the like.
75 "Heteropoiycycloaryl" :mans potycycloaryl, as defined herein, except one or more of the ring member carbon atoms indicated are replaced by a heteroatom moiety selected from -N:, -NR-, -O- or -S-, wherein R is hydrogen, (C,~)alkyl or a protecting group, and any carbocyclic ketone, thioketone or iminoketone derivative thereof.. For example, hetero(C~l~polycycloaryl includes 1',2'-dihydro-2H-[1,4']bipyridinylyl, chromanyl, imidazolinyl, indolinyl, isochromanyl, isoindolinyl, and the Iike.
"Hydroxy" means the radical -OH. Unless indicated otherwise, the compounds of the invention containing hydroxy radicals include protected derivatives thereof:
Suitable protecting groups for hydroxy moieties include benzyl and the like and both the unprotected and protected derivatives fall within the scope of the invention:
"Iminoketone derivative" means a derivative containing the moiety -C(NR)-, wherein R
is hydrogen or (C,,~)alkyl.

"Isomers" mean compounds of Formula I having identical molecular formulae but differ in the nature or sequence,of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and stereoisomers that are nonsupetimposable mirror images are termed "enantiomers" or sometimes "optical isomers". A carbon atom bonded to four nonidentical substituents is termed a "chiral center". A compound with one chiral center has two enantiomeric forms of opposite chirality is. termed a "racemic mixture". A
compound that has more than one chiraI center has 2"'' enantiomeric pairs, where n is the number of chiral centers.
Compoards with more than one chiral center may exist as ether an indiviiiual diastereomer or as a mixture of diastereomers, termed a "diastereomeric mixture". When one chiral center is present a stereoisomer may be characterized by the absolute configuration of that chiral; center.
Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and I'relog.
Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g. see "Advanced Organic Chemistry", 3rd edition, March, Jerry, John Wiley & Sons, New Yark, 1985). It is understood that the names and illustration used in this Application to describe compounds of Formula I are meant to be encompassed all possible stereoisomers arid any mixture, racemic or otherwise, thereof.
"Ketone derivative" means a derivative containing the moiety -C(O)-.
"Nitro" means the radical -NOz.
"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs arid instances in which it does not. For example, the phrase "(C~.~)alkyl optionally substituted with cyano, halo, vitro," means that the alkyl group referred to may or may not be substituted in order to fall within the scope of the invention.
"Oxalo" means the radical -C(O)C(O)OH.
"N-oxide derivatives" means a derivatives of compound of Formula I in which nitrogens are in an oxidized state (i.e., O-N) and which possess the desired pharmacological activity.
"Oxo" means the radical=O.
-2b-"Pathology" of a disease means the essential nature, causes and development of the disease as well as the structural and functional changes that result from the disease processes:
"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor . otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
"Pharrrlaceutically acceptable salts" means salts of compounds of Formula I
which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric t0 acid, hydrobrornic acid, sulfuric acid, nitric acid, pnosphuric acid, and the like; of with organic acids such as'acetic acid, propionie acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid; malonic acid, succinic acid, malic acid, malefic acid;
fumaric acid; tartatic acid, citric acid, benzoic acid; o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, madelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2Joct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-inethylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like.
Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic ox organic bases.
Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, ammonium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanoIamine, tromethamine, N
methylglucatnine and the like.
"Phenylene-1,2-dimethylene" means the divalent radical -CIi2C6H4CHz-, wherein the methylene moieties are attached at the 1- and 2-positions of the phenylene moiety. For example, a group of Formula (a) in which R'2 together with R9 forms optionally substituted phenylene-1;2-dimethylene is illustrated by the following formula:
-2'7-in which R is an optional hydroxy group and X3 and R' are as defined in the Summary. of the , Invention for Formulae I and Il.
"Polycycloaryl" means a bicyclic ring assembly (directly linked by a single bond or fused) containing the number of ring member carbon atoms indicated, wherein at least ane, bui not all, of the fused rings comprising the radical is aromatic, and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g. (Cø~2~olycycloaryl includes indanyl, indenyl, 1,2,3,4-tetrahydronaphthalenyl, I,2-dihydronaphthalenyl, cyclohexylphenyl, phenylcyclohexyl, 2,4-dioxo-l,2,3,4-tetrahydronaphthalenyl, and the like):
"Prodrug" means a compound which is convertible in vivo by metabolic means (e.g.
by hydxolysis) to a compound of Formula ()7. For example an ester of a compound of formula (I) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule. Alternatively an ester of a compound of Formula (I~ containing a carboxy group may be convertible by i5 hydrolysis in vivo to t!te parent molectlte. Suitable esters of compounds of Formula (I) containing a hydroxy group, are for example acetates, citrates, lactates;
tartrates, malonates;
oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-tolue~esulphonates, cyclohexylsulphamates and quinates. Suitable esters of compounds of Formula (I) containing a carboxy group, are for example those described by F.J.Leinweber, Drug Metab.
Res., 1987, 18, page 379. An especially useful class of esters of compounds of Formula (>) containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. aL, J. Med. Chem., 1989, 32 , page 2503-2507, and include substituted (aminomethyl}-benzoates, for example, dialkylamino-methylbenzoates in which the two alkyl -28_ groups may be joined together andlor interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yI)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates. A pro~lrug derivative of a compound of Formula I wherein R3 and R6 together are oxo is depicted by the following formula:
x13 r'~ O~

R X2,.~h1 Xl R7 R. ~~ RS
( )n in which X13 is a bond, straight, saturated ethylene or (-CHZCR"R$ZCPI2-), wherein R°' and R42 independently are hydrogen, halo or (C~_3)alkyl or taken together form methylene.
"Protected derivatives" means derivatives of compounds of Formula I in which a , reactive site or sites are blocked with protecting groups. Protected derivatives of compounds of Formula I are useful in the preparation of compounds of Formula I or in themselves may be active cysteine protease inhibitors. For example, the compound of Formula I
which is 2S-amino-N-(2-benzooxazol-2-yl-2-hydroxy-1S-phenethylethyl)-3-cyclohexylpropionamide (i.e., 1 b Compound 55, described in Example 6, infra) may be protected with a suitable amino protecting group, e.g. 9H-fluoren-9-ylmethoxycarbonyl, or a suitable hydroxy protecting group, e.g. reit-butyldimethylsilanyl, to provide, respectively, 9H-fluoren-9-yimethyl 1S-(2-benzooxazol-2-y1-2-hydroxy-1S-phenethylethylcarbamoyl)-2-cyclohexylethylcarbamate (i.e., Compound 51, described in Example 4, infra) and ~S-amino-N [2-benzooxazol-2-yl-2-(rerr-butyldimethylsiianyloxy)-1S-phenethylethyll-3-cyclohexylpropionamide (i.e., Compound S6, described in Example 7, infra). A comprehensive list of suitable protecting groups can be found in T.W. Greene, Protecting Groups in Organic Synthesis, John ~7Viley &
Sons, Inc.
1981.
"Ring member", as in fused heteropolycyclic ring system containing 8 to 14 ring member atoms, means that the atoms referred to are ring members of the fused heteropolycyclic radical, but not taking into account ring members of any substituents present.
Thus, for example, a heteropolycyclic radical containing 8 ring member atoms includes benzooxaxol-2-yl, benzofur-2-yl, 1H-indol-5-yl, benzothiazol-2-yl, and the like.
"Sulfamoyl" means the radical -S(O)2Nfi2. Unless indicated otherwise, the compounds of the invention containing sulfamoyl radicals include protected derivatives thereof. Suitable protecting groups for sulfamoyl radicals include acetyl, rert-butoxycarbonyl, benzyloxycarbonyl, and the like and both the unprotected and protected derivatives fall within the scope of the invention.
"Therapeutically effective amount" means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.
"Thioketone derivative" means a derivative containing the moiety -C(S)-.
"Treatment" or "treating" means any administration of a compaurid of the p~eszrn"
invention and includes:
(1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease, (2) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatoiogy of the diseased {i.e., arresting further development of the pathology and/or symptomatology), or {3) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology).
Specific Embodiments or the Invention:
Vdhile the broadest definition of the invention is set forth in the Summary of the Invention, certain aspects of the invention are preferred. A preferred aspect of the invention are compounds of Formula I in which X' is =C-. In particular, the heteromonocyclic ring or fused heteropolycyclic ring system A is selected from 4,5-dihydrooxazol-2-yl, benzooxazol-2-yl, benzoihiazol-2-yl and oxazol-2-yl, each substituted by a group R' and optionally substituted with a group R8, particularly wherein R' is hydrogen, halo, (C~,~alkoxy, (Cc~)alkoxycarbonyl, vitro or phenyl and R$ at each occurrence independently is halo, (C,~,)alkoxy, (C,.~alkoxycarbonyl, vitro or trifluoromethyl. The ring system A preferably is benzoxazoI-2-yI
substituted by a group R' and optionally substituted with a group R8, parricularly wherein R' i's hydrogen, halo, (C,~)alkoxy, (C,~)alkoxycarbonyl or vitro and R$ at each occurrence independently is halo, (C,.,)alkoxy, {C,.~alkoxycarbonyl, vitro or trifluoromethyl.
X~ particularly represents a bond or a divalent~group of Formula (a);
particularly, wherein within Formula (a) X3 is -C{Or; R9 represents hydrogen, R" represents hydrogen or methyl, typically hydrogen, and R'Z particularly represents (i) {C,.~)aikyl substituted with -SR'°, -S(O)R'° or -S(O~R''', wherein R'° is (C~.i~aryl(C~,)alkyl or hetero(Cs.,2)aryl(C~alkyl or (ii) (C~l~cycloalkyl(C~alkyl or (C~.,2)aryl(C~)alkyl; wherein within R'2 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C,~)alkyl, (C,,~)alkylidene, cyano~ halo, halo-substituted (C,~alkyl, nitro, _XsNR~aRta~ _X5~14C(~)ORi4~ _X5~14C(O)~14R14~ -XSNRI4C~Rt4)NR'4R14~ _X5~R14~
_XsSRio~ _XsC(O)pR~a~ _XsC(O)NR~aR~4' _XsS(O)a~nRae~ -Xsp(C)(ORra)OR", -XSOP(O)(OR'°)OR'4, -XsNR'°C(O)R'$, -XsS(O)R's, -XsS(O)ZR's and -XsC(O)R's, wherein Xs is a bond or (C,.~)alkylene, R'4 at each occurrence independently is hyi3rogen; {C,.~)alkyl or halo-substituted {Cy-3)alkyl and R's is .(C,.~)alkyl or halo-substituted (C,_s)alkyl.
Further preferred, within Formula (a), R'~ particularly represents a group having the following formula:
in which q is 0, 1, 2, 4 or 5 and R33 at each occurrence independently is selected from a group consisting of (C,~)alkyl, cyano, halo, halo-substituted (C,,~)alkyl, nitro, -XsNR"R'4, -XSOR", _xsSRve~ -XSC(O)~14R14y -XsC(O)OR~e~ _XsS(O)Ris~ _Xss(O)zR~s and -XSC(O)R'S, wherein Xs is a bond or {C,.~)alkylene, R'4 at each occurrence independently is hydrogen, (C,-3)alkyl or halasubstituted (C,-3)alkyl and R's is (C,_3)alkyl or halo-substituted (C,_3)alkyl; more particularly in which q is 0, I or 2 and R33 at each occurrence independently is selected from a group consisting of (C,~)alkyl, cyano, halo, halo-substituted (C,~,)alkyl, vitro,'-OR'4, -SR" and -C(O)OR'4, wherein R'a independently is hydrogen, (C,_3)alkyl or halo-substituted (C,_3)alkyl;
more particularly in which R33 at each occurrence independently is selected from a group consisting of {C,.~)aIkyI, bromo, carboxy, chloro, cyano, difluoromethoxy, fluoro, iodo, methoxy, vitro, trifluoromethoxy, trifluoromethyl and trifluorosulfanyl Further preferred, within Formula (a), R'2 particularly represents benzylsulfonylmethyl, 2-chlorobenzylsulfonyhwethyl, ~-cyanobenzylsulfonylmethyl, 2-difluoromethoxybenzylsulfonylmethyl, 3,5-dimethylisooxazol-~-ylmethylsulfonylmethyl, 2-methoxybenzylsuifonylmethyl, 4-methylpyrid-2-ylmethyIsulfonylmethyl, 2-nitrobenzylsulfonyhnethyl, pyrid-2-ylmethylsulfonyImethyl, o-tolylmethylsulfonylmethyl or 2-trifluoromethylbenzylsulfonylmethyl.
R' particularly represents -X6X'Rz°, wherein X6 is -C(O~ or -S(O)z-, X'.is a bond, -O-or -NRZ'-, wherein R2' is hydrogen ar (Cl~)alkyl, and R~° is (i) (C,~)alkyl optionally substituted by -C(O)OR'° or (ii) (C~~~}cycloalkyl(C~)alkyl, hetero(C3_,~cycloalkyl(C~)alkyl, (C~,Z)aryl(C~)alkyl or hetero(Cs.l2)aryl(Co..b)alkyl or (iii) (C3,~cycloalkyl(C;~)alkyl, hetero(C~,.~)cycloaIkyl(C~.6)alkyl, phenyl(C~)alkyl or hetero(C~)aryl(C~)alkyl, wherein said 1U cycloalkyl, heterocycloalkyl, phenyl or heteroaryl ring is substituted by -X50R~°; XSC(O)R~', .
-XSC(O)OR~, -X5C(O)NRZ'R~, -XSNR~'R~, -X5NR25C(O)R~', -XsNR'~C(O)OR~, ' -XsNR'~C(O)NR~'R~ or -XSNRZSC(NR'~)NRZ°R'~, wherein XS is a bond or (C,~)alkylene, R?~
is (C3.~)cycloalkyl(C~}alkyl, hetero(C~)cycloalkyl(C~)alkyl; phenyl(C~)alkyl or hetero(C~)aryl(Co.,6)alkyl and R~ is hydrogen or (C~~)alkyl; wherein within R' any alicyclic or aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (C~~alkyl, halo, halo-substituted (C~~)alkyI, -OR'4 and -C(O)OR'° wherein R'4 is hydrogen or (C»)alkyl, or when X'- is a divalent group of formula (a} then R' may be, but is not limited to, hydrogen or oxalo.
R' preferably is a group selected from acetyl, azetidin-3-ylcarbonyI, benzyloxycarbonyl, 2d 1-benzyloxycarbonylpiperidin-4-ylcarbonyl, benzylsuifonyl, bicyclo[2.2.2]hept-2-ylcarbonyl, bicyclo[2.2.1]hept-2-ylcarbonyl, tart-butoxycarbonyl, carboxyace3yl, 2-carboxyprogionyl, 3-carboxypropionyl, 2-cyclohexylacetyl, 4-cyclohexyibutyryl, 2-cyclohexylethylsulfonyl, cyclohexylmethoxycarbonyl, 3-cyclohexylpropionyl, 2-cyclopentylethylsulfonyl, 3-cyclopentylpropionyl, di(2-methoxyethyl)carbamoyl, dimethylcarbamoyl, 6-hydroxypyrid-3-ylcarbonyl,1H-imidazol-4-ylcarbonyl, iriethoxycarbonyl, methylsnlfonyl, 4-methylvaleryl, morpholin-4-ylcarbonyl, 2-rnorpholin-4-ylethylcarbonyl, naphth-1-ylacetyl, naphth-1-ylmethylcarbonyl, oxalo, 3-phenylpropionyl, piperazim-I-ylcarbonyl, piperidin-4-ylcarbonyl, pyrazin-2-ylcarbonyl, pyrid-3-yIcarbonyl, pyrid-4-ylcarbonyl, pyrid-3-ylaminocarbonyi, tetrahydropyran-4-ylcarbonyl and tetrahydropyran-4-yloxycarbonyl, R' especially represents morpholin-4-ylcarbonyl, methoxycarbonyl, methylsulfonyl;
piperidin-4-ylcarbonyl, pyrazin-2-ylcarbonyl pyrid-3-ylcarbonyl, pyrid-4-yIcarbonyl, tetrahydropyran-4-ylcarbonyl or tetrahydropyran-4-yloxycarbonyl.

RZ typically is hydrogen.
R3 particularly represents hydrogen, (C,~alkyl (optionally substituted with cyano, halo, vitro, -SRS, -C(O)ORS, -C(O)NR'~Rz6, -P(O)(OR~)OR~, -OP(O)(OR~)OR~, -S(O)RB', -S(O)2R~' or -C(O)RZ', wherein R~ at each occurrence independently is hydrogen, (C,~)alkyl, or halo-substituted (C~.3)alkyl and R~' is {C,.~alkyl or halo-substituted (C,.3)alkyl) or (C~.12)aryl(C~_3)aIkyl, wherein said aryl optionally is substituted further with 1 to 5 radicals independently selected from (C~,~)alkyl, (C,.~)alkylidene, cyano, halo, halo-substituted {G,~)alkYl, intro, -XsNR"C(0)OR'", -XsNR'°C(~)NR~aRt4, -XsNRI4C(NRI4)~tbRl4~
-xsOR~a~ -XsSR~a~ -XsC(O)OR~4~ -XsC(O)y aR~a~ -XsS(O)2y aR~a~ -Xsp(O)(OR'~)OR'4, -XSOP(O)(OR")OR'°, -XsNR'4C(0)R's, -XsS(0)R's, -XsS(0)zR's and ~XsC{0)Rt', wherein Xs is a bond or (C~~)alkylene, R'4 at each occurrence independently is hydrogen, {C,,~)alkyl or halo-substituted {C1.3)alkyl and R's is (C~.~)alkyl or halo-substituted {C,-3)alkyl, or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form (C~)cycloalkylene. In particular, R3 may be selected from hydrogen, (C,.~)alkyl (e.g. methyl;
ethyl, n-propyl, n-butyl), phenyl(C2.3)alkyl (e.g. pheneihyl) or (C,~)alkylsulfanyl(C~)alkyl (e.g.
2-methylsulfonylethyl) or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form (C3.~)cycloalkylene (e.g. cyclobutylene or cyclohexylene). R3 preferably is (Ct~)alkyl.
R° particularly represents hydrogen or R3 and R° taken together with the carbon atom to which both R3 and R" are attached form (C~)cycloalkylene (e.g:
cyclohutylene or cyclohexylene).
Rs and R6 preferably together form oxo.
Compounds of Formula II are preferred in which:
nis0;
1 X' is =C- and the ring system A is selected from 4,5-dihydrooxazol-2-yl, benzooxazol-2-yl, benzothiazol-2-yl and oxazol-2-yl, each substituted by a group R' and optionally substituted with a group RB, particularly wherein R' is hydrogen, halo, {C,~)alkoxy, (C~.~)aIkoxycarbonyl, vitro or phenyl and R8 at each occurrence independently is (Ct,~)alkoxy, (C~,~)alkoxycarbonyl, vitro or trifluoromethyl.
X8 methylene or ethylene;
R', R3 and R4 are as defined above;
Rs and R6 together form oxo;

R9 is hydrogen; and R'2 is -X9R3°, wherein X9 is methylene when X8 is methylene and X9 is a bond when Xg is ethylene, Rs° is -CR3sCHR36 or -CR~NR38; wherein R3s and R~ together with the atoms to which R3s and R~ are attached form (Cz.,e)alkenyl, (Cs.~2)cycloalkenyl, hetero(Cs.,~cycloalkenyl, (C,~12)aryl, hetero(C6~~aryl, (C~.1~}bieycloaryl or hetero(C&,~bicycloaryl and Rs' and R3$ together with the atoms to which Rs' and R38 are attached form hetero(Cs.,~cycloalkenyl, hetero(C~1Z)aryl or hetero(CB.,z)bicycloaryl, wherein within R3° said cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, bicyeloaryl or heterobicycloaryl may be substituted further by 1 to 5 radicals independently selected from (CL~)alkyl, (C~.~)alkylidene, cyano, halo, halo-substituted (C,~)alkyl, nitrb, -XsNR'''R'°, -XsNR'°C(O)OR'°, -XsNR~aC(O)NRtaR~a~ -x5~TR14C~14)~74RI4~ -XS~R14~ -XSSR14' -XsC(~)pRl4' -XsC(O)y4R~4~ _XsS(O)zWaRl~~a~~~-~Xsp(~)(OR'°)OR'°, -XSOP(O)(OR'°)OR'4, -XsNR'°C(O)R's, -XsS(O)R's, -XsS(O~R's and XsC(O)R's, wherein Xs is a bond or (Cl~)alkylene, R'4 at each occurrence independently is hydrogen, (C,~)aIkyl or halo-substituted (C1.3)alkyI and R's is (C,.~alkyl or halo-substituted (C,:3)alkyl.
Rs° particularly represents (C~t2)aryl or hetero(C~12)aryl, each optionally substituted by 1 to 5 radicals selected from a group consisting of (C~~)alkyl, cyano, halo, halo-substituted (Ci.4)alkyl, vitro, -XsNR'°R'4~ -XsOR'°, -XsSR'4, -XsC(O)NR'4Ra4' -XsC(O)ORa4, -XsS(O)R's, -XsS(O)ZR's and -X5C(O)R's, wherein Xs is a bond or (C,_~alkylene, R'° at each occurrence independently is hydrogen, (C~ 3)aIkyI of halo-substituted (C,.3)alkyl and R's is (C~_3)aIky1 or halo-substituted (C~.3)alkyl. Rs° more preferably represents biphenyl, isooxazolyl, naphthyl, phenyl, pyridyi or thienyi, each optionally substituted by 1 to 5 radicals selected from a group consisting of (C~~)alkyl, cyano, halo, halo-substituted (C,-°)alkyl, vitro, -XSNR'°R'4, -XsOR,4~ -XsSRu' -XSC(O)~14R14s _XsC(p,OR~4' -XsS(O)Ris4 -XsS(O)2Ris ~d -XsC(O)R's, wherein.X4 is a bond or (C,~)alkylene; R'° at each occurrence independently is hydrogen, (C,_3)alkyl or halo-substituted (C~ 3)alkyI and R's is (C'_3)alkyl or halo-substituted (Cy.3)alkyl: Rs° more preferably represents biphenyl-2-yl, 2,4-bistrifluoromethylphenyl, 2,5-bistrifluoromethylphenyl, 4-tert-butylphenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-bromo-5-fluorophenyl, 3-chloro-2-fluorophenyl, 2-chlorophenyI, 3-chlorophenyl, 4-chlorophenyl, S-chlorothien-2-yl, 2-chloro-5-trifluoromethyl, 2-cyanophenyl, 3-cyanophenyl;
4-cyanophenyl, 1,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 2-difluoromethoxyphenyi, 3-difluoromethoxyphenyl, 4-difluorornethoxyphenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,5-dimethylisooicaxol-4-yl, 3,5-dimethylphenyl, 2-fluoro-6-nitroptienyI, 2-fluorophenyl, 4-fluorophenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-4-trifluoromethylphenyl, 2-fluora-5-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyi, 4-fluoro-2-trifluoromethylphenyl, 4-fluoro-' 3-trifluoromethylphenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-methoxyphenyl, 4-methoxyphenyl, 2-methylphenyi, 3-methylphenyl, 4-methytphenyl, 6-methylpyrid-2-yI, 3-methyl-2-fluorophenyl, naphth-2-yl, 2-niirophenyl, 3-nitrophenyl, 4-nitrophenyl, 2,3,4,5,6-pentafluorophenyI, phenyl, prop-2-en-1-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, thien-3-yl, o-tolyl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, . 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-trifluaromethylsulfariyIphenyl, 3-trifluoromethylsulfanylphenyl, 4-trifluoromethylsulfanyIphenyl, 2,3,4-trifluorophenyl, °
2,3,5-trifluorophenyl, 2,4,6-trifluarophenyl, 2,4,5-trifluorophenyl or 2,3,6-trifluorophenyl.
A preferred group of compounds of Formula II are those in which -XgS(O)zR3z represents a group having the following formula:
r~~ (R33)9 S(O)2 NVW
in which Q is 0, 1, 2, 4 or 5 and R33 ai each occurrence independently is selected from a group consisting of (C~.a)alkyl, cyano, halo, halo-substituted (C~.a)alkyl, vitro, -XsNR'aR'a, -XSOR'4, .
-XsSR~a~ -XsC(O)yaR~a~ _xsC(O)ORn~ -Xss(O)R~s' _XsS(p)zRis and -X'C(O)R's, wherein .
Xs is a bond or (C,_~alkylene, R'4 at each occurrence independently is hydrogen, (Ct_3)alkyl or halo-substituted (C~_~alkyl and R's is (C~_3)alkyl or halo-substituted (C,°3)alkyl; more particularly "
in which q is 0, 1 or 2 and R33 at each occurrence independently is selected from a group consisting of (Ca~alkyl, cyano, halo, halo-substituted (CI,~)alkyl, nitra, -OR'a; -SR'a and -C(O)OR'a, wherein R'a at each occurrence independently is hydrogen, (C~_3)alkyl or halo-substituted (C,_3)alkyl; more particularly in which R33 at each occurrence independently is selected from a group consisting of (CI,~)alkyl, bromo, carboxy, chloro, cyano, difluoromethoxy, fluaro, iodo, methoxy, vitro, trifluoromethoxy, trifluoromethyl and trifluorosulfanyl.
In particular, -XaS(O)2R3z represents benzylsulfonyImethyl, 2-chlorobenzylsulfonyhnethyl, 2-cyanobenzylsulfonylmethyl, 2-difluoromethoxybenzylsulfonylmethyl, 3,5-dimethylisooxazol-4-ylmethylsulfonylmethyl, 2-methoxybenzylsulfonylmethyi, 6-methylpyrid-2-yhnethylsulfonyhnethyl, 2-nitrobenzylsulfonylmethyl, pyrid-2-yhnethylsulfonylmethyl, o-tolylmethylsulfonylmethyl or 2-trifluoromethylbenzylsulfonylmethyl.
Reference to the preferred embodiments set forth above is meant to include all combinations of particular and preferred groups:
Further preferred are compounds of Formula I selected from a group consisting of:
2S-acetylamino-N (1S-benzooxazol-2-ylcarbonyl}-3-phenylprapyl)-~t3 3-cyclohexylpropionamide; and N [ 1 S-( 1 S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-cyclohexylethylisonicotinamide; and the N oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
Further preferred are compounds of Formula I selected from a group consisting of:
N [1R-{1S-benzooxazol-2-ylcarbonylbutylcarbamoyl)-2-benzylsulfonylethyl]motpholine-4-carboxamide;
methyl 1R-( 1 S-benzooxazol-2-ylcarbonylbutyl carbamayl)-2-benzylsulfonylethylcarbamate;
N (1S-benzooxazol-2-ylcarbonylbutyl)-2R-methylsulfonylamino-3-benzylsulfonylpropionamide;
N (1S-benzooxazol-2-ylcarbonylbutylcarbamoyl)-2R-(3,~-dimethylureido)' 3-(2-methoxybenzylsuifonyl)propionamide;
N [1R-(1S-benzooxazol-2-ylcarbonylbutylcarbamoyl)-2-(2-difluoromethaxybenzylsulfonyI)ethyl]morpboline-4-carboxamide;
N [1R-(1S-benzooxazol-2-yicarbonylbutylcarbamoyl)_ 2-(2-methoxybenzylsulfonyl)ethyl]marphoIine-4-carboxamide;
N-[ 1 R-( 1 S-benzooxazal-2-ylcarbonylpentylcarbamoyl)-2-benzylsulfonylethyl]morpholine-4-carboxamide;
N [1R-(1S-benzooxazol-2-yicarbonylpentylcarbamoyl)-2-{2-chlorobenzylsulfonyl)ethyl]rnorpholine-4-carboxamide;
1R-(1 S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-(2-difluoromethoxybenzylsulfonyl)ethylcarbamate;
N [1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl}-2-{2-difluoromethoxybenzylsulfonyi)ethyllmorpholine-4-carboxyamide;
N-[ IR-( 1 S-benzooxazol-2-ylcarbonylpentylcarbamoyl~
2-(3,5-dimethylisoxazol.-4-ylmethylsulfonylethyl]isonicotinamide;
IV [ 1 R-(1 S-benzooxazol-2-ylcarbonylpentylcarbamoyl}-2-(2-nitrobenzylsulfonyl)ethyl]morpholine-4-carboxamide;
N [1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyIr 2-pyridin-2-yimethylsulfonylethyl]morpholine-4-carboxamide;
N [1R-(1S-benzooxazol-2-yIcarbonylpentylcarbamoyl}-2-o-tolylmethylsulfonylethyIJmorpholine-4-carboxamide;
N [1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-(2-trifluoromethylbenzylsulfonyl)zthyl]morpholine-4-carboxamide;
N [IR-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-benzylsulfonylethyl]nicotinamide;
N [1R-(IS-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl~
2-benzylsulfonylethyl]pyrazine-2-carboxamide;
N [1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(2-chlorobenzylsulfonyl)ethyl Jmorpholine-4-carboxamide;
N [1R-(iS-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl}-2-(2-cyanobenzylsulfonyl)ethyl]isonicotinamide;
N [1R-(1S-benzooxazol-2-ylcarbonyl-3-methylsulfonylpropylcarbamoyl}-2-(2-difluoromethoxybenzylsulfonyl}ethyl]morpholine-4-carboxamide;
N [1R-(1S-benzooxazol-2-ylcarbonyipentylcarbamoyI}-2-(2-difluoromethoxybenzylsulfonyI)ethyl3isonicotinamide;
N [1R-(1S-benzooxazol-2-ylcarbonyl}-3-phenylpropylcarbamoyl)-2-benzylsulfonyletliyllmorpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcaxbamoyl)-2-{6-methyipyrid-2-ylmethylsulfonyl)ethyl]isonicotinamide;
N-j1R-(IS-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(2-nitrobenzylsulfonyl)ethyljmorpholine-.4-carboxamide;
N [1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-pyrid-2-ylmethylsulfonylethyl]morpholine-4-carboxamide;
N [1R-{IS-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-oaolylmethyIsulfonylethyl]morpholine-4-carboxamide;
N [1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl~.
2-(2-trifluoiomethylbenzylsulfonyl)ethyl)tetrahydropyran-4-carboxamide;
tetrahydropyran-4-yl IR-(I S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-benzylsulfonylethylcarbamate; and N [1R-(IS-benzooxazol-2-ylcarbonyl-3-phenyipropylcarbamoyl}-2-(2-cyanobenzylsulfonyl}ethylJpiperidine-4-carboxamide; and the N-oxide derivatives, prodrug derivatives, protecaed derivatives, individual~isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
A preferred aspect of the invention are compounds of Formula I in which X' is =C-. In particular, the heteromonocyclic ring or fused heteropolycyclic ring system A
is selected from thien-2-yl, oxazol-2-yl, 4,5-dihydrooxazol-Z-yl, fur-2-yl, IH-indol-5-yl, pyrid-2-yl, pyrid-3-yl, 75 thiazol-2-yl, 1-methyl-1H-imidazol-2-yl, I-benzyl-1H-imidazol-2-yi, benzooxazol-2-yl, benzofur-2-yl, benzothiazol-2-yl, 1H-benzoimidazol-2-yl, I,1-dioxo-1H-I7~6-benzo[b]thien-2-yl, quinol-3-yl, (1,3]dioxolan-2-yI, naphtho[2,3-d]oxazol-2-yl, naphtho(I,2-d]oxazol-2-yl and naphtho(2,1-~oxazol-2-yl, each substituted by a group R' and optionally substituted with a group R8, particularly wherein R' is halo, vitro, -R~', -ORZ9, -C(O)R~°, -C(C?)ORs9,.-S{O)2NRZ9R~°, -C(O)NR~'R3° or -C(O)NHCHR43C(O)OR29, wherein R~° is (C,.~)alkyD, {C3.12)cYcloalkyl(C~)alkyl, hetero(C3_~~cycloalkyl(C~)alkyl, (C~.12)aryl(C~)alkYl, diphenyl(C~)alkyl, hetero{C~.,~aryl(C~)alkyl or hetero(C$:,~polycycloaryl(C~)alkyl and R29 is hydrogen or -R~°, wherein R2° is defined as above, wherein said heterocycloalkyl may be substituted with (C~.,~aryl(C0.3)alkyl, R~° at each occurrence is hydrogen or (CI~)alkyl and R'o is (C,.~)alkyl, and Rg at each occurrence independently is hydrogen, (Ca.~)alkyl or halo-substituted {C»)alkyl; wherein within R' any alicyclic or aromatic ring system present may be substituted further by I to 5 radicals independently selected from (C1~)alkyl, (C,.b)alkylidene, cyano, halo, halo-substituted (C,.~)alkyl, vitro, -XbNR'4R'4, -XbNR'4C(O}OR'4, _xs~taC(O)NR~aRl4~ -X6~14C~14)~14Ri4~ -X6OR74' -XbSRl4~ -X6C(o)OR14~
-XbC(U)NR'°R14~ -X6~(p)2NR"R14~ -Xbp(O)(oR'4)~R'4, -XbUP{O)(OR'4)OR'4, -X6NR'4C(O)R's, -XbS(O)R's, -X6S(O),R's and -XbC(O)R's, wherein X6 is a bond or (C,~)alkylene, R'° at each occurrence independently is hydrogen, (C'.~)alkyl or halo-substituted (C,.3)alkyl and R" (C,.~)alkyl or halo-substituted (C,.3)alkyl. .
The ring system A preferably is oxazol-2-yl, 4,5-dihydrooxazol-2-y1, benzooxazol-2-yl, naphthoj2,3-d]oxazol-2-yl, naphtho[1,2-dJoxazol-2-yl or naphtho[2,1-djoxazol-2-yl; each ' substituted by a group R' and optionally substituted with a group R8, particularly wherein R' is halo, -R29, -C(O)R~°, -C(O)OR29, -C(O)NR~'R3° or -S(O)2NR~''R~°, wherein R~° is (C,.~)alkyl, (C3.,~cycloalkyl(C~)alkyl, (C~.,2)aryI(C~alkyl, hetero{C5_l~aryi(C~alkyl or hetero(Cg.i2)polycycloaryI(Co..b)alkyl.
The ring system A more preferably is oxazol-2-yl, 4,5-dihydrooxazol-2-yl, benzooxazol-2-yl or naphtho[1,2-dJoxazol-2-yl, each substituted by a group R' and optionally substituted with a group Rg, particularly wherein R' is adamantan-I-ylmethylcarbamoyl, benzyl, benzytcarbamoyl; benzyl(methyl)carbamoyl, I-benzyloxycarbonyl-3-methylhutylcarbamoyl, 4-benzylpiperidin-1-carbonyl, ten-butyl, chloro, 2,3-dihydroindol-I-ylcarbonyl, 3,4-dihydro-IH-isoquinol-2-ylcarbonyl, 3,4-dihydro-IH-quinol-1-ylcarbonyl, diphenylmethylcarbamoyl, fur-2-yimethylcarbamoyl, hydrogen, 2-(1H-indol-3-yl)ethylcarbamoyl, methoxy, methoxycarbonyl, methyl, 3-methylbutylcarbamoyI, methylcarbamoyl, I-methylethylcarbamoyl, naphth-I-ylmethylcarbonyl, vitro, phenyl, phenylcarbamoyl, 2-phenylcyclopropylcarbamoyl, 1-phenylethylcarbamoyl, sulfamoyl, trifluoromethyl, phenethylcarbamoyl, 3-phenylpropylcarbamoyl, piperid-1-ylcarbonyl, pyrid-2-ylmethylcarbamoyl, pyrid-3-ylmethyIcarbamoyl, pyrid-4-ylmethylcarbamoyl or pyrrolidin-I-ylcaibonyl and R$ is methyl.
XZ particularly represents a bond or a divalent group of Formula (a), wherein within Formula (a) X3 is -C(0)-, R'represents hydrogen, R" represents hydrogen or methyl, typically 'hydrogen, and R'z particularly represents (C,~)alkyl, preferably isobutyl, sec-butyl or isopropyl.
R' particularly represents hydrogen or -X8X9R~°, wherein X$ is -C(O)-or -S(O)2-; X9 is a bond or -0- and RZ° is (Cl.~)alkyl, (C3.12)cyclaalkyl(Co.,b)alkyl, hetero(C3_l~cycloalkyl(Co-b)alkyl, (C~.l~aryl(C~)alkyl or hetero{CS.~~aryl(Cp,6,)alkyl; wherein within R' any alicyclic or aromatic ring system present may be substituted further by I to S
radicals independently selected from (Cl.~)alkyl, -C(O)OR'°, -X6NR'4R'4 and -X6NR"C{O)OR'", wherein X6 is a bond or (C,.~)alkylene, R" at each occurrence independently is hydrogen, {Cj.~)alkyl or halo-substituted (C, 3)alkyl and R's (C,.~)alkyl or halo-substituted (C~_3)alkyl.

R' particularly represents acetyl, benzoyl, benzyloxycarbonyl, benzylsulfonyl, bicyclo[2.2.2]hept-2-ylcaxbonyl,: tent-butoxycarbonyl, rent-butyryl, 4-tent-butoxycarbonylpiperazin-I-ylcarbonyl, I-tart-butoxycarbonyipiperidin-4-ylcarbonyl, 2-cyclohexylacetyl, 4-cyclohexylbutyryl, 2-cyclohexylethyIsulfonyl, 3-cyclohexylpropionyl, 2-cyclopentylethylsulfonyl, hydrogen, 4-methylpiperazin-I-ylcarbonyl, methylsulfonyl, 4-methylvaleryl, 3-rnorpholin-4-ylpropionyl, naphth-2-ylmethyl, 3-phenylpropionyl, piperazin-1-ylcarbonyl, piperidin-4-ylcarbonyl or pyrid-3-ylcarbonyl, wherein within Rl any alicycIie or aromatic ring system present may be substituted further by I to 3 radicals independently selected from 3-aminomethyl and 3-tart-butoxycarbonylaminomethyl.
R2 particularly represents hydrogen.
R3 preferably represents (C~~)alkyl or (C~.,o)aryl{C,,3)alkyl, more preferably phenethyl, or R3 and R° taken together with the carbon atom to which both R3 and R4 are attached form (C3~)cycloalkylene, more preferably cyclopropylene.
R4 preferably represents hydrogen or (C~.~)alkyl, preferably hydrogen or methyl or R3 and R4 or R3 and R° taken together with the carbon atom to which both R3 and R° are attached form (C~)cycloalkylene, more preferably cyclopropylene.
Rs and R6 preferably together form oxo.
Reference to the preferred embodiments set forth above is meant to include all combinations of particular and preferred groups.
Pharmacology and Utility:
The compounds of the invention are cysteine protease inhibitors, in particular the compounds of the invention inhibit the activity of cathepsins B, L, K and/or S
and, as such, are useful for treating diseases in which cathepsin B, L, K andlor S activity contributes to the pathology andlor symptomatology of the disease. For example, the compounds of the invention 2S are useful in treating tumor invasion and metastasis, in particular as anti-angiogenic agents, rheumatoid arthritis, osteo arthritis, pneumoeystis carinii, acute pancreatitis, inflammatory airway disease and bone and joint disorders. Furthermore, the compounds of the invention are useful in treating bone resorption disorders, e.g. osteoporosis.
The compounds of the invention are inhibitors of cathepsin S and, as such, are useful for 80 treating diseases in which cathepsin S activity contributes to the pathology andlor symptomatology of the disease. For example, the compounds of the invention are useful in ~40-treating autoimmune disorders, including, but not limited to, juvenile onset diabetes; multiple sclerosis, pemphigus vulgaris, Graves' disease, myasthenia gravis, systemic lupus erythemotasus, rheumatoid arthritis and Hashimoto's thyroiditis; allergic disorders, including, but not limited to, asthma; and allogeneic immune responses, including, but not limited to, organ transplants or tissue grafts.
Cathepsin S also is implicated in disorders involving excessive elastolysis, such as chronic obstructive pulmonary disease (e.g. emphysema), bronchidlitis, excessive airway elastolysis in asthma and bronchitis, pneumonities and cardiovascular disease such as plaque rupture and atheroma. Cathepsin S is implicated in fibril formation and, therefore, inhibitors of cathepsins S are of use in treatment of systemic amyloidosis.
The cysteine protease inhibitory activities of the compounds of the invention can be determined by methods known to those of ordinary skill in the art. Suitable in visro assays for measuring protease activity and the inhibition thereof by test compounds are known. Typically, the assay measures protease induced hydrolysis of a peptide based substrate.
_ Furthermore, the compounds of the invention are useful as intermediates in the preparation of other compounds of Formula I. For example, compounds of Formula I in which Rs is hydroxy can be used to prepare compounds of Formula I in which Rs and R6 taken together form axo.
Nomenclature:
The compounds of Formula I and the intermediates and starting materials used in their preparation are named in accordance with ICJ1PAC rules of nomenclature in which the characteristic groups have decreasing priority for citation as the principle group as follows:
acids, esters, amides, etc.. Alternatively, the compounds are named by AutoNom 4.0 (Beilstein information Systems, Inc.). For example, a compound of Formula I in which A is bert2ooxazol-2-y1; Xz is a group of Formula (a), wherein R9 is hydrogen and Rr2 is cyclohexylmethyl; R' is acetyl; RZ is hydrogen; R~ is phenethyl; R° is hydrogen; and RS and R6 together form oxa; that is, a compound having the following structure:

is named 2S-acetylamino-l1~ (1-benzooxazol-2-ylcarbonyl-3-phenylpropyl~.
3-cyclohexylpropionamide; and a compound of Formula I in which A is benzooxazol-2-yl; X'- is a group of Formula (a), wherein R9 is hydrogen and R~Z is benzyIsuifonylmethyl;
R' is morpholin-4-ylcarbonyl; Rz is hydrogen; R3 is phenethyl; R4 is hydrogen; Rs is hydrogen; and R6 is hydroxy; that is, a compound having the following structure:
is named N [1S-(2-benzooxazol-2-yl-2-hydroxy-1S-phenethylethylcarbamoyl)-2-benzylsuifonylethyl]-morpholine-4-carboxamide or morpholine-4-carboxylic acid i0 {{R)-1-[(S~-i-(1-benzooxazol-2-yl-1-hydroxy-methyl)-3-phenyl-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl }-amide; and a compound of Formula I in which A
is benzooxazol-2-yl; XZ is a group of Formula (a), wherein R9~is hydrogen and R'2 is cyclohexymethyl; R' is carboxyacetyl; Rz is hydrogen; R3 is phenethyl; R4 is hydrogen; and RS
and R6 together form oxo; that is, a compound having the following structure:

is named N-[1S-(IS-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-cyclohexylethyl]malonamic acid orN-{(S~-1-[(S~-1-(1-benzooxazol-2-yl-znethanoyl)-3-phenyl-propylcarbarnoylJ-2-cyclohexyl-ethyl )-malonamic acid; and a compound of Formula I in which A is benzooxazol-2-yl; Xz is a group of Formula (a); wherein R9 is hydrogen and R'~ is 2-nitrobenzylsulfonylmethyl; R' is moxpholin-2-ylcarbonyl; RZ is hydrogen; R3 is phenethyl; R° is hydrogen; and R' and R6 together form oxo; that is, a compound having the following structure:
O
II
is named N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(2-nitrobenzylsulfonyl)ethylJmorpholine-4-carboxamide or morphoIine-4-carboxylic acitt [(R)-I-[(S~-I-(1-benzooxazol-2-yI-methanoyl)-3-phenyl-propylcarbamoyl)-2-(2-nitro-phenylmethanesulfonyl)-ethyl]-amide; and a compound of Formula I in which A is benzooxazol-2-yI; XZ is a group of Formula (a), wherein R9 is hydrogen and R'2 is benzylsulfonylmethyl; R' is tetrahydropyran-4-yloxycarbonyl; Rz is hydrogen;
R~ is phenethyl;
R4 ZS hydrogen; and RS and R6 together form oxo; that is, a compound having the following structure:
is named tetrahydropyran-4-yl 1R-(IS=benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-benzylsulfonylethylcarbamate or l (R)-1-[(S}-1-(1-benzooxazol-2-yl-methanoyl)-3-phenyl-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl j-carbamic acid tetrahydro-pyran-4-yl ester, A compound of Formula I in which A is pyrid-2-yl; XZ is a group of Formula (a), wherein R9 is hydrogen and R" is 2-methylpropyl; R' is benzyloxycarbonyl; R2, Rd and Rs each are hydrogen; R3 is phenethyl; and R6 is hydroxy; that is, a compound having tlhe, following structure:
is named benzyl 1S-(1S-pyrid-2-ylcarbonyl-3-phenylpropylcarbamoyl)-3-methylbutylcarbamate ,.dq._ or { (S)-1-[(S)-1-(I-hydroxy-1-pyridin-2-yI-methyl)-3-phenyl-gropylcarbamoyl]-3-methyl-butyl }-carbamic acid benzyl ester; and a compound of Formula I in which A is thiazol-2-yl; Xz is a group of .Formula (a), wherein R9 is hydrogen and R" is 2-methylpropyl; R' is 4-methylpiperazin-1-ylcarbonyl; R2 and R'' each are hydrogen; R3 is phenethyl;
and Rs and R6 together form oxo; that is, a compound having the following structure:

~N~
/N J
is named N [3-methyl-1S-(3-phenyl-I-thiazol-2-ylcarbonylpropylcarbamoyl)butyl]-4-methylpiperazine-1-carboxamide or 4-methyl-piperazine-1-carboxylic acid or {
(S)-3-methyl-1-[(S)-3-phenyl-1-(i-thiazol-2-yl-methanoyl)-propylcarbamoyl)-butyl}-amide;
and a compound of Formula I in which A is 4,5-tetrahydro-4-methoxycarbonyloxazol-2-yl; X~ is a group of Formula (a), wherein R9 is hydrogen and R" is 2-methylpropyl; R' is benzyloxycarbonyI; RZ and R4 each are hydrogen; R3 is pijenethyl; aru ;5 and R5 together fornn oxo; that is, a compound having the following structure:

N\ ~ /~\~
\ OJ~H .~~ J vOr I
75 is named methyl 2S-(2S-benzyloxycarbonylamino-4-methylvalerylamino)-4-ghenylbutyryl-4,5-dihydrooxazole-4-carboxylate or 2-[(S)-2-((S)-2-benzyloxycarbonylamino-4-methyl-pentanoylamino)-4-phenyl-butanoylJ-4,5-dihydro-oxazole-4-carboxylic acid methyl ester.
Certain compounds. of Formula I exist in tautomeric equilibrium. Compounds of Formula I which exist as tautomers are named, illustrated or otherwise described in this application as one possible tautomer. However, it is to be understood that the all possible tautomers, are meant to be encompassed by such names, illustrations and descriptions.
Certain compounds of Formulae I and II exist in tautomeric equilibrium.
Compounds of Formulae I and II which exist as tautomers are named, illustrated or otherwise described in this application as one possible tautomer. However, it is to be understood that the all possible tautomers are meant to be encompassed by such names, illustrations and descriptions.
Administration and Pharmaceutical Compositions:
In general, compounds of Formula I will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with another therapeutic agent. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. For example, therapeutically effective amounts of a compound of Formula I may range from O.I micrograms per kilogram body weight (~,vglkg) per day to IO milligram per kilogram body weight (mglkg) per day, typically 1 iug~kg/day to I mg/kglday. Therefore, a therapeutically effective amount for a 80 kg human patient may range from 10 ~cg/day to 100 mglday, typically 0.1 mg/day to 10 mglday. In general, one of ordinary skill in the art, acting in reliance upon personal knowledge and the disclosure of this Application, will be able to ascertain a therapeutically effective amount of a compound of Formula i for treating a given disease.
The compounds of Formula I can be administered as pharmaceutical compositions by one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository) or parenteral (e.g., intramuscular, intravenous or subcutaneous). Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate composition and are comprised of, in general, a compound of Formula I in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the active ingredient. Such excipient may be any solid, liquid, semisolid or, in the case of an aerosol composition, gaseous excipient that is generally available -4b-to one of skill in the art.
Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, and the tike. Liquid and semisolid excipients may be selected from water, ethanol, glycerol, propylene glycol and various oils, including those of petroleum, animal, vegetable or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, sesame oil, or the like). Preferred liquid carriers, particularly for injectable solutions, include water, saline; aqueous dextrose and glycols.
The amount of a compound of Formula I in the composition may vary widely depending upon the type of formulation, size of a unit dosage, kind of excipients and other factors known to ' those of skill in the art of pharmaceutical sciences. In general, a composition of a~compound of Formula I for treating a given disease will comprise from 0.01 %w to 10%w, preferably 0.3%w to 1 %w, of active ingredient with the remainder being the excipient or excipients. Preferably the pharmaceutical composition is administered in a single unit dosage form for continuous treatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required. _ ... .~. _..
The compounds of Formula I can be administered alone or in combination with other compounds of Formula I or in combination with one or more other active ingredient(s). For example, the compounds of Formula I can be administered in combination with a therapeutically active amount of a bisphosphonic acid or acid ester derivative or any pharmaceutically acceptable salt thereof. Suitable bisphosphonic acids and acid ester derivatives include compounds corresponding to the following formula:
i (~)(OR43)OR43 R44 X 11,C X45 P(O)(OR43)OR43 wherein X" is a bond or (C~_,)alkylene, each R°3 independently is hydrogen or (C~.3o)alkyl, R'°
and R43 are selected independently from a group consisting of hydrogen, halo, optionally substituted (C,.ao)alkyl, (C3.3o)cyclaalkyl, hetero(C~.3o)cycloalkyt, optionally substituted (Cb,o)aryl, hetero(C~.~o)aryl, -NR°6R'~, -OR°~, -SR's, wherein each R~ independently is hydrogen, (C,_io)alkyl, (C3_~o)cycloalkyl, optionally substituted (C~.~o)aryl, provided that both R"
and R4s are not selected from hydrogen or hydroxy when X" is a bond; or R~ and R4s taken together form {C~.9)alkylene; wherein (C3_,~cycIoalkyl includes adarnantyl and the like, hetero(C~,okycloalkyl includes pyrrolidinyl and the like, (C~,o)aryl includes phenyl and naphthyl, and hetero(Cø,o)aryl includes quinolyl, isoquinolyl, pyridyl, furyl, imidazolyl, imidazopyridyl and the like.
Instances wherein R°~ andlor Ra5 are substituted (Cl_~~alkyl may include, but are not limited to, {C,_~)alkyl substituted by hetero(C~.,o)cycloallryl, (C~.,o)aryl, hetero(C~,o)aryl, -~47R4T' -pRa~ and -SR°', wherein each R'r' is independently hydrogen or {C,_,a)alkyl;
wherein hetero(C~.lo)cycIoalkyl includes pyrrolidinyl and the Like, (C~,o)aryl includes phenyl and naphthyl, and hetero(C~.,o)aryI includes quinolyl, isoquinolyl, pyridyl, furyl, imidazolyl, imidazopyridyl and the like. Suitable optionally substituted aryl groups include, but are not limited to, halo-substituted phenyl.
A non-limiting class of bisphosphonic acids and acid ester derivatives thereof suitable for administration in combination with compounds of Formula I include those in which R°" is selected from the group consisting of hydrogen, hydroxy or halo, and R'S is selected from the group consisting of optionally substituted (C,_~)alkyl, halo and -SR"~, wherein R''~ is (C,_,o)alkyl or phenyl.
A non-limiting subclass of bisphosphonic acids and acid ester derivatives thereof suitable for administration in combination with compounds of Formula I include those in which R~° is selected from the group consisting of hydrogen, hydroxy and chloro and R43 is selected from the group consisting of optionally substituted (C,_3o)alkyl, chloro and chlorophenylthio.
A non-limiting example of a bisphosphonic acid suitable for administration in combination with compounds of Formula I include that in which X" is a bond, each R43 is hydrogen, R"° is hydroxy and R45 is 3-aminopropyl, namely 4-amino-l-hydroxybutylidene-I,1-bisphosphonic acid (aka alendronic acid), or the monosodium trihydrate salt thereof, namely 4-amino-1-hydroxybutylidene-l,I-bisphosphonate monosodium trihydrate (aka alendronate monosodium trihydrate), described in LJ.S. Patents 4,922,00?, to Kieczykowski et al., issued May I, 1990; 5,019,651, to Kieczykowski et al., issued May 28, 1991; 5,510,517, to Dauer et al., issued April 23, I996; 5,648,491, to Dauer et al., issued July 15, 1997, all of which patents are incorporated by reference herein in their entirety. .
Further non-limiting examples of bisphosphonic acids suitable for administration in combination with compounds of Formula I include the following: .
cycloheptylaminomethylene-1,I-bisphosphonic acid (aka cimadronic acid), described in U.S. Patent 4,970,335, to Isomura et al., issued November 13, 1990;
1,1-dichloromethylene-1,1-diphosphonic acid (aka clodronic acid) and the disodium salt thereof, namely clodronate disodium, described in Belgium Patent 672,205 {1966) and J. Org.
Chem 32, 4111 (1967);
1-hydroxy-3-pyrrolidin-1-ylpropylidene-1,1-bisphosphonic acid (aka EB-1053);
1-hydroxyethyIidene-1,1-diphosphanic acid (aka etidronic acid);
1-hydroxy-3-(N-methyl-N pentylamino~ropylidene-1,1-bisphosphonic acid (aka ibandronic acid), described in U.S. Patent No. 4,927,814, issued May 22, 1990;
6-amino-l-hydroxyhexylidene-1,1-bisphosphonic acid (aka neridronic acid);
3-(dimethylamino)-1-hydroxypropyIidene-1,1-bisphosphonic acid {aka olpadronic acid);
3-amino-1-hydroxypropylidene-1,I-bisphosphonic acid (aka pamidronic acid);
2-pyrid-2-ylethylidene-1,1-bisphosphonic acid {aka piridronic acid), described in U.S.
Patent No. 4,761,406;
1-hydroxy-2-pyrid-3-ylethylidene-1,1-bisphosphonic acid (aka risedronic acid);
t5 4-chloraphenylthiomethylenebisphosphonic acid (aka tiludronic acid), described in U.S.
Patent 4,876,248, to Breliere et al., October 24, 1989; and I-hydroxy-2-(IH-imidazol-I-yl)ethylidene-1,1-bisphosphonic acid (aka zoledronic acid);
all of which patents and other documents referred to above are incorporated by reference herein in their entirety.
A non-limiting subclass of bisphosphonic acids suitable for administration in combination with compounds of Formula I include those selected from the group consisting of alendronic acid, cimadronic acid, clodronic acid, tiiudronic acid, etidronic acid, ibandronic acid, risedronic acid, piridronic acid, pamidronic acid, xolendronic acid, pharmaceutically acceptable salts thereof, and mixtures thereof. A further example of a bisphosphonic acid suitable for administration in combination with compounds of Formula I is alendronic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof. A further non-limiting example is alendronate. monosodium trihydrate.
Compounds of Formula i can be administered in combination with a therapeutically active amount of an estrogen receptor agonist. Non-limiting examples of estrogen receptor agonists suitable for administration in combination with the compounds of Formula I include naturally occurring estrogens such as estradiol, estrone and estroil, or synthetic estrogen receptor agonists such as [6-hydroxy-2-(4-hydroxyphenyl)benzo[b] thien-3-yl] [4-(2-piperidin-1-ylethoxy~henyl]methanone (aka raloxifene) and (2-{4-(1,2-diphenylbut-1-enyl~henoxy]ethyl )dimethylamine (aka tamoxifen). A non-limiting subclass of estrogen receptor agonists suitable for administration in combination with the compounds of Formula I include estrogen receptor partial agonists (i.e., estrogen receptor agonists with mixed agonisdantagonist properties), sometimes referred to as estrogen receptor modulators. Estrogen receptor partial agonists can exert tissue-selective estrogen agonist effects. Tamoxifen, for example, selectively exerts an estrogen agonist effect on the bone, in humans. Additional suitable estrogen receptor partial agonists are described in Tissue-Selective Actions Of Estrogen Analogs, Bone Col. 17, No. 4, October 1995, 18IS-190S.
0 Certain 3-[4-(2-phenylindol-1-ylmethyl)phenyl]acrylamides, described iri U.S: Patent 5,383,910 to Miller et al., November 16, 1999; 'benzothiphene compounds, described in U.S. Patent 5,985,897 to Meuhl et al., November 16, 1999; naphthyl compounds, described in U.S. Patent 5,952,350 to Cullinan et al., September I4, 1999; substituted benzothiophene compounds, described in U.S. Patent 5,962,475 to Schmid et, al., October 4, 1999, are suitable estxogen receptor partial agonists for administration with the compounds of Formula I;
all of which patents and other documents referred to above are incorporated by reference herein in their entirety.
More particularly a pharmaceutical composition of this invention may comprise a therapeutically effect amount of a compound of Formula I in combination with one or more active ingredients) selected from the group consisting of (i) a therapeutically effect amount of a bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof and (ii) a therapeutically effect amount of an estrogen receptor agonist or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable excipient(s). Non-limiting examples of such bisphosphonic acids include 1,1-dichloromethylene-i,l-diphosphonic acid, 1-hydroxy-3-pyrrolidin-1-yIpropylidene-1,1-bisphosphonic acid, 1-hydroxyethylidene-1,1-diphosphonic acid, 1-hydroxy-3=(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid, 6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid, 3-(dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid, 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid, 2-pyrid-2-ylethylidene-1,1-bisphosphonic acid,1-hydroxy-2-pyrid-3-ylethylidene-1,1-bisphosphonic acid, 4-chlorophenylttxiomethylenebisphosphonic acid and 1-hydroxy-2-(1H-imidazoI-1-yl)ethylidene-1,1-bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof; particularly 1,1-dichloromethylene-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof and preferably 1,1-dichloromethylene-l,l-diphosphonate monosodium trihydrate.
Chemistry:
Processes for Making Compounds of Formula I:
Compounds of Formula I in which Rs and R6 together form oxo can be prepared by proceeding as in the following Scheme i:
Scheme 1 Li\Xl R~
A
~(Rg)n R1 xz.N N.O~
R3 Ra l R ~XZ. N x? R~

(R8;~;
I(a) in which n, A, X', Xz, R', R2, R3, R4, R~ and R$ are as defined in the Summary of the Invention for Formulae I and II.
Compounds of Formula I in which Rs and R6 together form oxo (Formula I(a)) can be prepared by reacting an organometallic compound of Formula 2 with a compound of Formula 3.
The reaction is carried out in a suitable solvent (e.g. tetrahydrofuran ('I~iF~, ether, or the like) at -80 to -?0° C, preferably at about -78 ° C, and requires 30 minutes to an hour to complete. The organometallic compound of Formula 2 is generated by treating a corresponding organo compound, or a brominated derivative thereof, with n-butyllithium or tert-butyllithium in a suitable solvent (e.g. THF, ether, or the like) at -80 to -?0° C, preferably at about -?8 ° C, for approximately 30 minutes to an hour.

Compounds of Formula I in which the ring comprised by X' is a 4,5-tetrahydrooxazol-2-yl or oxazol-2-yl or moiety, Rs is hydrogen and R6 is hydroxy can be prepared by proceeding as in the following Scheme 2:
Scheme 2 Rvx~'N ~~' R3 R4 jrlrH

I~o~, R' H2N_:,:Rs s(a) Rvx2.N O ~R~
P

R
I(b) in which X2, R', Rz, R3, R°, R' and R8 are as defined in the Summary of the invention for Formulae I and II.
compounds of Formula I can be prepared by reacting a compound Formula 4 wi:>~:
a~
compound of the Formula s(a). The reaction is carried out in a suitable solvent (e.g.
70 chloroform, ethanol, or the Iike) at reflux temperatures and reguires 3 to 24 hours to complete.
In a similar fashion, using analogous reaction conditions to those described in Scheme r, compounds of Formula I in which A is a heteropolycyclic radical wherein X' is a ring member atom of an oxazole ring, RS is hydrogen and R6 is hydroxy can be prepared by reacting a compound of Formula 4 with a compound of Formula s(b):
HO
R~
H ~J
~-~'(~8)n in which n is 0, 1, 2 or 3 and B is a heteromonocyclic radical containing 5 to 6 ring member -s2-atoms or a fused heteropolycyclic radical containing $ to l l ring member atoms, wherein each "' ring contains 5 to 7 ring member atoms and each ring member atom is a carbon atom or a heteroatom, and R' and R$ is as defined in the Summary of the invention for Foranulae I and II.
Compounds of Formula I can be prepared by proceeding as in the following Scheme 3:
Scheme 3 R~ R4 A
(R~iry 1. RIXZOY
2. optionally deprotecting Rl~Xz~N X1 R7 R (R$)n I(c) in which Y is hydrogen or an activating group (e.g. 2,5-dioxopyrrolidin-1-yl (NBS), or the like) and n, A, X', X2, R', R2, R3, R', R' and R$ are as defined in the Su..rriary of the Inv~naon for Formulae I and II.
1 Q Compounds of Formula 1 can be prepared by reacting a compound of Formula 6, or a protected derivative thereof, with a compound of the formula R'XiOY, or a protected derivative thereof, and then optionally deprotecting. The reaction is carried out in the.presence of a suitable base (e.g. triethylamine, diisopropylethylamine, or the Iike) and in a suitable solvent (e.g. acetonirrile, N,N dimethylformamide (DMF), dichioromethane, or any suitable combination thereof, or the like) at 10 to 30°C, preferably at about 25 °C, and requires 24 to 30 hours to complete. When Y is hydrogen a suitable coupling agent (e.g. benzotriazole-1-yloxytrispyrrolidinophosphonium hexafluorophosphate (PyBOP~), I-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (FDG), O-benzotriazol-Z-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-1,1,3;3-tetramethyluronium hexafluorophosphate (HAT(n, 1,3-dicyclohexylcarbodiimide (DCC), or the like) and base (e.g. N,N
diisopropylethylamine, triethylamine, or the like) is required and the reaction requires 2 to 3 hours to complete.
Deprotection can be effected by any means which removes the protecting group and gives the desired product in reasonable yield. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Prmtecring Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981. Detailed descriptions of the preparation of a compound of Formula I in accordance with Scheme 3 are set forth in Examples 8, 9, IO and 12, infra.
Compounds of Formula I can be prepared by proce~.uing as in the following Scheme 4:
Scheme 4 ~2~N~ xI R7 R ~8)n RZ OH
R X2,~N xI R7 R3 R4 ~~ 8 I(c) (R )n.
in which R3' is -X7X8Rz° and n, X', X2, X', X~, R', RZ, R~, R4, R~, R$
and R~° are as defined in the Summary of the Invention for Formulae I and II.
Additional Processes for Preparing Compounds of Formula I:

Compounds of Formula i in which A is optionally substituted oxazol-2-yl can be prepared by oxidizing a corresponding compound of Formula I in which A is 4,5-dihydrooxazol-2-yl. The reduction is carried out in the presence of base (e.g.
I,8-diazabicyclo[5.4.0]under-7-ene (DBU), I,5-diazabicyclo[3.4.0]non-5-ene (DBN), or the like) in a suitable solvent (e.g. dichloromethane, or the like) at 20 to 25 ° C and requires 6 to I2 hours to complete.
Compounds of Formula I in which R' is -C(O)OH can be prepared from a corresponding compound of Formula I in which R' is methoxycarbonyl. The conversion can be effected by treating the methyl ester with sodium hydroxide in a suitable solvent (e.g, ethanol, or the like) at 20 to 25 ° C and requires 6 to 12 hours to complete.
Compounds of Formula I in which R' is -C(O)NR~'R~° or -C(O)NR"ZCHRe3C(O)OR=9, can be prepared by reacting a corresponding compound of Formula I in which R' is -C(O)OH
with a compound of the formula NHR~°RZ' or NHR42CHR43C(O)OR29, respectively. The reaction is carried out in the presence of a suitable coupling agent (PyBOP~, EDC, HBTU, DCC, or the like) and base (e.g, N,N diisopropylethyIamine, triethylarnine, or the like) in a suitable solvent (e.g., DMF, or the like) at 20 to 25° C and requires 2 to 4 hours to complete.
Compounds of Formula I fn R' is -X6X'R~°can be prepared by reacting a compound of Formula I in which R' is hydrogen with a compound of the formula R~°X'X60H. The reaction is carried out by procedures analogous to those described above for carrying out Reaction Scheme 3.
Compounds of Formula I in which Rs and R6 together form oxo can be prepared by oxidizing a compound of Formula I in which R5 is hydrogen and R6 is hydroxy.
The oxidation can be carried out with a suitable oxidizing agent (e.g. Dess-Martin periodinate, or the like) in a suitable solvent (e.g, dichloromethane, or the like) at 15 to 25° C and requires 10 to 20 hours to complete.
Compounds of Formula I in which R'Z contains a sulfonyl moiety can be prepared by oxidizing a corresponding compound of Formula I containing a sulfanyl moiety.
The oxidation is carried aut with a suitable oxidizing agent (e.g. potassium peroxymonosulfate (OXONE~, or the Like) in a suitable solvent (e.g. methanol, water, or the like, or any suitable combination thereof at ambient temperature and requires 16 to 24 hours to complete.
A compound of Formula I in which A is 1,1-dioxo-1H-1~.6-benzo[b)thien-2-yl can be prepared by oxidizing a corresponding compound of Formula I in which A is benzo[b)thien-2-yl.

Proceeding in this fashion benzyl 1-tl-11.I-dioxo-1H-l~,b-benzotblthien-2-ylcarbonvl~
3-nhenxluronvlcarbamoyll-3-meth ly burylca~bamate (Compound 209) was prepared.
'H NMR
(CDCI~: 8 0.83 - 0.95 (m, 6H), 81.35 - 1.52 (m, 1H), 81.61 - 1.69 (m, 2H), 8 2.07 ~ 2.20 (m, 1H), S 2.36 - 2.71 {m, 3H), 8 4.57 (m, 1H), 8 4.76 {m,1H), 8 4.98 - 5.26 (m, 3H), 8 5.35 (bs, 1H), 8 7.06 - 7.62 (m, 14H);
A compound of Formula I can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base farm of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound of Formula I can be prepared by reacting the free acid form of the compound with a r0 pharmaceutically acceptable inorganic ar organic base. Inorganic and organic acids acid bases ' suitable for the preparation of the pharmaceutically acceptable salts of compounds of Formula I
are set forth in the definitions section of this application. Alternatively, the salt farms of the compounds of Formula I can be prepared using salts of the starting materials or intermediates.
The free acid or free base forms of the compounds of Formula I can be prepaied from ~ 5 the corresponding base addition salt or acid addition salt form. For example, a compound of Formula I in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g. ammonium hydroxide solution, sodium hydroxide, or the like).
A compound of Formula I in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid {e.g. hydrochloric acid, etc).
20 The N oxides of compounds of Formula I can be prepared by methods known to those of ordinary skill in the art. For example, N oxides can be prepared by treating an unoxidized form of the compound of Formula I with an oxidizing agent (e.g.
trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the Like) in a suitable inert organic solvent (e.g. a halogenated hydrocarbon such as dichloromethane) at 25 approximately 0°C. Alternatively, the N oxides of the compounds of Formula I can be prepared from the N oxide of an appropriate starting material.
Compounds of Formula I in unoxidized form can be prepared from N oxides of compounds of Formula I by treating with a reducing agent (e.g. sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the 30 Like) in an suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.
Prodrug derivatives of the compounds of Formula I can be prepared by methods known to those of ordinary skill in the art (e.g. for-further details see Sauinier et al.(1994), Bioorganic and Medicinal Chemistry Levers. 4:1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound of Formula I with a suitable carbamylating agent (e.g. 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like).
Protected derivatives of the compounds of Formula I can be made by means known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981.
Compounds of Formula I can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carned out using covalent diasteromeric derivatives of compounds of Formula I, dissociable complexes are preferred (e.g. crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g. melting points, boiling points, solubilities, reactivity, and the like) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H: Wilen, Enantiomers, Racemates and Resolutions, Honh Wiley & Sons, Inc. {1981).
In summary, an aspect of the invention is a process for preparing a compound of Formula I, which process comprises:
(A) reacting an organometallic compound of Formula 2:
~\~1 R7 (R8)n with a compound of Formula 3:

~ ~ x2: N N.o~

wherein n, A; X', Xz, R', RZ, R3, R4, R' and R$ are as defined in the Summary of the Invention for Formulae'I and It, to give a compound of Formula I in which Rs and R6 together form oxo;
or (B) reacting a compound of Formula 4:
1E~2 OH
RI' 2.N p~
X

with a compound of Formula 5(a) or 5(b):
o sR~ H R7 H2N ~ B
H N--::~ s s (R )n CR )n 5 (a) 5 (b) wherein the dashed Iine represents an optional bond and B is a monocycIic radical containing 5 to 6 ring member atoms or a fused polycyclic radical containing 8 to I I ring member atoms, wherein each ring contains 5 to 7 ring member atoms and each ring member atom is a carbon atom or a heteroatom and n, R', R2, R', R°, R' and R8 are as defined in the Summary of the Invention for Formulae I and II, to give a compound of Formula I in which the ring corhprised by X' is a 4,5-tetrahydrooxazol-2-yI or oxazol-2-yl or moiety, respectively, R5 is hydrogen and R6 is ~ 5 hydroxy or (C) reacting a compound of Formula 6:

Hhi X1 R?
R3 R4 A s CR )n with a compound of the formula R'XzOY, wherein Y is hydrogen or an activating group and n, A, X', X2, R', R2, R3, R4, R' and R$ are as defined in the Summary of the Invention for Formulae I and II, to give a compound of Formula I in which Rs is hydrogen and R6 is hydroxy;
or (D) reacting a compound of Formula ?:

H X2..-N XI R7 R ~Rg)n or a protected derivative thereof, with R390H, wherein R39 is -X'XBR~°
and n, A, X', Xx, X', X8, R~, R3, R°, R', R$ and R2° are as defined in the Summary of the Invention for Formulae I and II, and deprotecting if necessary to give a compound of Formula I in which R' is -X'X$R~°, (E) optionally oxidizing a compound of Formula I in which Rs is hydrogen and R6 is hydroxy to give a compound of Formula I in which Rs and R6 together form oxo;
(F) optionally oxidizing a compound of Formula I in which A is optionally substituted 4,5-dihydroxyoxazol-2-yl to give a compound of Formula I in which A is optionally substituted oxazol-2-yl;
(G) optionally converting a compound of Formula I in which R' is -C(O)OK to a compound of Formula I in which R' is methoxycarbonyl;
(I~ optionally converting a compound of Formula I into a pharmaceutically acceptable salt, ()] optionally converting a salt form of a compound of Formula I to non-salt form;
(7) optionally converting an unoxidized form of a compound of Formula I into a pharmaceutically acceptable N oxide;
(I~ optionally converting an N oxide form of a compound of Formula I its unoxidized foam;

(L) optionally converting a non-derivatized compound of Formula I into a pharmaceutically prodrug derivative; and (M) optionally converting a prodrug derivative of a compound of Formula I to its non-derivatized form.
Processes for Preparing Intezmediates:
Compounds of Formula 3 can be prepared by reacting a compound of the Formula 8:
RZ O
HIV N.Oe with a compound of the formula R'XxOY, in which Y is hydrogen or an activating group (NBS, or the like). The reaction is carried out under conditions analogous to those set for Reaction ~ 0 Scheme 3.
Compounds Formula 8 can be prepared by reacting a corresponding amino protected carboxylic acid with N,O-dimethylhydroxylamine hydrochloride and then deprotecting. The reaction with the amine is carned out in the presence of a suitable coupling agent (PyBOP~, EDC, HBTU, DCC, or the like) and base {e.g. N,N-diisopropylethylamine, triethylamine, or the like) in a suitable solvent {e.g. dichloromethane, DNlF, or the like) at 20 to 30° C, preferably at about 25 ° C, and requires 2 to 4 hours to complete (e.g. see Reference i, infra.). Deprotecdon can be effected by any means which removes the protecting group and gives the desired product in reasonable yield (e.g. see Example 2, infra.): A detailed description of the preparation of a compound of Formula 8 is set forth in References Z and 6, infra.
Compounds of Formula 4 can be prepared by reacting a nitrite of Formula 9:

R1v 2~N
x 'CN

with ethanol. The reaction is carried out by adding the nitrite to a mixture comprising a catalytic amount of dry hydrogen chloride in a suitable solvent (e.g. chloroform, ethanol, or the like) and then allowing the reaction to proceed at 0 to 25 ° C for 4 to 6 hours.
Dry hydrogen chloride is conveniently generated by combining a slightly excessive amount of ethanol with acetyl chloride prior to adding the imidate to the reaction mixture. Alternatively, the hydrogen chloride is introduced to the reaction medium as a gas.
Compounds of Formula 6 cah be prepared by methods known to those of ordinary skill in the art. For example, compounds of Formula b in which A is optionally substituted benzooxazol-2-yl can be prepared by reacting a compound of Formula I0:
R? OH
I
R,~~~N OEt 10 in which R''° is a protecting group, with 2-aminophenol and deprotecting. The reaction with tlhe phenol is carried out in the presence of a suitable base (e.g.
diisopropylethylamine, triethylamine, or the Like) and in a suitable solvent (e.g. chloroform, or the like) at reflux temperatures to 25 ° C
and requires 10 to I2 hours to complete. Deprotection can be effected by any means which removes the protecting group and gives the desired product in reasonable yield. A detailed description of the preparation of a compound of Formula 6 is set forth in Reference , infra.
Compounds of Formula 7 can be prepared by condensing a compound of Formula 6 with a compound of the formula R'°X20Y, wherein R~° is a protecting group, and then deprotecting. The condensation is carried out in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, or the like) and in a suitable solvent (e.g. acetonitriie, DMF, dichloromethane, or any suitable combination thereof, or the like) at IO
to 34°C, preferably at about 25 °C, and requires 24 to 30 hours to complete.
When Y is hydrogen a suitable coupling agent (e.g. PyBOP~, EDC, HBTU, HATU, DCC, or the like) and base (e.g. N,N-diisopropylethylamine, triethylamine, or the like) is required and the reaction requires 2 to 3 hours to complete. Deprotecrion can be effected by any means which removes the protecting group and gives the desired product in reasonable yield.
Examples:

The following abbreviations used in this Application area defined as follows:
PyBOP~ = benzotriazole-1-yloxytrispyrroiidinophosphonium hexafluorophosphate;
THF = tetrahydrofuran;
OXONE~ = potassium peroxymonosulfate;
a EDC =1-(3-dimethylaminopropyl}-3-ethylcarbodiimide hydrochloride;
DMF = N,N dimethylformamide;
HATU = O-(7-azabenzotriazol-1-yt)-1,1,3,3-tetramethyluronium hexafluarophosphate;
HOBT = I-hydroxybenzotriazole hydrate.

Benz~l S ~N-methoxy-N-methvlcarbamovl)-3-nhenylnropylcarbamate A solution of 2-benzyloxycarbonylamino-4-phenylbutyric acid (5.05 g, I6.1 mmol) in dichloromethane (70 mL} was cooled to 0°C arid treated with diisopropylethylamine (2.82 mL, I6.2 mrnol) added dropwise and then PyBOP~ (8.53 g, 16.4 mmol) added in one portion. The mixture was stirred for 5 minutes and then treated with N,O-dimethylhydroxylamine hydrochloride (I.73 g, 1?.71 mmol) added in one portion. The mixture was neutralized with diisopropylethylamine (4.6 mL, 26.44 mmol) added dropwise, stirred for 2 hours at room temperature and then diluted with dichloromethane (70 mL). The dilution was washed sequentially with IN aqueous hydrochloric acid (3x 40 mL), saturated sodium bicarbonate (3x 40 mL) and brine (40 mL} and then concentrated. The product was purified from the residue by column chromatography eluting with 2:3 ethyl acetate/hexane to provide benz I S- N methoxv-N-methylcarbarno,Lrl,~ 3-ghenvlpropv)carbamate (5.48 g, 15.4 mmol) as an oil.
MS(PCI) mlz = 357 (M +1).
Proceeding as in Reference 1 provided tart-butyl IS-(N methoxv-N
methvlcarbamoyll-3 ~hen~lnropylcarbamate; 'H NMR (CDCl3): $ 1.35 (s, 9~, 8 I .64 - I .72 (m, 2H), 8 2.40 - 2.54 (m, 1H), b 2.60 - 2.77 (m, 1H), s 3.00 (s, 3H) 3.52 (s, 3H), S 4.23 (m, 1H), b 7.10 - 7.3'7 (m, SH).

ItE"FERENCE 2 3- 2- anobenz lsulfan 1 -2R- 'd-4- lcarbon lamino ro ionic acid A mixture of isonicotinic acid (3 g), N hydroxysuccinimide (2.79 g) and N,N dicyclohexylcarbodiimide (5.52 g) was stirred in THF (200 mL) for 16 hours. The solid was filtered off and the solvent evaporated under reduced pressure. The residue was triturated with ethyl acetate and more solid filtered off: The filtrates were concentrated under reduced pressure gave 2,5-dioxogyrrolidin-1-yl isonicotinate (5.27 g). MS: 22I [NIH]'.
A solution of L-cysteine (6 g) in ethanol (57 mL) was treated sequentially with aqueous 2N sodium hydroxide solution (30 mL) and 2-bromomethylbenzonitrile (9.71 g).
The reaction mixture was stirred 2 hours at room temperature then neutralized by addition of concentrated hydrochloric acid. A resulting solid was collected by filtration and wash sequentially with water, ethanol and diethylether to provide 2R-amino-3-(2-cyanobenzylsulfanyl)propionic acid as a white solid. MS: 237 [MH]''. MS: 235 [M]'.
A solution of 2R-amino-3-(2-cyanobenzylsulfanyl)propionic acid {590 mg) in --1~ dichloromethane was treated with 2,5-dioxopyrrolidin-1-yl isonicotinate (1.41 g) and -.
diisopropylethyamine (0.435 mL). The reaction mixture was stirred for 6 hours and then concentrated. The residue was treated with water and a resulting insoluble solid was filtered off. The aqueous filtrate was extracted twice with ethyl acetate and the combined extracts were dried over magnesium sulfate and then concentrated to provide 3-(2-cvanobenzyisulfa~ll-2R pvrid-3-carbonylaminopropionic acid (340 mg) as a gum. MS: 342 [MITj*.
HPLC:RT=.
10.63 minutes.

3-Benz Isulfan~J-2R-tetrahydropyran-4-yloxycarbonylaminopro~ionic acid A solution of tetrahydropyran-4-of (200 mg) in acetonitrile (5 mL) was treated with bis(2,5-dioxocyclopentyI) carbonate (0.753 g) and triethylamine (0.$I mL). The reaction mixture was stirred for 4 hours at room temperature and then concentrated. The residue was ' dissolved in ethyl acetate and the solution was washed with a.saturated sodium bicarbonate solution, dried over magnesium sulfate and then concentrated to provide 2,5-dioxo-pyrrolidin-1-yl tetrahydropyran-4-yl carbonate.

A solution of 2R-amino-3-benzylsulfanylpropionic acid (1 g) and triethylamine (0.8 mL) in dichloromethane (40 mL) was treated with 2,5-dioxo-pyrrolidin-1-yl tetrahydro-pyran-4-yI
carbonate (1.15 g). The mixture was stirred for 16 hours at room temperature and then concentrated. The residue was dissolved in ethyl acetate and the solution was washed sequentially with hydrochloric acid and brine, dried over magnesium sulfate and then concentrated. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:1, v/v) to provide 3-benzylsulfanvl-tetrahydronyran-4-ylox caY rbonylamino~~ropionic acid (800 mg) as an oil.

3-Benzyisulfanyl-2R-monphoIin-4.-vlcarbonvlaminopropionic acid A solution of 3-benzylsulfanyl-2R-aminopropionic acid hydrochloride (25 g, 0.118 mol) in 2N sodium hydroxide (59 mL, 0.118 mol) was cooled in an ice bath and then treated sirrmultaneousIy with morpholine-4-carbonyl chloride (I3.8 mL, 0.118 mol) and 1N sodium hydroxide (I I8 mL, 0.118 mol). The mixture was stirred at 0°C for 30 minutes and then filtered. The filtrate was acidified with SN hydrochloric acid and extracted with ethyl acetate (Sx 100 mL). The combined extracts were dried (MgSO,), filtered and concentrated to provide 3-benzvlsulfanyl-2R-morphoIin-4-ylcarbonylaminopropionic acid (19.65 g, 60.6 mmol) as a white solid.
REFERENCE S
3-Benzylsulfonyl-ZR-morpholin-4-ylcarbonylaminopro~ionic acid A solution of 3-benzylsulfanyl-2R-morpholin-4-ylcarbonylaminopropionic acid (17.58 g, 54.2 mmol), provided as in Reference 4, in methanol (550 mL) was treated with a solution of OXONE~ (50 g, 8I.4 mL) in water (550 mL). The mixture was stirred at room temperature for 2 hours and then concentrated to dryness. The residue was taken up into water (90 mL) and ethyl acetate (600 mL}. The mixture was stirred vigorously and the aqueous layer was separated and extracted with ethyl acetate (2x 100 mL). The combined ethyl acetate layers vi~ere dried (MgS04) and concentrated. The residue was triturated with diethyl ether and the solid material was collected by filtration to provide 3-benzvlsulfonvl-2R-momholin-4-ylcarbon3rIaniinonro~ionic acido 2-Amino-ld methoxy-N-metl~l-4-.phenylbutyramide trifluoroacetic acid salt A solution of tert-butyl 1-(N methoxy-N-methylcarbamoyl)-3-phenylpropylcarbamate (9.32 g, 29 mmol}, provided as~in Reference 1, in dichloromethane (100 mL) was cooled to 0° C
and then treated with anisole (5 naL, 46.5 mmol} and trifluoroacetic acid (50 mL, 296 mmoi).
The mixture was stirred for 30 minutes, while allowing it to warm to room temperature, and then concentrated. The residue was dissolved in toluene (10(1 mL) and the solution was concentrated. The residue was again dissolved in toluene (100 mL) and concentrated to provide 2-amino-N methoxv-N methyl-4-phenylbntyramide trifluoroacetic acid salt (9.74 g 29 mmoI) as a crude product. MS(PCI} mlz = 223 (M +1).

Ethyl 3S-benzyloxycarbonv)amino-2-hvdroxy 5 phen~pentanimidate i5 A suspension comprised of lithium aluminum hydride (0.885 g, 23.3 mmol) in anhydrous diethyl ether was cooled to -4S ° C under nitrogen and then treated with a solution of benzyl 1S-(N methoxy-N-methylcarbamoyl}-3-phenylpropylcarbamate (5.53 g, 15.53 mmol), provided as in Reference 1, in ether {75 mL) and THF (25 mL) added dropwise over a period of 30 minutes such that the temperature of the mixture was maintained at -40 to -45 ° C. The mixture was allowed to warm to 5 ° C and then recooled to -35 °
C. A saturated solution of sodium bicarbonate,(? mL, 0.5 M) was added dropwise and the mixture was allowed to warm to 0° C. The mixture was allowed to warm to room temperature and stirred far 1 hour to provide a precipitate. The precipitate was collected by filtration and washed with ether (I00 mL): The filtrate and washings were combined and washed sequentially with ice cold 1N
hydrochloric acid (2x SO mL), saturated sodium bicarbonate {2 x 50 mL) and brine (50 mL), dried (Na~SO~
and concentrated in vacuo to provide benzyl 1S-formyl-3-phenylpropylcarbamate (4.01 g, 13.5 mmol) as a colorless oil. MS (PCI) nnJz = 298 (M + I).
A solution of benzyl 1S-formyl-3-phenylpropylcarbamate (4.557 g, 15.3 mmol) in anhydrous dichloromethane (50 mir) was stirred while sequentially treated with 2-hydroxy-2-methylgroionitriIe {4.25 mL, 46.2 mmol) and triethylamine (1.28 mL, 9.20 mmol). The mixture was stirred for 4 hours at room temperature and concentrated in varua.
The residue was dissolved in ether (100 mL) and the solution was washed sequentially with water (S x 20 mL) and brine (20 mL), dried (MgSO,~ and concentrated to provide benzyi 2-cyano-2-liydroxy-1S-phenethylethylcarbamate (4.957 g, 15.3 mmol) as a yellow oil. 'H NMR
(CDC13) 81:75 - 2.01 (m, 2H), b 2.08 - 2.24 {m, III, b 2.51 - 2.80 (m, 2H), 8 3.70 - 4.02 (m, IH), 8 5.07,, & 5.33 (m, 3H?, E ?.10 - 7.47 (m, 10I~.
A mixture of chloroform (30 mL) and anhydrous ethanol (30 mL, 510 rnmol) was cooled .10 to 0° C and then treated with acetyl .chloride 132.6 mL, 459 mmol) added dropwise over a period of 30 ininutes. The mixture was cooled by adding a solution of crude benzyl 2-cyano-2-hydroxy-1S-phenethylethylcarbamate (4.957 g, 15.3 mmol) in chloroform (30 mL). The mixture was fitted for 2 hours at 0°C and then 6 hours at room temperature and concentrated in vacuo to,provide ethyl 3S-benzyloxvcarbonylamino-2-hydroxy-S-phenylpentanimidate (6.212 g 15.3 rnmol) as a crude yellow oil. MS (PCn mlz = 371 (M + I).

2S-Amino-4-vhenvl-1 ~4S=phen 1~-4.5-dihydrooxazol-2-yllbutan-1-of (a) A mixture comprised of ethyl 3S-benzyloxycarbonylamino-2-hydroxy-S-phenylpentanimidate (0.78 g, 1.92 mmol), provided as in Reference 7, diisopropylethylamine (0.218 pL, 1.26 mmol) and ZS-amino-2-phenylethanol (0.260 g, 1.9 mmol) in chloroform (2S mL) was heated at reflux for 3 hours and then was stirred for approximately i2 hours, while allowing to cool to room temperature. The mixture was concentrated and the residue was dissolved in ethyl acetate (50 mL). The solution was washed sequentially with O.SN sodium hydroxide (40 mL) and brine (40 mL), dried (MgSC)~) and then concentrated. Product was purified from the residue by flash chromatography eluting with 1:3 hexanes/ethyl acetate to provide benzyl 2-hydroxy-2-(4,5-dihydro-.4S-phenyloxazol-2-yl}-1S-phenyethylethylcarbamate (0.475 g, 1.1 mmol) as an oily mixture of diastereomers. MS (PCl7 miz = 445 (M +1).
(C27H~Nz04).
(b) A solution comprised of benzyI 2-hydroxy-2-(4,5-dihydro-4S-phenyloxazol-2-yl}-1S-phenyethylethylcarbamate (100 mg, 0.22 mmol) in methanol (10 mL) was placed under a nitrogen atmosphere and stirred while Pearhaan's catalyst (20 mg) was added.
The mixture was stirred vigorously under a hydrogen atmosphere until the reaction was complete and then filtered. The filter was washed with methanol (2 x 25 mL). The cambined filtrates were concentrated to provided 2S-amino-4-phenyl-1-l4S-phenyl-4 5-dih~drooxazol-2-vl)butan-1-of (51 mg, 0.16 mmol) as a clear oil. MS (PC>') mlz = 311(M +1). (C,~-IuNZO~.
Proceeding as in Reference 8 provided methyl 2-(2S-benzyloxycarbonylamino-1-hydroxy-4-phenylbutyl)-4,5-dihydroaxazole-4-carboxylate.

2S-Amino-1-oxazol-2-yl_4-phe~lbutan=1-of trifluoroacetic acid salt 90 A solution comprised of oxazole (0.25 g, 3.62 mmol) in T~' (20 mL) was treated with borane tetrahydrofuran complex (3.62 mL, 3.62 mmol).under nitrogen and the mixture was stirred for 30 minutes and then cooled to -78 °C. A solution comprised of sec-butyl lithium (2.78 v mL, 3.62 mmol) in cyclohexane was added dropwise and the mixture was stirred for 30 minutes.
A solution comprised of ten-butyl (S~l-formyl-3-phenylpropylcarbamate (0.476 g, I.81 mm~y 75 in T.I~ (25 mL} was added and the mixture was stirred and allowed to warm while the reaction proceeded to completion. The mixture then was cooled to -78°C, quenched by slowly adding 5% acetic acid in ethanol (20 mL), allowed to warm to ambient temperature and stirred for 18 hours. The mixture was concentrated to dryness and the residue was extracted with ether (2x25 mL}. The combined extracts were washed with brine, dried (MgSO~ and concentrated 20 to dryness to provide tert-butyl 2-hydroxy-2-oxazol-2-y1-1S-phenethylethylcarbamate (0.12S g, 0.376 mmol) as a yellow oil. MS (PCn m!z = 333 (M + 1).
A mixture comprised of tent-butyl 2-hydroxy-2-oxazol-2-yl-IS-phenethylethylcarban~
(0.125 g, 0.376 mmol), anisole (0.2 mL} and trifluoroacetic acid (0.6 mL) in dichlorornethane (20 mL) was stirred at room temperature for 2 hours and then concentrated to provide 25 2S-amino-1-oxazol-2-yi-4-yhenylbutan-1-of trifluoroacetic acid salt ( 0.08 g, 0.229 mmol) asa yellow oil. MS (PCI) m/z = 233 (M + 1}.

REFERENCE I U
Methyl 2-l2S-amino-1-h~rdroxv-4-QhenvlbutYl)oxazole-4-carboxylate A solution comprised of methyl 2-(2S-benzyloxycarbonylamino-l-hydroxy-4-phenylbutyl)-4,5-dihydrooxazole-4-carboxylate (0.100 g, 0.235 mmol), provided as in Reference 10, in dichloromethane (3 mL) was cooled to 0° C and then treated with DBU
(39 mL, 0.26 mmol) and bromotrichloromethane (26 mL, 0.26 mmol). The mixture was stirred for 6 hours at 0° C, washed with ammonium, chloride (10 mL) and concentrated. The residue was dried (MgSOd) to provide methyl 2-(2S-benzyloxycarbonylamino-I-hydroxy-4-phenylbutyl)oxazoIe-4-carboxylate. MS(PCn mlz = 425 (M ~I).
' ' Deprotecting provided methyl 2-l2S-amino-1-hydrox~
4-,~henylbutyl)oxazole-.4-carboxylate.

2-Benzooxazol-2-yl-2-pert-butyl-dimethvl-silanyloxy)-1S-phenethylethylamine A solution of 2S-amino-l-benzooxazol-2-yl-4-phenylbutan-I-of (600 mg), provided as in Referencel2, in dichlaromethane (IS mL) was cooled to 0°C and then treated with 2,6-lutidine (0.57 mL) followed by tert-butyldimethylsilyl trifluoromethanesulfonate (1.08 mL). The solution was stirred for 3 hours and then additional dichloromethane was added (SO mL).
The mixture was washed sequentially with a saturated sodium bi-carbonate solution (50 mL) and brine (50 mL x2), dried over magnesium sulphate and concentrated under reduced pressure to provide 2-benzooxazol-2:y1-2-ftert-butyl-dimethyl-silanyloxy)-IS-phenethylethyIamine as an orange oil.

2S-Amino-1-benzooxazol-2 y1-4-phenylbutan-1-oI
A solution of (S)-2-tern-butoxycarbonylamino-4-phenylbutyric acid (S00 g, 179 mmol), EDC (37.8 g, 197 mmol), H4BT (4l.lg, 269 mmol) and N,O-dimethylhydroxylamine hydrochloride (19.2 g, 197 mmol) in , dichIoromethane (S00 mL) was cooled in an ice bath and then treated with a solution of triethylamine (27.5 mL, 197 mmol) in dichloromethane (1S0 mL).
The ice bath was removed and the reaction mixture was stir at room temperature for approximately I2 hours. The mixture was concentrated by rotary evaporation and the residue was treated with ethyl acetate (450 mL), water (300 mL) and saturated sodium bicarbonate until all solids .were dissolved. The ethyl acetate layer was separated and washed sequentially with saturated sodium bicarbonate {100 mL), water (100 mL), IN hydrochloric acid (100 mL), water (i00 mL) and brine (50 mL). The solution was dried over anhydrous magnesium sulfate and concentrated to provide ten-butyl (S)-1-(N methoxy-N methylcarbamoyl~
3-phenylpropyicarbamate (53.41 g, 93°lo yield) as a clear, colorless oil.
The tert-butyl (S)-1-(N methoxy-N methyIcarbamoyl}-3-phenylpropylcarbamate provided above was divided into three portions (5.0 g 15.5 mmol; 4.88 g , 15.1 mmol; and 4.54 g, 14.1 mmol). Each portion was azeotroped with toluene by rotary evaporation and dried under reduced pressure to remove residual ethyl acetate and water. Each portion of the ester was taken up into anhydrous diethyl ether (75 mL) and the mixtures were cooled in an ice bath under nitrogen. Each of the mixtures were treated with lithium aluminum hydride (1M
in diethyl ether, 23.3 mL, 22.7 mL, and 21.1 mL, respectively) added by syringe and the mixtures were i5 stirred at 0°C for 90 minutes. The mixtures were treated with ethyl acetate (5 mL), stirred~for ZS minutes, further treated with saturated KIi2P04 (5 mL), 1N hydrochloric acid {I mL) and then additional 1N hydrochloric acid until the solid mass dissolved. The resulting solutions were combined and extracted with ethyl acetate (3x 200 mL). The extracts were dried over anhydrous magnesium sulfate and concentrated. The residue was dried under reduced pressure to provide tent-butyl (S)-I-formyl-3-phenylpropylcarbamate 111.61 g, 99%
yield).
A solution of tert-butyl (S)-1-formyl-3-phenylpropylcarbamate (1I.15 g, 42.3 mmol) in dichloromethane (25 mL) was cooled in an ice bath under nitrogen and then treated sequentially with acetone cyanohydrin (10.8 mL, I 19 mmol) and triethylamine (3.5 mL, 25.4 mmol). The reaction was stirred for approximately 12 hours at room temperature and then concentrated by rotary evaporation. The residue was dissolved in 1:1 hexanes:ethyl acetate (250 mL) and the solution was washed sequentially with water (3x I00 mL) and brine (50 mL), dried over anhydrous magnesium sulfate and concentrated. Product was purified from the residue by silica gel chromatography using 2:1 hexanes:ethyl acetate eluent to provide ten-butyl 2-cyano-Z-hydroxy-1S-phenethylethylcarbamate (12.05 g, 98% yield).
A mixture of chloroform (12.8 mL) and absolute ethanol (9 mL, 153 mmol), under a nitrogen stream with an attached Firestone valve bubbler, was cooled in an ice bath and then treated with acetyl chloride (9.2 mL, I29 minol) added by syringe. The mixture was allowed to stand for 5 minutes and then a solution of tent-butyl 2-cyano-2-hydroxy-1S-phenethylethylcarbamate (2.34 g, 8 mmol) in chloroform (19.2 mL) was added. The nitrogen inlet was removed and the mixture was stirred and slowly warm to room temperature over approximately I2 hours. The mixture then was concentrated by rotary evaporation and the residue was treated with absolute ethanol (40 mL)and o-aminophenol (873 mg, 8 mrnol). The mixture was heated at 95°C under nitrogen for 5 hours and then stirred at room temperature for approximately I2 hours. The mixture was treated with diethyl ether (150 mL) and the resulting solution was washed repeatedly with 1N KOH until the aqueous wash layer was colorless. The organic phase was separated, dried over anhydrous magnesium sulfate and concentrated. The residue was recrystallized from hot hexane and a minimum amount of ethyl acetate to give a tan powder (335 mg). The mother liquor was combined with the mixed fractions from a similarly performed reaction nan and purified by silica gel chromatography using 5% methanol in dichlorornethane to provide 2S-amino-I-benzooxazoI-2-yl-4.-nhenylbutan-1-of (L2? g, 52% average yield) as an orange semi-solid mass.
Proceeding as in Reference 22 provided the following compounds:
2-amino-1-benzooxazol-2-y1-ethanol;
2.-amino-I-benzooxazol-2-yI-2-methyl-propan-1-oI;
~,Sl-2-amino-I-benzooxazol-2-vI-hexan-1-ol;
I-ll-amino-cy.,clopropyl~-1-benzooxazol-2-yl-methanol;
(SZ2-amino-I-benzooxazol-2-yl-propan-1-ol;
~S)-2-amino-I-benzooxazol-2-girl-4-methanesulfonvl-butan-I-ol;
sS)-2-amino-i-benzooxazol-2 yl-pentan-I-oI;
~S~2-amino-7-benzooxazol-2yI-butan-I-ol; and 2-Amino-1-benzooxazol-2-yl-3-methoxy.propan-1-ol;'H NMR (CDC13): 7.70 (m, 1H), ?.53 (m, 1H), 7.34 (rn, 2H), 4.88-5.0 (rn, IH), 3.60 (m; iH), 3.53 (m, 3H), 3.3? (s,1H), 3.30 (s, 1H); .

XAMPLE 1 _.
N- 1R- 2-Benzaoxazol-2- 1-2-h drox -1 - he eth Ieth tcarbamo 1 -2-be z lsulf n leth rnorpholine-4-carboxamide (Compound 1) A mixture of 2S-amino-1-benzooxazol-2-y1-4-phenylbutan-I-of (2.2 g, ?.8 mrnol), provided as in Reference 12, 2-mozpholfn-4-ylcarbonylamino-3-benzylsulfonylpropionic acid _ , (2.78 g, 7.8 mmol), EDC (1.64 g, 8.57 mmol), 1-hydroxybenzotriazole hydrate (1.58 g;

11.7 mmoi) and N methylmorphoIine (2.4 mL, I7.1 mmoI) in dichloromethane was stirred for I
hour. The mixture was treated with additional amounts of EDC (0.1 eq) and I-hydroxybenzotriazole hydrate (O.I eq) and stirred for 30 minutes. The mixture was treated with an additional amount of EDC (0.1 eq) and stirred for 15 minutes: The mixture was treated with an additional amount of EDC .(0.1 eq) and stirred for 30 minutes. The mixture was concentrated and the residue was taken up into ethyl acetate. The mixture was washed sequentially with 1N hydrochloric acid (3x 50 mL), saturated sodium bicarbonate solution (2x 50 mL) and brine (50 mL), dried (MgS04) and concentrated to provide N 1R-(2-benzooxazol-2-yl-2-hydroxy-IS-ph nethylethvlcarbamoyl)-2-benzylsulfon~leth-yllmorrpholine-4-carboxamide (4 g, 6.44 mmol); tH NMR
(CDC13): 7.6$ (m, 1H), 7.52 (m, 1H), 7.10-7.45 (m, I2H), 6.0-6.25 (m, 1H), 4.95-5.1 (m, 1H), 4.52-4.80 (m, 1H), 4.i5-4.5 (m, 3H), 3.I-3.75 (m, lOH), 2.69 (m, 2H), 2.06 (m, IH), 1.80 (m, 1H);
IVlS: m/e 621.0;

ZS-Acet lamino-N 2-oxazol-2- 1-2-h drox -IS- heneth Ieth 1 -3-c clohex 1 ro ionamide (Compound 2) A mixture comprised of 2-acetylamino-3-cyclohexylpropionic acid {0.45 g; 0.211 mmol), PyBOP~ (0.1 I g, 0.21 mmol) and diisopropylethylamine (0.037 g, 0.211 mmol) in DMF (10 mL) was stirred for 15 minutes at room temperature and a solution comprised of 2S-amino-1-oxazol-2-yl-4.-phenylbutan-I-of trifluoroacetic acid salt, provided as in Reference 9, in DMF
and neutralized with diisopropylethylamine was added. Additional diisopropylethylamine (0.037 g, 0.211 mmol) was added and the mixture was stirred for 2 hours at room temperature and then poured into 100 mL of ice cold water. The aqueous phase was extracted with ethyl acetate (3 x 25 mL) and the combined organic layers were washed sequentially with 1 N
hydrochloric acid {2 x 2S mL), water (2 x 25 mL) and brine (2 x 25 mL), drricd (MgSO~j and concentrated. JProduct was purified fr~am the residue by flash chromatography eluting with i:3 hexanes/ethyl acetate to provide 2S-acetylamino-N l2-oxazol-2-vl-~-hydroxv-1S_phenethylethvl'i-3-cyclohexylpropionamide (0.036 g, 0.084 mmol) as an oil. MS
(ESI) m/z = 428 (M + i ); 'H-NMR {300 MHz, CD3OD): 8 0.80 (m, 2H), S L 12 (m, 4H), 8 1.40(m, 2H), 8 1.65 (m, 6H), s 1.80 (m, 1H), 8 2.00 (m, 4H), 8 2.70 (m, 1H), S 2.80 (m, 1H), 8 4.44 (m,1H), b 4.51 (m, iH), 8 7.1 I -:7.47 (m, 6H), b 7.99 {s, 1H), {C~H33~3~~~
Proceeding as in Example 2 provided the following compounds of Formula I:
3-c clohex 1-N- 2-h drox -2- 5- hen loxazol-2- 1 -1S- heneth leth 1 ro ionamide (Compound 3); MS (ESI) m/z = 448 (M + I ); 'H-NMR (300 MHz, CDC13): 8 0.89 (m, ZH), -?2-81.20 (m, 4H), b 1.45 (m,1H), E 1.65 (m, 6H), b 1.80 (m, iH}, 8 2.09 (m, 4H), b 2.73 (t, J = 4 ~-Hz, 2H), S 4.S I (m, 1 H), 8 4:96 (m, 2H), 8 6.00 {m, i H), 8 7.11 - 7.47 {m, 9H}, 8 7.60 (m, 2H);
{~H3~3~3)~
2S-acetxlamino-N-f 2-hvdroxy-I S-pheneth)!J-2-l5-phenvloxazoI-2-vI)ethyll-3-cyclohexvlvropionamide (Compound 4); MS (ESI) m/z = 505 (M + 1);'H-NMR (300 MHz, CDC13): b 0:80 (rn, 2H), 81.12 (m, 4H), $1.40 (m, 2H), b 1.65 (m, 6H), 81.80 (m, 1H), 8 2.00 (m, SH), 8 2.70 (m, 2H), 8 4.5I (m, IH), 8 4.96 (m, 2H), S 6.I9 (m, 1H), 8 6.98 (m, 1H}, 8 7.11 - 7.47 {m, 9H), 87.62 (m, 2H), {C3pH38N3~4)9 ~d N-( I S-benzothiazol-2-vlcarbonvl-3-phenylpropyl)-3-cyclohexylpropionamide {Compound 5);'H NMR: b 0.83 (m, 2H}, 8 1.20 (m, SH), 8 1.48 (q, 2H, J = 9 Hz), 81.67 (m, 4H), 8 2.20 (m, 3H), 8 2.48 (m, 1H), 8 2.75 (m, 2H), 8 5.95 (m, 1H), 8 6.35 (d, 1H, J = 9 Hz), 8 ?.2S (m, 5H), 8 7.57 (m, 2H), 8 7.93 (d, 1H, J = 9 Hz), 8 8.18 (d, 1H, J = 9 Hz); ES-MS mlz 435 (MH+}; and 2S-acetylamino-N (1S-benzothiazol-2-ylcarbonyl_3-phenylpropyl)-3-cyclohexyl_vropionamide (Compound 6);'H NMR: 8 0:87 (m, 8H), 8 1.22 (m, 6H), 8 1.92 (m, IH), 8 2.12 (m, 1H), 8 2.48 (m, iH), b 2.78 (m, 2H), b 3.87 (d, IH, J = 7 Hz), b 5.62 (m, 1H), b ?.20 (m, 6H), 8 7.53 (m, 2H), & 7.98 (d, 1H, J = 7 Iiz), S 8.18 (d, 1H, J =
7 Hz); ES-MS m/z 492 (MH+).
N-i 1 S-f 1 S-phenethvl-2-benzaoxazol-2-yl-1-oxoethylcarbamaylZ
2-naphth-2-ylethyllpi~eridine-4-carboxamide (Compound 7),'H NMR (DMSO-db}: 8 i.32 - 1.76 (m, 4H), 81.90 - 2.09 (m, 2H), 8 2.22. - 2.60 (m, 2H), 8 2.65 - 3.26 (rn, 6H), 8 4.?2 - 4.86 (m, 1H), b 5.26 (m,1H), 8 7.06 - 7.31 (m, SH), 8 7.45 (m, 4H), 8 7.55 (dt, J =
1.26, 7.84 Hz, 1H), 8 7.65 (dt, J = 1.18; 8.00 Hz, 1H), 8 7.72 - ?.88 (m, 3H), 8 7.90 (d, J = 8.06 Hz, 1H}, 8 7.99 (d, J ~ 7.86 Hz, 1H), 8 8.I4 (bs, IH), 8 8.24 (d, J = 8.04 Hz, IH), 8 8.46 (bs, 1H), 8 8.94 (d, J = 6.43 Hz; 1H);
2S-acetylamino-N (1S-benzooxazol-2 ylcarbonyl-3-nheny_lpropyl)-3-cyclohexy_Ipropionamide (Compound 8); MS (ESI) m1z = 476 (M + 1);'H-NMR (300 MHz, CDCl3): 8 0.85 (m, 2H), 8 I.26 (m, 4H}, 8 I.47 (m, 2H), S i.b4 {m, 6H), 8 1.99 (s, 3H}, 8 2.I5 (m, 2H), 8 2.41 (in, iH), 8 2.72 (t, J = 6Hz, 2H), b 4.59 (q, J = 4Hz, 1H), 8 5.65 (q, J = 2Hz, 1H), 8 6.26 (d, J = 6 Hz, 1H), 8 7.10 - 7.26 (m, 6H), 8 7.41 - 7.65 (m, 3H), 8 7.86 (d, J = 6Hz IH), (CZBH33N3o4}~
rerr-butyl 1 S-( 1 S-benzooxazol-2-ylcarbonyl-3-phenylt~ropylcarbamoxl)-2-cyclohexvlethylcarbamate (Compound 9);
N f 1-fbenzooxazol-2-ylcarbonyl)-3-phenylpropyll-3-c clohexylpropionamide (Compound IO);
3-cyclohex~-N f3S=phenyl-1 ~S-phenyloxazoI-2-ylcarbonyl_)pronyl~ropionamide (Compound 11 ); MS (ESl7 mlz = 445 (M + 1 ); 'H-NMR (300 MHz, CDCI3): 8 0.89 (m, ZH), 8 1.20 (m, 4H), 81.55 (m, 2H), 81.68 (m, 6H), ~ 2.12 (m, 1H), S 2.27 (t, J =
4Hz, 2H), 8 2.48 (m, 1H), S 2.76 (m, 2H), S 5.70 {m, 1H), S 6.35 (d, J = 4 Hz, IH), S 7.19 -7.30 (m, SH), 8 7.48 (m, 3H), 8 7.57 (s, 1H), 8 7.79 (d, J = 4Hz, 2H), (C2gH32N2o3)~
2S-acet5rlamino-N-f 1S-(5-phenyloxazol-2-ylcarbonvl)-3-phenylprop 3-cyciohexylpropionamide (Compound 12); MS (ESA m/z = 502 (N! + 1);''H-NMR
(300 MHz, CDCl3): 8 0.80 (m, 2H), 8 1.12 (m, 4H), b 1.50 (m, 1H), $ 1.65 (m, 6H), 8 1.80 (m, 1H), 8 2.05 (s, 3H), S 2.12 (m, 1H), S 2.48 (m, 1H), b 2.70 (t, J = 6Hz, 2H), b 4.52 (q, J
= 2Hz, 1H); 8 5.60 (q, J = 2Hz, iH), S 5.9$ (d, J = 6 Hz, 1H), 8 6.92 (d, J = 6Hz,1H), 8 ?.19 -7.30 {m, SH), 8 7.48 (m, 3H),. b 7.57 {s,. IH), S 7.79 (d, J = 4Hz, 2H), (C3pH~3N3~4}~
. benzvl 1 S-lbenzooxazol-2-ylcarbonvlmethyicarbamoyl)-3-methylbutvlcarbamate (Compound 13);
benzyl I S-(5-phenylbenzooxazol-2-vlcarbonvlmethylcarbamoyl)-3-meth~butylcarbamate (Compound 14);
2S-ace lamino-N- IS-oxazol-2- lcarbon 1-3- hen 1 ro 1 -3-c clohex I r ionamide (Compound 15); MS (ESA mlz = 426 (M + 1); 'H-NMR (300 MHz, CDCl3): e~ 0.85 (m, 2H), 8 1.20 (m, 4H), b 1.50 {m, 2H), 81.65 (m, 6H), S 2.05 (s, 3H), 8 2.48 (m, 1H), & 2.70 (t, J = 6Hz, 2H), 8 4.52 (q, J = 2Hz, 1H), 8 5.60 (q, J = 2Hz, 1H), F 5.93 (d, J =
~ Hz, IH), 8 6.89 (d, 3 = 6Hz, 1H), 8 7.19 - 7.38 (m, 5H), 8 7.47 (s, 1H), b 7.79 (s, 1H), (C~H3,N304);
benzyl 1S-benzooxazol-2-vlcarbonyl-3-phenylprop,~rlcarbamate {Compound 16);
2-acetylamino-N (1S-benzooxazol-2-ylcarbonvl-3-phenylpropvl)-3-,phenvlnropionamide (Compound 17);
N-~1S-benzooxazol-2 ylcarbonyl-3-oheny~propyl)benzvlsulfonamide (Compound 18);'H
NMR (CDC13): 7.88 (d, J=6.2Hz, 1H), 7.67 (d, J=6.2Hz, 1H), 7.60 (t, J=6.2Hz, 1H), 7.51 (t, J=6.2Hz, 1H), 7.35 (d, J=6.2Hz, 2H), 7.08-7.29 (m, 7H), 6.96 (t, J=6.2Hz, 1H), 5.52 (d, JK=9.4 Hz, 1H), 4.90 (td, J=9.4, 3.IHz, 1H), 4.31 (dd, J=10.9, 10.9Hz, 2H), 2.80 (m, IH), 2.27 (m, 1H), 2.04 (m, 1H}; MS: m/e=4.35.0;
N ~1S-benzooxazol-2-ylcarbonyl-3-phenvlpropvl)-2-cyclohexylethanesuIfonamide (Compound 19); 'H NMR (CDC13): 7.94 (d, J=6.3Hz,1H}, 7.70 (d, J=6.3Hz, IH), 7.62 (t, J=6.3Hz, 1H), 7.52 (t, J=6.3Hz, IH), 7.17-7.34 (m, SH), 5.42 (d, J~9.5Hz, 1H), 5.17-5.25 (m,' IH}, 2.79-3.09 (m, 4H), 2.38-2.55 (m, 1H), 2.08-2.21 (m, 1H), 1.52-1.79 (m, 7H), 1.08-1.34. (m, 4H), .77-I.O1 (m, ZH); MS m/e=455.3;
N (1-benzooxazol-2- lcarbonyl-3-nhenylpropyl)-3-cvclopentYlpropionamide (Compound 20);
N (IS-benzooxazoI-2-ylcarbonyl-3-phenylprogyl)-2-cvclohex~Iacetamide (Compound 21};
N-(1S-benzooxazoI-2-ylcarbonyl-3 phenylprop~rl)-2-bicyclof2.2.lyhept-2-ylacetamide 0 {Compound 22};
N-(1S-benzooxazol-2-ylcarbonyl-3-nhenylprog I)-4-met>~Ipentanamide (Compound 23) ;
N l1S-benzooxazol-2-vlcarbonvl-3-phenvlprop~-2-naphthaIen-1- l~tamide {Compound 24);'H NMR (CDC13): 7.96 (m, 1H), 7.84 (m, 2H), 7.82 (m, IH); 7.42-7.75 (nn, 6H), 7.14 {m, 4H), 6.86 (m, 2H), 6.25 (m,1H}, 5.64 (m, 2H), 4.08 (m, 1H), 2.45 (m, ZH),2.42 i5 (m, 1H), 1.90 (m, 1H); .
N (1-benzooxazol-2-ylcarbonyl-3-nhenylpropyl)-3-phenvloropionamide (Compound 25);
'H NMR (CDC13): 7.90 (d,J=B.OHz, 1H), 7.65 (d,J=8.OHz,1H), 7.59 (m, 1H}, 7.56 (m, 1T~, 7.05-?.35 (m, 11H), 6.20 (d,1=7.OHz, 1H), 5.76 (m, 1H), 2.97 (m, 2H), 2.5-2.7 (m, 4H), 2.4 (m, 1H), 2.1 (m, 1H);
?0 methyl2-(2-l3S-cvclohexvlpropionvlaminoy-4-nhenvlbutvrvll-4.5-dihvdrooxazole-4S-carboxvlate {Compound 26); MS {ESI) m!z = 429 (M + 1);'H-NMR
(300 MHz, CDC13): 8 0.89 (m, 2H), $ 1.22 (m, 4H), 81.51 (m, 1H), S 1.65 (m, 6H), 8 2.05 (m, IH), S 2.20 (t, J = 4 Hz, 2H), 8 2.46 (m, 1H), b 2.73 (m, 2H), b 3.80 (s, 3H), 8 4.55 {m, 1H), '~ 4.60 (m, 1H), 8 5.00 (m, 1H), 8 5.45 (m,1H), 8 6.15 (m, 1H), 8 7.13 - 7.35 (m, 5H), (~H32N2~5}~
methyl 2-f2-(3S-cvclohexvlpronionylaminol-4-phenylbutvrvlioxazole-4-carbox ly ate (Compound 27); MS (ESI) mlz = 427 (M + 1);'H-NMR (300 MHz, CDC13): 8 0.89 (m, 2H), 8 L22 (m, 4H), 8 1.49 (m, 1H), S 1.65 (m, 6H), & 2.20 (m, 3H), S 2.46 (rn, 1H), b 2.74 (m, 2H}, 8 3.99 (s, 3H), 8 5.62 (m, 1H), b 6.20 {d, J = 4Hz, 1H), S 7.15 - 7.35 (m, 5H), S 8.40 (s, IH), 30 (C~,H~IV20s);
benzyl I S-(I S-benzooxazol-2-y-lcarbon~)-3-phenvlpropvlcarbamo l~phthalen-2-ylet~lcarbamate {Compound 28);

2-acetvlarnino-,N~- 1S-benzooxazol-2-ylcarbonvl-3-phenvlnrovvll- .
3-(2-fluorophenYl)propionamide (Compound 29);
2S-acetvlamino-N (1S-benzooxazol-2-ylcarbonvl-3-phenvlpropyl)-2-methyl- .
3-nhen~nropionamide {Compound 30);
tert-butyl 1SS,IS benzooxazol-2-vlcarbonyl-3-phenylprop~lcarbarnovl)-3-nhenylprowlcarbamate (Compound 31);
- 1-benzooxazol-2- lcarbon 1 -3- hen 1 r 1 lohex Iy but~ramide (Compound 32);'H NMR (CDC13): 7.94 (d, J=7.9Hz, 1H), 7.68 (d, 7.9Hz, 1H), ?.58 (t,J=7.9Hz, 1H), 7.50 (t, J=7.9Hz, IH}, ?.10-7.32 (m, SH), 6.27 (d, J=lI.8Hz, 1H), 5.76-5.89 (m, 1H), 2.74-2.89 (ni, 2H), 2.42-2.61 (m, iH), 2.11-2.32 (m, 3H); 1.53-1.79 (m, 9H), 1.05-1.32 (m, 4H), 0.79-L0 (m, 2H); MS: mle=433;
methyl 2-f 2S-(3-cyclohexylpropionvlamino)-4-phen~t~r~ll-4y5-dihydrooxazol-4S-ylcarboxvlate (Compound 33); MS (ESI) mlz = 429 (M + 1);
'H-NMR
(300 MHz, CDCl3): 8 0.89 (m, 2H), 8 1.22 (m, 4H), & 1.51 {m, 1H), S 1.65 (m, 6H), S 2.05 (m, i5 1H), 8 2.20 (t, J = 4 Hz, 2H), 8 2.46 (m, 1H), fi 2.73 (m, 2H), 8 3.80 {s, 3H), 8 4.58 (m, 2H), 8 5.00 (m, 1H), S 5.45 (m, IH), 8 6.15 (m, 1H), 8 7.13 - 7.35 (m, SH), (C~H3ZN=OS);
3-c clohex 1-N 1- 5-methox benzooxazol-2- lcarbon 1 -3- hen 1 ro 1 ro ionamide (Compound 34); MS (ESn mlz = 449 (M + 1 ); 'H-NMR (300 MHz, CDC13): S 0.95 (m, 2H), 8 1.22 {m,~4H), 81.51 (m, 2H), b 1.65 {m, 6H), 8 2.15 (m, 1H), ~ 2.20 (t, 3 =
4 Hz, 2H), b 2.50 (m, 1 H), 8 2.7? (q, J = 2 Hz, 2H), S 3.92 (s, 3H), S 5.78 (m, 1H), 8 6.37 (m, 1H), 8 7.13 - 7.35 (m, SH), 8 7.53 (d, J = 6 Hz,1H), (C27H32N2~~~
2-acet~rl-N (1S-benzooxazol-2-vlcarbonvl-3-phenvlpro-p-yl)-1.2.3.4-tetrahydroisoquinoline-3S-carboxamide (Compound 35);
2S-acet~lamino-N-(I S-benzooxazol-2-vlcarbonyl-3-gheny~pron~!1) 3-(2-chlorophenyl)propionamide (Compound 36);
3-c clohex 1-N 1 S- 6-methox benzooxazol-2- lcarbon 1 -3- hen 1 ro 1 ro ionamide (Compound 37); MS (ESI) mlz = 449 (M + 1 ); 'H-NMR (300 MHz, CDCI3): S 0.95 (m, 2H), 81.22 (m, 4H), 81.51 (m, 2H), 81.65 (m, 6H), 8 2.15 (m, 1H), b 2.20 (t, J = 4 Hz, 2H), b 2.50 (m, 1H), 8 2.77 (q, J = 2 Hz, 2H), 8 3.95 (s, 3H), 8 5.78 (m; 1H), & 6.37 (d, J = b Hz, 1H}, 8 7.10 - 7.35 (m, SH), 8 7.77 (d, J = 6 Hz, 1H}, (CZ,H3zNaO,a;.
3-cyclohexyl-N-11S-l5-trifluoromethYlbenzooxazol-2-ylcarbonvl)-3-phenylprog~_lpropionamide (Compound 38); MS (ESI) m/z = 487 (M + 1); 'H-NMR
(300 MHz, CDC13): 8 0.95 (m, 2H), 8 I.22 (m, 4H), fi i.51 (m, 1H), b 1.65 (m, 6H), 8 2.20 (m, 3H), 8 2.S 1 (m, IH), 8 2.80 (g, J = 2 Hz, 2H), 8 5.76 (m, 1H), S 6.22 (d; J = 6 Hz, iH), 8 ?.15 - 7.35 (m, SH), 8 7.77 (m, 2H), S 8.25(s, IH), (Cnf~29F3N2~3)~
2-acetylamino-Nll-benzooxazol-2-ylcarbonyl-3-phenylpropyl)-3-l2-trifluorometh~~henyI,Zpro,~,~onamide (Compound 39);
- 1=benzooxazol-2- lcarbon I-3- hen 1 ro I 3-mo holin-4- 1 ro iona 'd {compound 40);;'H NMR (CDC13): 7.90 {m, 1H), 7.76 (m, IH), 7.06-7.36 (m, 7H), 4.00 (m, 1 H), 3. i 2 (m; 4H), 2.50-3.5 (m, ZH), 2.0-2.S (m, 2H), 1.83 (m, 4H); MS: mle-42 L9;
3-cvclohexvl-N I1S-(S-nitrobenzooxazol-2ylcarbon ly 1~.3-"phenyl-propvll~ropionamidg (Compound 41 ); MS (ESn m/z = 464 (M + 1 ); 'H-NMR (300 MHz, CDC13): 8 0.95 (m, 2H), 8 1.22 (m, 4H), S I .S 1 (m, 1H), 8 I .65 (m, 6H), 8 2.20 {m, 3H), 8 2.S 1 (m, IH), b 2.80 (m, 2H), 8 5.67 (m, 1H), b 6.17 (d, J = 6 Hz, 1H), 8 7.09 - 7.35 (m, SH), 8 7.?7 (d, J
= 6Hz, 1H), s 8so (a, J = 6 Hz, ll~, s 8.77 {s, ll~, (C~.H2gN3os);
meth 12- 2S- 3-c clohex l ro ion iamino -4- hen )but 1 benzooxazole-6-carbox late (Compound 42); MS (ESI) mlz : 477 (M + 1); 'H-NMR (300 MHz, CDC13): is 0.95 (m, 2H), -S I.22 (m, 4H), 8 l.Sl (m, 1H), ~ 1.65 (m, 6H), 8 2.23 (m, 3H), s 2.50.(m, 1H), & 2.77 (m, 2H), -8 4.00 (s, 3H), 8 S.?8 (m, 1H), b 6.27 (d, J = 6 Hz, IH), 7.15 - 7.35 (m, SH), 8 7.98 (d, J = 6 Hz, 1H), 8 8.22 (d, J = 6Hz, 1H ), b 8.39 (s, 1H), (C28H32N2Os):
N 1S- S-chlorobenzooxazol-2- lcarbon l -3- hen I ro l -3-c clohex I ro ionamide (Compound 43); MS (ESI} m/z = 4S3 (M + I);'H-NMR (300 MHz, CDC13); S 0.95 (m, 2H), S 1.22 (m, 4H), b 1.53 (m, 2H), & 1.65 (m, SH), $ 2.20 (m, 3H), 8 2.50 (m, 1H), b 2.77 (m, 2H), 8 5.74 (m, I H), b 6.20 (d, J = 6 Hz, 1 H); 8 7.09 - 7.35 (m, SH), 8 7.60 (m, 2H), & 7.90 {s, 1 H ), (C2~29c~2~3)~
benzyl 1S-(1S-benzooxazal-2-ylcarbonyl-3 phenvlpropytsulfamo-ylmeth~~-3-met>~lbutylcarbamate (Compound 44);'H NMR (CDC13): 7.92 (d, J=?.7Hz, IH), 7.64 (m, 1H), 7.57 {m,1H), 7.50 {m, 1H), 7.21-7.34 (m, lOH), 6.30 (d,j=9.ZHz,1H), 5.34 (m; IH), 5.11 (m, 1H}, 4.91 (dJ=9.6Hz, 1H), 4.51 (m, 1H), 3.1I (m, 2H), 2.89 (m,~2H), 2.50 (m, 1H), 2.20 (m, 1H), I.70 (m,1H), I.S (m, IH), 1.23-1.46 (m, 1H), 0.;92 (t,J=7.4Hz, H); MS:
m/e=5?8.1;
N lIS-f1S-Sbenzooxazol-2-ylcarbon l~phen~prop~sulfamoylmethyll-3-methvIbutvl~acetamide (Compound 45);'H NMR (CDC13): ?.89 (d,J=7.7Hz, 1H), 7.62 (m, 1H), 7.SS (m, IH), 7.49 {m, 1H), 7.18-'7.30 (m, SIi}, 6.7 (d, J=8.9Hz, 1H), 5.61 (d, J=9.4Hz, 1H), 5.34 {m, 1H), 4.86 (m, 1H), 3.06 (m, 2H), 2.90 (t, J=7.7Hz,. 2H), 2.24 (m, 1H), 2.22 (m, 1H), _77_ 2.04 (s, 3H), 1.66 (m, 1H), 1.48 (m, 1H), 1.38 (m,1H), 0.91 (t, I=6.2Hz, 6H);
MS: mle=486.1;
benzyl iRSIS-benzooxazol-2-vlcarbonyl-3-phenylpropylsulfamovlmethyl>
3-methvlbutylcarbamate (Compound 46)'H NMR (CDC13): ?.9 (m, 1H), ?.GO (m, 1H), 7.58 (m, iH), 7.S (m, 1H), 7.75-7.4 (m, lOH), 5.85 (m, 1H), 5.0-S.4 (m, 3H), 4.2 (m, 1H), 3.15-3.35 (m, 2H), 2.65-2.85 (m, 2H), 2.45 (m, 1H), 2.i5 (m, 1H), 1.9 (m, IH), 1.4-1.7 (m, 3H), 0.9 (m, 6H); MS: m/e=578.1; and N ~I~I-benzooxazol-2-vlcarbonyl-3-phen~propylsulfamoylmethvl>-3-methvlbutyllacetamide (Compound 47)'H NMR (CDC13): 7.9 (m, IH), 7.65 (rn,1H), ?.61 (m, 1H), 7.60 (m, 1H), 7.18-7.30 (m, SH), 6.0 (m, 1H), 5.85 (m, iH), 5.28 (m, 1H), 4.50 (m, iH), 3.20 (m, 1H), 2.85 (m, 1H), 2.70 (m, iH), 1.8-2.2 (m, 2H), 1 4S (S, 3H), 1.35-1.70 (m, 2H), 0.9 (m, 6H); MS: m/e=486Ø

tert-Butvl 1R-(2-benzooxazol-2 yl-2-h drox -1S- heneth leth lcarbamo I -2- 2-c anobenz lsulfan l th Icarbamate (Compound 48) il3 ~fl / \
w A solution of 2R-ten-butoxycarbonylamino-3-(2-cyanobenzylsulfanyl~ropionic acid (336 mg), 2S-amino-1-benzooxazol-2-yl-4.-phenylbutan-1-of (282mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (211 mg) and i-hydroxybenzotriazole (I97 mg) in 2~ dichloromethane (20 mL) was treated with N methylmorpholine (2.2 mL). The reaction mixture was stirred O.S hour and then concentrated by evaporation. The residue was dissol~red in ethyl _?8_ acetate (40 mL) and the solution was washed sequentially with water (20 mL), 1N hydrochloric acid (30 mL), a saturated sodium bicarbonate solution (30 mL) and then bryne (30mL), dried over magnesium sulfate and concentrated by evaporation. The residue was subjected to flash column chromatography on silica eluting with diethyl ether to provide tert-bu IR-l2-benzooxazol-2-yl-2-hvdrox -~1S-~henethylethvlcarbamovl)-2-(2-cyanobenzylsulfanyl)ethylc_arbamate as an off white solid. MS: 60I [MH]+.
Proceeding as in Example 3 provided ten-butyl 1R-(2-benzooxazol-2-vl-2-hvdroxy_ 1 ~henethvleth~lcarbamoyl~ 2-benzylsulfanvlethylcarbamate (Compound 49), MS:
S76 jh2FiJ''.

0 N~1R-(2-Benzooxazol-2- I-~2-hvdroxy-1S-phenethylethylcarbamovl~-2~,2-cyanobenzylsulfan ly lethyllisonicotinamide (Compound SO) O
\ w A solution of 3-(2-cyanobenzylsulfanyI)-2R-(pyrid..4-ylcarbonyl)aminopropionic acid (42S mg), provided as in Reference 2, 2S-amino-1-benzooxazoI-2-yl-4-phenylbutan-1-of (3Sb mg) and HAT'U (3S6 mg) in dimethylformamide (40 mL) was treated wilts diisopropylamine (0.239 mL). The reaction mixture was stirred for 16 hours at room temperature then concentrated by evaporation. The residue was dissolved in ethyl acetate and the solution was washed with saturated sodium bicarbonate solution, dried over magnesium _79_ sulfate and then concentrated by evaporarion. The residue was subjected to flash column chromatography on silica eluting with ethyl acetate to provide N f 1R-l2-benzooxazol-2;y1-2-h drox -1S- heneth leth lcarbamo l -2- 2-c anobenz lsul an 1 th 1 isonicoti ami (216 mg) as a gum. MS: 646 [MH]*. HPLC: Rz= 13.20 minutes.
Proceeding as in Example 4 provided 9H-fluoren-9-vlmethyl IS-(Z-benzooxazol-2-yl_-2-hydroxv-1S,-,gheneth Iy ethylcarbamoyl~-2-cvclohexYlethylcarbamate (Compound 51);
9H-fluoren- - Imeth 1 1S- 2-benzooxazol-2- 1-2- to -bu Idimeth Isilan lox 1S-phenethvlethvlcarbamoyll-2-cyclohexyleth lY carbamate {Compound 52), MS:
772 [MHJ+.

2R-Amino-N- 2-benzooxazol-2- 1-2-h drox -IS- heneth Ieth I -3- 2-c anoben Isulfan l -propionamide hydrochloride {Compound 53) A solution tern-butyl IR-(2-benzooxazal-2-yl-2-hydroxy-1S-phenethylethylcarbamoyI)-2-(2-cyanobenzylsulfanyl)ethylcarbarnate (145 mg), provided as in Example 3, in dioxane (20 mL) was treated with hydrogen chloride, bubbling the gas through the solution for 30 minutes. The reaction mixture was concentrated by evaporation and the residue was triturated with diethyl ether to provide 2R-amino-N (2-benzooxazol-2-vl-2-hydroxy 1S-phenethylethyl)-3-~cyanobenzylsulfanyl)proQionamide hydrochloride (I17 mg) as a an off-white solid. MS: 537 rvc Proceeding as in Example 5 provided 2R-amino-IV J2-benzooxazol-2-vl-2-~dro~y-IS- heneth leth I -3-benz lsulfon l ro ionamide h drochloride {Compound 54}, MS: 508 IMH~+.

2S-Amino-N 2-benzooxazol-2- 1-2-h drox -IS- heneth leth 1 -3-c clohex 1 o ianami (Compound 55) A solution of 9FI-fluoren-9-yImethyl 1S-(2-benzooxazol-2-yl-2-hydroxy-14 1S-phenethylethylcarbamoyl)-2-cyclohexylethylcarbamate (165 mg), provided as in Example 4, in dichloromethane (30 mL) was treated with tris(~-aminoethyl)amine bound to polysterene beads (4.48 g). The mixture was stirred at room temperature for 48 hours and then filtered.
The resin was washed four times with dichloromethane (20 mL) and the combined filtrates were concentrated under reduced pressure to provide 2S-amino-N ~2-benzooxazol-2 ~ rLl-I5 2-hydroxv-IS-nhenethyleth Iy )-3-cvclohexylpropionamide {14? mg) as a colourless oil.

2 -Amino-1V- 2-benzooxazol-2- 1-2- ten-bu ldimeth IsiIan lox -1 - heneth Ieth 1=
3-cycl~hexylQropionamide (Compound SG), a protected compound of Formula I
A.solution of 9H-fluoren-9-ylmethyl 1S-[2-benzooxazol-2-yl-2-(tent-butyldimethylsilanyloxy)-1S-phenethylethylcarbamoyl]-2-cyclohexylethylcarbamate (1.48 g), provided as in Example 4, in dichloromethane (50 mL) was treated with Iris-(2-aminoethyl)amine (14.4 mL). The reaction mixture was stirred for 75 minutes and then t0 additional dichloromethane was added (50 mL). The mixture was washed sequentially with brine (50 mL x4) and a pH 5.3 buffer (SO mL x3), dried over magnesium sulphate and concentrated to provide 2S-amino-N f2-benzooxazol-2-vl-2-ltert-butyldimethylsilanyloxv)-1S-phenethYlethyIl-3-cyclohe~lpro,~ionamide as an orange oil.
-82_ tert-Butvl 4-t 1 R-(2-benzooxazol-2-vI-2-hydroxv-I S-phenethylethvlcarbamovl)~
2-(2-clan obenzyl sulfan~l)ethvlcarbamovlpiperi dine-1-carboxvlate (Compound 57) A solution of 2R-amino-N-{2-benzooxazol-2-yl-2-hydroxy-1S-phenethylethyl) 3-(2-cyanobenzylsulfanyl)propionamide hydrochloride (170 mg), provided as in Example 5, in dimethylformamide (7 mL) was treated with 1-ten-butoxycarbonylpiperidine-4.-carboxylic acid tetrafluorophenyl ester tert-butyl ester on resin {excess), prepared according to the procedure described in International Patent Application No. W099167228, and triethylamine (0.053mL).
The suspension was agitated for 16 hours, then filtered, and the filtrate was washed with dimethylaforrnamide and then concentrated by evaporation. The residue was subjected to flash column chromatography on silica eluting with ethyl acetate to give tert-butyl _4-t 1 R-(2-benzooxazol-2-vl-2-hydroxy-1 S-phenethylethylcarbamovll-2-!2-c anobenzylsulfanvl)ethylcarbamoy,Ipiperidine-I-carboxvlate (95mg) as a gum.
Ms: 71 z ~x~+.
Proceeding as in Example $ provided benzvl 4-lIS-l2-benzooxazol-2-yl-2-l~droxy-1_S-nhenethylethvlcarbamoyl)-2-cyclohexylethylcarbamoyllpiperidine-I-carboxylate (Compound 58), MS: 681 jM]'.

NjIR-(2-Benzooxazol-2-yl-2-hydroxy-IS-pheneth ly ethylcarbamovl)-2-benzylsulfonvlethyll-tetrah"ydropvran-4-carboxamide (Compound 59) A mixture of 2R-amino-N (2-benzooxazoI-2-yI-2-hydroxy-IS-phenethylethyl~-3-benzylsulfonylpropionamide hydrochloride {0.3 g), prepared as in Example 5, tetrahydropyran-4-carboxylic acid (0.072 g), I-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0:116 g) and 1-hydroxybenzotriazole (0.112 g) in dichloromethane (20 mL) was treated with 4-N methylmorphoIine (O.IZ mL). After stirring at room temperature for 4 hours the reaction mixture was ieft to stand 16 hours and then concentrated by evaporation. The residue was treated with dichloromethane (50 mL) and the mixture was washed sequentially with 1N
hydrochloric acid solution {5 mL), saturated sodium bicarbonate solution {5 mL) and brine (S mL), dried over magnesium sulfate and then concentrated by evaporation. The residue was subjected to flash column chromatography on silica eluting with ethylacetate to provide N 1R-~2-benzoox azol-2-vI-2-hydroxy- I S-ph en ethyl_ethylc arbam oYl2 2-benz~rl sulfonvl etl~ll-tetrahydropyran-4-carboxamide {66 mg) as a cream solid. MS: 618 [MH]'.
Prcxeeding as in Example 9 ;provided the following compounds of Formula I:
N flR~2-benzooxazol-2-yl-2-hvdrox -L1S-phenethyleth~tlcarbam~l)-2-benzylsulfonvlethvll-nicotinamide (Compound 60), MS: 613 jMHJ'";

N IR- 2-benzooxazol-2- 1-2-h drox -1S- heneth leth lcarb mo 1 -2-ben lsulfon 1-ethyliplirazine=2~arboxamide (Compound 61), MS: 614 [N>Hj*;
dal.C=f~_hPnTnnxa~nf-?_-vi-2-hvdrc~xv-1 S-nhenethviethvlcarhgmnvil-~..c:vclnhPxvl..
ethylcarbarriov~]piperidine-1.-carboxylate (Compound 62); and 1V- S- 2~benzooxazol-2- l-2-h drox -1S- heneth Jeth lcarbamo 1 -2-c clohex leth 1 -iso~icotinamide (Compound 63).

tent-Butvl 4-f 1 R-l2-benzooxazol-2-v1-2-hvdrox~ 1 S-phenethylethvlcarbamoyll-2-f3-methvlpYrid-2-ylmethvlsulfonyl)ethvlcarbamovllpiperidine-1-carboxvlate (Compound 64) A solution of 2R-anvno-N (2-benzooxazol-2-yl-2-hydroxy-ls-phenethylethyl~
3-(3-methylpyrid-2-ylmethylsulfonyl)propionamide (178 mg), IiATU (137 mg) and 1-ten-butoxycarbonylpiperidine-4-carboxylic acid (69 mg) in dimethylformamide (10 mL) was treated with N,N-diisopropylethylamine (O.I74 mL). The reaction mixture was stirred for 9 hours and then concentrated by evaporation. The residue was dissolved in ethyl acetate and the solution was washed with saturated sodium bicarbonate solution, dried over magnesium sulfate and then concentrated by evaporation. The residue was subjected to flash column chromatography on silica eluting with ethyl acetate to provide te_rt-butyl 4-f 1R-(2-benzooxazol-2-yl-2-l~droxy_1S-phenethylethylcarbamoyll-2-l3-meth~pvrid-2-ylmethvlsulfon l~,e_th,~~carbamovllpiperidine-I-carboxylate (81 mg). MS: 734 Proceeding as in Example 10 provided the following compounds of Formula I:
tetrah dro ran-4- I 1R- 2-benzooxazol-2- 1-2-h drox -1S- heneth leth lcarbamo 2-benzvlsulfanyI_ethYlcarbamate (Compound 65);
N LI S-f2-benzooxazol-2-y1-2-hvdroxy=1 S-phenethylethylcarbamoyj,~
2-cvclohexvlethylltetrahydronyran-4-carboxamide (Compound 66), MS: 548 [M]*;
and N- 1S- 2-ben ooxazol-2- 1-2-h drox -1S- heneth leth lcarbamo 1 -2-c c1 hex Ieth 6-hvdroxynicotinamide (Compound fr7).

lV 2-Benzooxazol-2- I-2- tert-but Idimeth isiian lox -1S- heneth leth 1 -3-c clohe 1-~-f3-nyrid-3-vlureido)propionamide (Compound 68), a protected compound of Formula I
O
w N
~Si~
O
x N p -s 0 1~ a r~
A solution of 2S-amino-N-[2-benzooxazol-2-yl-2-{tert-butyldimethyIsilanyloxy~
1S-phenethylethyl]-3-cyclohexylpropionamide (200.1 mg), provided as in Example 7, in dichloromethane (10 mL) was treated with 3-pyridyI isocyanate (48 mg). The mixture was stirred at room temperature for I6 hours and the solvent evaporated under reduced presssure.
The residue was subjected to flash column chromatography on silica eluting with a mixture of pentane and ethylacetate (2:1, v/v) to provide N (2-benzooxazol-2-yl-2-(tent-bu ldirneth Isilan lox -1S- heneth leth l -3-c clohex 1-2S- 3- 'd-3- lureido ro ionamide (I72 mg) as a colorless oil.

N 1S- 2-Benzooxazol-2- 1- - tart-bu ldimeth lsilan lox -1S- heneth lath Icarbamo 1 - .
2-cycl ohexyl ethyl 1 morphoIine-4.-carboxamide (Compound 69), a protected compound of Formula I
A solution of 2S-amino-N-[2-benzooxazoI-2-yl-2-(ten-butyldimethylsilanyloxyr 1S-phenethylethylJ-3-cyciohexylpropionamide (200 mg), provided as in Example 7, in dichIoromethane (8 mL) was treated with 4-morpholinecarbonyl chloride (0.084 mL) and triethylamine (0.112 mL). The solution was stirred at room temperature for 2U
hours. The i 0 solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica eluting with a mixture of pentane and ethylacetate (2:I, v/v) to provide l~ i 1S-f2-benzooxazol-2-xI-2-pert-butyldirneth~rlsilanyloxW-1S-phenethylethvlcarbamoyll-2-cyclohexvlethvl lmorpholine-4-carboxamide (143 mg) as a white solid. MH~ 663.
_87_ ten-butyl 4-T 1R-l2-benzooxazol-2-yl-2-h~rdroxv-ZS-phenet~ylethylcarbamoyll-2-r_2-c~anobenzvlsulfonvl)ethylcarbamoylpiperidine-1-carboxylate (Compound 70) A solution of tent-butyl 4-[1R-(2-benzooxazol-2-yl-2-hydroxy-1S-phenethylethylcarbamoyl]-2-(2-cyanobenzylsulfanyl)ethylcarbamoylpiperidine-1-carboxylate (95 mg), provided as in Example 8, in methanol (8 mL) was treated with a solution of OXONE~
(246 mg) in water (8 mL). After stirring at room temperature for 10 hours the methanol was distilled under reduced pressure and the remaining aqueous phase was extracted four times with ethyl acetate (20mL). The combined extracts were dried over magnesium sulfate and then concentrated by evaporation. The residue was subjected to flash column chromatography on silica eluting with ethyl acetate to give the tent-butyl 4-t1R-l2-benzooxazol-2-yI-2-hydroxy;1S
heneth Ieth )carbamo I -2- 2-c anobenz lsuIfon 1 eth Icarbamo 1 i eridine-1-carbox at t5 (35 mg) as a gum. MS: 74.4 [MH]+.
Proceeding as in Example 13 provided N I1R-l2-benzooxazol-2yI-2-hvdroxy 1S-phenethylethvlcarbamoyl)-2-l2-cyanobenzvlsulfonyl)ethxllisonicotinamide (Compound 71), HPLC: RT= I2.89 minutes.
-88_ ~~Al~'L.E 14 tent-Bu 1 1R- 2-benzooxazol-2- 1-2-h drox -1S- a eth leth lcarb o 1 2-benzyl~ulfony,~ethvlcarbamate (Compound 72) A solution of tern-butyl 1R-(2-benzooxazol-2-yl-2-hydroxy-IS-phenethylethylcarbamoyl)-2-benzylsulfanylethylcarbamate (3.62. g), provided as in Example 3, in dichloromethane (174 mL) was treated with meta-chloroperbenzoic acid (6.9 g).
After stirring at room temperature for 5 hours the reaction mixture was diluted with dichloromethane i0 (100 mL), washed sequentially with a saturated sodium bicarbonate solution (100 mL) and brine (100 mL), dried over magnesium sulfate and then concentrated by evaporation.
The residue was subjected to flash column chromatography on silica eluting with a mixture of pentane and ethylecetate (1:1, v/v) to provide tent-butyl 1R-(2-benzooxazol-2-vl-2-hydroxv-1S-phenetl~lethylcarbamoyl~2-benzvlsulfonvlethylcarbamate (0.95 g) as a yellow solid. MS:
608 jMH]''.
Proceeding as in Example 14 provided N 11R-(2-benzooxazol-2y1-2-hydrox,~r-1S-phenethylethvlcarbar,~oyl)-2-nyrid-3-ylmethvlsulfonyleth~rllpyrazine-2-carboxamide (Compound 73).

~V~2-Benzooxazol-2-yl-2-~"~,icy-1S~phenet~ylethyl~3-cyclohexyl 2S-f3-pvrid-3_ylur~~dolprogionamide (Compound ?4) A solution of N [2-benzooxazol-2-yl-2-(tart-butyldimethylsilanyloxy)-1S-phenethylethyl]-3-cyclohexyl-2S-(3-pyrid-3-ylureido)propionamide (1?2 mg) in tetrahydrofuran (5 mL), provided as in Example 11, under an inert atmosphere at room temperatwre was treated with a.soiution of tetrabutylamrnoniumfluoride in 1M tetrahydrofuran (0.4 mL): After stirring at room temperature for 90 minutes, the solvent was distilled under reduced pressure.
The residue was subjected to flash column chromatography on silica eluting with a mixture of ethylacetate and pentane (5:1, vlv) to provide .,lV l2-benzooxazol-2-yI-2-hvdroxv-1S-pheneth~ethvll-3-cyclohex3rl-25~3-pyrid-3-Ylureido ropionamide (108 mg) as a white solid.
Proceeding as in Example 13 provided N ~1S-(2-benzooxazol-2-vl-2-hydroxy_ 1S-phenethylethylcarbamovl)-2-cyclohex l~ethvllmotpholine-4-carboxamidg (Compound?5).

EXAMPLE 16 ~.
ten-Bu 14- 1R- 1S-benzooxazo -2- lcarbon 1-3- hen 1 r lcarbamo 1 - - 2-c an benzylsulfonvl)ethylcarbamov_l,]pigeridine-1-carboxylate (Compound 76) A solution tert-butyl 4-[IR-(2-benzooxazol-2-yl-2-hydroxy-1S-phenethylethylcarbamoyI]-2-(2-cyanobenzylsulfonyl)ethylcarbamoylpiperidine-I -carboxylate (35 mg, prepared as in Example 13, in dichloromethane (10 mL) was treated with Dess-Martin reagent (60 mg). The reaction mixture was stirred at room temperature for 5 hours, then washed with sodium thiosulfate in saturated sodium bi-carbonate solution, dried over magnesium sulfate and then concentrated by evaporation. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:I, vlv) to give rert-butyl 4;f 1R-(1S-benzooxazol-2-vIcaibonvl-3-phenyipropylcarbam~ll-2-f2-eyanobenzylsulfonvl~ethvlearbarnoyIlp~peridine-1-carboxylate (26 mg) as a gum. MS: 742 [MH]'~-.
Proceeding as in Example 16 provided the following compounds of Formula I:
N f1R-fIS-benzooxazol-2-ylcarbonvl)-3-phen5rlpropylcarbamoyl)-2-benzylsulfonylethvlltetrahydrouvran-4-carboxamide (Compound ??), m.p. I78-I80°C, MS:
618 [MH]'';
N f iR-f 1S-benzooxazol-2-~lcarbonyl-3-phenylpropylcarbamoyl)-2-benzYlsulfonyleth~lnicotinamide (Compound ?8), m.p. 193-195°C, MS:
611 [MH]'';
~V_ -T1R-lIS-benzooxazoI-2-ylcarbonvl-3-phenvlpropvlcarbamo 2-benzylsulfon~rlethvllpyrazine-2-carboxamide (Compound ?9), m.p. 194-196°C. MS: 6I2 _91_ ~+.
t tent-butyl 4-f 1 S-(,1 S-benzooxazol-2-vlcarbonyl,-3-phenylpro,.p~rlcarbamovl)-2-cyclohexyi_ethylcarbamoyl]piperidine-1-carboxylate (Compound 80);
tert-butyl 4-f 1S-(1-benzooxazol-2-vlcarbonyl-3-phen~propYlcarbamoyl)-2-l6-meth~nvrid-2~rlmethylsulfonyl)ethylcarbamoyllpiQeridine-1-carboxvlate (Compound 81), MS: 732 [MH]+, HPLC: RT =15.I8 minutes;
N-f 1R-l1S-benzooxazol-2 ylcarbonvl-3-phenYlprogvlcarbamoyl)-2-f2-cvanobenzvlsulfon~)ethyllisonicotinamide (Compound 82), m.p. 2Q4-206°C, MS: 636 [h,~~.
tetrah dro an-4- 1 1R- IS-benzooxazol-2- lcarbon vl-3- hen 1 io lcarbamo 1 -2-benzylsulfon~rlethvlcarbamate (Compound 83), m.p. 93°C (with decomposition), MS: 634 [~7' benzyl 4-f 1 S-f 1 S-benzooxazol-2-ylcarbonvl-3-phenylpropvlcarbamovl) 2-cyclohexylethYlcarbamoyllpiperidine-1-carboxvlate (Compound 84), MS: 677 [M]';
N f1S-benzooxazol-2ylcarbonYl_-3-phenylpropy,~-Z 3-cvclohexvl-2S-f3p~rid-3 Xlureido ropionamide (Compound 85), MS: 554 [M]';
N-f 1SS1S-bentooxazol-2-vlcarbonvl-3-phenvIprop~IcarbamoyI) 2-cyclohexylethYllrnorpholine-4-carboxamide (Compound 86), MS: 547 [MHJ'";
N_J' 1 S~1 S-benzoox azol-2-ylcarbon~pheny~r~vlcarbamovl~
2-cyclohexylethyl_isonicotinamide (Compound 87), MS: 53? [M]';
N f1S-l1S-benzooxazol-2-vlcarbonvI-3-phenvlprop~rbamoyl)-2-cyclohexyleth~,lltetrahvdrop~-4-carboxamide (Compound 88), MS: 546 [M]+; and N f1S-(1S-benzooxazol-2-vlcarbonvl-3-vhenvlpropvlcarbamoyt)-2-cyclohexvlethvll-6-hydrox~nicorinamide (Compound 89); MS: SSS [M]'.

EXAMPLE I7 ..
N j1R-F1S-Benzooxazol-2-ylcarbonvI)-3-phenvlpropylcarbamoyl)-2-benzvlsulfonyleth~lmorpholine-4-carboxamide (Compound 90) O
N ~H
O
A mixture of N [1S-(2-benzooxazol-2-yl-2-hydroxy-1S-phenethylethylcarbamoyl)-2-benzylsulfonylethyl]morpholine-4-carboxamide (7.2 g, 11.6 mmol), prepared as in Example 1;
and Dess-Martin periodinane (9.87 g, 23.3 mmol) in dichloromethane (57 mL) was stirred at room temperature for 1 hour and then diluted with a solution of 0.26 M sodium thiosulfate in saturated sodium bicarbonate. The dilution was extracted with ethyl acetate and the extract was filtered. The filtrate was concentrated to provide N [1S-(1S-benzooxazol-2-ylcarbonyl)-3-phenylpropylcarbamoyl)-2-benzylsulfonylethyl]morpholine-4-carboxamide (2.33 g) as an orangeltan oil.
The solids collected from the filtration were taken up into dichloromethane (700 rnL) and the mixture was washed sequentially with water and saturated sodium bicarbonate solution, dried and - concentrated to provide N '( 1 R-t I S-benzoox azol-2-ylcarbonvt)-3-phenylpro_pvlcarbamovl)-2-benzylsulfonylethyllznor~phoIine-4-carboxamide (4.2 g) as a white powder. 'H
NMR (DMSO-d6) 8.024 (d, J=6.68Hz, 1H), 7.9787 (d, J=7.92Hz, ll~, 7.8857 (d, J=8.16Hz, 1H), 7.6471 (td, J=8.41, 0.99 Hz, 1H), 7.5455 (td, J=8.16, 1.24Hz, 1H), 7.3806 (s, SH), 7.2479 (m, 5H), 7..1210 (d, J=4.53Hz), 1H, 5.2578 (m, 1H), 4.7395 (m, 1>~, 4.509 (s, 2H), 3.5342 (m, 4H), 3.4082 (m, 2H), 3.30 (m, 4H (+water)), 2.6963 (m, 2H), 2.2768 (m, 1H), 2.0497 (m, 1H). MS
(M''1) 619.2.

Proceeding as in ExampIel7 provided the following compounds of Formula I:
N fIR-(2-benzooxazol-2-vl-1.1-dimethyl-2-oxoethylcarbamoyl~
2-benzvlsulfonvlet~llmorpholine-4-carboxamide (Compound 91);'H NMR: (1~MS0) 9.26 (s, IH), 7.79 (d, J=.8Hz,1H), ?.73 (d, J=BHz,1H), 7.56 (t, J=BHz, 1H), 7.47 (t;
J=8Hz, IH), 7.36-7.25 (m, SH), 6.70 (d, J=BHz,1H}, 4.67 (m,1H), 4.39 (d, J=I4Hz,1H), 4.32 (d, J=I4Hz, 1H), 3.49-3.00 (rn, lOH), 1.56 (s, 3H), 1.51 (s, 3H); MS: (M++1) 543;
N tIR ~,IS-benzooxazol-2-ylcarbonylpentylcarbamovl?-2-(3.5-dimethylisoxazol-4-ylmethylsulfonyllethvllmorpholine-4-carboxamide (Compound 92);'H
NMR: {DMSO) 8.66 (d, J=6.6Hz, 1H), 7.99 (d, J=BHz, 1H), 7.88 (d, J=8Hz, IJ~, 7.62 (t, - J=8Hz, 1H), 7.52 (t, J=8Hz, 1H), 7.02 (d, J=7.7Hz,1H), 5.24 (m, 1H), 4.?6 (m, IH), 4.39 (d, J=l4Hz, IH), 4.27 (d, J=l4Hz,1H), 3.63-3.20 (m, lOH), 2.33 (s, 3H), 2.15 (s, 3H}, L94 (m, IH), 1.69 (m, 1H), 1.40-1.22 (m, 4H), 0.$4 (t, J=6.7Hz, 3H); MS: (M*+1) 590; and N-f 1R-(1S-benzooxazol-2-ylcarbonvlpentylcarbamoyll~
2-(3.5-dimethvlisoxazol-4.-ylrnethvlsulfonylethyliisonicotinamide (Compound ~3);'H NMR:
(DMSO) 9.23 (d, J=8Hz, 1H), 8.87 (d, J=7Hz, 1H), 8.71 (m, 2H), 7.98 (d, J=8Hz, 1H), 7.87 (d, J=8Hz, 1H), 7.70 (m, 2H), 7.62 (t, J=BHz, IH), 7:51 (t, J=8Hz, IH), 5.28 (m, IH), 5.10 (m, 1H), 4.44 (d, J=l4Hz,1H), 4.37 (d, J=l4Ha, 1H), 3.80-3.52 (m, 2H), 2.33 (s, 3H), 2.14 (s, 3H), 1.95 (m, 1H}, 2.69 (m, 1H}, 1.40-1.22 (m, 4H}, 0:82 (t, J=6.7Hz, 3H); MS: (M''+I) s82.
_9ø

N jl R-l I S-Benzooxazol-2-v~carbon~rl- ,:
- hen 1 ro Icarbamo 1 -2- 2-c anobenz lsulfon I th i ridine-4-carboxamide {Compound 94) A solution of tert-butyl 4-[1R-{1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-{2-cyanobenzylsulfonyl)ethylcarbamoyl]piperidine-1-carboxylate (26 mg), provided as in Example 16, in ethyl acetate (10 rnI,) was treated with hydrogen chloride, bubbling the gas through the solution for 3 minutes. A white solid formed which was filtered and dried under reduced pressure to provide N-f 1R-(1S-benzooxazol-2-vlcarbony-I-3-phenylprop Icarbamoxl)-2-f2-c~,nobenzylsulfonXl~,yllp~eridine-4-carboxamide (19 mg) as a solid, m.p.
=155-157°C.
MS: 678 [M13J+.
Proceeding as in Example 18 provided N f IS-(1S-benzooxazol-2- lcarbony~
3-phenylpropylcarbamoyl)-2-cvclohexylethvllpiperidine-4-carbaxamide hydrochloride (Compound 95), MS: 634 [MH]+; and N f1R-(1S-benzooxazoI-2-ylcarbonyl-3-phenylpropy)carbamo 2-(6-methylnyrid-2-ylmethylsulfonyl?ethyllpiperidine-4-carboxamide {Compound 96), MS: 632 [MH]'', HPLC: Rr = 12.05 minutes.

N t 1S-Benzooxazol-2-vlcarbonylbutyl)-2R-methylsulfonvlamino-3-benzvlsulfonvlQropionamide' (Compound 159) Qt ~~
~'S~N
H
A solution of (R)-2-(2-methylsulfonylacetyIamino)-3-benzylsulfonylpropionic acid (212 mg, 0.66 mmol), (S7-2-amino-l-benzooxazol-2-ylpentan-I-of (150 mg, 0.66 mmol), EDCI
(L65 mg, 0.858 mmol) and HOBT (1 I0 mg, 0.726 xnmol) in methylene chloride (3 mL) was stirred at room temperature for 2 hours, sequentially washed with hydrochloric acid, sodium bicarbonate solution and brine and then concentrated. The residue was dissolved in dichloromethane and the solution was treated with Dess-Martin reagent (340 mg, 0.8 mmoI) for 1 hour. The mixture was stirred with a sodium thiosulfate/sodiurn bicarbonate solution and the mixture was extracted with ethyl acetate. The extract was washed sequential) with dilute f~ydrochloric acid, sodium bicarbonate and brine, dried (MgSO~ and then concentrated to provide N f1S-benzooxazol-2-vlcarbonvlbutvl)-2_R-methylsulfonylamino-3-benzy)sulfonylpropionamide (49 mg, 0.09 mmol). 'H
NMR (DMSO):
9.0 (d,J = 7Hz, IH), 8.0 (d,J = BHz,1H), 7.90 (d,J = 9Hz, IH), 7.66 (t,J =
8Hz, IH), 7.55 (t,J
=9Hz; IH), 7.39 (s, SH), 5.32 (m, 1H), 4.55 (m, 3H), 3.35 (m, 3H), 2.95 (s, 3H), 1.94 (m, IH), 1.71 (m, 1H),1.45(m, 2H), 0.92 (t, J=8Hz, 3H); MS: mle=522.03.

Meth 1 1R- 1S-benzooXazol-2- lcarbon lbu lcarbamo 1 2-Benz lsulfon leth lcarbamate (Compound 158) A solution of (R)-2-(2-methoxycarbonyIamino)-3-benzyIsulfonylpropionic acid (200 mg, 0.66 mmoI), (S')-2-amino-I-benzooxazol-2-ylpentan-1-of (150 mg, 0.66 mmol), EDCI (165 mg, 0.558 mmoI) and HOBT (110 mg, 0.726 mmol) in methylene chloride (3 mL) was stirred at room temperature for 2 hours, sequentially washed with hydrochloric acid, sodium bicarbonate solution and brine and then concentrated. The residue was treated with Dens-Martin reagent (340 mg, 0.8 nuuol) in dichlr~romethane (4 mL) for 1 hour. The mixture was stirred with a sodium thiosulfate/sodium bicarbonate solution and the mixture was extracted with ethyl acetate.
The extract was washed sequentially with dilute hydrochloric acid, sodium bicarbonate and brine, dried (MgSO,) and then concentrated. The residue was heated with ethyl acetate and then treated with tent-butyloxymethyl. The mixture was let stand for approximately 12 hours and then cooled in an ice bath. Resulting solids were collected by filtration and washed with cold ethyl acetate to provide meth I
1R-f1S-benzooxazoI-2-vlcarbon~rlbutylcarbamovl)-2-benzvlsulfonylethylcarbamate (133 mg, 0.26 mmol).'H NMR {DMSO): 8.77 (d,J =7Hz, 1H), 8.01 (d,J = 9Hz,.lH), 7.90 (dyJ =
9Hz,1H), 7.6 (m, 2H), 7.55 (t,T=9Hz, 1H), 7.39 (s, SH), 5.3 (m, 1H), 4.68 (m, 1H), 4.48 (s, 2H), 3.55 (s, 3H);
3.52-3.4 (m, 1H), 3.3 (m, IH), 1.92 (m, 1H), 1.73 (m, 1H), 1.42 (m, 2H), 0.91 (t, J=SHz, 3H);
MS: m/e=502.05.

l1~-f 1 R-f 1 S-Benzooxazol-2-~arbonvJbutvlcarbamoyl)-2-benzvlsulfonylethyllmorpholine .4-carboxamide I JN~H II m~
O O
A solution of (R)-2-(2-morpholin-4-ylcarbonylamino)-3-benzylsulfonylpropionic acid (356 mg, 1 mmol}, EDCI (240 mg, mmoi) and HOBT (178 mg, mmol) in methylene chloride (8 mL) was (S)-2-amino-1-benzooxazol-2-ylpentan-I-of (220 mg, mmol). The mixture was stirred at room temperature for 1.5 hours and then treated with addtional F..DCI (80 mg). The mixture was stirred for an additional 0.5 hours and then poured into cold, dilute hydrochloric acid. The mixture. was extracted with ethyl acetate (2x) and the extract washed sequentially with aqeous sodium bicarbonate and brine, dried (MgS04) and concentrated. The residue was dissolved in methylene chloride (8 mL) and the solution was treated with Dess-Martin reagent (544 mg) .
The mixture was stirred for 1.5 hours and then stirred a sodium thiosuifate/sodium bicarbonate t5 solution for 15 minutes. The mixture was extracted with ethyl acetate (2x) and the extract was washed with brine, dried (MgS04) and then concentrated. The residue was triturated with ethyl acetate and then hexanes. The mixture cooled in an ice bath and resulting solids were collected and dried to provide N fIR-l1S-benzooxazol-2-ylcarbon l~tvlcarbamovll-2-benzvlsulfonvlethyllmor-~holine-4-carboxarnide (408 mg, 73°lo yield).
1H NMR 300m1'iz: 8.65 (d,J=7.1H3, 1H), 8.0i (d, J=8.8H3, 1H), 7.91 (d, J=9.1H3, 1H), 7.65 (t, J=8.2H3, 1H}, 7.55 (t, J=9.1H3,1H), 7.38 (s, SH}, 7.05 (d, J=9.4H3; 1H), 5.29 (m, 1H), 4.73 (m, 1H), 4.48 (s, 2H), 3.53 (m, 4H), 3.4-3.2 (m, 6H}, 1.94 (m, 1H), I.73 (m, 1H), 1.42 (m, 2H), 0.91 (t, J=8H3, 3H);
MS=557.21 M+=556.20.

(compound 158) Proceeding by methods analogous to those described in this Application provided the following compounds of Formula I:
2S-acetylamino-lV~,2-benzooxazol-2-yl-1 S-butyl-2-hydroxvethyl)-3-c_vclQhexylp;opionamide (Compound 97);'H NMR (CDCl3): 7.6? (d, J=8.OHz, 1H), 7.53 (d, J=6.OHz, 1H), 7.34 (m, 2H), 6.64 (d, J=8.lHz, IH), 5.99 (d, 3=8.lHz, 1H), 5.03 (m, 1H), 4.39 (m, 2H), 2.02-0.70 (m, 22Hz); MS ESI: MH'' 430;
2S-acetylamino-N (IS-benzooxazol-2-vlcarbonvlpentvll-3-cvclohexylpr~ionamide (Compound 98);'H NMR (CDCl3): 7.93 (d, J=7.SHz,1H), 7.67 (d, J=8.lHz, 1H), 7.54 (t, J=7.2Hz, 1H), 7.46 (t, J=7.8Hz, 1H), 6.78 (d, J=7.2Hz, 1H), 5.91 (d, J=8.4Hz, 1H), 5.63 {m, 1H), 4:59 (m, 1H), 2.09-0.85 (m, 24Hz); MS ESI: MH+ 428;
tent-buqrl 1S-f 1-benzooxazol-2-ylcarbonyl'~-3 phenylpropylcarbamoylO-2-cyclQhexylethyllcarbamate (Compound 99);
2S-acetylamino-N ll-benzooxazol~2-ylcarbonyl~
3-nhen~rlvropyl~ 3-cyclohex~propionamide (Compound I00);
i5 2S-ace lam'no-N- 1-benzooxazol-2- Icarbon Ic clobu I 3-c clohex ro ionamid (Compound 101);
2S-acetylamino-N (IR-benzooxazoI-2-ylcarbonvl-3-phenvlnrouyl~-3-cyclohexyIpropionamide (Compound L02);
2S-acetylamino-N-(2-benzooxazol-2-vl-2-hydroxy-lR:phen~ethylethy~l 3-c~clohexylpropionamide (Compound 103);
N-fIS-(IS-benzooxazol-2- Ic~n~-3-pheny3prowlcarbamoyll-2-c~rclohexylethyllsuccinamic acid (Compound 104);'H NMR {CDC13): 7.87 (m,1H), ?.62 (m, IH), 7.52 (m, 1H), 7.43 (m, 1H), 7.15 (m, bH), b.89 (m, 1H), 5.62 (an, 1H), 4.5b (m,1H), 2.75 (m, 2H), 2.70 (m, IH), 2.48 (m, 2H), 2.16 (m,1H), 1.6 (m, 7H), 0.7-1.4 (m, 7H); MS: role 534;
N f 1S-(2-benzooxazgl-2-y1~2-hydro~-IS-phenethvlethylcarbamoyl)-2-c-yclohexylethyl~succinamic acid (Compound 105);'H NMR
(CDC13): 12.04 (s, 1H), 7.89 (m, 1H), 7.80 (m, 1H), 7.65 (m, 2H), 7.36 (m, 2H), 7.13-7.29 (m, 4H), 6.08-b.23 (m, 1H), 4.62-4.93 (m, IH), 4.15 (m, IH), 2.64 (m, iH), 2.50 (m, 1H), 2.34 (m, 6H), 1.78 (m, 1H), 1.45-1.68 (m, 4H), I.37 (m, 1H), 0.95-1.3 (m, 3H), 0.87 (m, 2H); MS:
role=535.8;

hvI]oxalamic acid (Compound 106);'H NMR (CDC13): 6.6-7.9 (m,lOH), 3.6 (m, 1H), 4.5 (nz;_ IH), 2.72 (m, 1H), 2.45 {rn, 1H), 0.8-2.1 {rn, 15H); MS: m/e 506.2;
3X-irnidazoIe=4-carboxamide (Compound 107);'H NMR (CI)Cl3): 8.1 (m,lH), 7.3-7.15 (m, 3H), 6.95-7.2 (m,, 8H), 5.62 (m, TH), 4.74 {m, 1H), 2.77 (m, 2H), 2.38 (m, 1H), 2.25 (m, IH), 0.8-1.9 (m, 13H); IviS: mle 528.2;
2-c'r~clohexyJethyl_'j~3H-imidazole-4-carboxamide {Compound 108);'H NMR
(CDCI3): 7.0-7.6 (rn; I2H), 5.05 {m, IH), 4.S (m, 1H), 2.75 (m, 2H), 0.6-2.2 (m, ISH); MS: mle 529.6;
(Compound 109), m.p. = 70-85°C, MH'' 542;
2-cvclohex~ethyllmalonamic acid {Compound I10);'H NMR (CI3Cl3): 6.8-7.9 (m, 9H), 5.63 (m, 1H);:4.56 (m, 1H), 2.6-2.8 (m, 4H), 2.0-2.4 (m, 2H), 0.7-2:0 {m, 13H); MS:
m/e 520.4;
_N:~1R-(1S=benzooxazol-2-vlcarbonvl-3-~henvlpropylcarbamoyl)-2-o-tolylmethylsulfonylethyllmor_pholine-4-carboxamide (Compound I11);'H NMR
300mHz (DIvISO-db) PPM, 8.841 (d, J=6.2Hz, IH), 7.942 (d, I=5.2Hz, 1H), 7.860 (d, J=
8.4Hz, 1H), 7.618 (t, J=8.lHz, IH), 7.516 (t, J=8.IHz,1H), 7.16 (m, lOH), 5.22 (m, 1H), 4.78 {m, 1H), 4.516 (s, ZH), 3.S67 (m, 2H), 3.500 (m, 6H), 3.3 (s, 3H), 2.75 {m, 1H), 2.65 (m, 1H), 2.44 (m, 1H), 2.26 (m, 2H), 2.01 (m, 1H); MS: M+=633.4 M'=631.4;
N f1R-(1S-benzooxazol-2-Ylcarbon~l-3-,phenvlpropylcarbamo,~)1-2-(2-nitrobenzylsulfonyl)ethyllinorpholine-4-carboxamide (Compound 112);'H
IVMR 300mHz (DMSO-db) PPM, 8.840 {d, J=7.OHz, 1H), 8.025 (d, J=8.OHz, 1H), 7.950 (d, J=8.4Hz, IH), 7.858 {d, J=7.7Hz, 1H), 7.730 (d, J-8.8Hz, IH), 7.646 (i; J=8.4Hz,1H), 7.515 (t, J=7.7Hz, 1H), 5.223 (m, 1H), 5.004 (s, 2H), 4.694 (m, IH), 3.561 (m, 2H), 3.SI0 (m, 6H), 2.756 (m, IH), 2.652 (m, IH), 2.429 (m, 2H), 2.243 (m, IH), I.983 {m, IH); MS: M''=664.2 M-=662.4;
N fIR-lIS-benzooxazol-2-vlcarbon~-3-phenytpropylcarbamovl)-2-I2-chlorobenzXlsuIfonvl)ethyllmorpholine-4-carboxamide (Compound 1 i3); 'H
NMR 300mHz (DMSO-db) PPM, 8.851 (d, J=6.2Hz, IH), 7.953 (d, J=8.8Hz, 1H), 7.855 (d, J=8.4Hz, 1H), 7.627 (t, J=6.6Hz, lI~, 7.498 (m, 3H), 7.365 (m, 2H), 7.211 (m, 6H), 5.220 (m, 1H), 4.774 (m, 1H), 4.659( m, 2H), 3.578 (m, 2H), 3.499 (m, 6H), 2.752 (m, 1H), 2.648 (m, 1H), 2.472 (m, 2H), 2.243 (m, 1H), 1.992 (m, IH); MS: M+=653.2;
N-f 1R-(1S-benzooxazol-2-ylcarbonylventvlcarbamoyl)..
2-benzylsulfon I~yllmorpholine-4-carboxamide (Compound 114); NMR 300n~iz {DMSO-d~, 8:64 {d, J-7.4H3, 1H), 8.01 (d, J=8.8H3, IH), 7.91 (d, J=9.1H3, 1H), 7.68 (t, J=6H3, 1H), 7.55 (t, J=8.2H3,1H), 7.38 (s, SH), 7.05 (d, J=9.6H, 1H), 5.26 (m, 1H), 4.'72 (m, 1H), 4.49 (s, 2H), 3.55 (m, 4H), 3.5-3.2(m, 6H), 1.96 {m,1H), 1.76 (m, 1H), 1.38 (m, 4H), 0.87 (t, J=7.4H3, 3H); MS:
571.24 M'=570.20;
N-f 1 R-( I S-benzooxazol-2-ylcarbon~~lpentylcarbamoyl)-2-o-to~lmethylsulfon ley thvllmorpholine-4-carboxamide (Compound II5); NMR
300mHz (DMSO-db), 8.70 {d, J=6.9H3, 1H), 8.01(d, J=9.1H3, 1H), '7.91 (d, J=8.8H3, 1H), 7.67 (i, J=8H3, 1H), 7.55 (t, J=8.SH, 3H), 7.3-7.I (m, 4H], 7.05 (d, J=9.6H~ H), 5.26 (m, 1H), 4.80 (m, 1H), 4.53 {s, 2H), 3.58 (m, 4H), 3.33 (m, 6H), 2.33 (s, 3H), 1.96 (m, IH), 1.72 (m, 1H), I.35 (m, 4H);
0.87 (t, J=7.7H3); MS=585.30, M*=584.23;
~V f IR-f IS-benzooxazol-2~rlcarbonyl~entvlcarbamovl~
2-(2-nitrobenzylsulfonyl~ethvllmorpholine-4.-carboxamide (Compound 116); NMR
300m.Hz (DMSO-d~), 8.70 (d, J=7.2H3, 1H), 8.1-7.5 (m, HH), 7.05 (d, J=9.3H3, 1H), 5.26 (rn, 1H), 5:01 (s, 2H), 4.70 (m, IH), 3.57 (m, 5H), 3.30 (m, SH), 1.96 (m, IH), I.72 (m, IH), I.34 (m, 4H), 0.87 {t, J=7.7H3, 3H); MS: 616.09 M*=615.20;
N fIR-(1S-benzooxazol-2-vJcarbonylpentylcarbamovl)-2dJ 2-(2-chlorobenzylsulfonyl)ethyllmorgholine-4-carbQxamide (Compound 117);
NMR 300mHz (DMSO-da), 8.71 (d; J=7.IH3, 1H), 8.1-73 (m, 8H), ?.06 (d,J=9.6H3, 1H), 5.26 (m, IH), 4.79 (m, 1H), 4.72 (d, J=I5H3, 1H), 4.65 (d, J=ISH3, 1H), 3.56 (m, 4H), 3.30 (m, 6H), 1.96 {m, 1H), I.73 {m, 1H), I.35 (m, 4H), 0.87 (t, J=7.7H3, 3H); MS: 605.24 M+=605.10;
N f1R-(2-benzooxazol-2-vl-1.~-dimethyl-2-oxoethylcarbamo"yl~
2_-o-tolvlmeth ls~ ulfonylethyl morpholine-4-carboxamide (Compound I 18); MS:
{M*+1) 557;
N-f IR-(2-benzooxazol-2-yl-1.1-dimethyl~2-oxoethylcarbamovll-2-l2-chlorobenzylsulfonyl)ethxlimorpholine-4.-carboxamide (Compound 119); MS:
(M*+1) 578;
N f 1R-(2-benzooxazol-2-yl'l,l-dimethyl-2-oxoethvlcarbamoyl)-2-(2-nitrobenz Isulfonyl)ethyllmorpholine-4-carboxamide (Compound I20);'H NMR:
{DMSO) 9.34 (s, 1H), 8.02 (d, J=7.7Hz, 1H), 7.82-?.45 (m, 7H), 6.74 (d, J=8.8Hz, iH), 4.87 (m, 2H), 4.64 (m, IH), 3.44-3.1I (m, lOH), I.56 (s, 3H),1.50 (s, 3H); MS: (M'+1) 588;
N~ IR-(IS-benzooxazol-2-ylcarbonyl-3,-,phenvlpropylcarbamolrl~

~,p 'rid-2-ylmethvlsulfonylethyllpiperidine-4-carboxamide (Compound 121);
MS:m/e +I=616.2;
N-f 1R-(1S-benzooxazol-2- lcarbonvIpent"~lcarbamovl)-2-pyrid-2 ylmethvlsulfonvlethyllmorpholine-4-carboxamide (Compound 122); 'H
NMR : 8.62 {d; 6.9 Hz, 1 H), 8.55 (d, 3.2 Hz, 1H), 8.00 (d, 7.0 Hz, 1H), 7.86 (m, 2H), 7.65 (t. 6:2 Hz, lI~, 7.48-7.58 (m, 2H), 7.40 {m, 1H), 7.06-7..25 (m, 3I~, 5.28 (m, 1H), 4.74 (m, 1H), 4.67 (d, 1.1 Hz, 2H), 3.53 (m, 4H), 3.3 I (m, 4H), 1.99 (m, I H); 1. 75 (m, I H), 1.32 (m, 4H), 0.87 (t, 6.7 Hz, 3H);
MS: M+1= 571.8;
N I1R-(IR-benzooxazol-2-yJcarbonvl-3-phe~Ipropylcarbamovl)-2-benzvlsulfonylethylimorpholine-4-carboxamide (Compound 123);
'f0 N f 1R-(1-benzooxazol-2-ylcar'~c::ylcvclobutylcarbam~l)-2-benzyIsuIfon~rlethylimorpholine-4-carboxamide (Compound 124), MH* 555;
benzvl 1 S-(2-benzooxazol-2-vl-2-hvdroxvethvlcarbamoyl)-3-methylbutvlcarbamaie (Compound 125);
2S-ace - lamino-N (2-benzooxazol-2-y1-1 S-methyl-2-oxoethyl)-3-cyclohexvlnropionamide {Compound 126); 'H
NMR (CDCl3): 7.92 (d, J=8.4Hz, IH), 7.73-7.67 (m, 1H), 7.60-7.48 (m, 2H), 5.94 (d, J=8.7Hz, 1H), 6.65 (m,1H), 2.03 (d, J=7:2Hz, 2I-1], I.64 {m, 6H), 1.56-0.92 (m, IOHz);
MS ESI: MH*
386;
ten-butyl IR-(I-benzooxazol-2-ylcarbonylcYclobutylearbamoyl~
2-benzylsulfan~rlethvlearbamate (Compound 127);
N f 1R-(1S-benzooxazol-2-ylcarbonvl-3-methylsulfonJrlprop lcarba~royl) 2-benzylsulfonvleth~~IimorphoIine-4-carboxamide (Compound 128);'H NMR (CDCI~:
7.89 (d, J=7.4Hz, 1H)', 7.65 (m, 1H), 7.57 {m, 1H), 7.48 (m, 1H), 7.4 (m, 5H), 6.0 (m, 1H), 5.7 (m, 1H), 4.93 (m, 1H), 4.33 (m, 3H), 3.70 (m, SH), 3.25-3.4 (m, 7H), 2.93 (m, 3H), 2.8 (m, 1H), 2.35 (m, IH); MS: m/e 653.2;
- N 1I-(1S-benzooxazol-2-ylcarbon~pentylcarbamoyl)-3-phenarlsulfanylpropyllmoroholine-4-carboxamide (Compound 129);'H NMR
(DIviSO): 8.52 (d,J = 8Hz, 1H), 8.98 (d,J = 8Hz, 1H), 8.88 (d,J = 9Hz, 1H), 7.64 (t,J =
8Hz,1H), 7.53 (t,J =
9Hz, 1H), 7.30 (m, 4H), 7.19 (m, 1H), 5.25 (m, lI-1?, 4.35 (m, 1H); 3.51 (m, 4H), 3.26 (m, 4H), 2.94 (t, J=8Hz, 2H), 2.9 (m, 3H), 1.7 (m, IH), 1.31 {m, 4H), 0.86 (t,J=BHz, 3H), 6.53 (d,J=9Hz, 1H); MS: mle=539.24;
N-1 IR-(1 S-benzooxazoI-2-vlcarbony_I-pentvlcarbamo,~l) 2-(2-trifJuolromethvlbenzylsulfonyl)ethxllmorpholine-4-carboxamide (Compound 131);'H NMR:
(DMSO) 8.78 (d, J=8Hz, 1H), 8.06-7.50 (m, 8H), 7.04 (d, J=8Hz, 1H), 5.27 (m, 1H), 4.82-4.64 (m, 3H), 3.65-3.25 (m, l0H),1.96 (m, 1H), 1.7I (m, 1H), 1.4I-1.22 (m, 4H), ), 0.84 (t, J=7Hz;
3H). MS: (M++1) 639;
~V-i 1 R-f i S-benzooxazol-2- Iy cax_b_onyl-3-phenyl-progvlcarbamovl)-2-pyrid-2;~rlmethylsulfonvlethylimor~holine-4-carboxamide (Compound I3Z);'H
NMR (DMSO):
8.78 (d,J=?.2Hz, 1H), 8.56 (d,J=5.4Hz, 1H), 7.98 (d;J=8.4Hz, 1H), 7.85 (m, 2H), 7.64 {t,J=12.1Hz,1H), 7.52 (m, 2H), 7.38 (xn, 1H), 7.10-7.34 (m, 8H), 5.25 (m, 1H), 4.70 (m, 3H);
3.55-3.70 (m, 4H), 3.35 (s, 4H), 2.80 (m, 2H), 2.25 (m, 1H), 2:0 (m, 1H); MS:
mle {+I) = 620.0;
N fIR-(IS-benzooxazol-2-ylcarbonvl-3-methylsulfon~vropylcarbamovl)-2-pyrid-2-vlmeth Is~ylethy~morpholine-4-carboxamide (Compound I33); '~i NMR
(DMSO): 8.83 (d,J=7.6Hz, 1H), 8.55 (d,J=4.OHz, 1H), 7.97 (d,J=7.6Hz, 1H), 7.88 (m, 3H), 7.64 (t,J=7.2Hz, 1H), 7.39-7.54 (m, 4H), 7.15 (d, J=7.6Hz, IH), 5.36 (m, 1H), 4.70 (m, 3H); 3.56 (m, 6H), 3.24 (m, 4H), 2.40 (m, 1H), 2.I5 {m, IH), 2.99 (s, 3fi); MS: mle (+I) =
622.2;
2-f2~1-benzooxazol-2-ylcarbonvlpentylcarbarnovl)-2-morpholin-4-ylcarbonylamino)ethanesulfonylmethyl~,pyridine l=oxide (Compound 134);'H
NMR (DMSO): 8.?5 (d, 3=6.SHz, 1H), 8.38 (m, 2H), 7.96 (d, J=?.7Hz, IH), 7.89 (d,J=7.7Hz, IH), 7.48-7.69 (m, 6H), 7.05 (d, J=6.8Hz, 1H), 5.22 (m, 1H), 4.95 (d, J=2.?Hz, 2H), 5.85 (m, 1H), 5.53 (rn, 4H), 3.30 (s, 4H), 1.95 (m, 1H), 1.70 (m, 1H), 1.30 (m, 4H), 0.88 (t, J=5.4Hz, 3H);
MS: MW = 587.65 M+1 = 588.2;
N ~1R-(IS-benzooxazol-2 y-Jcarbonylbutylcarbamoyll-2-(2-difluoromethoxybenzylsulfonYl ethyllmorpholine-4-carboxamide (Compound 135); NMR
300mHz (DMSO-db), 8.70 (d, J=7.IH3, 1H); 8.01 {d, J=8.8H3, 1H), 7.91,(d, J=9.1H3, 1H), 7.65 (t, J=8H3, 1H), 7.55 (t, J=8.2H), 7.I I {t, J=8.2H), ?.4-6.8 (m, SH), 5.28 (m, 1H), 4.76 (m, 1H), 4.5 (s, 2H), 3.SS (m, 4H), 3.3 (m, 6H), 1.93 (m, 1H), I.71 (m, 1H), 1.42 (m, 2H), 0.91 (t, J=8H3, 3H); MS: 623.38 M+=622.19;
N f3-ghen ls~ulfonyl~
1- 1S-benzooxazol-2- lcarbon 1 en lcarbamo I ro 1 rno holine-4-carboxamide {Compound I36);'H NMR (DMSO): 8.5 (m, 2H), 8.00 (d,J = 9Hz, 1H), 7.9-7.5 (m, 8H), 6.54 (t,J = 9Hz, IH), 4.28 (m, IH), 3.49 (m, 4H), 3.24 (m, 6H), 1.90 (m, 3H), 1.65 (m, 1H), 1.31 (m, w 4H), 0.85 (t,J=7Hz, 3H); MS: m/e =571.39;
N IIR-(1S-benzooxazol-2-~rlcarbonylpentylcarbamoyl)-.

2-~2-difluoromethoxvbenz Is~ulfo_nyI)ethYllmo~holine-4-carboxyamide (Compound 137);'H
NMR: {DMSO) 8.66 (d, J=6.6Hz, 1H), 7.99 (d, J=8Hz,1H),.7.87 (d, J=8Hz,1H), ?.67-6.83 (m, 8H), 5.25 (tn, 1H), 4.73 (m, 1H), 4.54 (s, 2H), 3.60-3.23 (m, lOH), 1.93'(m, 1H), 1.68 (m, 1H), 1.40-I.22 (m, 4H), 0.84 (t, J=6.7Hz, 3H); MS: (M++1) 637;
~V t1R-~1S-benzooxazol-2-vlcarbonylpentylcarbamoyll-2-(2-difluoromethoxybenzvlsulfonvl)ethvllisonicotinamide (Compound 138); IH
NMR: (DMSU) 9.22 (d, J=8Hz, 1H), 8.87 (d, J=6Hz, iH), 8.70 (m, 2H), 7.97-7.i9 (m, 10H), 7.08 (t,.J~74Hz, IH), 5.30-5.09 (m, 2H); 4.58 (s, 2H), 3.73-3.59 (m, 2H), 1.94 (m, 1H), 1.71 (m, IH), 1.41-1.22 (m, 4H), ), 0.82 (t, J=6.7Hz, 3H); MS: {M++1) 629;
N-11R-(IS-benzooxazol-2-~~lcarbonylbutYlcarbamoyl)-2-pyrid-2=ylmethylsulfonyl)ethylimorpboline-4-.carboxamide (Compound 139);'H
NMR
(DMSO): 8.6 (m, 2H), 8.05 (d,J=S.lHz, 1H), 7.85 (m, 2H), 7.3-7.8 (m, 4H), 7.2 (m, 3H), 5.32 {m, 1H), 4.72 (m, IH), 4.65 (d,J=3.lHz, 2H), 3.21-3.75 (m, 8H),1.90 (m, 1H);
1.75 (m; 1H), 1.45 (m, 2H), 0.90 (t,J=4.SHz, 3Ii~; MS:m/e +1=558.2;MS: m/e {+I) = 558.2;
i5 2-f 2R-(1 S-benzooxazol-2-ylcarbonylbutvlcarbamovl)-2-morpholin-4-ylcarbon~inoethylsulfonylmethYl~p~ridine 1-oxide (Compound 140);'H NMR
(DMSO): 8.57 (m, 3H), 7.97 (m, 1H), 7.63-7.82 (m, 3H), 7.35-7.45 (m, 4H), 6.93 {rn, 1H), 4.50-4.95 (m, 2H), 4.18 (m, ZH), 3.10-3.80 (m, 8H), 1.10-1.70 (m, 4H), 0.82 (t,J=5.4Hz, 3H); MS:m/e (+1 ) =574.2;
1 R-l I S-benzooxazol-2-ylcarbanylpentylcarbamoyl)-2-l2-difluoromethoxvbenzvlsulfon~)eth>rlcarbamate (Compound 141 ); MS: (M'+1 ) 582;
N fIR-(1S-benzooxazol-2-vlcarbonvlventvlcarbamovl)-2-benzylsul onylethy~Lsuccinamic acid (Compound 142);'H NMR: {DMSO) 12.09 (s, 1H), 8.63 {d, J=6Hz, IH), 8.51 (d, J=8Hz, 1H), 7.98 (d, J=BHz, 1H), 7.87 (d, J=BHz, 1H), 7.62 (t, J=8Hz, IH), 7.52 (t, J=8Hz, 1H), 7.38-7.30 (m, SH), 5.25 (m, IH), 4.84 (m, 1H), 4.46 {s, 2H), 3.53-3.21 (m, 2H), 5.28-5.25 (m, 4H), I.93 (m, 1H), 1.68 (m, 1H), I.40-1.22 (m, 4H), 0.84 (t, J=6.2Hz, 3H); MS:
(M'+I) 558;
2R-f3,3-bis(2-methoxyethyl)ureidol-N-(I S-benzooxazol-2-ylcarbonvlpentyl)-3-benzylsulfonyl~ropionamide (Compound 143);'H NMR: (DMSO) 8.50 (d, J=6.6Hz, 1H), 7.98 (d, J=8Hz, 1H), ?.88 (d, J=8Hz, 1H), '7.62 (t, J=8Hz, 1H), 7.52 (t, J=8Hz, 1H), 7.38-7.30 (m, SH), 6.82 (d, J=8Hz, 1H), 5.26 (m, 1H), 4.70 (m, IH), 4.46 (s, 2H), 3.52-3.22 (m, lOH), 3.31 (s, 6H), 1.94 (m, IH), 1.69 (m, IH), I.40-1.22 (m, 4H), 0.85 (t, J=6.6Hz, 3H); MS:
(M'+1) 617;
_N-11R-(1S-benzooxazol-2-ylcarbonyI-3-pheny~rogylcarbamovl)-2-l6-methv~vrid-2-ylmethylsulfon~rl)ethyIlisonicotinamide (Compound 144);'H
NMR (DMSO): -8069 (t,J =6Hz, 1H), 8.55 (d,J =9Hz, IH), 7.91 (m, 2H), 7.51 (m, 3H), 4.51 (m, IH), 4.I I (d,J
6Hz, 2H),1..5 (m, 15H); MS: m/e=328:05;
N f1R-lIS-benzooxazol-2-vlcarbonvl-3-phenyprogylcarbamoyl,~
2-benz lsulfonylethyl~succinamic acid (Compound 145); MS (ESI] MH+ 478:2;
N fIR-(IS-benzooxazol-2-ylcarbonyli3-phenylpropylcarbamo~)-252-trifluoromethylbenzylsulfonyl)ethylltetrah ~1_dropyran-4-carboxamide (Compound I46);
N f 1R-(IS-benzooxazol-2 ylcaTbonvl-3-pheny3propylcarbamoyl~
2-thien-3-vlmethylsulfonylethyllisonicotinamide (Compound 147);
N-fIR-l1S-benzooxazol-2-ylcarbonyl-3phenvIprotiylcarbamovl)g~
2-(6-meth~rlpyrid-2-vlmethylsulfonyl~ethvlltetrahydrovvran-4-carboxamide (Compound 14$);
N f 1R-(1-benzooxazol-2-ylcaibonylcyclobutylcarbamoyl)-2-(2-trifluorometh lbenzylsulfonyl~ethyl3tetrahydropyran-4-carboxamide (Compound 149);
N f 1R-l1S-benzooxazol-2-ylcarbonvl-3-phen~rlpropylcarbamovll-2-gvrid_3-~vlsulfonylethvIlpyrazine-2-carboxamide (Compound I50);
N-f I-(I-benzooxazol-2 ylcarbonvl-3-Qhenylpropylcarbamoyl)-2-thien-3-ylmethylsulfon Iy ethyllpiperidine-4-carboxamide (Compound 151);
N f I S-(I S-benzooxazol-2-vlcarbonyl-3 phenvlpropylcarbamovl)-2-thien-3 ylrnethvlsuIfonylethyllazetidine-3-carboxamide (Compound 152);
N-fIR-f1S-benzooxazol-2-ylcarbon~)but~arbamoxl)-2-pvrid-3- I~methvlsulfonylethylimorpholine-4-carboxamide (Compound 153);'H
NMR
(DMSO): 8.66 (d, J=6.7Hz, 1H), 8.56 (m, 3H), 8.01 (d, J=7.9Hz, 1H), 7.90 (d,J=8.lHz, 1H), ?.79 (m, 1H), ?.65 (t, 3=7.lHz, 1H), 7.55 (t, J=7.lHz, 1H), 7.43 (dd, J-4.9,7.9Hz, 2H), 6.g3 (d, J=8.40Hz,1H), 5.30 (m, J=lHz, IH), 4.76 (m, IH), 4.57 (d, J=3.?Hz, 2H), 3.24-3.?0 (m; 8H), 1.91 (m, IH), 1.73 (m, IH), 1.40 (m, 2H), 0.82 (t, J=5.4Hz; 3H); MS:mle (+1) =
555.8;
N-f l R-(1 S-benzooxazol-2 ylcarbonyl-3-phenv_lpro~, vlcarbamo~I)-2-benzylsulfo~lethyllninerazine-I-carboxamide (Compound 154);
N-f 1 R-( 1 S-benzooxazol-2"vlcarbonyl-3-meth~lsulfonvlpro~ylcarbamovl)-2 ~2-difluoromethoxvbenzylsulfonyl~,eth-yllmorpholine-4-carboxamide (Compound 155);'H NMR -(CDCL~, 300MHz) 7.8944 (d, J=7.92Hz, 1H), 7.67 (m, 1H), 7.58 (m, 1H), 4.49 (m, 2H), 7.415 (m, IH), 7.24 (m, 3H), 6.5811 (t, J=?3.24Hz, IH), 5.7633 (m; IH), 4.9199 (m, IH), 4.4871 (dd, J=13.61, 23.75Hz, 2H), 3.7101 (m, 4H), 3.4189 (m, 4H), 3.27 (m, 2H), 2.9289 (s, 3H), 2.77 (m, 1H), 2.37 (rid;' lI~; MS: (M*) 687.3 (M') 685.6;
1V [1R-(IS-benzooxazoI-2-ylcarbonyl-3-methvlesulfonvlnronvlcarbamovll-2-(2-methoxybenz Isy ulfonvi)ethvllmorpholine-4-carboxamide (Compound 156);'H
NMR
(CDCI3): ?.89 (m, 1H), 7.45-7.8 (m, 3H), 7.35 (m, ZH), 6.9-7.05 (m, 2H), 5.83-5.9 (m,1H), 5.62-5.8 (m, .1H), 4.82 (m, IH), 4.40 (m, 2H), 3.89 (s, 3H), 3.70 (m, 5H), 3.25-3.42 (m, 7H), 2.95 (s, 3H);-2.75 (m, 1H), 2.35 (m, IH); MS: m/e 651.4;
N f1R-(1S-benzooxazol-2-ylcarbonylpentYlcarbamoyI)-2-benzvlsulfonylethvllpiperazine-1-carboxamide {Compound I57);'H hTMR: (DMSO) 9.20-9.11 (m, 2H); 8.73 (m, IH), 7.98 (d, J=BHz, 1H), 7.88 (d, J=8Hz, 1H), ?.63 (t, J=BHz, 1H), 7.52 (t, J=8Hz, IH); 7.39-7.30 (m, SH), 5.24 (m, IH), 4.74 (m, IH), 4.50 (s, 2H), 3.62-3.30 (m, 6H), 3.05-2.95 (m, 4H), L94 {m,1H), 1.69 (m, 1H), 1.40-1.22 (m, 4H), 0.84 (t, 7=6.6Hz, 3H); MS:
(M'+1 ) 570;
N (1S-benzooxazole-2-vlcarbonyl-3-methvlsulfonylpronvl)-2R-methvlsulfonvlamino-3-bent Iy sulfonylpropionamide (Compound 160);'H NMR (DMSO-d6) 7.9498 (m, 2H), 7.657?
(m, IH), 7.5556 (m, 1H); 7.3870 (m, SH), 5.4016 (m, 1H), 4.5444 (m, 3H), 3.32 (m, 2T~, 2.9?84 (s, IH), 2.9326 (s, 1H), 2.49 (m, 1H), 2.20 (m, 1H); MS: (M+) 586.0, (M-) 584.0;
methyl 1 R-( 1 S-benzooxazol-2-ylcarbonyi-3-3-phenvlpropyl carbam oyI)-2-pyrid-2-vlmethvlsulfon-yleth~rlcarbamate (Compound 161); MS: m/e (+1) =
564.6;
meth l 1R- 1S-benzooxazol-2- lcarbon 1-3-meth lsulfon i ro lcarbamo 1 2-benzylsulfon,~ethylcarbamate {Compound 162); 'H NMR (DMSO): 9.03 (d, J=7.ZHz,1H), 7.97 (d, J-7.9Hz, IH), 7,90 (d, J=8.2Hz, IH), 7.65 (td, J=7.2, l.2Hz, 1H), ?.55 (t, J=7.9Hz, 1H), 7.37 (m; SH), 5.32 (m, IH), 4.65 (m, 1H), 4.50 (m, 2H), 3.53 (m, IH), 3.49 (s, 3H), 3.33 (s, 2H), 3.24 (m, IH), 2.98 (s, 3H), 2.41 (tn, 1H), 2.18 (m, 1H); MS: m/e 653.2;
N-(IS-benzooxazoI-2-vlcarbonylpentyl)-ZR-f3.3-di(2-methoxyethvl)ureidol-3 pvrid-2~imeth5rlsulfonyloropionamide {Compound 163); MS:m/e +1= 615.6;
N f 1R-(1S-benzooxazol-2-vlcarbonylbutylcarbamovl~
2-(2-methoxybenzvlsuifon l~ethyllmorgholine-4-carboxamide (Compound 164);'H
1~1MR
(DMSO): 8.66 (d,J =6Hz, 1H), 8.03 (d,J = 9Hz, IH), 7.93 (d,J = 9Hz, 1H), 7.68 (t,3 = BHz, 1H), 7.58 (t,J =9Hz, fH), 7.36 (m, 2H), 7.0 (m, 3H), 5.29 (m, 1H), 4.77 (m, 1H), 4.54 (d,J = l4Hz, IH), 4.43 (d,J =I4Hz, 1H), 3.84 (s, 3H), 3.5-3.3 (m, lOH), 1.95 (m; 1H), 1.74 (m, 1H), 1.46 (m, 2H), 0.93 (t, J=8Hz, 3H); MS: mle=587.31;
N (1S-benzooxazol-2-vlcarbonvlbutvlcarbamoyl~-2R-(3 3-dimeth Iureido>".

3-(2-methoxvbenz Is~nyl)propionamide (Compound lb5); NMIt 300mHz (DiVISC)-d6), 8.63 y (d, J=6.9H3,1H), 8.03 {d, J=8.8H~; 1H), 7.92 (d, J=9.1, IH), ?:70 (t, J=8:8H3, 1H), 7.38 (t, J-8.ZH3, IH), ?.37 (m, 2H), 7.08 (d, J=9.IH3, IH), 6.98 (t, J=8.2H3, IH), 6.71 (d, J=9.iH3, 1H);
5.27 (m, 1H), 4.?? (m, 1H), 4.55 (d, J=IS.IH3, 1H), 4.43 (d, J=15.IH3, 1H), 3.79 (s, 3H), 3.47 {d, J=6.9H3, 2H), 2.83 (s, 6H), I.93 (m, 1H), L?5 (xn, IH), I.43 (m, 2H), 0.93 (t, J=8H3, 3H);
N l1S-benzooxazol-2-ylcarbonylbutyl)-2-meth~rlsulfonvlamino-3S2-methoxvbenzylsulfonvl)propionamide (Compound 166);'H NMR (DMSO): 9.0 (d,J
= 6Hz, IH), 8.01 (d,J = 8Hz, 1H), 7.9i (d,J = 8Hz,1H), 7.67 (t,J = ?Hz,1H), 7.57 (t,J
= g~, 1H), 7.36 (t, J=BHz, 2H), 7.07 (d, J=8Hz, 1H), 6.97 (dt, J=2,7Hz, 1H), 7.85 (m, 1H); 5.33 (m, 4H), 4.5 0 (m, 3H), 3.8 (s, 3H), 3.35 (m, 2H), 2.92 (s, 3H), 1.93 (m, I H), 1.72 (m>
IH~, 1.44 (m, 2H), 0.9 i ' (t, J=7Hz, 3H); MS: rnle=552.19; .
3-cvclohexvl-N f2-hvdroxv-2-(5-nitrobenzooxazol-2-vly-ISphenethylethyllpro~ionamide (Compound 167); MS (ESI) miz = 466 {M + I);'H-NMR (300 MHz, CDC13): b 0.95 (m, 2H), 81.22 (m, 4H), $ I.S1 (m, 2H), 8 I.65 (m, 6H), S 2.15 (m, 2H), 8 2.65 (m, 2H), 8 4.15 (in, 1H), 8 4.50 (m,1H), b 5.08 (m; 1H), b 5.80 (d, J = 6 Hz, IH), b 6.09 (m, IH), 8 7.00 - 7.35 (m, SH), 8 7.60 (m, IH), S 8.40 (m, 1H), 8 B.SS (rxi, iH), (C~H3,N30s);
methyl 2-f 2S-(3-cyclohexvlprogi onylamino)-1-hvdroxv-4-phenylbut~llbenzooxazole-6-carboxvlate (Compound 168); MS (ESI) m/z = 478 {M
+ 1);
'H-NMR (300 MHz, CDCl3): 8 0.84 (m, 2H), 81.22 (m, 4H), 8 1.51 (m, 7H), 81.90 (m,1H), ?0 8 2,11 (m; 2H), 8 2.65 (m, 2H), 8 3 .95 (s, 3H), 8 4. i 9 (m, 1 H), 8 4.50 (m,1 H), 8 5.09 (s, 1H), 8 6.09 (m, IH), 8 6.49 (m, 1H), b 7.01 - 7.35 (m, SH), & 7.65 (m, 1H), 8 8.01 (m, 1H), 58.17 (m, IH)9 (CzaH3aNzos)~
N-f2-(5-chlorobenzooxazol-2-yl)-2-hydroxv-lSphenethylethyll-3-cyclohex.,y_lpro~ionamide (Compound 169); MS
(ESI) mlz ~ 455 (M +.1 ); 'H-NMR (300 MHz, CDCI~: s 0.84 (m, 2H), 8 1.12 (m, 4H), 81.20 (m;
2H), 8 1.51 (m, 6H), b 2.00 (m, 3H), 8 2.65 (m, 2H), b 4.21 (m, IH), 8 4.50 (m,1H), 8 5.02 (s, ll~; 8 6.44 (m, 1H), 8 7.01 - 7.47 (m, 7H), b 7.65 (s,1H), (C~6H31cIN2Og);
benzyl 1 S-(2-benzooxazol-2-yl-2-hydroxv-i S-nhenethylethylsulfamoylmethvl)-3-methylbutylcarbamate {Compound i70);'H NMR (CDCi3): 7.71 (m,1H), 7.52 m, 1H); 7.20-7.40 (m, 12H), 5.9 (m, O.SH), 5.6 (m, O.SH), 4.80-5.20 (m, SH),,4.1-4.3 (m, 2H), 2.7-2.9 {m, 4H), 1.7-2.0 {m, 2H), 0.90 (m, 3H), 0:79 (m, 3H), 3.30 (m, 1H);
N 1S- 2-benzooxazol-2- 1-2=h drox - S- heneth let Isulfamo (meth 1 3-methyibutvllacetamide (Compound 171 );
benzyl 1S(2-benzooxazoI-2 y,I-2-h,Ydroxy-lSphenethylethvlsulfamoylmethyl)-3-methvlbutvlcarbamate (Compound 172); 'HNMR
(DMS4): 7.71 (m, 1H), 7.5 (m, 1H), 7.0-7.4 (m, 12H), 4.9-6.2 (m, 6H), 4.0-4:35 (m, 2H), 3.75 (m, 1H), 3.20-3.60 {m, 2H), 2.5-3.0 (m, 2H), 1.15-2.15 (m, 3H), O.b-1.05 (m;
6H); MS: m!e 580.1;
N fIR-(2-benzooxazol-2-y1-2-hvdroxv-1S-phenethylethylsulfamovimeth~
-methylbutvllacetamide (Compound 173);
2S-acetvlamino-N (2-benzooxazol-2-yl-2-hydrox -~Qheneth ly ethyl~
3-cvclohex~mropionamide (Compound 174);
tent-but~S (2-benzooxazol-2-yI-2-hydroxy-IS-phenethyleth~ll-2-cvclohexyleth~arbamate (Compound 175);
2-acet~lamino-N 2-benzooxazol-2- ~Ll-1,1-dimeth.,yl-2-oxoethyl)-3-cyclohexylvronionamide (Compound 176);
benzvl 1S-f2-t5-phenylbenzooxazol-2- l~-hydroxyethylcarbamovll-3-methylbutylcarbamate (Compound 177);
jV-(2-benzooxazol-2-y1-2-hydroxy-1S-phenethylethyl)-3-c clopentylpropionamide (Compound 178);'H NMR {CDC13): 7.72 (m, 1H), 7.53 (m, 1H), 7.08-7.19 (m, 8H), 5.98 (m;
1H), 5.05 {m, 2H), 4.51 (m, 1H), 2.6-2.8 (m, 4H), 2.17-2.29 (m, IH), 1.95-2.15 (m, 2H),1.8-1.95 (m; 1H), 1.68-1.78 (m, IH), I.3-I.7 (m, 6H), 1.0-1.12 (m, 1H), 0.85-1.0 {m, 1H);
N (2-benzoo~cazol-2 yl-2-hydroxy-1S-pheny_ethvlethvl!~-2-bicycloj2.2.Ilhept-2-~lacetamide (Compound 179);
N-(2-benzooxazol-2-vI-2-hvdroxy-1S-pheneth ~Iy ethyl)-2-naphthalen-1-ylacetamide {Compound 180);
N (2-benzooxazol-2-v1-2-hvdroxv-1S-pheneth ly ethyl)-3-phenylpropionamide (Compound 181);'H NMR (CDC13): 7.69 (m, IH), 7.53 (m, 1H), 7.37 (m, ZH), 7.03-7.35 {m, lOH), 5.9 (m,1H), 4.98 {m, 1H), 4.40-4..55 (m, 1H), 3.0 (m, 1H), 2.80 (t, J=?.7Hz; 2H), 2.55 (m, 2H), 2.38 (t, J=7.SHz, 2H);
methyl 2-f2S-(3-cyclohexvlpro~~ionvlamino)-1-hydroxy-4 ~henylbut~ll-4.5-dih drooxazole-4S-carhoxylate (Compound 182); MS (ESI) rnlz = 431 {M -~
1);'H-NMR
(300 MHz, CDCl3): 8 0.89 (m, 2H), 8 1.20 {m, 4H), 81.48 (m, 2H), 8 1.65 (m, 6H), 8 2.00 (m, 2H), S 2.15 {m, 2H), 8 2.73 (t, J = 4 Hz, 2H), 8 3.76 {s, 3H), 8 4.30 - 4.65 (m, SH); 8 6.00 (d, J = 6H2, 1H), b 7.13 - 7.35 (m, SH), (C~H~N20~;
methyl 2-f 2S-!3-cvclohexylp~opi onvlamino~- I -hydroxy.
4-phenvlbut~rlloxazole-4.-carboxvlate (Compound 183);
N !2-benzooxazol-2-yl-2-hydroxY-1S-phenethvl>_4-cyclohexvlbu mide (Compound 184);'H NMR (CDCl~: 7.62-7.73 (m,1H), 7.46-7.59 (m, 1H), 7.05-7.43 (rn, 2H), 6.22-6.38 (m, 1H), 5.11 (s, 1H), 4.50-4.69 (m, 1H), 2.58-2.82 (m, 2H), 2.14-2.24 (m, 1H), 2.0, 2.I4 (m, 1H), i.54-I.76 (m, 6H), 1.31-1.50 (m, 1H), 0.94-1.31 (m, 7H), 0.63-0.93 (m, 2H); MS:
m/e=435.1;
methyl 2-f 2S-!3-cyclohexylpropionylaminol-1-hydroxy-4-phen~butyll-4.5-dihvdrooxazole-4R-carboxvlate (Compound 18~); MS (LSI) mfz = 431' (M +
1);'H-NMR
(300 MHz, CDCl3): 8 0.89 (rn, 2H), 81.20 (m, 4H), S 1.48 (m, ZH), 81.65 (m, 6H), 8 2.00 (m, 2H), 8 2.15 (m, 2H), b 2.?3 (t, J = 4 Hz, 2H), 8 3.76 (s, 3H), S 4.35 - 4.72 (m, SH), b 5.75 (m, 1H), 8 7.13 - 7.35 (m, SH), (C~,H~N20s);
3-c cly ohexx-N f2-hydroxy-2-!5-trifluoromethvlbenzooxazol-2-yl)-1S-phenethylethvllpropionamide (Compound 186); MS (ESI~ mlz = 489 (M + 1);'H-NMR (300 MHz, CDC13): 8 0.77 (m, 2H), b 1.22 (~, 4H), s 1.51 (m, 2H), 8 1.60 (m, 6H), 8 2.15 (m, 4H), 8 2.70 (m, 2H), 8 4.51 (m, 1H), 8 5.11 (s, 1H), 8 6.10 (d, J = 6 Hz, 1H), 8 7.00 - 7.35 (m, SH), 8 7.56 (s, 2H), b 7.99 (s, 1H), (CnH3tF3Na03);
2S-acetylamino-N-!2-benzooxazol-2-vl-2-hvdroxy-1 S-phenethylethyl~
3-!2-trifluorometh~phenvl~pro~ionarnide (Compound 187);
methyl_1-~I-benzooxazol-2-y ~,carbonyl-3-phenylpropvlcarbamovl)-2-cvclohex~ethvlcarbamate (Compound 188);'H NMR (CDCl~: ?.89 (d,J=7.4Hz, 1H), 7.62 (M, 1H0, 7.54 (m, 1H), ?.46 (m, 1H), 7.13-7.30 (m, IH), 6.87 (d, J=7.9Hz, IH), 5.68 (m, 1H), 5.04 (d, J=9.6Hz, 1H), 4.24 (m, 1H), 3.66 (s, 3H), 2.75 (S,J=8.3Hz, 2H), 2.45 (m, 1H), 2.19 (m, 1H), 2.00 (M, 1H), 1.52-1.80 (m=SH), 1.44 (m,1H), I.12-1.27 (m, 4H), 0.89 (m, 2H); MS:
mle=492.04;
N !1-benzooxazol-2-ylcarbonvl-3 ~henypropyl)-3-cvclohexyl-2-meth isulfonvlaminopropionamide (Compound 189);'H NMR (CDCI3): 7.87 (m, 1H), 7.62 (m, 1H), 7.55 (m; IH), 7.46 (m, 1H), 7.13-7.28 (m, SH), 6.79 (d, J=7.9Hz, 1H), 5.71 (m,1H), 4.92 (m, 1H), 4.00 (m, 1H), 2.95 (2, 3H), 2.75 (m, 2H), 2.48 (m, IH), 2.21 (m, 1H); 1.78 (m, 1H), 1.61 (m, SH), 1.45 (m, 1H), 1.16 (m, 4H), 0.89 (m, 2H);
cvclohexylmethyll-benzooxazoI-2-ylcarbonvl-3-phenylpropylcarbamate -(Compound 190);'H NMR (CDC13): 7.88 (m,1H), 7.62 (m,1H), 7.52 (m, 1H), 7.49 (m, IH), 7.13-7.23 (m, 5H), 5.57 (m, 1H), 3.89 (d, J=6.5Hz, 2H), 2.79 (m, 2H), 2.42 (m, 1H), 2.I2 (m, 1H), 1.50-1.73 (m, 6H),1.24 (m, 6H), 0.89 (m, 2H); MS: mle=421.0;
benz~~-benzooxazol-2-ylcarbonyl-3-phenxlpropylsulfamo i~yl3-2-methylbutylcarbamate (Compound 191);'H NMR (CDC13): 7.88 (d.J=7.7Hz, 1H), 7.62 (m, 1H), 7:55 (m, IH), 7.4? (m, IH), 7.33 (m, 5H), 7.19 (m, SH), 6.35 (d, J=7.7Hz, iH), 5.45 (m, 1H), 5.13 (s, 2H), 5.0 (m, 1H), 4.43 (m, 1H),.3.06 (m, 1H), 2.87 (m, IH), 2.45 (m, 1H), 2.I5 (m, 1H), 1.41 (m, 1H), 1.07 (m, 1H), 0.88 (m, 6H); MS: mle=5.78.1;
N-f 1R-(iS-benzooxazol-2-ylcarbonyl-_ 3-phenyl~~ropylcarbamovl)-2-(6-methyl-nvrid-2-ylmethvlsulfonvl iethvllthionhene-3-carboxamide (Compound 192);
N j1R i1S-benzooxazol-2-ylcarbonyl~-3- hen I ro lcarbamo 1 -2- 2-meth 1 'd-3- lmeth Isulfon 1 th 1 nicotinamide (Compound 193);
N-f 1R-(1S-benzooxazol-2- l~onyl-3-phenvIpropylcarbamoyl)-2-(2-cvanobenzylsulfon~lZethyllazetidine-3-carboxamide (Compound 194);
ten-butyl 1R-(1-benzooxazol-2-vlcarbonylcyclobutylcarbamovl)-2-(2-difluQromethoxybenzvlsulfonyl)ethylcarbamate (Compound 195);
ten-butyl 1 R-( 1 S-benzooxazol-2-ylcarbonyI-3-phenylpropylcarbamovl)-2~4-trifluoromethylpvrid-3-vImeth 11L sulfonyl)ethvlcarbamate (Compound 196);
N f 1R-f 1-benzooxazoI-2-ylcarbon~cyclobutylcarbamovl?-2 ~2-difluoromethoxvbenz lsy ulfonyl)eth~morpholine-4-carboxamide (Compound I97);
N jIR-l1S-benzooxazol-2-~rlcarbonylpentvlcarbamovll-2-wrid-3 ~rimethylsulfonvlethvllisonicodnamide (Compound 198);
methyl 1R-(1S-benzooxazol-2-vlearbonylbutvlcarbamovl)-2-~2-methoxybenz-ylsuIfon-yllethylcarbamate (Compound 199);
N j1R-t1S-benzooxazol-2-ylcarbonylpronylcarbamoyl~
2-benzvJsulfonyl_ethvlimor~,pholine-4-carboxamide (Compound 200); NMR 300mHz (DIVISO-d~, 8.65 (d, J=?.1H3, 1H), 8.01 (d, J=8.2H3, IH), 7.9I (d, J=8.8H3, 1H), 7.66 (t, J=8H3, 1H), 7.55 (t., J=7.7H3, iH), 7.38 (s, 5H), 7.05 (d, J=9.4H3, 1H), 5.21 (m, 1H), 4.75 (m, 1H), 4.49 (s, 2H), 3.53 (m, 4H), 3.45 (m, 21~, 3.32 (m, 4I-~, 2.02 (m, lI~, 1.77 (m, 1H), 0.96 (t, J=8H3, 3H);
M=543.24 M'=542.61;
N SIR-benzooxazol-2-vlcarbonvlpropvll-2-(3.3-dimethylurei do)-3-(2-methox~nzylsulfonvl)propionamide (Compound 201); NMR 30dmHz (DMSO-d6), 8.61 (d, J=7.4H3, 1H), 8.01 (d, J=8.SH3, IH), 7.90 (d, J=7.1H3, 1H), 7.GS {t, J=8H3, IH), 7.55 (t, I=8H3, 1H), 7.33 (m, 2H), 7.OS (d, J=8.8H3, 1H), 6.96 (t, J=8.2H3, IH), 6.70 (d, J=9.1I33, 1H), 5.20 (m, 1H), 4.53 (d, J=1S.4H3, 1H), 4.41 (d, J=15.4H3, 1H), 3.77 (s, 3H), 3.45 {d, J=7.1H3, ZH), 2.81 (s, 6H), 2.0 (m, IH), 1.7 ( m, 1H), 0.96 (t, J=8H3, 3H); MS=651.33 M°=650.59;
methyl 1R-(1S-benzooxazol-2-ylcarbonylpropylcarbamoyl)-2:L2-methoxybenzylsulfonylethyl)carbamate (Compound 202);
N (1-benzooxazol-2-ylcarbonylpentyl)-2R-f3.3-bis(2-methoxvethvl)ureidoL
3-wrid-3-ylmethylsulfony)propionamide (Compound 203);
~1S-benzooxazol-2-ylcarbonvlpentyl)-2R-f3.3-bis(2-methoxyetlivl)ureidol-33.5-dimethylisoxazol-4- lmethylsulfonyl)propionamide (Compound 204);
N-(1S-benzooxazol-2-vlcarbonvlnropvl)-3-(3,S-dimethylisoxazoI-4-ylmeth Isulfonyl)-2R-methylsulfonylaminopropionamide (Compound 20S); 'H NMR: (DMSO) 9.04 (d, J=6.6Hz, 1H), 8.00-7.87 (m, 3H), 7.63 (t, J=BHz, 1H), 7.53 (t, J=8Hz, 1H), S.2S (m, IH), 4.61-4.36 (m, 3H), 3.56-3.31 (m, ZH), 2.91 (s, 3H), 2.36 (s, 3H), 2.17 (s, 3H), 2.02 (m, 1H), 1.74 (m, 1H), 0.96 (t, J=7Hz, 3H); MS: (M++1) 527;
metl~l 1R-ll S-benzooxazol-2-vlcarbonylpropylcarbamoyl)-2-(3,S-dimeth~rlisoxazol-4-ylmethvlsulfonyl)ethylcarbamate (Compound 206);'H
NMR:
(DMSO) 8.?8 {d, J=S.8Hz, 1H), 7:99 (d, J=BHz, 1H), 7.87 (d, J=8Hz, 1H), 7.69 (d, J-8.SHz, 1H), 7.62 (t, J=8Hz, 1H), 7.52 (t, J=8Hz, 1H), 5.20 (m, IH), 4.68 (m, 1H), 4.39 (d, J=l4Hz, 1H), 4.29 {d, J=l4Hz, 1H), 3.52 (s, 3H), 3.60-3.28 (m, 2H), 2.37 (s, 3H), 2.15 (s, 3H), 2.02 (m, IH), 1.74 (m, 1H), 0.95 (t, J=?Hz, 3H); MS: (M''+1) 507;
N f 1R-(1-benzooxazol-2=ylcarbonYlpentylcarbamoxl)-2.pyrid-2-ylmethylsulfonylethyllisonicotinamide (Compound 207); NMR 1H: 9.15-9.30 (m, lI~, 8.4-8.9 (m, 4 H), 7.32-8.OS (m, 9H), 5.28 (m, 1H), 5.10 (m, 1H), 4.75 (m, 2H), 3.75 (m,1H), 3.62 (m, 1H),1.95 (m, 1H), 1.75 (m, 1H), 1.OS-1.45 (m, 4H), 0.87 (m, 3H); MS:
M+1= 564.0;
and 4-f 1R-(1S-benzooxazol-2-ylcarbonylnenty)carbamoyl~
2-p 'md-2=vlmethylsulfonvlethvlcarbamoyllnvridine I-oxide (Compound 208).

Benzyl 1S-IN methoxy-N methylcarbamoyl)-3-phe~lnropylcarbamate A solution of 2-benzyloxycarbonylamino-4-phenylbutyric acid (S.OS g, 16.1 mmol) in methylene chloride (70 mL) was cooled to 0°C and treated with diisopropylethylamine (2.82 mL, 16.2 mmol) added dropwise and then PyBOP~ (8.53 g,16.4 mmol) added in one portion. The mixture was stirred for 5 minutes and then treated with N,O-dimethylhydroxylamine hydrochloride (1.73 8,17.71 mmol) was added in one portion. The mixture was neutralized with diisopropylethylamine (4.6 mL, 26.44 mmol) added dropwise, stirred for 2 hours at room temperature and then diluted with methylene chloride (70 mL). The dilution, was washed with 1N aqueous hydrochloric acid (3x 40 mL), saturated sodium bicarbonate (3x 40 mL) and brine (40 mL) and rlnen concentrated. 'The product was purified from the residue by column chromatography eluting with 2:3 ethyl acetate/hexane to provide benzyl 1 S-fN-methoxy-N methylcarbarnoyl)-3-phenylpropylcarbamate (5.48 g, 15.4 mmol) as an oil. MS(PC.1] mfz = 357 (M +1).
Proceeding as in Reference 13 provided tent-butyl 1S-tN-methoxy-N methylcarbamoyl)-3-phenylpropylcarbamate; 'H NMR (CDC13): b 1.35 (s, 9F~, 81.64 -1.72 (m, 2F~, 8 2.40 - 2.54 (m, lI~, 8 2.60 ~~ 2.77 (m, 11T), S 3.00 (s, 3I~ 3.52 (s, 3I~, 8 4.23 (m, llE~, S 7.10 - 7.37 (m, SH).

2S-Amino-N methoxy-N methyl-4-phenylbu amide trifluoroacetic acid salt A solution of tert-butyl 1-(N-methoxy-N-methylcarbamoyl)-3-phenylpropylcarbamate .
(9.32 g, 29 mmol), provided as in Reference 13, in methylene chloride (100 mL) was cooled to 0° C and then treated with anisole (5 mL, 46.5 mmol) and trifluoroacetic acid (50 mL, 296 mmol). The mixture was stirred for 30 minutes, while allowing it to warm to room temperature, .and then concentrated. The residue was dissolved in toluene (100 mL) and the solution was concentrated. The residue was again dissolved in toluene (100 ml) and concentrated to provide 2S-amino-N methox~-N meth-4-phenylbutyramide trifluoroacetic acid salt (9.74 g 29 mmol) as a crude product. MS(PCn mlz = 223 (M +1).

Benzyl 1-f 1-lN-methoxy-N methvlcarbamovl)-3S-phenylnropylcarbamoyli 3-meth~lbutvlcarbamate A solution comprised of 2S-amino N methoxy-N methyl-4-phenylbutyramide trifluoroacetic acid salt (9.74 g, 29 mmol), provided as in Reference 2, in D1VIF (?5 mL) was cooled to 0° C and then neutralized with diisopropylethylamine added dropwise. A solution comprised of 2,5-dioxopynrolidin-I-yl 2-benzyloxycarbonylamino~-methylvalerate (I0.50 g, 29 mmol) in D1VlF (?5 m>~..} and an additional amount of diisopropylethylamine (10.10 mL, 58 mmol) were added to the cooled butyramide solution. The mixture was stirred for 2 hours, while allowing it to warm to room temperature, and then poured into ice water (300 mL). 'fee mixture was let stand for I hour to provide a white precipitate. ~e precipitate was collected by fltration and dried (P205} under vacuum to provide benzvl I-f 1-fN methoxy-N methvTcarbamoylZ3-phenylpropylcarbamovli-3-methylbutvlcarbamate (12.24 g, 26.1 mmol).
'H NMR (CDCI3}: 8 0.91 (d, J = 5.88 Hz, 6H), 81.45 -1.55 (m, 1H), 81.45 -1.S5 (m, 2I~, 8 1.77 - 2.00 (m, 1H), 8 2. i I - 2.22 (m, 1H}, 8 2.70 (m, 2H), b 3.20 (s, 3H) 3.60 ('s , 3H) 4.25 (m, lH), 8 5.00 (m, 1H), 8 5.15 (s, 2I~, 8 6.6 (d, J = 8.15 Hz, 1H}, 8 7.15 -7.45 (m, 1 OIL.

Ethyl_3S-benzXloxycarbo~lamino-2-hydroxy-5-phe~lpentanimidate A suspension comprised of lithium aluminum hydride (0.885 g, 23.3 mmol) in anhydrous diethyl ether was cooled to -45 ° C under nitrogen and then treated with a solution of benzyl IS-(N methoxy-N-methylcarbamoyl)-3-phenylpropylcarbamate (S.S3 g, 15.53 mmol), provided as in Reference I3, in ether (7S mL) and THF (25 mL) was added dropwise over a period of minutes such that the temperature of the mixture was maintained at -40 to -45° C: The mixture was allowed to warm to 5° C and then recooded to -35° C.
A saturated solution of 25 sodium bicarbaonate (7 mL, 0.5 IvI) was added dropwise and the mixture was allowed to warm to 0° C. The mixture was allowed to warm to room temperature and stirred for I hour to provide a precipitate. The precipitate was collected by filtration and washed with ether (100 mL}. The filtrate and washings were combined and washed with ice cold 1N
hydrochloric acid {2x 50 tnL), saturated sodium bicarbonate (2 x 50 mL) and brine (50 mL}, dried (Na2S04) and concentrated in vacuo to provide benzyl IS-formyl-3-phenylpropylcarbamate (4.01 g, I3.5 mmol) as a colorless oil. MS (PCI) m/z = 298 (1VI + 1).
A solution of benzyl 1S-formyl-3-phenylpropylcarbamate (4.557 g, 15.3 mmol) in anhydrous methylene chloride {SO mL) was stirred while sequentially treating with 2-hydroxy-2-methylpropionitrile (4.25 mL, 46.2 mmol) and triethylamine (I.28 ml, 9.20 mmol). The mixture was stirred for 4 hours at room temperature and concentrated in vacuo. The residue was dissolved in ether (100 mL) and the solution was washed with water (5 x 20 mL) and brine (20 mL), dried (MgS04) and concentrated to provide benzyl 2-cyano-2-hydroxy-1S-phenethylethylcarbamate (4.957 g, 15.3 mmol) as a yellow oil. 'H NMR
90 (CDCl3): s 1.75 - 2.01 (m, 2I-i), b 2.08 - 2.24 (m, 1H), 8 2.51 - 2.80 (m, 2I~, S 3.70 - 4.02 (m, II-~, 8 5.07, 8 5.33 (m, 3I~, 8 7.10 - 7.47 (m, 10I~.
A comprised of chloroform (30 mL) and anhydrous ethanol (30 mL, 510 mmol) was cooled to 0° C and then treated with acetyl chloride (32.6 mL, 459 mmol) added dropwise over , a period of 30 minutes. The mixture was cooled with solution of crude benzyl 2-cyano-2-hydroxy-1-phenethylethylcarbamate {4.957 g, .15.3 mmol) in chloroform (30 mL). 'Ihe mixture was stirred for 2 hours at 0°C and then 6 hours at room temperature and concentrated in vacuo to provide ethyl 3S-benzyloxvcarbonylamino-2-hydrox~-5-phenYlpentanimidate (6.212 g 15.3 mmol) as a crude yellow oil. MS (PCn m/z = 371 {M + 1).

2S-Amino-4-phenyl-1-(4S-phenyl-4.5-dihydrooxazol-2-vl)butan-1-of A mixture comprised of ethyl 3S-benzyloxycarbonylaxnino-2-hydroxy-5-phenylpentanimidate (0.78 g, 1.92 mmol), provided as in F~eference I6, diisopropylethylamine (0.218 ~tL, 1.26 mmol) and 2S-amino-2-phenylethanol (0.260 g, 1.9 mmol) in chloroform (25 mL) was heated at reflux for 3 hours and then was stirred for approximately 12 hours, while allowing to cool to room temperature. The mixture was concentrated and the residue was dissolved in ethyl acetate (30 rnl). The solution was washed with O.SN sodium hydroxide (40 mL) and brine (40 mL), dried (MgS04) and then concentrated. Product was purified from the residue by flash chromatography eluting with 1:3 hexaneslethyl acetate to provide benzyI 2-hydroxy-2-(4,5-dihydro-4S-phenyloxazol-2-yI)-1S-phenyethylethylcarbamate (0.475 g, 1.1 mmol) as an oily mixture of diastereomers. MS (PCI) m/z = 445 (M +1). (CZ~H~Nz04).

A solution comprised of benzyl 2-hydroXy-2-(4,5-dihydro-4S-phenyloxazol-2-yI~
1S-phenyethylethylcarbamate (100 mg, 0.22 mmol) in methanol (10 raL) was placed under a nitrogen atmosphere and stirred while Pearlman's catalyst (20 mg) was added.
The mixture was stirred vigorously under a hydrogen atmosphere until the reaction was complete and then filtered. The filter was washed with methanol (2 x 25 mL). The combined filtrates were concentrated to provided 2S-amino-4-nhenyl-1-f4.5-dihvdro-4S phenvloxazol-2=yt)butan-1-of (51 mg, 0.16 mmol) as a clear oil. Ma (PCI) m/z = 311 (M +1). (C~gH~NzO~.

2S-Amino-1-oxazol-2-yl-4-phenylbutan-1-oI
A solution comprised of oxazole (0.25 g, 3.62 mmol) in THF (20 mL) was treated with borane tetrahydrofuran complex (3.62 mL, 3.62 mmol) under nitrogen and the mixture was stirred for 30 minutes and then cooled to -78°C. .A solution comprised of sec-butyl lithium (2.78 ml, 3.62 mmol) in cyclohexane was added dropwise and the mixture was stirred for 30 minutes.
A solution comprised of tert-butyl (,f~~~1-formyl-3-phenylpropylcarbamate (0.476 g; 1.8I mmol) in THF (25 mL) was added and the mixture was stirred and allowed to. warm while the reaction proceeded to completion. The mixture then was cooled to -78°C, quenched by slowly adding 5% acetic acid in ethanol (20 mL), allowed to warm to ambient temperature and stirred for 18 hours. The mixture was concentrated to dryness and the residue was extracted with ether (2x25 mL). The combined extracts were washed with brine, dried (MgS04) and concentrated to dryness to provide tert-butyl 2-hydroxy-2-oxazol-2-yl-1S-phenethylethylcarbamate (0.125 g, 0.376 mmol) as a yellow oil.
MS (PCn m/z = 333 (M + 1).
A mixture comprised of tent-butyl 2-hydroxy-2-oxazol-2-yl-1S-phenethylethylcarbamate (0.125 g, 0.376 mmol), anisole (0.2 mL) and trifluoroacetic acid (0.6 mL) in methylene chloride (20 mL) was stirred at room temperature for 2 hours and then concentrated to provide 2S amino-1-oxazol-2-yl-4-Q,henylbutan-1-of trifluoroacetic acid salt ( 0.08 g, 0.229 mmol) as a yellow oil. MS (PC>] zn/z = 233 (M + 1 ).

Methyl 2-(2S-amino-1-hydroxy-4-phenylbut~xazole-4-carboxvlate A solution comprised of methyl 2-(2S-benzyloxycarbonylamino-1-hydroxy-4-phenylbutyl)-4,5-dihydrooxazole-4-carboxylate (0.100 g, 0.235 mmol) in methylene chloride (3 mL) was cooled to 0° C and then treated with DBU (39 mL, 0.26 mmol) and bromotrichloromethane (26 ml, 0.26 mmol). The mixture was stirred for 6 hours at 0° C, washed with ammonium chloride (10 mL) and. concentrated. The residue was dried (MgSO~ to provide methyl 2-(2S-benzyloxycarbonylamino-1-hydroxy-4-phenylbutyl)oxazole-4-carboxylate.
MS(PCl7 m/z = 425 (M +1). ' Deprotecting provided methyl 2-(2S-amino-1-h~x~r-4-nhenylbut-,yl)oxazole-4-carbox lLate.

Benzyl 1S f2-(4:S-dihydrooxazol-2-yl)-2-hydroxy-1S-phenethylethylcarbamoyll-3-methvlbutvlcarbamate (Compound 210) 'I N
\ O~H
O
A mixture comprised of ethyl 3-(2-benzyloxycarbonylamino-4-methylvalerylamino~
2-hydroxy-5-phenylpentanimidate (0.327 g, 0.63 mmol), diisopropylethylamine (0.218 mL, 1.26 mmol) and ethanolamine (38.4 mg, 0.63 mmol) in chloroform (20 mL) was heated (reflex temperature) for 3 hours and then stirred at room temperature for approximately 12 hours. The mixture was concentrated and the residue was dissolvcd in ethyl acetate (50 mL). The solution was washed with 0.5 M sodium hydroxide (40 mL) and brine (40 mL), dried (MgSO4) and concentrated in vacuo. Product was purified from the residue by flash chromatography eluting with 3:1 ethyl acetate/hexanes to provide benzyl 1S-f2-(4,5-dihydrooxazol-2-vl~-2-hydroxy-1S-phenethvleth~rlcarbamoyll-3-methvlbutylcarbamate (38 mg, 0.079 mmol) as a white solid.
MS (PCI] m/z = 482 (M +1). y71333~3~3)' Proceeding as in Example 19 provided benzyl IS-12-(IX benzoimidazol-2-vI)-2-hvdrox -~henyethylethylcarbamo~-3-meth l~txlcarbamate (Compound 211);

Benzyl 1S-12-(4.5-dihydro-4S-phenvloxazol-2-yl)-2-hvdroxy-1S-phenethyleth~rlcarbamoyl7- .
3-rnethylbutylcarbamate (Compound 212) O
\ 0 A solution comprised of 2S-amino-4-phenyl-1-(4S-phenyl-4,5-dihydrooxazol-2-yl)butan-1-of (51 mg, 0.165 mmol), provided as in Example 18, in DMF:(2 mL) was cooled to 0° C and a second solution comprised of 2,5-diaxopyrroIidin-1-yl 2S-benzyloxycarbonylamino-4-methylvalerate {0.063 g, 0.174 mmol) and diisopropylethylamine (30.3 p,L, 0.174 mmoI) in DMF (3 mL) was added. The mixture was stirred for 2 hours, while allowing to warm to room temperature, and then concentrated. Product was purified from the residue by column chromatography eluting with ethyl 1:1 acetate/hexane to provide benzyl 1S-!2-(4,5-dihvdro-4S-phen~oxazol-2-yl)-2-h~roxy-1S-phenethylethylcarbamo~rll-3-methylbut~lcarbamate (34 mg, 0.061 mmol) as a clear oil. MS (PC17 m/z =
558(M +1).
{C33H39"3o3)' Proceeding as in Example 20 provided the following compounds of Formula I:
ben zyl 1 S-f 2-benzooxazoI-2-yl-2-hvdroxy- I S-phenethylethylcarbam ~1);
3-methylbu-t,~lcarbamate (Compound 213); MS (ESn mIz = 530 (M + I);'H-NMIt (300 MFiz, CDCl3,): b 0.65 - 0.7 {dd, 6H), 8 0.98 (d, J = 6 Hz 2H), b I.IO - L55 (m, 3H), S 1.65 - I.85 (m, 1H), 2.08 (m, IH), b 2.70 (m, 2H), 8 3.99 - 4.I3 (m, IH); b 4.50(~a, IH), 8 4.90 - 5.2I (m, 3H), 8 6.40 - 6.70 {dd,1H), 8 7.05 - 7.35 (m, IOH), 8 7.47 (d, J = 4 Hz, 2H), ~
7.5I (d, J = 2 Hz, 2H), ~~fH3~3~~~
benzvl 1-f 2-(4.S-dihvdro-S-x~henvloxazol-2-vI)-2-hydroxv-1-ahenethvlethylcarbamovll-3-methylbutylcarbamate (Compound 2I4);
90 benzvll-f2-(4,5-dihvdro-4S-methyl-SS-phenvloxazol-2-y1?-2-hydroxy-1 phenvethvlcarbamovll-3-methylbutvlcarbamate {Compound 215);
benzyl 3-methyl-1-(2-hvdroxy-2-naphthof2,3-dloxazol-2 y1-1-nhenethyleth~Icarbamo~,Lbutyicarbamate (Compound ZI6); MS (ESn m/z = 580 (M
+ 1);
'H-NMR (300 MHz, CDCI~: S 0.65 - 0.95 (m, 6H), S 1.25 (m, 3H), b 1.54 (m, 3H), 8 2.20 (m, i5 1H), fi 2.82 (t, J = 4 Hz, 2H), 8 4.00 - 4.20 (m, 1H), 8 4.35 - 4.55 (m, 1H), 8 4.90 - 5.09 (m, 3H), 8 6.60 (m, 1H), b 7.23 (m, lOH), s 7.56 (m, 2H), b 7.96 (m, 3H), S 8.18 (s, IH), (C~H3zN3O3);
benzvl IS-(2-benzooxazol-2-yl-2-hydroxv-1S-phenethylethvlcarbamovl)-2-methYnro~Ylcarbamate (Comgound 217);
benzvl 1S-(2-benzooxazol-2-Y1~2~,hydroxy-1S-phenethylethylcarbamoyl)-20 3-methylbutvlcarbamate (Compound 2I8);
benzvl 1S-f2-l4.S-dihydro-4.4-dimethyloxazol-2.;yI~-2-h droxv-1S phenethvlethylcarbamoyll-3-methyIbutylcarbamate (Compound 2l9), MS(PCI) m/z ~ SIO
(M -rl); 'H NMR (CDCI~: 8 0.8 - 0.99 (d, J = 6 Hz, 6H) , 1.11 - I.35 (m, 6H), S I.4 -1.78 (m, ' 3H), b 1.82 - 2.01 (m, 2H), 8 2.55 - 2.72 (m, 2H), 8 3.95 (m, 1H), 8 4.0 -4:25 (m, 3H), 8 4.30 25 (s,1H), b 5.10 (s, 2H), 8 5.35 (s, IH), s 6.58 (m, lI3) 7.1 - 7.37 (m, lOH); (C29H3sN3O~;
~nethyl 2-f2-(2-benzylox~carbonylamino-4-meth Iy valerylamino)-1-hydroxy-4-phenylbutyll-4.5-dihydrooxazola-4-carboxyIate (Compound 220), MS(PC>7 m/z =
540 (M +1);
'H NMR (CDCI~: cS 0.8 - 0.99 (d, J = 6 Hz, 6H) ,1.25 (m, 1H), F 1.47 (m, IH) I.65 (m, ZH), 8 1.99 (m, 2H), 8 2.15 (s, 1H), 8 2.65 (t, J = 4Hz, 2H), 8 3.70 (s, 3H) 4.18 (m, II-~, 30 8 4.25 - 4.50 (m, 3H), 8 4.51 - 4.64 (m, 2H), 8 5.17 (m, 2H), 8 5.35 (d, J
= SHz, IH) 6.65 (d, J = 6Hz, IH), b 7:17 - 7.45( m, 10H); (C~H37N30~);

methyl 2-f2-f2,2-dimethvlpropionylamino)-4-phenylbut~rylloxazole-4-carboxylate (Compound 221); MS (ES17 m/z = 373 (M + 1); 'H-NMR (300 MHz, CDCI~: S 1.25 (s, 9H), & 2.20 (m, 1H), 8 2.46 (m,1H), 8 2.77 (t, J = 4 Hz, 2H), b 3.99 (s, 3H), 5 5.55 (m, 1H); 8 6,41 (d, J = 4 Hz,1H), S 7.20.- ?.38 (m, SH), 8 8.41 (s, 1H), (C~T~IV20s);
tert-butyl 4-f IS-f2-lS-ten-but~benzooxazol-2-yl)-2-h~droxy!-IS-phenethylethylcarbamoyll-3-methylbutylcarbarnoyllpiperidine-I-carbox l~
(Compound 222);
tert-butyl 4-f 1S-f2-hydroxv-IS-phenethyl-2- 5-sulfamo Ibenzooxazol-2- 1 eth Icarbamo 1 -3-meth lbu lcarbamo I i eridine-70 I-carboxylate (Compound 223);
tert-bu 14- 1S- 2-h drox -2-na htho 1 2- oxazol-2- 1-1S- heneth leth Icarbamo 3-methylbutylcarbamoyl~piperidine-1-carbox~late (Compound 224);
tent-bu 14- 1S- 2-h drox -2-na htho 2.1- oxazol-2- 1-1S- heneth leth lcarbamo 3-meth,~rlbutylcarbamoyllpiperidine-1-carboxvlate (Compound 225);
i5 tent-butyl 4-f 1S-f2-hydroxy-IS-phenethyl-2-l5-nhenvlbenzooxazol-2-vI)ethvlcarbamovll-3-methvlbutvlcarbamovl)piperidine-I-carboxvlate (Compound 226);
tent-butvl4-fIS-(2-benzooxazol-2-vI)-2-hydroxy-IS- hp enethylethyIcarbamovl>~
2methylbutylcarbamoyl"Ipiperidine-I-carbox~ lr_ ate (Compound 227); MS (ESn mlz = 607 (M +
20 1); 'H-NMR (300 MHz, CDCI3): 8 0.50 - 0.6I (m, 1H), b 0.75 - 0.98 (m, 6H), 8 1.22 (m, 1H), 8 1.41 (s, 9H), b 1.81 - I.85 (m, IH), 8 1:99 - 2.06 (m, 1H), S 2.70 (m, 2H);
4.24 (d, J = 2 Hz 2H), S 4.50 - 4.70 (m, 1H), 8 4.99 - 5.14 (m, 2H), 8 6.96 - 7.81 (m, 15H), (C34H,~N,,O6);
tert-butyl 3-f 1 S-(2-benzooxazol-2-vI)-2-hydroxy-1 S-pheneth~rlethvlcarbamoyll-2-methylbut~carbamoyljb_enzylcarbamate (Compound 228);
25 te_n-butyl 4-f 1S-(2-benzooxazol-2-yl)-2-hey-IS-phanethylethvlcarbamoyl~
2-cyclohexylethylcarbamoyllpiperidine-1-carboxy_late (Compound 229);
benzyl 3-methyl-1 S= j2-hydroxy-1 S-~henethvl-2-__(5 phenyloxazol-2-yl ethylcarbamoyllbuylcarbamate (Compound 230); MS (ESl7 m/z = 556 (M + I);'H-NMR (300 MHz, CDCt3): 8 0.75 - 0.95 (m, 6H), S 1.25 - 1.80 (m, 5H), b 2.00 (m, 30 ZH), 8 2.67 (m, 2H), S 4.15 (m, IH), 8 4.55(m, 1H), $ 4.85 - 5.20 (m, 2H), S 5.50 (m, 1H), b 6.80 (d, 3 = 6Hz, 1H), 8 7.12 - 7.48 (m, 14H), 8 7. 62 (d, J = 2 Hz, 2H), (C33H37N3C5)~
pyrid-3-yl 3-methyl-1S-[2-hydroxy-1S-phenethyl-2-(5-phenyloxazol-2-yl)ethylcarbamoyl]butylcartiamate (Compound 231); MS (ESn m/z = 527 (M + 1);'H-NMR (300 MHz, CDCl3): 8 0.75 - 0.95 (m, 6H), b 1.45 -1.75 (m, 5H), b 2.00 (m, 2H), 8 2.67 (m, 2H), S 4.40 - 5.10 (m, 3H), b 5.60(s, 1H), 8 7.00 - 7.47 (m, 10H), 8 7.62 (m, 2H), b 8.15 (m, 1H), 8 8.65 ( m, IH), 8 9.15 (m, IH), (C3,H~N404); and benzyllS-[2-hydroxy-1S-phenethyl-2-(5-phenyloxazol-2-yl)ethylsulfamoylmethyl]-2R-methyIbutylcarbamate (Compound 232); MS
(ESn mlz = 606 (M + 1 ); 'H-NMR (300 MHz, CDC13): 8 0.75 - 0.95 (m, 6H), S
1.30 -1.50 (m, 5H), 8 1.98 (m, 2H), 8 2.77 (m, 3H), b 3.55 (m, 2H), 8 4.09 (m, 1H), 8 4.90 -5.10 (m, 3H), S 5.60 (m, 1H), 8 7.02 - 7.47 (m, 14H), 8 7.62 (m, 2H), (C33H39N306s)~
t 0 EXAMPLE 21 Benz~rl 3-methyl-1S-(IS_pyrid-2-vJcarbonvl-3-phenylpropylcarbam~l)but~~lcarbamate (Compound 233j H
p p A solution comprised of 2-bromopyridine (0.291 mL, 3.06 nunoI) in dry 1~ (2 mL) was cooled to -78° C and then a solution of n-butyllithium (L6 ml,, 2.?2 mmol) in pentane was added dropwise over 2 minutes. The mixture was stirred at -78° C for 10 minutes and then a solution of benzyl 1-[1-(N methoxy-N methylcarbamoyl)-3-phenylpropylcarbamoyl]-3-methylbutylcarbamate (0.3 g, 0.64 mmol) in T.~iF' (2 mL) was added slowly.
The mixture was _ stirred, while allowing to slowly warm to room temperature, and then poured into a solution comprising acetic acid (0.163 mL) in diethyl ether (50 mL). The organic phase was washed with brine (40 mL), dried (MgSO~ and concentrated in vacuo. Product was purred from the 'residue by flash chromatography on silica gel eluting with 1:2 ethyl acetate/hexanes to provide benzyl 3-methyl-1-(1-pyrid-2-ylcarbonyl-3-phenylpropylcarhamoyl)butylcarbamate (82 mg, 0.17 mmol) as a white solid. MS (ESl) mlz = 488 (M + 1); 'H NMR (CDCI~I: 8 0.8 -1.05 (d, 3 = 4 Hz, 6H) , 1.5 (m, IH), 81.6 - L78 (t, 2H), $1.99 - 2.20 (m,1H), 8 2.6 -2.9 (m,1H), 8 2.55 - 2.85 (m, 2H), 8 4.25 (m, 1H), 8 5.17 (s, 2H), S 5.25 (m, ITS, 8 6.00 (m,1H), 8 6.85 - 6.95 (d, J = lOHz, 1H), 8 7.1 - 7.4 (m, lOH) 7.50( t, J = 4Hz, 1H), s 7.85 (t, J = 6Hz, IH) 8.01 (d, J = 8 hz, 1H), 8 8.69 (m, 1H). Anal (C~~I~N3O,).
Proceeding as in Example 21 provided the following compounds of Formula I:
bent 1 I- I- 'd-3- Icarbon 1 -3- hen 1 ro vlcarbamo 1 -3-meth lbu lcarbamate (Compound 234), MS(PCI) m/z = 488 (M +1); 'H NMR (CDCI~: 8 0.8 - LOS (d, J = 4 Hz, 6H) , 1.5 (m, IH), B 1.6 - 1.78 (t, 2H), 8 I .80 - 2.01 (m, 2H), 8 2.25 (m, IH) 2.6 - 2.9 (t, J =3 Hz, 1H), 8 2.55 - 2.85 (m, 2H), 8 4.30 (m, 1H), 8 5.17 (s, 2H), 8 5.35 (d, J =
6Hz, 1H), S 5.55 {m, 1H), 8 7.02 (d, J = 8Hz, IH), 8 7.1- 7.4 (m, l OH) 8.05( d, J =5 Hz, IH), 8 8.78 (d, J = 4Hz, 1H), 8 9.10 (s,1H); (C~H33N3O~; and benzvl I-~i-fquinol-3-ylcarbonyl)-3-phenylpropylcarbamovll-3-methylbutylcarbamate (Compound 235), MS(PCn m/z = 538 (M +1 ); 'H NMR (CDC13): b 0.8 -1.05 (d, J =
4 Hz, 6H) 1.5 (m, 1H), b 1.6 - 1.78 (m, 2H), S L99 - 2.20 {m,1H), 8 2.6 - 2.9 (m, 1H), 8 2.55 - 2.85 (m, ZH), S 4.35 (m, 1H), S 5.17 - 5.25 (m, 3H), 8 5.70 (m, IH), S 6.75 - 6.85 (d, J = lOHz, 1H), 8 7.20 - 7.45 (m, IOH), c5 7.65 (t, J = 6Hz, IH), 8 7.77 - 7.90 (m, 2H), 8 8.22 (d, J = 7, 1H), $ 8.46 (s, 1H), b 9.4 (s, 1H); (C~H~N30,~.

BenzY 1-~I-(IH-indol-5-ylcarbonvl)-3-phenylpronvlcarbamoyll-3-meth ~Ibut-ylcarbamate (Compound 236) A mixture comprised of potassium hydride (0.29 g, 2.56 mmol; 67% in mineral oil) in anhydrous ether (5 mL) was cooled to 0° C and then a solution comprised of 5-bromo-lH-indole (0.5 g, 2.56 mmol) in anhydrous ether (5 mL) was added. The mixture was stirred for minutes and then cooled to -?8 ° C under nitrogen. A solution comprised of ten-butyllithium (3 mL in pentane, 5.08 mmoI) in anhydrous ether (S mL) was cooled to -?8° C and added to the 10 indole mixture over 2 minutes. The mixture was stirred for 10 minutes and then a solution comprised of benzyl 1-[1-(N methoxy-N-methylcarbamoyl)-3-phenylpropylcarbamoyl]-3-methyIbutylcarbamate (0.3 g, 0.64 mM) in ether (IO mL) was added. The mixture was allowed to warm to room temperature and then poured into a cold solution at 0° C of phosphoric acid (25 mL, 1 M in water). The aqueous layer was separated and extracted with ethyl acetate 15 (25 mL). The organic layers were combined and washed with saturated sodium bicarbonate (25 mL), dried {MgSO~ and concentrated. The product was purred from the residue by flash chromatograpby on silica gel eluting with I:2 ethyl acetatelhexanes to provide benzyl I-[I-(IH-indol-2-ylcarbonyl)-3-phenylpropylcarbamayl]-3-methylbutylcarbamate (1 I2 mg, 0.21 mmol) as a white solid. MS (ESn mlz = 526(M + 1); 'H NMR (CDCI3): 8 0.8 -1.05 (d, J = 4 Hz, 6H) , 1.5 (s, IH), S 1.5 - I.?8 (m, 3H), 8 2.00 (m, 1H), 8 2.4 (m, lI~, $ 2.65 (m, 2H), 8 4.35 (m; 1H), S 5.17 (s, 2H), 8 5.25 (d,J = 6 Hz 1H), S 5.75 (m, 1H), 8 6.55 {s, 1H) 7.05 (d, J = 4Hz, IH), 5 7.1 - 7.45 (m, lOH) 7.?( d, J = 4Hz, 1H), 8 8.I5 (d, J = 4Hz, 1H) 8.78 {m, 1H).
(~~35~3~4)~

benzYl 1-f 1-tbenzofur-2-vlcarbonvl)-3 phen~propvlcarbamoyll-3-methylbutylcarbamate (Compound 23'7) A solution comprised of benzofuran {0.302 g, 2.56 mmol) in anhydrous ether (S
mL) was cooled to -1S ° C under a nitrogen atmosphere and then a solution of n-buryllithium (1.6 mL
in hexanes) was added dropwise over 2 minutes. The mixture was stirred for 1 how and then a solution comprised of benzyl 1-[1-(N rnethoxy-N methylcarbamoyl)-3-phenyIpropylcarbamoyIJ-3-methylbutylcarbamate,(0.3 g, 0.64 mmol) in diethyl ether was added. The mixture was stirred at -1S ° C until the reaction was complete. The mixture was quenched with a solution of acetic acid (0.153 mL) in diethyl ether (50 mL). The organic phase was washed with brine (40.mL), dried (MgS04) and concentrated in vacuo. The product was purified from the residue by flash chromatography eluting with 2:3 ethyl acetatelhexanes to provide Benz 1 I-f 1-(benzofur-2-ylcarbonyl)-3-phen~propylcarbamoyll-3-methvibutylcarbamate (?0 mg, 0.13 mmol) as a white solid. 'H NMR (CDC13): 8 0.8 - 0.99 (d, J = 4 Hz, 6H) , 1.5 (m, 1H), 8 I.6 - 1.72 (m, 2H), 8 1.99 - 2.18 (m, IH), 8 2.22 - 2.41 (m, 1H), ~ 2.6 -2.75 (m, 2H), 8 4.21 (m, 1H), 8 S.Ol (m, 1H), 8 5.17 (s, 2H), 8 5.50 (m, 1H), 8 6.75 - 6.81 (d, J =
7 Hz, 1H), 8 7.I0 - 7.37 (m, I IH) 7.4 - 7.59( m, , 3H), 8 7.64 (d, J = 7 Hz, 1H).
(C32H~N20s).
Proceeding as in Example 23 provided the following compounds of Formula I:
benzvl 1-f 1-lbenzothiazol-2-ylcarbon Iy )-3=phenylpronvlcarbamovl7-3-methYlbutvlcarbamate (Compound 238),'H NMR (CDC13): 8 0.91 (d, J = 5.88 Hz, 6H), 81.39 - LS4 (m,1H), fi 1.60 -1.72 (m, 2H), S 2.11 - 2.25 (m, 1H), S 2.40 -2.54 (m, 1H), b 2.?2 {m, 2H), S 4.21 (m, 1H), 8 5.10 (s, 3H), 8 5.84 (m, 1H), S 6.87 (d, J = 8.15 Hz, IH), 8 ?.10 - ?.40 (m, l OH), 8 7.54 (dt, J = 1.62, 8.1U Hz, 1H), 8 ?.58 (dt, J =
1.46, 7.80 Hz, 1H), S 7.97 (dd, J = 1.80, 8.15 Hz, l I~, 8 8.17 (dd, J = 1.66, 7.67 Hz,1H);
benzyl 3-methyl-1S-(3-phenyl-1 S-thiazol-2-vlcarbonvlpropylcarbamovl)butylcarbamate (Compound 239);
N f3-methyl_-IS-(3-phenyl-1S-thiazol-2-ylcarbonylpropylcarbamo 1)y butvf~
4.meth~nip~-1-carboxamide (Compound 240);
tent-butyl 4-f3-methyl-1S-f3-phenyi-IS-thiazol-2-vlcarbonvlpropvlcarbamo l~r )bu_tylcarbamoyllpiperazine-1-carboxylate (Compound 241 );
benz~3-methyl-1S (3-phenyl-IS-thien-2-ylcarbonylpropylcarbamoyl)butylcarbaniate (Compound 242);
benzyl IS-f1S-(1-methyl-1X imidazol-2-ylcarbonyl-3-phenyl_propylcarbamoyll-3-methylbutvlcarbamate (Compound 243);
benzyl IS (1S-thiazol-2-ylcarbonyI-3-phenylnropylcarbamoyl)-2-methylprogylcarbamate (Compound 244);
N f3-methyl-1S-(3-Then"Yl-1S-thiazol-2-ylcarbonylpr_opylcarbamovl~butvllninerazine-I-carboxamide (Compound 245);
benzyl 1 S-f 1 S-(4-methylthiazol-2-vlcarbonyl)-3-phenvlpropylcarbamoyll-3-methylbut,~lcarbamate (Compound 246);
benzyl 1 S-f 1 S-furYl-2-ylcarbonyl-3-phenvlpropylcarbamoyl)-3-methylbutylcarbamate {Compound Z47), 'H IVMR {CDCI3): s 0.9I (d, J = 6.I8 Hz, 6I-~, S L42 - 1.?0 (m, 3I~, 81.98 - 2.13 (m, 1H), S 2.19 - 2.37 (m, 1H), 8 2.69 (t, J = 7.60 Hz, 2H), 8 4.22 (m, 1H), 8 5.10 (d, J = 7.76 Hz, 1H), S 5.12 (s, 2H), S 5.54 {m, 1H), 8 6.76 (d, J = 8,15 Hz, 1H), 8 7.16 - ?.36 (m, lOH), 8 7.39 (dt, J = 1.82, 7.86 Hz, 1H), 8 7.47 (dt, J =1.63, 7.79 Hz, 1H), 8 7.69 (s, 1H), S 7.80 (d, J = 7.15 Hz, I H), 8 7.85 (d; J = 8. I 8 Hz, 1 H);
benzyl 1S-f 1S-(I-benzyl-IH imidazol-2-ylcarbonyl-3-nhe~lpropylcarbamovll-3-meth3rlbutylcarbamate (Compound 248);
benzvl 3-phenyl-1-(4,5-dihydro~-4S-p,~enyloxazol-2-vlcarbonvl)propyllcarbamate (Compound 249);
benzvl 3-phenyl-1-(4,5-dihydro-5-nhenvloxazol-2-ylcarbonylpropvllcarbamate (Compound 250);

benzvl f 1-f4.5-dihydro-4S-methyl-5S-nhenvloxazol-2-vlcarbonvl)-3-phenyinropvllcarbamate (Compound 251); and ethyl 2-12-f2-benzyloxycarbon~ylamino-4-methvlvalerylaminol-4-phenvlbutyr~rl~thiazole-4-carboxvlate (Compound 252}.

Methyl 2-f2-(2-benzyloxycarbon~amino-4-methvlvalerylamino)-1-hvdrox"y 4-phenylbutylloxazole-4-carboxylate (Compound 2.53) A solution comprised of methyl 2-[2-(2-benzyloxycarbonylamino-4-methylvalerylamino)-I-hydroxy-4-phenylbutyl]-4,5-dihydrooxazole-4-carboxylate (0.036 g, 0.067 mmol) in methylene chloride (3 mL) was cooled to 0° C and then DBU {11.2 mg, 72.7 ~Cmo1) and bromotrichloromethane {14.6 mg, 73.7 umol) were added. The mixture was stirred for 6 hours at room temperature and concentrated. The residue was dissolved in ethyl acetate (20 mL) and the solution was dried (MgSO,) and concentrated. The product was purified from the residue by flash chromatography eluting with 1:3 hexaneslethyl acetate to provide meth 2-'~2_-(2-benzylox carbonvlamino-4-ri~ethvlvalerylamino)-I-h~droxy-4-Qhenvlbutylloxazole-4-carboxylate (12 mg, 0.022 mmol) as a white solid. MS(PCn m/z = 538 (M +1)'H
NMR
(CDCI~: 8 0.8 -1.05 (d, J = 4 Hz, 6H), 81.55 -1.?0 (m, 3H), 8 2.00 (m, lI~, 8 2.40 (m, III, ~ 2.69 (m, 2I~, 8 3.99 (m, 3H) 4.45 (m, 1H), fi 5.17 (s, 2H), 8 5.78 (m, IH), & 7.01 (d, J = 4Hz IH), 8 7.I4 - 7.47 (m, IOH) 7.72( d, J = 4Hz, IH), ~ 8.40 {s, 1H).
(CZ~H~SN30,).

2-T2-l2-BenzVloxycarbonvlamino-4-methvlvalervlamino)-1-hvdrox~phenylbutvlloxazole-4-carboxylic acid (Compound 254) A mixture comprised of methyl 2-[2-(2-benzyloxycarbonyiamino-4-methylvalerylamino)- , 1-hydroxy-4-phenyIbutyl]oxazole-4-carboxylate (2.I6 g, 4.02 mmol), provided as in Example 18, and sodium hydroxide (0.815 mL, 1.63 M in water) in methanol (10 mL) was stirred for approximately 12 hours at room temperature, acidified with 1 M hydt~ochloric acid and concentrated. The residue was dissolved in ethyl acetate (50 mL) and the solution dried (MgSO~. The product was recrystallized from methanol and ether to provide 2-[2-(2-benzyloxycarbonylamino-4-methylvalerylamino~ 1-hydroxy-4-phenylbutyl]oxazole-4-carboxylic acid (1.77 g, 3.38 mmol) as an off white solid.

Benz~l, 3-methyl-112-h~drox~-1-ghenethyrl-2-(4-vhenvlcarbamovloxazol-2- I~ethylcarbamoyllbutylcarbamate (Compound 255) A solution comprised of 2-[2-(2-benzyloxycarbonylarnino-4-meihylvalerylamino~
1-hydroxy-4-phenylbutylJoxazole-4-carboxylic acid (0.05 g, 0.096 mmol), provided as in Example 7, in DMF (5 mL) was stirred while PyBOP~ (0.05 g, 0.096 mmoI) and aniline (9 mg, 0.096 mmoI) were added. The mixture was stirred for an additional 2 minutes and t0 diisopropylethylamine (12.4 mg, 0.096 mmol) was added. The mixture was stirred for 2 hours at room temperature, poured into cold water 0° C ai and extracted with ethyl acetate 14 x 30mL).
The extracts were combined, dried (MgSO~ and then concentrated. 'The product was purified from the residue by flash chromatography eluting with 1:2 hexaneslethyl acetate to provide benzyl 3-methyl-1-j2-hydroxy-1-phenethyl-2-(4-phenylcarbamoyloxazol-2-yl)ethylcarbamoyl]butylcarbamate (30 mg, 0.05 mmol) as a white solid. MS (ESI) ) m/z = 599 (M + 1);'H NMR (CDCl3): 8 0.8 - I.05 (d, J = 4 Hz, 6H) ,1.35 (m, IH), b 1.55 (m, 1H), 8 2.00 - 2.15 (m, 2H), 8 2.62 (m, 2H}, 8 2.80 (m, 2H), ~ 3.65 (m, 2H), 8 4.11 (m, 1H), S 4.30 (m, 1H), 8 4.45 (m, 1H), 8 4.95 (s, 1H) 5.17 (s, 2I~, 8 5.2 (d, J =4Hz, 1H), 8 6.70 (d, J = SHz 1H), S 7.1 - 7.45 (m,15H) 7.7( d, J = 4Hz, 1H), 8 8.19 (s, 1H), b 8.99 (s, IH). (C~H3gN40~.
Proceeding as in Example 26 provided the following compounds of Formula I:

benzyl l-f2-!4-benzvlcarbamov6oxazol-2-v)1-2-hvdroxv-1-nhenethYlethvlcarbamovll-3-methvIbutylcarbamate (Compound 256), MS (ESn ) m/z = 613 (M + 1);'H NMR
(CDCI~):
b 0.8 -1.05 (d, J = 4 Hz, 6H), 81.25 - I .7S (m, 3H), 8 2.00 - 2.20 (m, 2H), 8 2.69 (m, 2H), 8 3.85 (m,,1H), S 3.95 (m, 1H), 8 4.25 (m, 1H), 8 4.60 (m, 2H), S 4.$0 (s, IH), 8 S.I7 (s, 2H), S
5.59 (xn, IH), S 6.59 (d, J = 4Hz 1H), 3 7.05 - ?.47 (m, 15H), 8 8.20 (s, IH);, (C35H,QN,~06); and benzyl 3-methyl-1-f2-hydroxy-I pheneehyl-2-!4-ghenvethvlcarbamoyloxazol-2-vI)eth lcy arbamoyllbutylcarbamag (Compound 257), MS
(ESI] ) mlz = 627 (M + 1);'H NMR (CDCl3): 8 0.8 -1.05 (d, J = 4 Hz, 6H), 81.25 - 1.75 (m, 4H), S 2.00 (m, 2H), b 2.59 (m, 2H) 2.88 (m, 2H), $ 3.65 (m, 2H), S 4.02 (m, 1H),. 8 4.25 (m,lH), 8 4.80 (s, 1H), 8 S.I7 (s, 2H), 8 6.59 (d, J = 4 Hz, 1H), 8 7.00 -?:42 (m, 15H), S 8.20 ($, 1~~ (~6H42N4~6)~

benzyI 1-fI-!4 5-dihvdro-4S-ghenvloxazol-2-vlcarbonyll-3-phenylpropy)carbamoyl_1-3-met~lbutylcarbamate (Compound 258) ~~o~
i A solution comprised of benzyl 1S-[2-(4,5-dihydro-4S-phenyioxazol-2-yl)-2-hydroxy-1S-phenethylethylcarbamoyl]-3-methylbutylcarbamate (0.038 g, 0.0?8 mmol), provided as.in Example 14, and Dess-Martin Periodinane (0.031 g, 0.072 mmol) in methylene chloride (5 mL) was stirred while a mixture of 0.001:1 methylene chloride/water (2 mL) was slowly added. The mixture was stirred until the reaction was complete and then concentrated. The residue was dissolved in ethyl acetate (50 mL) and the solurion was washed with saturated sodium bicarbonate (40 mL), sodium thiosulfate (40 mL, 109'o wdwt), water (40 mL) and brine (40 mL), dried (MgSO~ and then concentrated. Product was purified from the residue by flash chromatography eluting with-3:1 ethyl acetateJhexanes to provide benzyl I-[1-(4,5-dihydro-.
4S-phenyloxazol-2-ylcarbonyl)-3-phenyIpropylcarbamoylJ-3-methylbutylcarbamate (0.0148, 37.5%) as a white solid. MS (PCI] m/z = 556 (M +I)'H NMR (CDC13): S 4.8 -1.05 (d, J = 6 Hz, 6H), 81.4 -1.78 (m, 3H), b 1.87 - 2.12 (m, IH), 8 2.40 (m, 1H), ~ 2.65(t, J = 4Hz, 2H), b 4.25 (t, J = 3Hz, 2H), 8 4.75 (t, J = 4 Hz, IH), 8 S.I O (s, ZH), 8 5.40(d J
= 3Hz , 1H), 8 5.50 (t, J = 4 Hz, IH), 8 6.97 (d, J = 3Hz, 1H) 7.I - 7.49( m, 15H). (C33H37N3o5)' Proceeding as in Example 27 provided the following compounds of Formula I:
70 benzyllS-(IS-benzooxazol-2-ylcarbonvl-3-phenylpropylcarbamoyl)-3-methylbutvlcarbamate (Compound 259);
benzyl 1S-f1S-(4.5-dihvdrooxazol-2-ylcarbonvh-3 phenylpropylcarbamoyll-3-meth~lbutvlcarbamate (Compound 260), MS (PCI) miz = 480 (M +1)'H NM;It (CDC13):
s 0.8 - 1.05 (d, J = 6 Hz, 6H), 81.4 - 1.78 (m; 3H), 8 1.82 - 2.01 (m, 2H), 8 2.65 (t, J = 5 Hz 2H), 8 2.99 (t, J = 4Hz, IH), 8 3.75 (d, J = 3Hz,lH), b 4.10 - 4.35 (m, 3H), s 4.50 (m,1H), S 5.17 (s, 3H), S 6.85 (s, IH), 8 7.I - 7.49( m, IOH), (C27H33Na0~;
N 13-methyl-IS-f3-phenyl-1S-benzooxazol-2-ylcarbonylpropylcarbamo ly )butyllgiperidine-4-carboxamide (Compound 261), 'H NMR (DMSO-db): b 0.83 (d, J = 6.9I Hz, 6H), fi 1.34 - 1.87 (m, 7H), 8 1.92 -2.07 (m, IH), 8 2.20 - 2.33 (m, IH), 8 2.41 - 2.54 (m, 1H), 8 2.62 - 2.92 (m, 4H), 8 3.26 (bd, J = 12.12 2H), 8 4.39 (m, 1H), S 5.18 (m, 1H), b 7.16 - 7.33 (m, SH), 8 7.54 (t, J = 7.64 Hz, 1H), 8 7.64 (t, ?.82 Hz, 1H), 8 7.87 (d, J = 8.40 Hz, IH), 8 7.96 (d, J = 7.67 Hz, 1H), 8 8.07 (d, J = 8.15 Hz,1H), 8 8.29 (hs, IH), 8.8.60 (bs, IH), S 8.76 (d, J = 6.45 Hz, IH);
benzyl 1-lI-f4.~5-dihydro-5-phenyloxazol-2-ylcarbonyl~
3-phenyl_propylcarbamoy113-rnethylbutylcarbamate (Compound 262);
benzyl 1-1I-f4.5-dihvdro-5S-phell-4S-methvloxazol-2-ylcarbonyl)-3-phenylpropylcarbamoyll-3-methJrIbutylcarbamate (Compound 263);
benzyl_ IS-(1S-phenethyl-2-benzimidazol-2-yl-1-oxoethylcarbamovll-3-methylbutylcarbamate (Compound 264),'H IVNflZ (CDCl3): 8 0.82 - 0.96 (m, 6~, 8 1.44 - I.75 (m, 3H), S 2.17 - 2.32 (m, 1H), $ 2.43 - 2.56 (m, 1H), S 2.61 -2.80 (m, 2H), 8 4.55 (m, 1H), & S.I3 (m, 2H), 8 5.35 (d, J = 8.6? Hz, 1H), S 5.70 - 5.88 (m, IH), S
7.00 - 7.42 (m, 14H), 6 7.50 - ?.83 (m, 2H);
benzvl I-f I-(naphthof2,3-dloxazol-2-ylcarbonyl)-3-phenylpron l~carbamoyll-3-methylbutvlcarbamate (Compound 265);
b methvl2-f2-f2-be,~z,~rloxycarbonylamino-4-methylvalervlaminol-4-phenvlbutvrvll-4_,,5-dihvdrooxazole-4-carboxvlate (Compound 266), MS(PCn m/z = 538 (M +1);'H
NMIt (CDCI~: 8 0.8 - 0.99 (d; J = 6 Hz, 6H) ,1.25 (m, 1H), 8 1.47 (m, 1H} 1.65 (m, 3H), S L99 (ra, 1H), b 2.35 (m, 1H), s 2.65 (m, 2H), 8 3.70 (m, 3H) 4.18 (m, 2H), s 4.55 (m, 1H), 8 5.17 (s, 2H), 8 5.35 (m, IH) 6.75 (m, 1H), 8 7.1? - 7.45( m, lOH}, (C2c,H35N307)' ~ benz I IS- 1S- 4 5-dih dro-4 4-dimeth loxazoi ~- Icarbon I 3- lien 1 ro lcarbamo 1 3-methYlbutylcarbamate (Compound 267), .MS(PCI} mlz = 508 (Nl +1);'H NMR
(CDCIs}:
S 0.8 - 0.99 (d, J = 6 Hz, 6H), 81.36 (s, 6H), 81.5 (m, iH), 8 1.65 {rn, 2H) 1.82 - 2.01 (m, lIi), S 2.35 (m, 1H}, 8 2.6 (t, J = 6 Hz, 2H), b 4.05 (s, 2I~, 8 4.25 (m, 2H), 8 5.I0 (s, 2I~, ~ 5.4 (m, IH), 8 6.75 (d J = BHz, 1H) 7.1- 7.38( m, lOH); (Cz9H~N3~s);
15- benzyllS-(1S-benzooxazol-2-ylcarbonyl-3-phen~propylcarbamovl)-2-methylpropYcarbamate (Compound 268),'H NMR (CDCl3): b 0.90 (d, J = 6.91 Hz, 3H), 8 0.97 (d, J = 6.94 Hz, 3H), 8 2.06 - 2.25 (m, 2H), b 2.38 - 2.55 (m, 1H), s 2.74 {m, 2H), 8 4.03 (dd, J =1.73, 6.45 Hz, 1H), 8 5.10 (s, 2H), b 5.29 (d, J = 8.67 Hz, 1H), $
S.'73 (m, iH); 8 6.6G (d, 3 = 7.42 Hz, 1H), $ 7.09 - 7.40 (m, l OH), 8 7.4b (dt, J = 1.62, 8.10 Hz, 1H), 8 7.55 (dt, J = L83, 7.76 Hz,1H), 8 7.64 (d, J = 8.06 Hz, IH), 8 7.89 (d, J = 7.46 Hz, IH);
benz~l 1 S-( 1 S-benzooxazol-2~1_carbon~ 1-3-phen,yluronvlcurbamo~I~-2-meth~butycarbamate (Compound 269),'H NMR (CDCI3): 8 0.88 (t, J = 7.43 Hz, 3H), $ 0.9i (d, J = 6.67 Hz, 3H), 8 1.04 -1.21 (m, 1H), S I.40 -1.55 (m, 1H), b I.78 -1.93 (m, IH), b 2.10 - 2.24 (m, 1H), 8 2.40 - 2.54 {m, IH), 8 2.74 (t, J = 7.60 Hz, 2H), 8 4.06 (t, J = 6.21 Hz, 1H), 8 5.09 (s, 2H), 8 5.29 (d, J = 8.67 Hz, IH), 8 5.72 (m, 1H), 8 6.66 (d, J
= 8.00 Hz, IH), 8 ?.09 - 7.39 (m,10H), 8 7.46 (dt, J = 1.68, 7.80 Hz, 1H), S 7.55 (dt, J =
1.44, 7.56 Hz, IH), 8 7.63 (d, J = 8.04 Hz, 1H), 8 7.89 (d, J = 7.82 Hz,1H);
benzyl 1S-~'IS-(S-chlorobenzooxazol-2-ylcarbonyt)-3-phen,~lgropylcarbamoyll-3-methylbut,~carbamate (Compound 270),'H NMR {CDCI3): 8 0.90 (m, 6H), 8 1.39 -1.53 (m, IH), S 1.59 - I.70 (m, 2H), S 2.07 - 2..21 (m, 1H), S 2.37 - 2.52 (m, 1H), S
2.73 (t, J = 7.91 Hz, 2H), 8 4.20 (m, 1H), 8 5.06 (d, J = 7.91 Hz, 1H), S 5.10 (s, 2H), 8 5.64 (m, 1H), b 6.77 (d, 3 = ?.6? Hz, IH), 8 7.09 - 7.37 (m, I OH), 8 7.53 (dq, J = 1.86, 8.91 Hz, 2H), & 7.89 {d, J =1.73 Hz, IH);
N ( 3-methyl-1 S-f 3-phenyl-1 - 5-chlorobenzooxazol-2- lcarbon 1 ro learbamo 1 but I i eridine-4-carboxamide (Compound 271);
N f2-cyclohex ly~-1,S-l3 phenyl-IS-benzooxazol-2-y~Icarbonylpropylcarbamo ly-,)ethyllpiperidine-4-carboxamide (Compound 272);
MS (EST) mlz = 54S (M + 1); 'H-NMR (300 MHz, CDCI~, CD30D): 8 0.85 (m, 2H), 8 1.02 - 1.58 (m, 4H), 8 1.40 - 1.71 (m, 7H), S 1.75 - 2.21 (m, SH), $ 2.38 (m, 1H), S 2.51 (m, 1H), 8 2.69 (t, J = 4 Hz, 2H), 8 3.32 {m, 2H), 8 4.39_ (q, J = 6 Hz IH), 8 5.53 (q, J =.3 Hz 1H), S 7.11 - 7.21 (m, SH), 8 7.24 (s, 1H); 6 7.38 - 7.61 (m, 3H), 8 7.73 (d, J =
6'Hz, 1H), 8 7.82(d, J = 6 Hz, 1H), (C3zHaoNdC4);
methyl 2-(2-benzyloxvcarbonylamino-4-meth ly valervlamino)-4-phen~ loxazole-4-carboxvlate (Compound 273);
Benz 1 1- 1- 4- hen lcarbamo loxazol-2- lcarbon 1 -3- hen 1 ro Icarbamo 1 -3-methylbutvlcarbamate (Compound 274), MS (ESI) ) m/z = 597 (M + 1);'H NMR
(CDGI3):
8 0.8 - 1.05 (d, J = 4 Hz, 6H), b I.55 {m, IH), 81.70 (s, 2H), a 2.00 - 2.20 (m, lI~, 8 2.40 (m, 1H), b 2.69 (m, 2H); b 2,97 (t, J = 4 Hz, 2H), 8 3.70(q, J = 3 Hz, 2H) 4.25 {m, 1H), b 5.17 (s, 2H), $ 5.59 (m, 1H), 8 6.99 (d, J = 4Hz 1H), 8 7.14 - 7.47 (m, ISH) 7.72( d,.J
= 4Hz, 1H), 8-8.47 (s, 1H), 8 8.65 (s, IH), (C34H3~4~~~
benzvl 1-f 1-(4-benzylcarbamoyloxazol-2-~~Icarbonyl)-3,=phenylpr~ylcarbamoyIl-3-meth Iy butlr)carbamate (Compound 275), MS (ESn ) mlz = 611 (M + 1);'H NMR
(CDC13):
$ 0.8 - 1.05 (d, J = 4 Hz, 6H), S 1.45 -1.70 (m, 4H), b 2.00 - 2.20 (m, 1H), 8 2.40 (m, 1H), 8 2.69 (m, 2H), 8 4.25 (m, IH), 6 4.67 (t, J = 3 Hz, 2H), S 5.17 (m, 3H), S
5.59 {m, 1H), 8 6.85 {d, J = 4Hz IH), s 7.10 - 7.47 (m, 15H), 8 8.47 (s, 1H), (C3sH38N40s);
ten-bu 14- 1S- 1S- 5-tent-bu lbenzooxazol-2- lcarbon 1 -3- hen 1 ro lcarbamo 3-methylbutvlcarbamovl lpineridine-1-earboxylate (Compound 2?6),'H NMR
(CDCl3):
8 0.86 - 0.97 (m, 6H), 8 1.34 - L85 (m, 7H), b 1.38 (s, 9H), $ 1.43 (s, 9H), 8 2.09 - 2.30 (m, 2H), S 2.37 - 2.52 (m, IH), 8 2.72 (m, 4H), 8 4.I 1 (bd, J =12.85, 2H), 8 4.49 (m, 1H), 8 5.66 (m, 1H); S 5.97 (d, J = 7.91 Hz, 1H), 8 6.89 (d, J = ?.67 Hz, 1H), S 7.11- 7.2?
(m, SH); S 7.50 - 7.64 (m, 2H), 6 7.86 (d, J = 1.56 Hz, 1H);
tent-butyl 4-- j i S-f 1 S-l5-sulfamov)benzooxazol-2-ylcarbonyl)-3-phenv)propvicarbamoyll-3-methylbutvlcarbamovl~piperidine-1-carboxylate (Compound 277),'H NMR
(CDCI3):.

8 0.85 - 0:96 (m, 6H), 81.37 -1.82 (m, 7H), S 1.42 (s, 9H), 8 2.08 - 2.46 (m, 3H), 8 2.71 (m, 4H), 8 4.02 (bs, 2H), 8 4.56 (m, 1H), ~ 5.38 (bs, IH), 8 5.78 (bs, 2H), 8 6.38 (d,~J = 8.42 Hz, 1H), b 7.07 - 7.25 (m, SH), 8 7.70 {dd, J = 3.48, 8.64 Hz,1H), 8 8.08 (dd, J
=1.73, 8.67 Hz,1H), 8 8.41 ~ (dd, J = 1.49, 3.96 Hz, 1 H);
S N (3-methyl-1S-f3-phen~-155-tent butvlbenzooxazol-2-ylcarbonyl_lrn~onylcarbamovllbutvl lniveridine-4-carboxamide (Compound 278), 'H NMR (DMSO-cte): 8 0.82 {t, J = 6.18 Hz, 6H), b 1.36 (s, 9H), b 1.33 - 1.88 (m, 7H), 81.91 - 2.06 (m, 1H), b 2.19 - 2:34 (m, 1H), 8 2.42 - 2.54 (m, 1H), 8 2.61 - 2.92 (m, 4H), fi 3.27 (bd, J = 12.02 2H), 8 4.39 (m, IH), 8 5.19 (m, 1H), b 7.15 - 7.33 (m~ SH), 8 7.74 (dcl, J = 1.97, 7.9I Hz, 2H), 8 7.90 (d, J = L83 Hz, iH), 8 8.0? (d, J = 8.15 Hz, ~lH), 8 8.27 (bs, 1H), 8 8.56 {bs, 1H), 8 8.72 (d, J = 6.43 Hz, 1H);
N !3-methyl-1S-L3-phen~=
,~S-(5-sulfamoylbenzooxazol-2 ylcarbonyl)propylcarbamo~Lbutyl lpiperidine-4-carboxamide (Compound 279),'H NMR (DMSO-db): 8 0.80 - 0.88 (m, 6H), 8 1.31 - 1.86 (m, ?H), 8 1.92 - 2.05 (m, IH), 8 2.22 - 2.33 (m, 1H), 8 2.41- 2.52 (m, 1H), 8 2.63 -2.89 (m, 4H), 8 3.26 (bd, J =11.88 ZH), 8 4.40 (m, 1H), 8 5.i3 {m,1H), $ 7.16 - 7.31 (m, 5H), 8 7.57 (s, 2H), 8 8.05 (m, 3H), 8 8.25 (bs, 1H), 8 8.32 (s, 1H), 8 8.55 (bs, IH), 8 8.82 (d, J = 6.18 Hz, 1H), 8 8.88 (d, J = 6.84 Hz, 1H);
tart-butyl 4-f 1S-(1S-naphthof 1.2-dloxazol-2-ylcarbony,I-3-phenylpropylcarbamoyl)-3-methvlbutylcarbamov_l]piperidine-1-carbox~ (Compound 280),'H NMR (CDCI~:
8 0.87 - 0:95 (m, 6H), 81.39 - 1.85 (m, 7H), 8 1.44 (s, 9H), 8 2.I3 - 2.32 (m, 2H), 8 2.45 - 2.60 (m, 1H), 8 2.65 - 2.8i {m, 4H), fi 4.12 (m, 2H), 8 4.53 (m, 1H), 8 5.79 (m, 1H), $ 6.00 (d, J = 7.94 Hz, IH), 8 6.90 (d, J = 7.67 Hz, IH), 8 7.12 - 7.26 (m, SH), 8 7.56 -7.8U (m, 3H), S 7.93 - 8.00 (m, 2H), b 8.52 (dd, J =1.97, 8.00 Hz, 1H);
tart-bu 14- I - 1S-na htho 2 1- oxazol-2- lcarbon 1-3- hen 1 ro lcarba o 3-methylbut~carbamo~jpiperidine-I-carboxylate (Compound 281),'H NMR (CDC13):
8 0.88 - 0.97 (m, 6H), 81.38 -1.86 (m; ?H), 81.43 {s, 9H), s 2.15 - 2.31.(m, 2H), 8 2.43 - 2.57 (m, 1H), 8 2.67 - 2.?9 (m, 4H), 8 4.11 (m, 2H), b 4.52 (m, 1H), 8 5.73 (m, 1H), 8 5.96 (d, J = 7.94 Hz,1H), 8 6.90 {d, J = 7.91 Hz, IH), 8 7.12 - 7.26 (m, 5H), 8 7.66 (m, 2H), 8 7.85 (s, IH), 8 7.99 (dd, J =1.85, 7.80 Hz, 1H), 8 8.33 (dd, J = 1.97, 7.94 Hz, 1H);
tart-bu 1ty 4-~ 1S-f 1S-f5-phenvlbenzooxazol-2-ylcarbonyl)-3-phenylpro~rlcarbamo 3-methylbut~carbamo~~pigeridine-I-carboxylate (Compound 282); MS (ESl~ m/z =
681 (M +

I);'H-NMR (300 MHz, CDC13): s 0.85 - 0.98 (m, 6H), 8 1.43 (s, 9H), b 1.60 -1.85 (m, SH), 8 2.14 - 2.30 (m, ZH), ~S 2.56 (m, 1H); ~ 2.75 (m, 4H), 8 4.12 (m, 2H), 8 4.52 (m, 1H), 8 5.69 (m,1H), S 5.92 (d, J = 6 Hz, 1H), 8 6.85 (d, J = 6 Hz, ,1H), S 7.13 - ?.26 (m, 7H), S 7.36 - 7.80 (m, 7H), 8 8:05 (s, 1H), (C,,~H~N406);
N 13-methyl-1S-f3-phenyl-iS- na htho 1 2- oxazol-2- lcarbon 1 ro Icarbamo 1 but 1 i ridine-4-carboxamid (Compound 283),'H NMR (DMSQ-d~: 8 0.81 (m, 6H), 81.35 - 1.86 (m, 7H), 8 1.96 -2.11 (m, 1H), $ 2.26 - 2.53 (m, 2H), 8 2.64 - 2.9I (m, 4H), 8 3.26 (bd, J = 11.63 2H), 8 4.42 {m, 1H), 8 5.27 {m, 1H), 8 7.19 - 7.36 (m, SH), 8 7.70 (t, i =_ '~.~1 Hz, 1H), 8 7.83 (t, J = 7.43 Hz, 1H), 8 8.OI (d, J = 8.91 Hz, 1H), 8 8.08 (m, 1H), S 8.18 (d, J = 8:91 Hz, 2H), S
8.27 (bs, 1H), 8 8.39 (d, J = 7.91 Hz, 1H), S 8.56 (bs, 1H), 8 8.75 (d, J = 6.45 Hz, 1H);
N 13-methyl-1S,_[3-phenvl-1S-fnaphthof2,I-dlbenzooxazol-2-yl_carbonyl)propylcarbamovllbut ~~ltpiperidine-4-carboxamide (Compound 284),.'H NMR (DMSO-d6): 8 0.81 (t, J = 6.43 Hz, 6H), 81.34 - I.8?
(m, 7H), 81.97 - 2.12 (m, 1H), b 2.24 - 2.38 (m, 1H), S 2.42 - 2.53 (m, IH), b 2.66 -2.93 (m, 4H), 8 3.26 (6d, J =10.12 2H), S 4.41 (m,1H), S 5.26 (m, 1H), 8 7.16 - 7.34 (m, SH), b 7.77 (m, 2H), b 7.97 (d, J = 8.91 Hz, IH), 8 8.05 (d, J = 8.86 Hz, 1H), b 8.07 (d, J = 8.64 Hz, 1H), S 8.19 (d, J = 7.91 Hz, IH), 8 8.26 (bs, IH), 8 8.28 (d, J = 7.67 Hz, 1H), 8 8.56 (bs, 1H), 8 8.78 (d, J = 6.43 Hz, 1H), N 13-methyl-1-[3-phenvl-I-f5phen~benzooxazol-2~lcarbony~,propvlcarbamo 1L, lbutvl?piperidine-4-carboxamide (Compound 285);
benz~ I-II-(4-nhenyeth~!Icarbamoytoxazol-2-ylcarbonyl)-3-phenvlprapylcarbamoyll-3-methylbut~carbamate (Compound 286), MS (ESn ) m/z = 625 (M + 1); 'H NMR
(CDCI~:
8 0.8 - 1.05 (d, J = 4 Hz, 6H), 81.50 (m,1H), 8 i.65 (m, 3H), 8 2.00 - 2.20 (m, IH), 8 2.35 (m, IH), S 2.60 {m, 2H), 8 2.99 (t, J = 4Hz, 2H), S 3.67(9, J = 3 Hz, 2H),4.19 (m, 1H), S 5.17 (s, 2H), ~ 5.59 (m, IH), 8 6.85 - 6.98 (gin, 2H); 8 7.10 - 7.4? (m, 15H), 8 8.43 (s, IH);
(''36'i40"4o6h benzyl 1-hl -t4-~3-phenxpropxlcarbamoylloxazol-2-vlcarbonyll-3-nhenylprop~rlcarbamoyl I-3-methXlbutylcarbamate (Compound 287); M5 (ESI) m/z = 639 (M +
1); 'H-NMR (300 MHz, CDCl3): 8 0.95 (d, J = 6 Hz, 6H), 8 1.50 (m, IH), S 1.65 (m, 3H), S 2.00 (m, 4H), 8 2.35 (m, 1H), 8 2.67 (m, 4H), 8 3.49 (m, 2H), S 4.20 (m, 1H), 8 5.09 (s, 2H);

8 5.50 (m, 1H), 8 6.85 {m, 1H), 8 7.23(m, 15H), ~ 8.35 (s, IH), b (C3,H42N40~;
ten-butyl 4-f 1 S-(I S-benzooxazol-2-vIcarbonyI-3-phenvlpropylcarbamoyl)-2-methylbutylcarbamoyl'~piperidine-I-carboxylate (Compound 28$);
tent-butyl 3-f 1S-(1S-benzoaxazol-2-vlcarbonyl-3-phen~propvlcarbam~l)-2-methvlbutylcarbamoy~llbenzylcarbamate (Compound 289);
N--,L-methyl-1 S-(3-phenyl-IS-benzooxazol-2;ylcarbonyl_prop I~bamo l,~.tyllpiperidine-4-carboxamide (Compound 290);
N f2-methyl-1S-(3_,phen-y1-IS-benzooxazol-2-ylcarbonylprop r~Icarbamo~rl)butvll-3-aminomethylbenzamide (Compound 291); t '10 benzy_1 1-11-L-(2-indol-3 ylethyicarbarnoyi)oxazol-2-vlcarbonyll-' 3-nhen~nro~,vlcarbamoyl ~,-3-meth l~r butylcarbarnate (Compound 292); MS (ES)n m/z = 664 (M +
I); 'H-NMR (300 MHz, CDC13): b 0.94 (d, J = 6 Hz, 6H), b 1.40 -1.70 (m, 6H), 8 2.00 (m, IH), 8 2.25{m, 1H), b 2.67 (m, 2H), 8 3.09 {m, 2H), b 3.52 - 3.85 (m; 2H), 8 4.20 (na, 1H), 8 5.09 (s, 2H), 8 5.50 (m, IH), $ 6.80 (d, J = 6 Hz, IH), S 6.99 - ?.41(m, 14H), & ?.65 (d, J = 6 Hz, 1H), & 8.35 (s,1H), 8 8.39 (s, IH), (C38H4,N306);
benzyl 1-f 1-(4-meth~carbamoyloxazol-2-ylcarbon l~phenylpropylcarbamoyl~
3-methvlbutlr)carbamate (Compound 293); MS (ESI] m/z = 535 (M + 1); 'H-NMR
(300 MHz, CDC13): S 0.95 (d, J = 6 Hz, 6H), 8 1.33 - 1.70 (m, 5H), 8 2.00 (m,1H), E 2.28 (m, 1H), S 2.67 (m, 2H), 8 2.99 (d, J = 2 Hz,.3H), $ 4.15 (m, 1H), 8 5.09 (m, 2H), ~ 5.50 (m, 1H), 8 6.88 (m, IH}, 8 ?.09 -?.38 (m, lOH), 8 8.35 (s, IH), (C2~3~N406);
benzyl 2-I 2-f 2-(2-berizyloxycarbonylamino-4-rnethylvaler-yiamino)-4-phen l~t~rylloxazol-2=ylcarbo~larninolvalerate (Compound 294);
benzyl 1S-d 1S-f4-(4-benzyIpiperidin-1 ylcarbonyl)oxazol-2 ylcarbonyll-3-phenylprop~rbamoyl l-3-met~lbu~lcarbamate (Compound 295); MS l~~ m/z = 679 (M +
1);'H-NMR (300 MHz, CDC13): s 0.92 (m, 6H), b I.25 (m, IH), S I.48 (q, J = 4 Hz, 1H), a 1.52 -1.85 (m, 6H), 8 2.09(m, IH), f 2.36 (m, 1H), 8 2.53 - 2.?? (m, 3H), b 3.03 (t, J = 8 Hz, 4H), 8 4.19 (m,1H), S 4.65 (m, 1H), 8 5.02 - 5.13 (m, 3H), 8 5.53 (m,1H), 8 6.68 (d, J -- 6 Hz, 1H), 8 7.08 - 7.39 (m, 15H), 8 8.28 (s, 1H), (C,oH,~N,Cb);
benzyl 1S-f1S-(4-fur-2 ylmethYlcarbamoyloxazol-2-ylcarbonyl~
3-phenylpropylcarbamoyll-3-methyIbutvlcarbamate (Compound 296); MS (ESl') m/z = 601 (M +
1); 'H-NMR (300 MHz, CDCI~: 8 0.98 (d; J = 6 Hz 6H), 8 1.58 (q, J = 6 Hz IH), 1.62 (m, 4H), 8 2.00 (m, 1 H), b 2.27 (m, I H), 8 2.76 (m, 2H), S 4.20 (m, 1 H), 8 4.70 (d, J - 4 Hz, 2H), 8 4.98 - 5.18 {m, 2H), 8 5.56 (m,1H), S 6.82 (m, iH), 8 ?.OS - 7.42 (m,13H), 8 8.32 (d, J = 4 Hz, 1H)~ (C~Har~4o~)~
benzyl 3-methyl-1S-f1S-(4-pyrid-2-vlmethylcarbamovloxazol-2 ylcarbonyll-3-nhenvInronvlcarbamoyllbutylcarbamate (Compound 297); MS (ESI) m/z = 612 {M +
I);
'H-NMR (300 MHz, CDCl3): 8 0.98 (d, J = 6 Hz 6H), 8 1.4 - 2.I5 (m, SH), 8 2.32 (m,1H~, 8 2.71 (m, 2H), 8 4.21 (m, IH), S 4.75 (d, J = 2 Hz, 2T-i), S 5.09 (m, 2H), 8 5.15 - 5.5 (m, IH), S 7.10 - 7.38 (m, I3H), S 7.7 (t, J = 4 Hz, IH), 8 7.95 (m, 1H), S 8.32 (d; J
= 4 Hz, IH), 8 8.59 (s~ iH), (~3~Ns~s);
benzyl 3-methyl-1S-f 1S-f4-pyrid-3-ylmethylcarbamoyloxazol-2- Icarbonyl~
3-phenylpropylcarbam~llbutylcarbamate (Compound 298); MS (hSI) m/z = 612 (M +
1);
'H-NMR (300 MHz, CDC13); 8 0.98 (d, J = 6 Hz 6H), 8 1.5 (q, J= 4 Hz, 1H), 81.65 (m, 2H), 8 1.95 (m, 3H), 2.25 b (m, 1H), S 2.68 (m, 2H), 8 4.19 (m, iH), b 4.72 (d, J =
2 Hz, ZJ;3), 8 5.09 (s, 2H), 8 5.41 (m, IH), 8 6.90 (t, J= 2, Hz, iH), b 7.05 - 7.35 (m, l OH), 8 7.46 (m, 1H), ~ 7.72 (d, 3= 6 Hz, 1H), 8 8.31 (d, J = 4 Hz, iH), 8 8.62 (d, J = 4 Hz 1H), 8 8.73 (s, 1H), (C3oHsiNsDt~:
benzvl 3-methyl-1 S-f 1 S-(4-pyri d-4-ylmethylcarbamoyloxazol-2-ylcarbonyl)-3-~henylpropylcarbamoyI~butyIcarbamate (Compound 299); MS (ESI) mJz = 6I2 (M +
1);
'H-NMR (300 MHz, CDCI~: b 0.98 (d, J = 6 Hz, 6H), 81.5 (q, J = 4 Hz, IH), 1.65 (m, 2H), 1.95 (m, 3H), 2.25 (m, IH), 2.68 (m, 2H), 4.I9 (m, IH), 4.72 (t, J = 2 Hz, ZH), S.I1 (d, J= 4 Hz, 2H); 5.43 (m, 1H), 6.92 {d, J= 6 Hz, Ice, 7.05 - 7.35 (m, I 1H), ?.46 (m,1H), 8.33 (d, J =
4 Hz, 1H), 8.58 (m, 2H), (C3aH37Ns~6):
benzvl 1S-11 S-f4-(2-chlorobenzylcarbamoyl)oxazol-2-,~Icarbon,~l-3-phenylpropylcarbamoyl 1-3-methylbutylcarbamate (Compound 300); MS (ESn mlz =
646 (M +
1);'H-NMR (300 MHz, CDCl3): S 0.98 (d, J = 6 Hz, 6H), 8 1.5 (q, J = 4 Hz, 1H), 81.62 (m, 4H), 1.95 b (m, 1H), 8 2.30 (m, 1H), 8 2.65 (m, 2H), 8 4.19 (m, 1H), 8 4.70 (d, J = 2 Hz, 2H), 8 5.09 (m, ZH), 8 5.47 (m, 2H), 8 6.82 (m, IH) 8 7.05 - 7.45 (m, 14H), 8 8.33 (d, J = 4 Hz, 1H), (~37~4~~~
benzyl 1 S-11 S-f4-(3-chlorobenzylcarbamoyI)oxazol-2-ylcarbon~l-3-phenylpropylcarbamoyl l-3-meth l~butYlcarbamate (Compound 301); MS (ESI) m/z = 646 (M + I);'H-NMR (300 MHz, CDC13): 8 0.98 (d, ~ J = 6 Hz, 6H), 8 1.5 (q, J = 4 Hz, IH), 8 1.62 (m, 4H), S 2.00 (m, 1H), 8 2.25 (m, 1H), S 2.65 (m, 2H), S 4.20 (m, 1H), 8 4.68 (d, J = 2 Hz, 2H), b 5.09 (gin, 2H), 8 5.43 (m, 1 H), 8 8.85 (d, J = 6 Hz, 1 H), 8 7.05 -7.45 (m,14H), b 8.33 (d, J = 4 Hz,1H)~ (C3sHs~~NaD6)'.
benzvi 1S-( 1S-f4-(4-chlorobenzylcarbamoyl)oxazol-2=ylcarbon 3-nhenvlnro~ylcarbamo~l l-3-methylbut~carbamate (Compound 302); MS (ESl) m/z =
646 (M +
1 ); 'H-NMR (300 MHz, CDCI~: S 0.98 (d, J = 6 Hz, 6H), 8 L5 (q, J = 4 Hz, 1H), S 1.62 (m, 4H), s 2.00 (m, IFij, 8 2.25 (rn, 1H), ~ 2.65 (m, 2H), $ 4.20 (m, IH), S 4.68 (d, J = 2 Hz, 2H), 8 5.09 (m, 2H), 8 5.43 (m, 1H), b 6.85 (m, 1H), S 7.05 - 7.45 (m, i4H), 8 8.33 (d, J = 4 Hz, 1H), (~sHs~C~sD~;
benzyI 3-methyl-IS-( IS-f4-(ZS-nhenylcyclonron-1S-vlcarbarnoylloxazol-2-ylca~bonyll-3-vhenvlprow)carbamoyl~ 3-methvlbutylcarbamatg (Compound 303); MS (ESl) m/z =
637 (M +
1 ); ~'H-NMR (300 MHz, CDC13): b 0.92 (d; J = 6 Hz, 6H), 81.46 -1.78 (rri, 6H), b 2.00 (m, 3H), 3 2.31 (m, III, S 2.67 (m, ZH), ~ 2.99 - 3.22 (m, 1H), 8 4.20 (rn, IH), .8 5:04 .(d, J = 6 Hz, IH), S 5.11 (s, 2H), 8 5.54 (m, 1H), S 6.87 (m, IH), S 7.08 - 7.47 (m, 1~SH), S 8.30 (d, J = 2 Hz;
l~s (C374O~~
benzvl 3-methyl-1S-f 1S-(4-dinhenvlmethylmethvlcarbamovloxazol-2-ylCarbonvll-3-phenvlpropylcarbamoyll-3-methylbutytcarbamate (Compound 304); MS (ESn m/z ~
68? (M +
1); 'H-NMR (300 MHz, CDC13): 8 0.98 (d, J = 6 Hz, 6H), 81.48 (q, J = 4 Hz, 1H), 81.62 (m, 2H), S 2.00 (m,1H), b 2.30 (m, 1H), 8 2.67 (m, 2H), b 4.18 (m, 1H), 8 5.09 (m, 3H), 8 5.43 (m, 1H), b 6.42 (d , J = 6 Hz, 1H), 8 6.80 (d, J = 6Hz, 1H), 8 7.02 - 7.72 (m, 20H), 8 7.79 (d, J = 6 Hz, IH), E 8.33 (d, J = 4 Hz, IH), (CaaH4zNa~s)~
benzyl 1 S-f 1 S-(4-adamantan-1 ~rlmethylcarbamoyioxazol-2-vicarbonyll-3-phenvlpropylcarbamoyll-3-methvibutylcarbamate (Compound 305); MS (ES>] m/z =
670 (M +
1 ); 'H-NMR (300 MHz, CDCI3): 8 0.92 (m, 8H), 8 L I B - 1.78 (m, 16H), S 2.00 (m, 1H), 8 2.31 (m, 1H), S 2.67 (m, 2H), 8 2.99 - 3.09 (m, 2H), 8 4.21 (m, 1H), 8 5.11 (m, 3H), 8 S.SI_ (m, lI~;
S 6.87 (m, 1H), 8 7.02 (m, 1H), 8 7.08 - 7.47 (m, lOH), S 8.31 (d, J = 2 Hz, IH), (CN40,~;
benzyl 1-f I-f4-(1-methylethylcarbamoyl)oxazol-2-ylcarbonyI1-3-phenylpropylcarbamoyl}-3-meth"ylb~lcarbamate (Compound 306);
benzvl 1-i 1-f4-(IS phenvlethvlcarbamoyl oxazol-2-ylcarbonyll-3-phenvlpron lc~bamoyl )-3-methylbutylcarbamate (Compound 307); MS (ESn m/z =
625 tM +
I); 'H-NMR (300 MHz, CDCI3): 8 0.92 (d, J = 6 Hz, 6H), S 1.54 - I.65 (m, 7H), 8 2.00 (m, IH), 8 2.25 (m, IH), S 2.65 (m, 2H), 6 4.15 (m, 1H), 8 4.99 (d, J = 2 Hz, 1H), i; 5.09 (s, 2H), S 5.32 (m, 1H), 8 5.43 (m, 1H), 8 6.79 (d, J = 6 Hz, 1H), 8 7.05 - 7.45 (m, 15H), 8 8.3I (s, 11~, (~4~4~6~i benzyl 1-I I-f4-!1R-phenvlethvIcarbamoyIZoxazol-2-yl_carbon-,yll-3;phenylpropylcarbamoyl )-3-methylbut~carbamate (Compound 308); MS (ESI) mlz =
625 (M +
1); 'H-NMR (300 MHz, CDCI~: 8 0.92 (d, J = 6 Hz, 6H), S 1.45 -1.68 (m, 7H), 8 2.00 (m, 1H), 8 2.25 (m, IH), 8 2.65 (m, ZH), f 4.15 (m, 1H), 8 4.99 (d, J = 2 Hz, 1H), 8 5.09 (s, ZH), S 5.32 (m;1H), 8 5.43 (m,1H), S 6.79 (d, J = 6 Hz; S 1H); 8 ?.O5 - 7.45 (m, 15H), 8 8.31 (s, 1H), (C~H,,aNdO~;
benzvl 1-I 1-f4-tN benzyl-N methylcarbamoyl)oxazol-2~ylcarbonyll-3-phenylprop,~lcarbamovl 1-3-met~lbutylcarbamate (Compound 309); MS (ESI) mlz = 625 (M +
1 ); 'H-NMR .(300 MHz, CDCl3): 8 0.9G (d; J = 6 Hz, 6H), S L27 -1.68 (m, 4H), 8 2.00 (m, 1H), S 2.25 (m, 1H), 8 2.65 (m, ZH), i; 3.I0 (s, IH), 8 4.19 (m, 1H), S 4.71 ~(s , 2H), S 5.09 (s, 2H), 8 5.22 (m, 1H), b 5.43 (m, IH), 6 6.99 (d, J = 6 Hz, 1H), S 7.OS - 7.45 (m, 1SH), 8 7:60 (m, IH), 8 8.31 (s, IH), (C36H40N4~~~
benzyl I-f I-(4-pyrrolidin-I-ylcarbonvloxazol-2-vlcarbonvl)-3 phenyprop~rlcarbamovll 3-methylbut5rlcarbamate (Compound 310); MS (ESI) mlz = S7S (M + I); 'H-NMR
(300 MHz, CDC13): 8 0.93 (d, 1= 6 Hz, 6H), 51.45 -1.73 (m, 3H), b 1.85 - 2.I2 (m, SH), 8 2.34 (m, 1H), S 2.64 (m, 2H), b 3.62 {t, J = 4 Hz, 2H), 8 3.82 (m, 2H), b 4:21 (m, 1H), 4.99 - 5.11 (m, 2H), 8 S.SS (m, 1H), 8 5.43 (m, 1H), $ 6.79 (m, IH), 8 7.OS - 7.45 (m, lOH), 8 8.31 (d, J = 2Hz, 1H), (~~38N4~6)i benzvl I-f 1-(4-vineridin-I-vlcarbonvloxazol-2- lcy arbonyl)-3-phenvlpropylcarbamoyll-3-meth l~tylcarbamate (Compound 311); MS BSI) ~z = 589 ~ + 1); 'H-NMR (300 MHz, CDCI3); 8 0.90 (d, J = 6 Hz, 6H), 8 x.25 (m, 2H), S 1.49 -1.66 (m, 6H), 8 2.12 (m, 1H), b 2:34 (m, IH), S 2.64 (m, 2H), 8 3.65 (m, 2H), 8 3.85 (m, 2H), 8 4.17 (m, 1H), 8 4.99 - 5.11 (m, 3H);
8 S.SS (m, 1H), b 6.67 (m, 1H), 8 7.08 - 7.39 (m, I1H), S 8.27 (s, IH), (C33H,,oN4O~;
benzvl I-f I-f4-f2.3-dihydroindol-1-vlcarbonvl)oxazol-2-ylcarbon,~ll 3-nhenvlnropyl_carbamoyl ~,3-methylbutvlcarbamate (Compound 312);
benzvl l-I 1-f4-t3.4-dihvdro-1H-isoauinol-2-vlcarbon~~oxazol-2-ylcarbonvll-3-phenvlprogylcarbamoyl )-3-meth~b-utvlcarbamate (Compound 313); MS (ESI} mlz = 637 (M +
1); 'H-NMR (300 MHz, CDCl3): 8 0.90 (d, J = 6 Hz, 6Hj, b 1.25 (m, 2H); 81.45 ~
1.79 (m, 4H), b 2.11 (m, IH), 8 2.40 (m, IH), S 2.68 (m, ZH), 8 2.95 {t, J = 4 Hz, 2H), 8 3.96 (t, J = 4 Hz,1H), 8 4.15 (m, 2H), S 4.86 (d, J = 6 Hz, 1H), S 4.99 - S.I 1 (m, 3H), 8 5.59 (m,1H), 86.70 (m, 1H), a 7.OS - 7.45 (m, I2H), 8 8.35 (s, 1H), (C37H~406)s benzvt 1-1I-f4-(3.4-dihvdro-2H-quinol-I-yl-carbonyl)oxazol-2-ylcarbon ~~11-(d, J = 4 Hz,1H)~ (C3sHs~~NaD6)'.

3-nhenLrlnropylcarbamovI 1-3-meth l~tylcarbamate (Compound 314); MS BSI) ~z =
637 ~ +
1); 'H-NMR {300 MHz, CDCI3): 6 0.90 (d, J = 6 Hz, 6H), 8 1.25 (m, 2H), 81.40 -1.69 (m, 3H), 8 2.05 (m, 2H), 8 2.52 (t, J = 6 Hz, 2H), 8 2.82 (t, J = 4 Hz, 2H), 8 3.80 - 4.21 (m, 4H), 8 4.86 (d, J = 6 Hz, 1H), 8 5.09 (s, 2H), 8 5.21 (m, 1H), 8 6.62 (m, lI~, b 6.85 - 7.31 (m, 11I~, 8 7.SI (m,1H), 8 7.67 (m, 1H), 8 8.31 (s, IH), (C37HaoN4~6)i benzvl 1-f 1-(4-naphth-1-ylmethylcarbamoyloxazol-2:ylcarbon,~,>~.
~nhen ly nronyl_carbamoyll-3-methvlbutylcarbamate (Compound 3I5); MS (ESI) m/z = 661 (M +
1); 'H-NMR (300 MHz, CDC13): 8 0.90 (d, J = 6 Hz, 6H), 8 I.25 (m, 2H), 81.54 (m, 3H), 8 2.05 (m, iH), 8 2.59 (t, J = 6 Hz, 1H), 8 2.82 (t, J = 4 Hz, 2H), 8 4.12 (m, 1H~ S 4.90 - 5.09 (m, 4H), 8 5.34 (m, 1H), 8 6.71 (m, 1H), 8 6.95 - 7.12 (m, 3H), 8 7.27 (m, lOH), 8 7.51 (m, 2H), 8 7.88 {t, J = 6 Hz, 1H), 8 8.06 (d, J = 6 Hz, 1H), b 8.35 (s, IH), (C3gH,,~N40,~;
tent-butyl 4-f 1S-(1S-benzooxazol-2-vlcarbonvl)-3-phenrr_lprogylcarbamoyl)-2-cyclohexylethylcarbamoyllpi~erid~ne-1-carboxylate (Compound 316);
1 S-11S-f4-(3,4-dihydro-2H-auinol-1-ylcarbonvl)oxazol-2-ylcarbonyll-ethvlcarbamoyl 1-3_-methylbutylcarbamate (Compound 317);
benzvl 3-meth-1 S-f 1 S-(5-ghenyloxazol-2-ylcarbon,Yll-3-phenylprop~carbamoyllbutylcarbamate (Compound 318); MS (ES)] mlz = 554 (M +
1);
'H-NMR (300 MHz, CDCI3): 8 0.97 (d, J = 4 Hz, 6H), 8 1.50 (t, T = 4 Hz, 1H), 8 1.65 - 1.82 (m, 3H), b 2.20 (m, 1H), 8 2.48 (m, 1H), 8 2.75 (t, J = 4 Hz, 2H), 8 4.2? (m, 1H), 8 5.09 (s, 2H), 8 5.65 (m,1H), b 6.85 (d, J = 6Hz, 1H), 8 7.12 - 7.G2 (m, 14H), 8 7. 77 (d, J
= 2 Hz, 2H), {~3H35N3o3)i pvrid-3-y1 3-methyl-1 S-11 S-f S-phenyloxazol-2-vlcarbonvl)-3-phenylpro~vlcarbamoyllbutylcarbamate (Compound 319); MS (FS~ m/z = 525 (M +
1);
'H-NMR (300 MHz, CDCI3): S 0.80 - 1.05 (m, 6H), 8 1.27 (m, 3H), 8 1.72 (m, 3H), 8 2.I5 (m, IH), 8 2.46 (m, 1H), 8 2.77 (t, J = 4 Hz, ZH), 8 4.75 (m, 1H), 8 5.65 (m, IH);
8 6.95 (d, J = 4Hz, 1H), 8 7.02 (d, J = 4Hz, 1H), 8 7.09 - 7.35 (m, SH), 8 7.37 - 7.62 (m, 3H), 8 7.80 (d, J = 4 Hz, 1H), 8 8.15 (d, J = 6Hz,1H), 8 8.75 ( m, 1H), 8 9.09 (s, 1H), (C3,H~N40~;
benzyl 1S-f 1S-(5-phe~rloxazol-2-ylcarbon~
3-phenylpronYlsulfamo_ytmethyll-2R-methylbut~rlcarbamate (Compound 320); MS
(ESl] m/z =
604 (M + 1);'H-NMR (300 MHz, CDC13): i; 0.95 (m, 6TH, 8 1.25 (m,1H), $ L49 (m, lHj, 81.65 (m, 1H), 8 2.15 (m, 1H), 8 2.48 (m, iH), 8 2.85 (m, 2H), 8 3.12 (m, 2H), 8 4.46 (m, 1H), 8 4.99 (d, J = 8Hz, 1H), 8 S.I2 (m, 3H), 8 6.32 (d, J = 6Hz, 1H), 8 7.19 -7.55 (m, I4H), 8 7.76 (Tn~ ~~ {~~37N3~6'S~i benzyl 3-meth~rl-1 j2-hvdroxy-1-phenethyl_~
4- 3- hen 1 ro Icarbamo I oxazol-2- I eth lcarbamo I bu lcarbamate (Compound 321);
benzyl_I-T2-hydroxy-2-f4-(2-indol-3- ly ethylcarbamo lY)oxazal-2-vli-I-phenerhyleth~lcarbamo-yl~-3-methylbutvlcarbamate (Compound 322); MS (ESI) m/z = 666 {M
+ 1); 'H-NMR (300 MHz, CDC13): 8 0.90 (d, J = 6 Hz, 6fI); 81.40 - L80 (m, 6H), 8 2:(10 (m, 1H); 8 2.6? (m, 2H), S 3.09 (m, 2H), & 3.52 - 3.85 (m, ZH), 8 3.99 - 4.20 (m, ZH), 8 4.26 - 4:44 (m, IH), S 4.81 (s, 1H), S 5.09 (s, 2H), ~ 5.50 (m, IH), 8 6.?2 (d, J = 6 Hz, IH), 8 6.99 - 7.41 (m, 14H), 8 8.18 {s, IH), 8 8.39 (s, 1H), (C3$H43IVs0~;
benzvl3-methyl-1-f2-hydroxy-2-(4-methylcarbamoyloxazol-2-vl)-' 1-phenethvlethylcarbamoylibuty,~carbamate (Compound 323);, MS (ESn mlz = 53?
(M + I);
'H-NMR (300 MHz, CDC13): 8 0.90 (d, J = 6 Hz, 6H), b L33 - L80 (m, 6H), 8 2.00 (m, 1H), 8 2.b7 (m, 2H), 2.89 (m, 3H), 8 4.10 (m, 1H), 8 4.25 (m, 1H), 8 4.81 (s, 1H), 8 5.09 (m, 3H), 8 6.68 (d, J = 4 Hz, IH), 8 ?.09 - ?.38 (m, l OH), 8 8.18 (s, IH), (CZgH3bN4~,~}i b_enzvl 2-f 2-f2-(2-henzyloxvcarbonylamino-4-rnethvlvalerylamino)-I-hydroxy-4-phenvlbutylioxazol-2-vlcarbonylamino? valerate (Compound 324); MS (ESn inlz = ?2? (M +
I);'H-NMR (300 MHz, CDC13): 8 0.95 (m, 12H~, fi 1.45 - 1.80 {m, 9H), S 2.00 (m, IH), $ 2.6?
(m, 2H); 8 3.99 - 4.15 {m, 2H), b 4.85 (m, 2H), 8 5.09 (m, 4H), 6 5.50 (m, IH), b 6.88 (m,1H), 8 ?.12 - ?.45 (m, ISH), S 8.18 (s, lI-~, (C4~H~IV408);
benzyllS-12-f4-(4-benzylpiperidin-1-vlcarbonyl)oxazol-2-yli-2-hydroxv-1S-phenethvlethvlcarbamovl~-3-methvlbu"t~lcarbamate (Compound 325);
benzvl 1 S-f 2-l4-fur-2-vlmethylcarbam ovl ox azol-2-~rI)-2-h)rdroxv-IS-phenethvlethvlcarbamovll-3-meth~rlbutylcarbamate (Compound 326);
benzyl 3-methyl-I S-T2-hydroxy_1 S-nhenethyl:. .
2-(4-pvrid-2-ylmethylcarbamoyloxazol-2=ylleth~)carbamoylibu~t rlcarbamate (Compound 32?);
benzyl 3-methyl-1S-f2-hydroxY lS~henethyl-2_-_(4-pyrid-3-ylmethylcarbamoyloxazo~-2-~I ethylcarbamoyllbutylcarbamate (Compound 328);
benzvl 3-methyl-1S-f2-hydroxy-1S-pheneth_yl-2-(4-pvrid-4 ylmeth~rlcarbamoyloxazol-2-yl)eth~rlcarbamo-yl~butvJcarbamate (Compound 329);
benzvl3-methyl-1S-(2-f4-(2-chlorobenzylcarbamoyl)oxazol-2-vll-2-hydroxv-1S-phenethyleth~bamoyllbu~lcarbamate (Compound 330);
benzvl 3-methyl-1S-f 2-14-(3-chlorobenzylcarbamovI)oxazol-2-~~Il-2-hydroxv-IS-nhenethylethvlcarbamoyl Ibut~carbamate (Compound 331);
benzvl 3-meth~rl-1S-I2 j4-(4-chlorobenzylcarbamovl)oxazoI-2-y11-2-hvdroxv-1 S-nheneth,Xlethvlcarbamoyl }but~carbamate (Compound 332);
benzvl 3-methyl-1S-{,2-hvdroxv-1S-ahenethvl-- 4- 2R- hen lc clo ro -1S- Icarbamo 1 oxa ol-2- 1 eth lcarbarno 1 bu lcarbamate (Compound 333);
benzyl 1 S-f 2-(4-adamantan-1-ylmethylcarbamovloxazol-2-vl~
2-hvdroxv-methyl)-IS-nhenethvlethylcarbamovlT-3-methvlbutylcarbamate (Compound 334);
benzvI 3-methy-1 S-f2-~droxy-I S-phenethyl-2-(4-dinhenylmethylcarbamoyloxazgl-2-vllethylcarbamo ly lbutylcarbaxnate (Compound 33~);
benzyI 3-methyl-1-I2-hydroxv-2-f4-(I-methyIethylcarbamovl~oxazol-2-yll-I- h~ enet~lethyl_carbamoyl lbutvlcarbamate (Compound 336);
benzvl 3-methvt-1-I2-hydroxy-I-phenethvl-2- 4-f , (IS:phenvlethylcarbamoyl,~oxazol-2- lY lethylcarbamovl lbutylcarbamate (Compound 337);
benzyl3-methyl-I-I2-hxdroxy-I-ghenethvl-2-f4-(IR_phenvlethylcarbamovl)oxazol-2- ly lethylcarbamoyl but rLlcarbamate (Compound 338);
benzSrl 3-meth~I-1~2-f4-(N benzyl-N meth lcarbamoylOoxazol-2- ly 1-2-hydroxy_ I-nhenethvlethylcarbamoyl Ibut~lcarbamate (Compound 339);
benzyI 3-methyl-I~j2-hydroxv-1-ohenethyl-2~gyrrolidin-I-vlcarbonyloxazol-2-~rl~eth~rlcarbamoylibutylcarbamate (Compound 340);
benzvl 3-methyl-I-f2-hydroxv-I-nhenethvl-2 S4-pi~eridin-1-~carbonvloxazol-2-vi~ethylcarbamoyllbutylcarbamate (Compound 34I);
benz~ 3-methyl-I-( 2-~4-(2,3-dihydroindol-1 ylcarbonyl)oxazol-2_yl_]-2-hydroxy_ 1-phenethylethvlcarbamovl Iburylcarbamate (Compound 342);
benzvl 3-methyl-I-I2-f4-X3,4-dihydro-IH isoqninol-2-ylcarbonyl~oxazoI-2- ly 1-2-hvdroxy l~henethylethvlcarbamovllbut~rlcarbamate (Compound 343);
bent I 3-meth 1-I- 2- 4- 3 4-dih dro- H- uinot-1- Icarbon- 1 oxazol-2- 1 -2-dr x -1-phenethylethylcarbamovl Ibutylcarbamate (Compound 344);
benz~rI3-inethvl-I-f2-hydroxy-2-(4-naphth-1-ylmeth l~bnyloxazol-2-yl)-I-pheneth~eth~lcarbamovllbuylcarbamate (Compound 345); and benzyl 1S-I2-f4-(3,4-dihvdro-2H quinol-I-~ibonyl)oxazoi-2_,yll-2-hydroxv-IS-methylethylcarbamovl I-3-rrZethylbut~carbama~e (Compound 3415).

.. v vv..wa. . .
Proceeding by methods analogous to those described above provided the following compounds of Formula I:
N f3-methvl-?S-f1S-thiazol-2-ylcarbon;rlethylcarbamoyllbutyll~
4-moz~holin-4-ylbenzamide (Compound 34?); and N ?S- 2-benzooxazo -2- 1-1 1-dimeth l-2-oxoeth lcarbamo 1 -3-meth Ibu f - .
4.-(4-methvlniperazin-1-yl~benzamide (Compound 348).
Proceeding by methods analogous to those set forth in this Application compounds of Formula I are provided which are comprised by the elements A, B, C and D
listed in the following Table 1.
, TABLE 1 A B " R,i C ~ ~ ~ D
_ ~ ~~x A Its .
- ~~( rt' A1 B1 Ci ' Dl f l .o r C« /
''o _ N ,..-* * ., Nf ~C *N c*
H O ~t o A2 82 / ~ C2 . D2, o ~

~.-, ~ ,C, * *N C*
H O

I I i 1 ~ I ~ 6 _~4~-A3 B3 ~ C3 D3 O O
O.vr *~ C* N
H O

I N *N C,k 01 F i ~ » o ~N'' *N ~*
. a a AS BS / ~ CS DS
H ~ *N c* NJ
N* C*- i~ a~ ' l a H O
A6 ~ ' ~ B6 F o F C6 ~ , D6 l ~ O1 w ~S . ~, N
~O
*N i~~"' H O .~ O
A? B7 / C? ~ D7 o O \ 0.:*
NJ
*N r*
N* C*
a 8 O
H O.

~~ V VVI~7Jt~
AS o B8 / ~ C8 D8 F . *N . C*
'J

Ni '(;*
A9 B9 N i ~ C9 D9 ~/

I *N/~.O* <D
I II .

*~
Nj IC
H O

o ~
N~NH
o, *N~C.~*

*~ * 8 O
N~ IC
All B11 N Cll Dil i p \~ O.
~p~ ~yS~O (~ NH
N* C*
N~ IC* H O
H. O
i A12 B12 N~ ~ C12 D12 ~ ~ O_S,, o O~S~ O HN-~C
.O ~ .NH .
~ N* C, N! n H O
' H
Al3 B13 ~ C13 ~ D13 ~ *.O, O~S~~O NL~C* ~N 1 ~ .
*~ * H O
N! C
H O

O, S'' O *~ * i N
N I ~C' * H
*N c O
m H O
A15 B15 ~ C15 D15 O
w O' S.~O . N I 'C' I : *''N
W
H O
*N C*
s n A16 B16 ~ C16 i D16 .
O N ! SN
*~ * * *
NH O NH O ~ ' o D ~~
NI C*
e~
*N e* H o a O
AI8 i B18 ~ C1$ '~ D18 I / ° ~ 1 ~gIN ..
F *yq C~
N* C* r 1~
H ~ ~ $ O

~ /
o~ o >~ ~ N* c~ ;N
o r y i ,~ " °
N* C' ( n H
Azo szo , CZO Dza ~ ~
o wI N
°;S " <~ ~~
~ ~ a ~ ~ NH O'k N' C*
I rr H O

azi B2i ~ cm Dzi ~N
o . O
o~~r N
NH O NI ,C*
H O
,~2 B22 O C22 D22 O ~ / N
1 . O,, .O s O S *~ I
N*~~G,* , * ~ 1~
l NI n M O .
H O
A23 ~ B23 / ~ C23 D23 \ Ohl _ *I
N* C* N* C*
H p H O
A24 B24 ' ~ ~ C2~E ~ D24 O
~ NJ * o \ ~F
*
N~ C'"
C~ NH ~ H p I I I J I i I

11 V VVIJJt'ri N ~/
O . .. <O, S I F N..
r \ I N* . C* NH OC*
I ii H O
A26 B26 ~ ~ a6 ~6 OH
F
F
*
N I ~~
H O
N* C*
I n H O
p27 B2~ ~ C27 D27 r N OH
t . F *~
Q
* *
F
r v N~ ,~
H o N* .~ C*
n H O

y ~ ,,,.
c pH
I i \ F F
NI ~C*
H O
N* C* ~ v I il H O ' I 1 L l I 1 I I I

WVUUI~'d~1°1 _ avarv~avwvvw..
A29 B29 ~ C29 D29 i N a y /., ... O . NI c*
er * H
NI oC;
H O

O NJ ~ ".N\
° ~N~
i ~ ,.,, ~*
8~ N* Cr* ee n H O
H O

F ~' \ N O-- H
r H s I O y. N N
O
a.. *...J
*~ * H
N~ ~C
H O

o . N~ o-H
O ~ /: ,N
N. c. Nf C* ~l~ ~~
H O e~
H O

*-N' NH ; r. ~ ~
NH O
*
N) ~~
H O

~~48-NrH
H

* ~*
NI ~
~* ~* H
H O
A35 B35 ~ C35 ~ D35 N~H *N C*
a N* wCa.
H O
A36 B36 C36 ~ D3b 0 0.,~. S..O

I w N,H
cF, ~
* *
NH p ~ *N C*
I II
H
A37 B37~ D37 _ ~
w. N~H
N*~
I C
H O
A38 B38 ~ D38 o N.H
i ~~O
I NH O
> > > ~ i ~

A39 B39 ~ F D39 ~ /
o ~ ~ . ~ y\.\
~ / ~ /
NI e~
H O ' A40 B40 ~ F'~ ~ ' D40 ~~
S O
\ \ .\
I / ~ /
N* C*
i n H O
A41 . B41 F F D41 p /
1 O~~S ~ ! w \ \
I / ~ /
N* C*
I a H O

P-1. .~
NO
,~~ \ \ \
N *~ *
NI 'C
H O
I I I I I I

~ ..O
s..o ~ ~ s>
ao a~ a NH O
Aaa B44 ~. ~ na4 o N
~.~J t o ' aN a*
s A45 ~,g,w~ B45 ~ D45 '' N
~* O
aN Its H ~
A46 B45 L~46 o =s .o , s N C ' ~ \
O
H O~ *r~~
A47 i B47 ' ' ~7 W \
aN '~°C*

ti O

A48 O B48 ~ ~ D48 f ~ \
N ~ /
cs ci i t i~
H O
A49 ~VB49 N D49 ~N
O S O
*N C*
! ii H O
ASO i B50 ~ D50 ~ ~ /
'N / sN
H
*N C*
! !I
Ei O

nsa ~ B5a F nsa N

. ,i W N
...~~
~540 *N C*
i il H
A32 i B52 F D52 S
~ I
O=S=O
*N C*
1 it H O
A53 ~ B53 F D53 * / ~N
J F / ~
. _ .F
1~. i *N C*
1 tt H O

A54 ~ B54 N DS4 ~ I ~ *.N
<° , _ > , N
o~s'o *N C*

H O
A55 ' ~ DSS' I w y o i s A56 j DS6 ~ '*
~ i i A57 ~ D57 -. \
A58 ~ D58 ~ \
w \ - _ ~*
N
A59 j D59 ~ \
N
On O

A60 i . D~ /
N ' \
/, N
Ab! . ~ D61 - N
\ N~
A6~ ~ D62 ~ \
\ N- v HO N
Ab3 ~ D63 * / \
a \
~N
N
A64 ~ D64 1~"~ r w LN
A65 ~ ~ D65 / \
N
*-N
A66 ~ D66 , ~ N ~
~ N ~~~
Asp ~o~~~ ~s7 __ l i ! I I ~ I I I

A68 ~ D68 ~ . \
~*
A69 ~~ D69 \
~.~" (i A70 °S° D70 ~ \
. . las!*.

A7I ~~~ D71 * .
~N
N \ s . ~ . ' i ~N
N
A72 ~ °~ D72.
I w I w a .i i N
A73 °ya D73 * \ ..'~N
F) ~ S ' / ~N
F
A74 ~ ~p D74 \ N' ". S' . *~~~~ .
A75 pro D'75 ~.~ ~ N
LN~N
~ ~ ~ t -i~~-~~V VVIJJJ<'~~
A76 u D76 N

\ '~
F 'N N

A7 . o~s~o . D~ \ N1 7 ~

v L~N~
F

\ Nr ~.
Cl~

0 o D79 ~ N
A79 ~ ~

y f I - ~ i N

A$0 ,so D80 * ~ ~ .:.

h y l A8! D8! ~ wN
~
*

r ~
N

A82 ~ ~ D82 ~ ~ N

~~ J
N

A83 , ono ' D83 ~ N;

i , i '~ '' A~ p~ , \ N1 ~"' Dss Ass *.N ~
A86 OSO D86 *,O a ~N ~
N
.
A87 ' S~ D87 ;o , ~
N
A88 D88 \O ~ w N
N r S
A89 s s~,o ~ D89 N r A90 OHO _ ~ \ N''*
I r ..J
N
A91 O~O D91 1 S O
Het O

WO OOISSI44 _ d'i:l/UJUU1UOD~ _"_ A9a s~p ~ *,N
W
A93 p JQ D93 ~O~
F
OH
A94 S ~ ~ D94 ' O
NR
/ ~
A95 D O D95 a ~w S ~
A96 p ~ D96 R
_ A97 °S D97 I ~ ~
N
A98 OSO D98 *. R
l ,...

R
-IJr9-A100 D100 p ...
AIOI . ~ O D101 *.~ ~
O S vN I /
A102 w,° ~ D102 s ~i ~ . 1 w o°

vS w 1~ ~
'* .
r N
A104 s° D104 O
w /
'O
A105 O Diu$ O
~O~S ~
r of A106 O'~O D106 =,W~.
S ' S \\S ~ /
-iso-A107 O S D10~

S . ~ a ~.N
vt A108 . ~ J~DI08 \ w i NsN
A109 ~ O O ~ D109 a g ~S
\l e1 A110 S OS DI10 ' O
m (/
CI
A112 °g° D1I2 ' n . N
A113 ~.p~ DI13 ~*
i N
A114 ~~° D114 ~ N
I I I 1 ~ ~ ~ ~ J

AI O S~ DI o IS l5.

S

AI16 . . o~~ D116 O

S ~ /

A117 OSO , DI17 Br A118 p'"o DII$ ~
v J

S / N
~ ' H

r AI19 . DI19 w A
i /
N

N

A120 .. DI20 r N
i H

A121 , o~S - D121 o <
~

A1Z2 0~,,,0 DI22 w ~ I
~rs N

A123, O D123 O.C *N
. C\ N

ii C

a y.C
Ales O
ii C
Ai27 F O
U
C

n of n C
N

AI30 O~ O
O~C

~~ o n \ C
A 132 i CN, i F $*
F~o F
While any combination of the elements A, B snd C may comprise the compounds of the Invention, certain combinations are preferred For example; the following combinations All-BS-C4-Dl A17-BS-C4-D1 A66-BS-C4-D1 A75-BS-C4-Dl A128-BS-C4-Dl All-Bb-C4-Dl A17-Bb-C4-Dl A66-B6-C4-Dl f0 A75-Bb-C4-Dl A128-Bb-C4-Dl All-B8-C4-Dl A17-B8-C4-Dl A66-B8-C4-Dl A75-B8-C4-D1 AI28-B8-C4-DI Al I-B12-C4-DI

A17-B12-C4-Dl Ab6-B12-C4-Dl A75-B12-C4 Dl , A128-B12-C4-Dl All-B11-C4-Dl A17-B11-C4-Dl A66-B1I-C4-Dl A75-B11-C4-Dl A128-BIi-C4-Dl All-B14-C4-Dl A17-BI4-C4-Dl A66-BI4-C4-DI

i5 A75-B14-C4-Dl A128-B14-C4-DI All-B3-C4-D2 A17-BS-C4-D2 A66-BS-C4-D2 A75-BS-C4-D2 A128-BS-C4-D2 All-B6-C4-D2 AI7-Bb-C4-D2 A66-B6-C4-D2 A75-Bb-C4-D2 AI28-Bb-C4-D2 All-B8-C4-D2 A17-B8-C4-D2 A66-B8-C4 D2 A75-B8-C4-D2 AI28-B8-C4-D2 All-B12-C4-D2 ~A17-B12-C4-D2A66-BI2-C4-DZ

A75-B12-C4-D2 Ai28-B12-C4-D2 All-B11-C4-D2 A17-B1I-C4-D2 A66-B i I-C4-D2A75-B 11-C4-D2 A128-B I 1-C4-D2Al l-B 14-C4-D2 ~

A17-B i 4-C4-D2A66-B 14-C4-D2 A75-B 14-C4-D2_AI28-B 14-C4-D2 _ A61-B5-C4-Dl. A64-B5-C4-Dl A37-B5-C4-D1 A38-B5-C4-Dl A90-B5-C4-Dl A92-B5-C4-Dl Ai33-B5-C4-Dl A61-B6-C4-Dl A64-B6-C4-Dl A37-B6-C4-D1 A38-B6-C4-Dl A90-B6-C~4-Di A92-B6-C4-Di A133-B6-C4-DI A61-B12-C4-DI A64-B12-C4-Dl A37-B12-C4-DI A38-B12-C4-DI A90-B12-C4-D1 A92-B12-C4-Dl 10A133-B12-C4-Dl All-B31-C4-D1 A75-B31-C4-Dl. AI28-B31-C4-DlAli-BI3-C4-Dl A75-Bi3-C4-Dl A128-B13-C4-Di All-B21-C4-D1 A75-B21-C4-D1 A128-B21-C4-DlAlI-B46-C4-D1 A75-B46-C4-Dl A128-B46-C4-Dl Aii-B49-C4-D1 A75-B49-C4-D1 ~ A128-B49-C4-DlAI1-B50-C4-D1 15A75-B50-C4-Dl A128-B50-C4-Dl All-B51-C4-Dl A75-B51-C4-Dl Ai28-B51-C4-DIAli-B52-C4-Dl A75-B52-C4-D1 AI28-B52-C4-Dl All-B53-C4-D1 A75-B53-C4-Dl AI28-B53-C4-Dl Al i-BS-C36-DlA75-B5-C36-Di A128-BS-C36-DlAl l-B6-C36 Dl B6-C36-DI AI28-B6-C36-Di Ail-B12-C36-D1A75-B12-C36-Dl A75 =

20A128-BI2-C36-DlAI1-B5-CI1-Dl A75-BS-Cll-DB Ai28-B5-C11-Dl Ali-B6-C11-D1 A75-B6-C11-Dl AI28-B6-C11-DlAil-B12~~C11-DI

A75-BI2-Cli-D1A128-B12-Cll-DIAll-BS-C10-Dl A75-BS-~10-Dl A128-BS-C10-DIAll-B6-C10-D1 A75-B6-C10-Dl A128-Bfr-CIO-DI

All-B12-C10-DlA75-B12-C10-Dl A128-B12-C10-DlAll-B5-C35-DI

25A75-B5-C35-Dl Ai28-BS-C35-D1 All-B6-C35-Dl A75-B6-C35-DI

A128-B6-C35-DlAli-B12-C35-D1 A75-B12-C35-DlAi28-B12-C35-Di All-B5-C4-D33 A75-B5-C4-D33 A128-B5-C4-D33AI1-B6-C4-D33 A75-B6-C4-D33.Ai28-B6-C4-D33 AIi-B12-C4-D33A75-B12-C4-D33 AI28-B 12-C4-D33Al l-B5-C4-D83 A75-B5-C4-D83 A128-B5-C4-D83 30Ail-86-C4-D83 A75-B6-C4-D83 A128-B6-C4-D83Ai1-B12-C4-D83 A128-BS-C4-D86All-B6-C4-D86 A75-B6-C4-D86 A128-B6-C4-D86 All-B12-C4-D86 A75-B12-C4-D85 AI28-B12-C4-D85 All-BS-C4-D123 A75-BS-C4-DI23 AI28-BS-C4-DI23 AII-Bb-C4-DI23 A75-Bb-CøDI23 A128-Bb-C4-DI23 All-Bi2-C4-DI23 A75-BI2-C4-D123 A128-B12-C4-D123 Cathepsin B Assay Solutions of test compounds in varying concentrations were prepared in I0 ~.L
of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 p,L, comprising:
N,N bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM (pI~ 6);
polyoxyethylenesorbitan monolaurate, 0.05%; and dithiothreitol (DTT), 2.5 mM).
Human cathepsin B (0.025 pMoles in 25 p.L of assay buffer) was added to the dilutions. The assay solutions were 'mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes -at room temperature. Z-FR-AMC (20 nMoles in 25 ~L of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at ( 7~. 460 nm) for 5 minutes.
Apparent inhibition constants (K.~ were calculated from the enzyme progress curves using standard mathematical models.
Compounds of the invention were tested by the above-described assay and observed to exhibit cathepsin B inhibitory activity with a K; of less than or equal to 10 ~M.

Cathepsin K Assay Solutions of test compounds in varying concentrations were prepared in 10 JCL
of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 ~L, comprising: MES, 50 mM
(pH 5.5); EDTA, 2.5 mM; and DTT, 2.5 mM]. Human cathepsin K (0.0906 pIVdoles in 25 p,L of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. Z-Phe-Arg-AMC (4 nMoles in 25 ~tL of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at ( ~, 4b0 nm) for 5 minutes. Apparent inhibition constants (K;) were calculated from the enzyme progress curves using standard mathematical models.
Compounds of the invention were tested by the above-described assay and observed to ~~ V Vweira--~
exhibit cathepsin K inhibitory activity with a K; of less than or equal to 10 ACM.

Cathepsin L Assay Solutions of test compounds in varying concentrations were prepared in 10 fCL
of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 fCL, comprising: MES, 50 mM
{pH 5.5); EDTA, 2.5 mM; and DTT, 2.5 uiM). Human cathepsin L (0.05 pMoles in 25 pL of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-.10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. ~ Z-Phe-Arg-AMC (I
nMoles in 25 fCL of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at ( ~, 460 nm) for 5 minutes. Apparent inhibition constants (Ka were calculated from the enzyme progress curves using standard mathematical models.
Compounds of the invention were tested by the above-described assay and observed to exhibit cathepsin L inhibitory activity with a K; of less than or equal to 10 ~M.

Cathepsin S Assay Solutions of test compounds in varying concentrations were prepared in 10 ~tI.
of dimethyl sulfoxide (DMS~) and then diluted into assay buffer (40 p,L, comprising: MF.S, SO mM
(pH 6.5); EDTA, 2.5 mM; and NaCI, 100 mM). Human cathepsin S (0.158 pMoles in 25 p.L of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. Z-Val-Val-Arg-AMC
(9 nMoIes in 251CL of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometricaIly at ( ~. 460 nm) for 5 minutes. Apparent inhibition constants (I~
were calculated from the enzyme progress curves using standard mathematical models.
Compounds of the invention were tested by the above-described: assay and observed to exhibit cathepsin S inhibitory activity with a I~ of less than or equal to 10 p,M.

Ovalbunun Challenge Mouse .

C57 mice (female) were sensitised with ovalbumin (10~g, i.p.) administered together with aluminium hydroxide adjuvant (20 mg; i.p.) on days 0 and 12. Mice are challenged on either day 22,'23 or 24 by exposure for 60 minutes to an aerosol of ovalbumin (10.g / 1) twice, 4 hours apart. Mice are dosed p.o. with either vehicle 5 ml/kg (0.5%MCI0..2 °!o Tween 80 in Hi0) or test compound at 0, 8, 23.5 29, 33, 48 and 56 hours.
Mice were euthanized with pentobarbitone i.p. after 86 hours (72 haurs after the first challenge). The lungs were insufflated for histological examination as soon as possible after euthanization. Lungs were insufflated with IO°~o neutral buffered formalin (NBF), at 30 cm water pressure. The Lungs were removed and placed in pots of 10% NBF. After fixation in 109b NBF for a minimum of 24 hours the lungs were processed through graded alcohols to wax.
The lungs were blocked longitudinally and one 2 Icm section for each animal was cut at the level of the main bronchi. Sections then were stained with haematoxylin and eosin.
Pathological assessment of sections is performed and a grading is assigned.
Histopathological evaluation of the lung tissue demonstrate a dose dependant anti-inflammatory effect on vascular and mucosal beds after treatment with compounds of the invention between 0.03 and 30 mg/kg.

~/ V VW VV1~~

Representative Pharmaceutical Formulations Containing a Compound of Formula I
ORAL FORMULATION

Compound of Formula I 10-100 mg Citric Acid Monohydrate 105 mg Sodinrn Hydroxide 18 mg Flavoring Water qa. to 100 ~~ .

INTRAVENOUS FORMULATION

Compound of Formula I 0.1-10 mg Dextrose Monohydrate q.s. to make isotonic Citric Acid Monohydrate ~ 1.05 mg Sodium Hydroxide 0.18 mg Water for Injection q.s. to 1.0 mL

l5 TABLET FORMULATION
Compound of Formula I 1R6 Microcrystalline Cellulose ?3%
Stearic Acid 2596 Colloidal Silica ~ 1°k.
The resulting tablets are useful for administration in accordance with the methods of this invention for treating or preventing a cathepsin mediated disease state, such as osteoporosis, juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Craves' disease, myasthenia gravis; systemic lupus erythemotasus, rheumatoid arthritis,~Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchioIitis, excessive airway eIastolysis in asthma and bronchitis, pneumonities, plaque rupture, atheroma and systemic amyloidosis.

Claims (18)

1. A compound of Formula I:
in which:
A comprises a benzooxazole or naphthooxazole ring, each substituted by a group R7 and optionally substituted with a group R8, wherein R7 is hydrogen, halo, (C1-4)alkoxy, (C1-4)alkoxycarbonyl, nitro or phenyl, R8 at each occurrence independently is halo, (C1-4)alkoxy, (C1-4)alkoxycarbonyl, nitro or trifluoromethyl;
n is 0, 1, 2 or 3;
X1 is =C-;
X2 is a bond or a divalent group of Formula (a):
X3 is -C-(O) or -CH2S(O)2-;
wherein within Formula (a) R9 is hydrogen, R11 is hydrogen or methyl and R12 is (C1-6)alkyl substituted with -SR14, -S(O)R14 or -S(O)2R14, wherein R14 is (C6-12)aryl(C0-6)alkyl or hetero(C5-12)aryl(C0-6)alkyl; wherein within R12 the aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5SR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5 is a bond or (C1_6)alkylene, RI4 at each occurrence independently is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl and R15 is (C1-6)alkyl or halo-substituted (C1-3)alkyl;
R1 is -X6X7R20, wherein X6 is -C(O)- or -S(O)2-, X7 is a bond, -O- or -NR21-, wherein R21 is hydrogen or (C1-6)alkyl, and R20 is (i) (C1-6)alkyl optionally substituted by -C(O)OR14 or (ii) (C3-12)cycloalkyl(C1-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl or hetero(C3-12)aryl(C0-6)alkyl or (iii) (C3-6)cycloalkyl(C0-6)alkyl, hetero(C3-6)cycloalkyl(C0-6)alkyl, phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by -X5OR24,-X5C(O)R24, -X5C(O)OR24, -X5C(O)NR24R25, -X5NR24R25, -X5NR25C(O)R24, -X5NR25C(O)OR24, -X5NR25C(O)NR24R25 or -X5NR25C(NR25)NR24R25, wherein X5 is a bond or (C1-6)alkylene, R24 is (C3-6)cycloalkyl(C0-6)alkyl, hetero(C3-6)cycloalkyl(C0-6)alkyl, phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl and R25 is hydrogen or (C1-6)alkyl; wherein within R1 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (C1-6)alkyl, halo, halo-substituted (C1-4)alkyl, -OR14 and -C(O)OR14 wherein R14 is as defined above, or when X2 is a divalent group of formula (a) then R1 may be, but is not limited to, hydrogen or oxalo;
R2 is hydrogen;
R3 is hydrogen, (C1-66)alkyl (optionally substituted with cyano, halo, nitro, -SR24, -C(O)OR24, -C(O)NR24R24, -P(O)(OR24)OR24, -OP(O)(OR24)OR24, -S(O)R25, -S(O)2R2s or -C(O)R2s, wherein R24 at each occurrence independently is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl and R25 is halo, (C1-6)alkyl or halo-substituted (C1-3)alkyl) or (C6-12)aryl(C2-3)alkyl, wherein said aryl optionally is substituted further with 1 to 5 radicals independently selected from (C1-6) alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro,-X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NT214R14 -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5 is a bond or (C1-6)alkylene and R14 and R15 are as defined above, or R3 and R4 or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene;

R4 is hydrogen or as defined above; and R5 and R6 together form oxo; and the N-oxide derivatives, and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 in which:
A is benzoxazol-2-yl substituted by R7, wherein R7 is hydrogen, halo, (C1-4)alkoxy, (C1-4)alkoxycarbonyl or nitro and R8 at each occurrence independently is halo, (C1-4)alkoxy, (C1-4)alkoxycarbonyl, nitro or trifluoromethyl;
X2 is a bond or a divalent group of Formula (a), wherein within Formula (a) X3 is -C(O)-, R11 is hydrogen and R12 is a group having the following formula:
in which q is 0, 1, 2, 4 or 5 and R33 at each occurrence independently is selected from a group consisting of (C1-4)alkyl, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5OR14, -X5SR14, -X5C(O)NR14R14, -X5C(O)OR14, -X5S(O)R15, -X5S(O)2R15, and -X5C(O)R15, wherein X5 is a bond or (C1-6)alkylene, R14 at each occurrence independently is hydrogen, (C1-3)alkyl or halo-substituted (C1-

3)alkyl and R15 is (C1-3)alkyl or halo-substituted (C1-3)alkyl;
R1 is selected from a group consisting of acetyl, azetidin-3-ylcarbonyl, benzyloxycarbonyl, 1-benzyloxycarbonylpiperidin-4-ylcarbonyl, benzylsulfonyl, bicyclo[2.2.2]hept-2-ylcarbonyl, bicyclo[2.2.1]hept-2-ylcarbonyl, tert-butoxycarbonyl, carboxyacetyl, 2-carboxypropionyl, 3-carboxypropionyl, 2-cyclohexylacetyl, 4-cyclohexylbutyryl, 2-cyclohexylethylsulfonyl, cyclohexylmethoxycarbonyl, 3-cyclohexylpropionyl, 2-cyclopentylethylsulfonyl, 3-cyclopentylpropionyl, di(2-methoxyethyl)carbamoyl, dimethylcarbamoyl, 6-hydroxypyrid-3-ylcarbonyl, 1H-imidazol-4-ylcarbonyl, methoxycarbonyl, methylsulfonyl, 4-methylvaleryl, morpholin-4-ylcarbonyl, 2-morpholin-4-ylethylcarbonyl, naphth-1-ylacetyl, naphth-1-ylmethylcarbonyl, oxalo, 3-phenylpropionyl, piperazin-1-ylcarbonyl, piperidin-4-ylcarbonyl, pyrazin-2-ylcarbonyl, pyrid-3-ylcarbonyl, pyrid-4-ylcarbonyl, pyrid-3-ylaminocarbonyl, tetrahydropyran-4-ylcarbonyl and tetrahydropyran-4-yloxycarbonyl;
R3 is selected from hydrogen, (C1-4)alkyl, phenyl(C2-3)alkyl or (C1-4)alkylsulfonyl(C2-4)alkyl or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form (C3-6)cycloalkylene;
R4 is hydrogen or as defined above; and the N-oxide derivatives, and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

3. The compound of Claim 2 in which q is 0, 1 or 2, R1 is morpholin-4-ylcarbonyl, methoxycarbonyl, methylsulfonyl, piperidin-4-ylcarbonyl, pyrazin-2-ylcarbonyl pyrid-3-ylcarbonyl, pyrid-4-ylcarbonyl, tetrahydropyran-4-ylcarbonyl or tetrahydropyran-4-yloxycarbonyl, R3 is methyl, ethyl, n-propyl, n-butyl, 2-methylsulfonylethyl or phenyethyl or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form cyclobutylene and R33 at each occurrence independently is (C1-4)alkyl, cyano, halo, halo-subsituted (C1-4)alkyl, nitro, -OR14, -SR14 or -C(O)OR14, wherein R14 at each occurrence independently is hydrogen, (C1-3)alkyl or halo-substituted (C1-3)alkyl; and the N-oxide derivatives, and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

4. The compound of Claim 3 in which R33 at each occurrence independently is selected from a group consisting of (C1-4)alkyl, bromo, carboxy, chloro, cyano, difluoromethoxy, fluoro, iodo, methoxy, nitro, trifluoromethoxy, trifluoromethyl and trifluorosulfanyl; and the N-oxide derivatives, and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

5. The compound of Claim 1 in which within Formula (a) R12 is benzylsulfonylmethyl, 2-chlorobenzylsulfonylmethyl, 2-cyanobenzylsulfonylmethyl, 2-difluoromethoxybenzylsulfonylmethyl, 3,5-dimethylisooxazol-4-ylmethylsulfonylmethyl, 2-methoxybenzylsulfonylmethyl,

6-methylpyrid-2-ylmethylsulfonylmethyl, 2-nitrobenzylsulfonylmethyl, pyrid-2-ylmethylsulfonylmethyl, o-tolylmethylsulfonylmethyl or 2-trifluoromethylbenzylsulfonylmethyl; and the N-oxide derivatives, and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
6. A compound of Formula II:
in which:
A comprises a benzooxazole or naphthooxazole ring wherein X1 is a ring member carbon atom;
n is 0, 1, 2 or 3;
X1 is =C- or -CH-;
X8 is (C1-2)alkylene;
R1 is hydrogen, carboxy, oxalo, carbamoyl or -X6X7R20, wherein X6 is -C(O)-, -C(O)C(O)- or -S(O)2-, X7 is a bond, -O- or -NR21-, wherein R21 is hydrogen or (C1-6)alkyl, and R20 is (i) (C1-6)alkyl optionally substituted by cyano, halo, nitro, -NR14R14, -NR14C(O)OR14, -NR14C(O)NR14R14, -NR14C(NR14)NR14R14, -OR14, -SR14, -C(O)OR14, -C(O)NR14R14, -S(O)2NR14R14, -P(O)(OR14)OR14, -OP(O)(OR14)OR14, -NR14C(O)R15, -S(O)R15, -S(O)2R15, -C(O)R15, -OR22, -SR22, -S(O)R22, -S(O)2R22, -C(O)R22, -C(O)OR22, -C(O)NR22R23, -NR22R23, -NR23C(O)R22, -NR23C(O)OR22,-NR23C(O)NR22R23 or -NR23C(NR23)NR22R23, wherein R14 at each occurrence independently is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl, R15 is (C1-6)alkyl or halo-substituted (C1-3)alkyl, R22 is (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl, hetero(C5-12)aryl(C0-6)alkyl (C9-12)bicycloaryl(C0-6)alkyl or hetero(C8-12)bicycloaryl(C0-6)alkyl and R23 at each occurrence independently is hydrogen or (C1-6)alkyl, or (ii) (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl, hetero(C5-12)aryl(C0-6)alkyl, (C9-12)bicycloaryl(C0-6)alkyl or hetero(C8-12)bicycloaryl(C0-6)alkyl or (iii) (C3-6)cycloalkyl(C0-6)alkyl, hetero(C3-6)cycloalkyl(C0-6)alkyl, phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl substituted by -X5OR24, -X5SR24, -X5S(O)R24, -X5S(O)2R24, -X5C(O)R24, -X5C(O)O24, -X5C(O)NR24R25, -X5NR24R25, -X5NR25C(O)R24, -X5NR24C(O)OR24, -X5NR25C(O)NR24R25 or -X5NR25C(NR25)NR24R25, wherein X5 is a bond or (C1-6)alkylene, R24 is (C3-6)cycloalkyl(C0-6)alkyl, hetero(C3-6)cycloalkyl(C0-6)alkyl, phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl and R25 at each occurrence independently is hydrogen or (C1-6)alkyl; wherein within R1 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R14, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5, R14 and R15 are as defined above;
R2 is hydrogen or (C1-6)alkyl;
R3 is (i) (C1-6)alkyl optionally substituted with cyano, halo, nitro, -NR14R14, -NR14C(O)OR14, -NR14C(O)NR14R14, -NR14C(NR14)NR14R14, -OR14, -SR14, -C(O)OR14, -C(O)NR14R14, -S(O)2NR14R14, -p(O)(OR14)OR14, -OP(O)(OR14)OR14, -NR14C(O)R15, -S(O)R15, -S(O)2R15, -C(O)R15, -OR16, -SR16, -S(O)R16, -S(O)2R16, -C(O)R16, -C(O)OR16, -OC(O)R16, -NR16R17, -NR17C(O)R16, -NR17C(O)OR16, -C(O)NR16R17, -S(O)2NR16R17, -NR17C(O)NR16R17 or -NR17C(NR17)NR16R17, wherein R14 at each occurrence independently is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl, R15 is (C1-6)alkyl or halo-substituted (C1-3)alkyl, R16 is (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl, hetero(C5-12)aryl(C0-6)alkyl, (C9-12)polycycloaryl(C0-6)alkyl or hetero(C8-12)polycycloaryl(C0-6)alkyl and R17 is hydrogen or (C1-6)alkyl, and wherein within R16 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected from -R18, -X5OR18, -X5SR18, -X5S(O)R18, -X5S(O)2R18, -X5C(O)R18, -X5C(O)OR18, -X5OC(O)R18, -X5NR18R19, -X5NR19C(O)R18, -X5NR19C(O)OR18, -X5C(O)NR18R19, -X5S(O)2NR18R19, -X5NR19C(O)NR18R19 or -X5NR19C(NR19)NR18R19, wherein X5 is as defined above, R18 is hydrogen or (C1-6)alkyl and R19 is (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl, hetero(C5-12)aryl(C0-6)alkyl, (C9-12)polycycloaryl(C0-6)alkyl or hetero(C8-12)polycycloaryl(C0-6)alkyl, or (ii) a group selected from (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl, hetero(C5-12)aryl(C0-6)alkyl, (C9-12)polycycloaryl(C0-6)alkyl and hetero(C8-12)polycycloaryl(C0-6)alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected from -R18, -X5OR18, -X5SR18, -X5S(O)R18, -X5S(O)2R18, -X5C(O)R18, -X5C(O)OR18, -X5OC(O)R18, -X5NR18R19, -X5NR19C(O)R18, -X5NR19C(O)OR18, -X5C(O)NR18R19, -X5S(O)2NR18R19, -X5NR19C(O)NR18R19 or -X5NR19C(NR19)NR18R19, wherein X5, R18 and R19 are as defined above; wherein within R12 and/or R13 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5, R14 and are as defined above, or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form (C3-8)cycloalkylene or (C3-8)heterocycloalkylene, wherein said cycloalkylene or heterocycloalkylene is optionally substituted with 1 to 3 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5, R14 and R15 are as defined above;
R4 is hydrogen, (C1-6)alkyl or as defined above;
R5 is hydrogen and R6 is hydroxy or R5 and R6 together form oxo;
R7 is a group selected from cyano, halo, nitro, -R29, -X5NR29R30, -X5NR30C(O)OR29, -X5NR30C(O)NR29R30, -X5NR30C(30)NR29R30, -X5R29, -X5SR29, -X5C(O)OR29, -X5C(O)NR29R30, -X5S(O)2NR29R30, -X5P(O)(OR30)OR29, -X5OP(O)(OR29)OR29, -X5NR30C(O)R31, -X5S(O)R31, -X5S(O)2R31 and -X5C(O)R31, wherein X5 is as defined above, R29 is hydrogen or -R31, R30 at each occurrence is hydrogen or (C1-6)alkyl and R31 is (C1-6)alkyl, (C3-12)cycloalkyl(C1-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl or hetero(C5-12)aryl(C0-6)alkyl, wherein within R7 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5, R14 and R15 are as defined above; and R8 at each occurrence independently is selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5N14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5, R14 and R15 are as defined above;
R9 is hydrogen or (C1-6)alkyl; and R32 is (C1-8)alkyl, (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl, hetero(C5-12)aryl(C0-6)alkyl, (C9-12)polycycloaryl(C0-6)alkyl or hetero(C8-12)polycycloaryl(C0-6)alkyl, wherein within R32 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5, R14 and R15 are as defined above; and the N-oxide derivatives and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

7. The compound of Claim 6 in which:
A is benzooxazol-2-yl substituted by a group R7 and optionally substituted with a group R8, wherein R7 is hydrogen, halo, (C1-4)alkoxy, (C1-4)alkoxycarbonyl, nitro or phenyl, R8 at each occurrence independently is halo, (C1-4)alkoxy, (C1-4)alkoxycarbonyl, nitro or trifluoromethyl;
X1 is =C-X8 is methylene or ethylene;
R1 is -X6X7R20, wherein X6 is -C(O)- or -S(O)2-, X7 is a bond, -O- or -NR21-, wherein R21 is hydrogen or (C1-6)alkyl, and R20 is (i) (C1-6)alkyl optionally substituted by -C(O)OR14 or (ii) (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl or hetero(C5-12)aryl(C0-6)alkyl or (iii) (C3-6)cycloalkyl(C0-6)alkyl, hetero(C3-6)cycloalkyl(C0-6)alkyl, phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by -X5OR24,-X5C(O)R24, -X5C(O)OR24, -X5C(O)NR24R25, -X5NR24R25, -X5NR25C(O)R24, -X5NR25C(O)OR24, -X5NR25C(O)NR24R25 or -X5NR25C(NR25)NR24R25, wherein X5 is a bond or (C1-6)alkylene, R24 is (C3-6)cycloalkyl(C0-6)alkyl, hetero(C3-6)cycloalkyl(C0-6)alkyl, phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl and R25 is hydrogen or (C1-6)alkyl; wherein within R1 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (C1-6)alkyl, halo, halo-substituted (C1-4)alkyl, -OR14 and -C(O)OR14 wherein R14 is as defined above, or when X2 is a divalent group of formula (a) then R1 may be, but is not limited to, hydrogen or oxalo;
R2 and R9 each are hydrogen;
R3 is hydrogen, (C1-6)alkyl (optionally substituted with cyano, halo, nitro, -SR24, -C(O)OR24, -C(O)NR24R24, -P(O)(OR24)OR24, -OP(O)(OR24)OR24, -S(O)R25, -S(O)2R25 or -C(O)R25, wherein R24 at each occurrence independently is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl and R25 is (C1-6)alkyl or halo-substituted (C1-3)alkyl) or (C6-12)aryl(C2-3)alkyl, wherein said aryl optionally is substituted further with 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro,-X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5, R14 and R15 are as defined above, or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene;
R4 is hydrogen or as defined above;
R5 and R6 together form oxo; and R32 is -X9R34, wherein X9 is methylene when X8 is methylene or is a bond when X8 is ethylene, R34 is -CR35=CHR36 or -CR37=NR38, wherein R35 and R36 together with the atoms to which R35 and R36 are attached form (C2-6)alkenyl, (C5-12)cycloalkenyl, hetero(C5-12)cycloalkenyl, (C6-12)aryl, hetero(C6-12)aryl, (C9-12)bicycloaryl or hetero(C8-12)bicycloaryl and R37 and R38 together with the atoms to which R37 and R38 are attached form hetero(C5-12)cycloalkenyl, hetero(C6-12)aryl or hetero(C8-12)bicycloaryl, wherein within R34 said cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, bicycloaryl or heterobicycloaryl may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5NR14C(O)OR14, -X5NR14C(O)NR14R14, -X5NR14C(NR14)NR14R14, -X5OR14, -X5SR14, -X5C(O)OR14, -X5C(O)NR14R14, -X5S(O)2NR14R14, -X5P(O)(OR14)OR14, -X5OP(O)(OR14)OR14, -X5NR14C(O)R15, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5 is a bond or (C1-6)alkylene, R14 at each occurrence independently is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl and R15 is (C1-6)alkyl or halo-substituted (C1-3)alkyl; and the N-oxide derivatives and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

8. The compound of Claim 7 in which:

A is benzooxazol-2-yl, wherein R7 is hydrogen, halo, (C1-4)alkoxy, (C1-4)alkoxycarbonyl or nitro and R8 at each occurrence independently is halo, (C1-4)alkoxy, (C1-4)alkoxycarbonyl, nitro or trifluoromethyl;
-X8S(O)2R32 is a group having the following formula:
in which q is 0, 1, 2, 4 or 5 and R33 at each occurrence independently is selected from a group consisting of (C1-4)alkyl, cyano, halo, halo-substituted (C1-4)alkyl, nitro, -X5NR14R14, -X5OR14, -X5SR14, -X5C(O)NR14R14, -X5C(O)OR14, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5 is a bond or (C1-2)alkylene, R14 at each occurrence independently is hydrogen, (C1-3)alkyl or halo-substituted (C1-3)alkyl and R15 is (C1-3)alkyl or halo-substituted (C1-3)alkyl;
R1 is selected from a group consisting of acetyl, azetidin-3-ylcarbonyl, benzyloxycarbonyl, 1-benzyloxycarbonylpiperidin-4-ylcarbonyl, benzylsulfonyl, bicyclo[2.2.2]hept-2-ylcarbonyl, bicyclo[2.2.1]hept-2-ylcarbonyl, tert-butoxycarbonyl, carboxyacetyl, 2-carboxypropionyl, 3-carboxypropionyl, 2-cyclohexylacetyl, 4-cyclohexylbutyryl, 2-cyclohexylethylsulfonyl, cyclohexylmethoxycarbonyl, 3-cyclohexylpropionyl, 2-cyclopentylethylsulfonyl, 3-cyclopentylpropionyl, di(2-methoxyethyl)carbamoyl, dimethylcarbamoyl, 6-hydroxypyrid-3-ylcarbonyl, 1H-imidazol-4-ylcarbonyl, methoxycarbonyl, methylsulfonyl, 4-methylvaleryl, morpholin-4-ylcarbonyl, 2-morpholin-4-ylethylcarbonyl, naphth-1-ylacetyl, naphth-1-ylmethylcarbonyl, oxalo, 3-phenylpropionyl, piperazin-1-ylcarbonyl, piperidin-4-ylcarbonyl, pyrazin-2-ylcarbonyl, pyrid-3-ylcarbonyl, pyrid-4-ylcarbonyl, pyrid-3-ylaminocarbonyl, tetrahydropyran-4-ylcarbonyl and tetrahydropyran-4-yloxycarbonyl;

R3 is selected from hydrogen, (C1-4)alkyl, phenyl(C2-3)alkyl or (C1-4)alkylsulfonyl(C2-4)alkyl or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form (C3-6)cycloalkylene;
R4 is hydrogen or as defined above; and R34 is (C6-12)aryl or hetero(C5-12)aryl, each optionally substituted by 1 to 5 radicals selected from a group consisting of (C1-4)alkyl, cyano, halo, halo-substituted (C1-4)alkyl, nitro -X5NR14R14, -X5OR14, -X5SR14, -X5C(O)NR14R14, -X5C(O)OR14, -X5S(O)R15, -X5S(O)2R15 and -X5C(O)R15, wherein X5, R14 and R15 are as defined above; and the N-oxide derivatives and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

9. The compound of Claim 6 in which q is 0, 1 or 2, R1 is morpholin-4-ylcarbonyl, methoxycarbonyl, methylsulfonyl, piperidin-4-ylcarbonyl, pyrazin-2-ylcarbonyl, pyrid-3-ylcarbonyl, pyrid-4-ylcarbonyl, tetrahydropyran-4-ylcarbonyl or tetrahydropyran-4-yloxycarbonyl, R3 is ethyl, butyl, 2-methylsulfonylethyl, phenethyl or propyl and -X8S(O)2R32 is benzylsulfonylmethyl, 2-chlorobenzylsulfonylmethyl, 2-cyanobenzylsulfonylmethyl, 2-difluoromethoxybenzylsulfonylmethyl, 3,5-dimethylisooxazol-4-ylmethylsulfonylmethyl, 2-methoxybenzylsulfonylmethyl, 6-methylpyrid-2-ylmethylsulfonylmethyl, 2-nitrobenzylsulfonylmethyl, pyrid-2-ylmethylsulfonylmethyl, o-tolylmethylsulfonylmethyl or 2-trifluoromethylbenzylsulfonylmethyl; and the N-oxide derivatives and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

10. The compound of Claim 9 selected from a group consisting of:
N-[1R-(1S-benzooxazol-2-ylcarbonylbutylcarbamoyl)-2-benzylsulfonylethyl]morpholine-4-carboxamide;
methyl 1R-(1S-benzooxazol-2-ylcarbonylbutylcarbamoyl)-2-benzylsulfonylethylcarbamate;
N-(1S-benzooxazol-2-ylcarbonylbutyl)-2R-methylsulfonylamino-3-benzylsulfonylpropionamide;
N-(1S-benzooxazol-2-ylcarbonylbutylcarbamoyl)-2R-(3,3-dimethylureido)-3-(2-methoxybenzylsulfonyl)propionamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylbutylcarbamoyl)-2-(2-difluoromethoxybenzylsulfonyl)ethyl]morpholine-4-carboxamide;

N-[1R-(1S-benzooxazol-2-ylcarbonylbutylcarbamoyl)-2-(2-methoxybenzylsulfonyl)ethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-benzylsulfonylethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-(2-chlorobenzylsulfonyl)ethyl]morpholine-4-carboxamide;
1-R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-(2-difluoromethoxybenzylsulfonyl)ethylcarbamate;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-(2-difluoromethoxybenzylsulfonyl)ethyl]morpholine-4-carboxyamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-(3,5-dimethylisoxazol-4-ylmethylsulfonylethyl]isonicotinamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-(2-nitrobenzylsulfonyl)ethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-pyridin-2-ylmethylsulfonylethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-o-tolylmethylsulfonylethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl)-2-(2-trifluoromethylbenzylsulfonyl)ethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-benzylsulfonylethyl]nicotinamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-benzylsulfonylethyl]pyrazine-2-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(2-chlorobenzylsulfonyl)ethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(2-cyanobenzylsulfonyl)ethyl]isonicotinamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-methylsulfonylpropylcarbamoyl)-2-(2-difluoromethoxybenzylsulfonyl)ethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonylpentylcarbamoyl) 2-(2-difluoromethoxybenzylsulfonyl)ethyl]isonicotinamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl)-3-phenylpropylcarbamoyl)-2-benzylsulfonylethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(6-methylpyrid-2-ylmethylsulfonyl)ethyl]isonicotinamide;

N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(2-nitrobenzylsulfonyl)ethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-pyrid-2-ylmethylsulfonylethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-o-tolylmethylsulfonylethyl]morpholine-4-carboxamide;
N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(2-trifluoromethylbenzylsulfonyl)ethyl]tetrahydropyran-4-carboxamide;
tetrahydropyran-4-yl 1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-benzylsulfonylethylcarbamate; and N-[1R-(1S-benzooxazol-2-ylcarbonyl-3-phenylpropylcarbamoyl)-2-(2-cyanobenzylsulfonyl)ethyl]piperidine-4-carboxamide and the N-oxide derivatives and individual stereoisomers and mixtures of stereoisomers thereof; and the pharmaceutically acceptable salts thereof.

11. The compound of Claim 6 which is A128-B14-C4-D1 of Table 1 and having the structure:

namely N-[1R-(1S-benzooxazol-2-ylcarbonylprop-1-ylcarbamoyl)-2-(2-methylprop-1-ylsulfonyl)ethyl]morpholine-4-carboxamide; and the pharmaceutically acceptable salts thereof.

12. The compound of Claim 6 designated as A128-B46-C4-D1 of Table 1 and having the structure:

namely N-[1R-(1S-benzooxazol-2-ylcarbonylprop-1-ylcarbamoyl)-2-cyclopropylmethylsulfonylethyl]morpholine-4-carboxamide; and the pharmaceutically acceptable salts thereof.

13. A pharmaceutical composition comprising the compound of any one of Claims 6 to 12 or a N-oxide derivative thereof; or an individual stereoisomer or mixture of stereoisomers thereof; or a pharmaceutically acceptable salt thereof in admixture with at least one suitable excipient.

14. A pharmaceutical composition comprising a compound of any one of Claims 1 to 5, or a N-oxide derivative, individual stereoisomer, or mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof in admixture with at least one suitable excipient.

15. Use of the compound of Claims 1 to 5 or a N-oxide derivative thereof; or an individual stereoisomer or mixture of stereoisomers thereof; or a pharmaceutically acceptable salt thereof, to treat, in an animal, a disease selected from the group consisting of juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonitis, plaque rupture and atheroma.

16. Use of the compound of any one of Claims 6 to 12 or a N-oxide derivative thereof; or an individual stereoisomer or mixture of stereoisomers thereof; or a pharmaceutically acceptable salt thereof, to treat, in an animal, a disease selected from the group consisting of juvenile onset diabetes; multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonitis, plaque rupture and atheroma.

17. Use of the compound of any one of Claims 1 to 5 or a N-oxide derivative thereof; or an individual stereoisomer or mixture of stereoisomers thereof; or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use to treat, in an animal a disease selected from the group consisting of juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonitis, plaque rupture and atheroma.

18. Use of the compound of any one of Claims 6 to 12 or a N-oxide derivative thereof; or an individual stereoisomer or mixture of stereoisomers thereof; or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use to treat, in an animal, a disease selected from the group consisting of juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonitis, plaque rupture and atheroma